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Abstract 
 
The synthesis of two sets of different orthogonally protected lanthionine ready for 
incorporation into solid phase peptide synthesis to form cyclised peptides is described in this 
thesis, along with the cyclisation of individual rings D and E and the overlapping rings D and 
E. 
 
Previously developed orthogonally protected lanthionine containing Aloc, allyl, Fmoc and 
tBu protecting groups was synthesised using published synthetic route developed by Tabor’s 
group. A novel orthogonally protected lanthionine containing Teoc, TMSE, Fmoc and Tce 
group derivative has also been synthesised, after carrying several synthetic pathways. Both 
lanthionine residues contain protecting groups which are orthogonal to each other, which are 
also orthogonal to the transient Fmoc and permanent Boc/tBu protecting groups which are 
used in Fmoc based solid phase peptide synthesis. 
 
Incorporation of the previously developed lanthionine with Aloc/allyl protecting groups was 
carried out to form an analogue of ring E of nisin for the first time. Deprotection of the 
Aloc/allyl protecting groups were carried out with Ph(PPh3)4 using N’,N-dimethyl-barbituric 
acid (NDMBA). 
 
The second orthogonally protected lanthionine was also incorporated into solid phase peptide 
synthesis to synthesise an analogue of ring D of nisin. This was also to see whether this can 
be used to synthesise lanthionine-containing thio-ether bridged cyclic peptide by solid phase 
peptide synthesis. Teoc and TMSE deprotection was carried out in the presence of TBAF 
without effecting the other side chain and Fmoc protecting groups. Full characterisation of 
individual rings D and E were obtained. 
 
Quadruply orthogonal protecting group strategy was used to synthesise bicyclic peptide with 
two overlapping lanthionine bridges rings D and E. An effective methodology has been 
developed for the synthesis of the overlapping rings D and E of nisin by solid phase peptide 
synthesis.  
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 1. Introduction 
 
Diseases caused by bacterial infection have always played a major part in human history, and 
continue to be a threat even in the 21
st
 century. Mortality due to bacterial infections has been 
decreased dramatically by improved hygiene and the use of antibiotics. However, bacteria 
evolving resistance to antibiotics through mutations is a major problem, making many drugs 
rapidly obsolete and this makes the search for new antibiotics with novel mechanisms a 
constant challenge. 
 
There are large numbers of antibiotics known; an important class of antibiotics are peptidic in 
nature. These include: vancomycin, which is used in serious and life-threatening infections by 
Gram-positive bacteria; 
1
 polymyxin, used for serious Gram-negative infections; and the 
lantibiotic nisin, which is one of the few used as a food preservative. 
2
   
 
The lantibiotics are a family of thio-ether bridged antimicrobial peptides
 
produced by Gram 
positive bacteria. Their name is indicative of the fact that they contain the amino acid 
lanthionine. 
3, 4
 Many of these peptides show antibiotic activity against Gram-positive 
bacteria and anaerobic prokaryotes, 
5
 believed to be mediated through a variety of 
mechanisms. 
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1.1.  Overview of lantibiotics  
 
1.1.1. Unusual amino acids 
 
All lantibiotics contain one or more of the unusual, double headed amino acid lanthionine 
(Lan) 1. Incorporation of a lanthionine residue into a peptide sequence results in a peptide 
with a thio-ether linkage between the side-chain of two alanine residues. In lantibiotics a 
cyclic peptide structure with a side-chain to side-chain thio-ether bridge is formed (Figure 1 
shows the cyclised ring C of nisin). The unique properties of lantibiotics, such as 
conformational constraints and stability to degradation by proteases result from these thio-
ether bridges. In most lantibiotics the lanthionine residues have the meso-stereochemistry 
(Figure 1).  
 
Most lantibiotics also contain threo- -methyl lanthionine (MeLan) 2. They also typically but 
not always contain the modified amino acids 2, 3-didehydroalanine 3 (Dha), 2, 3-
didehydrobutyrine 4 (Dhb), 2-aminovinylcysteine 5 (AviCys), methyl-2-aminovinylcysteine 
6 (AviMeCys), lysinoalanine 7 (LysN-Ala) and 3-hydroxyaspartic acid 8 (HyAsp) (Figure 1). 
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Figure 1: Structures of unusual amino acids Lan, MeLan, Dha, Dhb, AviCys, 
AviMeCys, LysN-Ala, HyAsp and a cyclic peptide. 
 
Studies of a range of lantibiotics confirm that the unusual amino acids play a key role in the 
stability and activity of these antibiotic peptides. It has been demonstrated that by 
mutagenesis of the lantibiotic encoding genes the structures of lantibiotics can be modified 
and that this may lead to profound changes in activity. For example, the replacement of the 
dehydroamino acids with the corresponding saturated amino acids can lead to a significant 
reduction of the antibacterial activity. 
6
 Thus the antibacterial activity of these lantibiotics are 
at least in part due to the electrophilic centres of the dehydroamino acids which can readily 
react with nucleophilic groups present in bacterial DNA and enzymes, and without these 
unusual amino acids these lantibiotics do not possess significant activity. 
7, 8
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1.1.2. Structure and mode of action 
 
To date more than 50 lantibiotics have been isolated from Gram positive bacteria and they 
show a variety of structures, sizes, and, modes of action. Based on the topology of lantibiotic 
ring structures and the biological activity, Jung 
9
 classified the lantibiotics as Type A and 
Type B.  
 
Type A lantibiotics (Figure 2) such as nisin, subtilin, nukacin, Pep5, Epidermin and lacticin 
are flexible, elongated amphipathic screw-shaped cationic peptides, and their lanthionine 
bridges have similar arrangements. 
3, 10 
They are primarily active against Gram-positive 
bacteria strains, however when ion chelaters such as EDTA or citrate 
11, 12
 are used to disrupt 
the outer membrane Gram-negative bacteria are also affected. 
13
 Type A lantibiotics such as 
nisin form pores in the biological membrane and have a positive charge overall.  
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Type A lantibiotics continued 
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Figure 2: 
3 
Simplified representative structures of Type A lantibiotics. 
 
The Type B lantibiotics include mersacidin, actagardine, lacticin 481 and cinnamycin (Figure 
3). These lantibiotics are more globular and compact in structure, with a greater number of 
overlapping thio-ether bridges. At pH 7 they have no net charge or negative charge. 
3
 Like 
Type A lantibiotics, they are also active against a range of Gram-positive bacteria. They are 
not active against Gram negative bacteria, due to these peptides being unable to pass the outer 
membrane of bacteria and unable to penetrate the cell membrane. 
13
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Figure 3: 
3 
Simplified representative structures of Type B lantibiotics. 
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In total, there are 5 broad subclasses of lantibiotics depending on the differences in the 
chemistry and biosynthesis. Based on the structures, Type A lantibiotic are further divided 
into three subtypes, namely Type A (I), Type A (II) and A (III), whilst Type B consists of 
two component lantibiotics, lantibiotics that are globular and compact in structure and 
lantibiotics of unknown structures. 
14
   
 
1.1.3. Type A (I) and Type A (II) lantibiotics 
 
Type A (I) lantibiotic leader sequences have a high percentage of charged amino acids which 
are generally hydrophilic. They have a net negative or a slightly positive charge. 
15
 The 
formation of Lan and MeLan residues occurs by the action of two distinct enzymes (LanB 
and LanC) which lead to the dehydration of Ser and Thr residues and cyclisation to form the 
thioether bridges (Section 1.1.4). The presence of LanB and LanC enzymes classifies the 
lantibiotic as Type A (I) lantibiotic and an example of Type A (I) lantibiotic is nisin. 
3 
 
Type A (II) lantibiotic leader sequences tend to comprise highly negative net charges and 
unlike Type A (I) they possess consensus sequences. 
15
 Formation of Lan and MeLan are 
catalysed by a single enzyme (LanM) in Type A (II) lantibiotics.
 
An example of a Type A (II) 
lantibiotic is Lactocin. 
3
  
 
Table 1 shows a list of Gram positive bacteria and the lantibiotics they produce. It can be 
seen that similarities can occur between different lantibiotics; for example nisin and 
epidermin have ring sizes which are similar and located near the amino terminal, whereas 
ring B is completely conserved. This sequence conservation can be used to distinguish further 
sub-categorisations. Thus conservation of rings, high charges and the N-terminal blocked 
with hydroxyl-, butyryl-, or propionyl groups categorises Pep 5 and Epidicin 280 within the 
same subgroup. 
 
 
 
 
 
 
32 
 
Lantibiotic  Producer strain Lan MeLan Dha Dhb Other Amino acids Type  
  
Ref 
Nisin A Lactococcus lactis 1 4 2 1 - 34 A (I) 
 
 
 
16 
Nisin Z  Lactococcus lactis 1 4 2 1 - 34 A (I) 
  
17 
Subtilin Bacillus subtilis 1 4 2 1 - 32 A (I) 
  
18 
Epidermin Staphylococcus epidermis 2 1 0 1 AviCys 22 A (I) 
 
 
 
19 
Gallidermin Staphylococcus gallinarium 2 1 0 1 AviCys 22 A (I) 
  
20 
Mutacin 1140 Streptococcus mutans 2 1 1 1 AviCys 22 A (I) 
  
21 
Mutacin B-Ny266 Streptococcus mutans 2 1 1 1 AviCys 22 A (I) 
  
22 
Mutacin III Streptococcus mutans 2 1 1 1 AviCys 22 A (I) 
  
23 
Mutacin I Streptococcus mutans 3 0 2 0 AviCys 24 A (I) 
  
24 
Pep 5 Staphylococcus epidermis 2 1 0 2 D-Ala, 2-Oxobutyryl 34 A (I) 
  
25 
Epicidin 280 Staphylococcus epidermis 1 2 0 1 2-Hydroxypropionyl 30 A (I) 
  
 
26 
Epilancin K7 Staphylococcus epidermis 2 1 2 2 2-Hydroxypropionyl 31 A (I) 
  
 
27 
           
Lacticin 481 Lactococcus lactis 2 1 0 1 - 27 A (II) 
  
28 
Lactocin S Lactobacillus sakei 2 0 0 1 2-oxopropionyl 37 A (II) 
  
29 
Mutacin II Streptococcus mutans 2 1 0 1 - 27 A (II) 
  
30 
Variacin Micrococcus varians 2 1 0 1 - 25 A (III) 
  
31 
Salivaricin A Streptococcus salivarius 1 2 0 0 - 22 A (II) 
  
32 
Streptococcin A-FF22 Streptococcus pyogenes 1 2 0 1 - 26 A (II) 
  
33 
Cypemycin Streptomyces 0 0 0 4 AviCys, AlaMe2 22 A (II) 
  
34 
Plantaricin C Lactobacillus plantarum 1 3 1 0 - 27 A (II) 
  
35 
Butyrivibriocin OR79A Butyrivibrio fibriosolvens 1 2 0 1 - 25 A (II) 
  
36 
           
Cinnamycin Streptomyces cinnamoneus 1 2 0 0 Asp-OH, LysNAla 19 B 
  
37 
Duramycin Streptoverticillium hachijoense 1 2 0 0 Asp-OH, LysNAla 19 B 
  
38 
Duramycin B Streptoverticillium 1 2 0 0 Asp-OH, LysNAla 19 B 
  
39 
Duramycin C Streptomyces griseoluteus 1 2 0 0 Asp-OH, LysNAla 19 B 
 
 
 
39 
Ancovenin Streptomyces sp. 1 2 1 0  19 B 
  
40 
Mersacidin Bacillus sp. Strain 0 3 1 0 AviMeCys 20 B 
  
41 
Actagardine Actinoplanes linguriae 1 2 0 0 MeLan- Sulfoxide 19 B 
  
42 
Ala-(0)-actagardine Actinoplanes linguriae 1 2 0 0 MeLan- Sulfoxide 20 B 
  
5 
           
Lacticin 3147A1 Lactococcus lactis 2 2 0 2 D-Ala 30 
Two-component 
lantibiotics 
  
 
43 
Lacticin 3147A2 Lactococcus lactis 1 2 0 2 D-Ala x2, 2-oxoproionyl 29 Two-component 
 43 
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Table 1: 
3
 Examples of Gram positive bacteria with the lantibiotics produced, the 
number of amino acids, number of Lan and MeLan and other amino acids produced 
and the category.  
 
1.1.4. Lantibiotic biosynthesis 
 
The structural genes for the lantibiotics encode linear prepeptides that consist of two parts: a 
leader peptide and a prolantibiotic. The biosynthetic pathway of a lantibiotic involves the 
ribosomal synthesis of the prepeptide consisting of the N-terminal leader sequence followed 
by a prolantibiotic part. 
42
 The prolantibiotic contains only the 20 proteinogenic amino acids, 
which may then undergo extensive posttranslational modification by specific enzymes.  
 
Dehydration of serine and threonine residues introduces α,β-unsaturated amino acid residues 
that may participate in intramolecular Michael-type additions with cysteine to form thio-ether 
cross links. 
44
 Dha and Dhb are vulnerable to nucleophilic addition and addition of the thiol 
groups of cysteine 
45
 generates Lan 1 and MeLan 2 respectively (Figure 4). There are 
occasions where the cysteine residues located at the C-terminus of the lantibiotic may oxidise 
and decarboxylate followed by the nucleophilic addition of its thiol group to Dha and Dhb. 
This leads to forming 2- aminovinyl-D-cysteine (AviCys) as in the case of epidermin. 
45
 The 
active form is generated upon cleavage of a leader peptide. 
46 
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Figure 4: Dehydration of serine and threonine followed by addition with the thiol 
during biosynthesis. Serine is transformed into Dha when R = H and threonine is 
transformed into Dhb when R = Me. 
47
  
 
Lan is the generic symbol given to lantibiotic genes; however a more specific name is given 
for some individual lantibiotics such as Nis for nisin. The 57 amino acid prepeptide for nisin 
is ribosomally synthesised, encoded for by the NisA gene (Figure 5). NisB catalyses the  
dehydration of the underlined Ser and Thr residues to Dha and Dhb. Thio-ether bonds are 
formed by Michael addition of the appropriate cysteine residue giving five of the Dha (green) 
34 
 
and Dhb (magenta) residues, producing the five characteristic lanthionine rings, one of which 
is cross-linked by lanthionine (red) and the other four methyllanthionines (blue). 
2
 The NisC 
enzyme catalyses the conjugate addition of Cys residues to Dha and Dhb in a regio- and 
stereo-specific manner. Once the dehydration and cyclisation is complete, the leader peptide 
is removed proteolytically by NisP protease (Figure 5). 
48 
 
 
 
 
 
 
 
Please see: A. W. van der Donk; J. Org. Chem.; 2006, 71, 9561 to see Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:
 
Posttranslational maturation process of lantibiotic. Picture adapted from Van 
der Donk. 
48
 
 
Similarly to most other biosynthetic pathways in bacteria, the genes for nisin biosynthesis are 
clustered (Figure 6) and it has been found that this cluster consists of 11 genes. 
49
 During 
lantibiotic biosynthesis a leader peptide is produced that contains multi-residue extension 
known as the N-terminal, this is followed by a C-terminal propeptide moiety which 
undergoes enzymatic modifications to give the mature lantibiotic. The modifications involve 
the formation of unusual amino acids, dehydration of serine and threonine residues to Dha 
and Dhb, cyclisations of Dha and Dhb residues forming the thio-ether rings and cleavage of 
35 
 
the leader peptide. 
3, 10
 NisA genes encodes for the 57 amino acid prepeptide. NisB gene is 
involved in the dehydration of serine and threonine to Dha and Dhb whilst NisC gene 
catalyses the ring formation by conjugate addition of cysteine residues to these dehydro 
amino acids. NisIFEG is concerned with self immunity, protecting the organism producing 
nisin from its toxic effects. NisK and NisR genes are regulatory genes which consist of a two 
component sensory system which are important for regulation of lantibiotic production. NisT 
an ATP-binding cassette (ABC) transporter is involved in the secretion of the final product 
whilst protease NisP is responsible for the removal of the leader peptide. 
3, 45
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Figure 6: Roles of genes in lantibiotic biosynthesis. 
 
1.1.4.1. Classifications of antimicrobial peptides 
 
Classification of the antimicrobial peptides depends on the biosynthetic mechanism of 
ribosomally synthesised peptides or bacteriocins. Depending on the biochemical and genetic 
properties there are up to four Classes. 
50, 51
 Class I and Class II bacteriocins are membrane 
active peptides that are cationic and amphiphilic as small as 3-10 kDa.  Unusual amino acids, 
lanthionine and methyllanthionine are contained within Class I lantibiotics or bacteriocins. 
Modification of Class I bacteriocin are engineered by two enzymes LanB and LanC and an 
example of a Class I bacteriocins is the most studied lantibiotic nisin. Class II bacteriocins 
only contain one enzyme LanM which catalyses dehydration and cyclisation. Class II 
bacteriocins are subdivided into further three groups: i) Class IIa which contains the 
conserved sequence Y-G-N-G-V-X-C near the N terminus; ii) Class IIb which consists of two 
lantibiotic peptides and both are required for antimicrobial activity; iii) Class IIc are peptides 
that are thiol activated. 
50
 Examples of Class II lantibiotics are mercasidin, actagardine and 
two component lantibiotics such as cytolysin. Class III lantibiotics are larger, with molecular 
masses > 30 kDa and have other functions rather than just antimicrobial activity such as 
36 
 
being heat-labile proteins. 
3
 Class IV lantibiotics are more complex peptides which contain 
carbohydrate or lipid moieties which are important for activity. 
52 
 
1.1.4.2. LanB and LanC enzymes 
 
LanA is present in all lantibiotics which encode the ribosomally synthesised precursor 
peptides known as the prepeptide. The prepeptide is biologically inactive and carry the leader 
sequence, containing 23-29 amino acids which are unaffected during post-translational 
modification. The leader sequences play a role in protection by keeping the antibiotic inactive 
within the cell and act as a recognition sequence for the biosynthetic enzymes.  
 
LanB encode proteins as large as approximately 1000 residues that are hydrophilic by nature 
and have some hydrophobicity. LanB has been reported to play a key role; in nisin 
production, the secretion of nisin only takes place when NisB is detected. It was found that 
when nisin variants: [Trp30] nisin and [Lys27, Lys31] nisin were produced by strains, Ser33 
was not transformed to Dha33 by dehydration in 50 % of the total peptide produced. 
53 
However
 
fully modified nisin was produced when NisB was cloned and overexpressed in 
these strains indicating there was complete transformation of Ser to Dha in the mature 
peptide. 
54
 This shows the importance of NisB in dehydration of Ser residues.  
 
Products of LanC gene range from 398 (PepC) to 455 (EpiC) amino acids. The key role of 
this enzyme is the formation of thio-ether bridges after the dehydration of the prelantibiotic. 
Koponen et al. 
55
 illustrated the first direct evidence of NisC being responsible for the 
cyclisation of thio-ether rings. They formed mutant strains of L. lactis lacking the NisB and 
NisC genes. They used a precursor peptide of nisin which was tagged with histidine to ensure 
simple purification of the final peptide. It was discovered that no dehydration or cyclisation 
took place when the tagged prepeptide was exposed to a strain lacking NisB. Whereas when 
the same tagged prepeptide was used in a strain lacking NisC, a dehydrated propeptide was 
engineered however cyclised peptide was not obtained.        
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1.1.4.3. LanM enzymes 
 
LanB or LanC are not present in the gene clusters of class II lantibiotics such as lactosin S, 
mersacidin, lacticin 481, actagardine, and a two component lantibiotic cytolysin. LanM 
present in class II lantibiotics encodes proteins of 900 - 1000 amino acid. The C-terminal of 
LanM proteins shows similarity to the C-terminal of the LanC proteins. However there is no 
similarity in the N-terminal of LanM with that of the N-terminal of LanB. This indicated that 
the possibility for the origin of LanM existing from the fusion of LanB and LanC was 
unlikely. Due to other enzymes not being present in the gene clusters for catalysing the 
posttranslational modification, this showed that LanM was responsible for both dehydration 
and cyclisation reactions. 
56
 This was confirmed when the production of the mature lantibiotic 
was prevented when the LctM was disrupted in lacticin.    
 
1.1.4.4. Two - component lantibiotics  
 
Lacticin 3147 is a two component lantibiotic, containing two LtnM genes which is an unusual 
feature of the gene cluster.  The presence of two LtnM genes is unique; it can be assumed that 
one LtnM protein is responsible for the dehydration while the second is responsible for the 
formation of thio-ether rings similar to LanB and LanC. This however is made unlikely due to 
the absence of the second enzyme in lactosin S, cytolysin and lacticin 481. Lacticin is 
composed of two small peptides 3-4 kDa, where LtnA1 and LtnA2 genes are proposed as 
candidates for the structural genes of lacticin 3147. McAuliffe et al. 
57
 demonstrated for 
activities each prepeptide require separate modification enzymes. They demonstrated that 
LtnM1 is responsible for modifying LtnA1 peptide, whereas LtnM2 modifies LtnA2 peptide. 
There is no similarity in the sequence of lacticin 3147 and cytolysin peptides however it can 
be seen from the protein sequence that LtnA1 and LtnA2 are closely related to staphylococcin 
C55 components. Also compared to lacticin 3147 and staphylococcin C55 the peptide 
components in cytolysin are closely related to each other. This may be why lacticin 3147 
require two LanM modification enzymes whilst cytolysin requires one LanM proteins.        
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1.2. Nisin 
 
Nisin is a lantibiotic produced by Lactococcus lactis. It is a 34 residue pentacyclic peptide 
with a molecular weight of 3353 Da, with 13 residues post-translationally modified (Figure 
7). Nisin was discovered one year prior to penicillin 
58
 in 1928 
59, 60
 although the structure 
was only elucidated in 1971. 
16
 It has been used as a food preservative for many years and is 
part of a Type A lantibiotic which is elongated and shares similar characteristics with other 
antimicrobial peptides. Effective inhibition of Gram-positive bacteria was carried out by 
inhibiting bacterial cell wall synthesis. This was due to nisin interfering with energy 
transduction at the cytoplasmic membrane. 
15
 Gram-negative bacteria inhibition also took 
place. Generally nisin does not have bactericidal effect on the growth of Gram negative 
organisms or intact Gram negative organisms such as Salmonella. This is due to the outer 
membrane preventing access of the hydrophobic substances to the petidoglycan layer.  
However chemical agents like EDTA 
12
 disrupt the outer lipopolysaccharide membrane 
which allows nisin to enter the membrane where lipid II is present. This leads to nisin 
inhibiting Gram negative bacteria. Nisin also inhibits the outgrowth of spores of Bacilli and 
Clostridium, this activity is believed to take place by nucleophilic attack from Cys residues 
on Dha5 which results in the modification of a target on the spore. 
3, 61 
During spore 
outgrowth, nisin targets the thiol groups on the exterior of spores from Bacillus cereus 
interfering with modifications of sulfhydryl groups. 
62 
Nisin has been used as a potential 
antibacterial agent in health care products, in the pharmaceutical and veterinary sectors. 
63 
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Figure 7: 
3
 Structure of nisin. 
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1.2.1. Nisin Isoforms 
 
Nisin A and nisin Z (Figure 8) are two naturally occurring nisin isoforms 
2, 17, 64 
with similar 
activities. Nisin Z is produced from Lactococcus lactis strain NIZO 22186 with antimicrobial 
activity. It has been characterised with a molecular weight that is identical to nisin which is 
produced by a various Lactococcus lactis strains including NIZO R5.  
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Figure 8: Structures of nisin isoforms A and Z. 
 
1.2.2. Interaction of nisin with target membranes 
  
Model systems have been used to determine molecular aspects of pore formation 
2 
by initial 
interaction of nisin with the membrane. Sahl et al. 
65 
was the first group to show that nisin can 
permeabilise membranes composed of phospholipids. They showed that membranes that are 
composed of zwitterionic phospholipid dioleoylphosphatidylcholine (DOPC which forms 
stable bilayer) could be permeabilised by nisin at a peptide/lipid molar ratio of 1:20. Nisin, 
pep-5 and subtilin were used to investigate their influence on non-energised membranes. It 
was found that nisin had considerable effect on the fluidity of DOPC vesicles containing 3 % 
pyrenedecanoic acid (PDA) but there was no effect by pep-5 and subtilin. Nisin and pep-5 
had an increased effect on the fluidity of DOPC/DMPS (dimyristoylphosphatidylserine) 
vesicles but a decreased effect for pure phosphatidylserine (PS) membranes. This suggests 
that the affinity of the peptides were dependent on the electrostatic interactions and that the 
negative charged phospholipids are essential for pep-5 and nisin membrane interactions. 
65
 
40 
 
Sahl et al. 
65 
found the hydrophobic central domain of subtilin partially penetrated into the 
membranes due to the tryptophan. Once DOPC vesicles at a peptide/lipid ratio of 1:400 was 
added the polarity of the tryptophan decreased. This shows the transfer of the indole ring to 
the surrounding area of the aliphatic chains. The indole ring of tryptophan in subtilin enters 
the hydrophobic core of the membrane slightly whilst the remaining of the tryptophan residue 
is located close to the water-lipid interface. 
65
             
 
1.2.3. Binding of nisin to model membranes 
 
Binding to the target membrane is the first step in the antibacterial action of nisin. It is 
thought that the C-terminus of nisin is responsible for the initial interaction with the 
membrane surface, as the major part of the positive charge is concentrated within this part of 
the molecule. Breukink et al. 
66
 showed in detail the anionic lipid dependency of the 
membrane interaction of nisin. The process was mimicked using unilamellar vesicles which 
were composed of zwitterionic lipids DOPC and DOPG forming stable bilayer.  
 
Nisin Z and negatively charged [Glu-32]-nisin Z were used to observe the membrane 
interaction. The study demonstrated that nisin Z has a higher affinity for membranes 
containing negatively charged lipid DOPG than membranes containing zwitterionic DOPC. 
For efficient binding, insertion and pore formation to take place the negatively charged lipid 
DOPG is essential compared to the zwitterionic DOPC.
 66
 
 
Mutations at the C-terminus of nisin affect the binding to model 
phosphatidylcholine/phosphatidylglycerol (PC/PG) lipid membranes particularly in lipid 
systems with greater than 40 % PG present. An increase in negative charge at position 32 
opposed the attraction of positively charged residues to the negatively charged bacterial 
membrane leading to elimination of the anionic lipid-dependent binding of nisin (Figure 9). 
67 
The sensitivity of Gram-positive bacteria to nisin can be explained by the fact that generally 
the plasma membranes of Gram-positive bacteria are found to possess greater concentrations 
of anionic lipids than Gram-negative bacteria.  
 
Gram-negative bacteria are not generally sensitive to nisin. This is due to the outer membrane 
of Gram-negative bacteria acting as a permeability barrier for the cell, preventing molecules 
41 
 
such as detergents, dyes and antibiotics from entering the cytoplasmic membrane. It is the 
magnesium ions which stabilize the lipopolysaccharide layer of the outer membrane. 
12
 As 
previously mentioned Gram-negative bacteria can be sensitised to nisin by combining nisin 
treatments with chelating agents such as EDTA. EDTA binds to the magnesium ions present 
in the lipopolysaccharide layer, this removes magnesium ions from the lipopolysaccharide 
layer of the outer membrane leading to loss of lipopolysaccharide which forms cells that are 
susceptible to antibiotics and detergents.  
 
 
 
Please see: E. Breukink, B de Kruijff; Biochim. Biophys. Acta.; 1999, 1462, 223 
And L. Lins, P. Ducarme, E. Breukink, R. Brasseur; Biochim. Biophys. Acta.; 1999, 
1420, 111 to see Figure 9. 
 
 
 
Figure 9: 
2 
Binding of nisin Z (    ) and [Glu-32]-nisin Z (   ) to lipid vesicles with 
different DOPG/DOPC ratios at constant nisin: phospholipids molar ratio of 1:25. 
Graph adapted from R. Brasseur et al. 
67 
 
1.2.4. Membrane insertion of nisin 
 
Breukink et al. 
66 
injected
 
nisin Z underneath monolayers made up of DOPG and DOPC 
mixtures.  The changes in surface pressure were measured to analyze the ability of nisin to 
insert into the lipid part of the membrane. For efficient insertion of nisin Z into the 
monolayer, the presence of DOPG in the monolayer is essential.  
 
After the initial binding of nisin to the membrane the insertion into the lipid phase is then  
facilitated by the amphiphilic properties of the peptide. Monolayer studies 
2, 66 
show anionic 
phospholipids are essential for effective insertion. Changes to the C-terminus do not affect 
the insertion, 
2, 66 
however changes to the N-terminus drastically reduced the ability of nisin to 
insert into the lipid monolayer. This shows that the N-terminal part of the nisin inserts into 
the lipid phase of the membrane. Molecular hydrophobicity potential calculation of nisin 
42 
 
shows that the N-terminus of nisin is most hydrophobic (Figure 10). 
2, 67, 68
 It is this 
hydrophobic interaction which plays a key role for the insertion of the N-terminus of nisin 
into the lipid phase of the membrane. 
2, 67 
 
 
The hydrophobic side of nisin is inserted into the outer leaflet 
69
 of the bilayer by the 
amphiphilic properties of the peptide. Van de Hooven et al. 
70
 described the interaction 
between nisin and cellular membranes; they report that nisin is located at the surface of 
zwitterionic dodecylphosphocholine (DodPCho) and the anionic sodium dodecylsulphate 
(SDS) micelles. It was found that residues Ala3 – Ala19 except Ile4 of the N-terminal form 
the hydrophobic region which is immersed below the charged surface of the micelles. The C-
terminal residues Lys22, Ala23, Ala26 and His27 are positioned on one side resulting in the 
hydrophilic part, residing at the charged surface of the micelle. Residues Met21, Ala24, 
Ala25 and Ala28 are on one side forming the hydrophobic part of the C-terminal which is 
immersed in the hydrophobic interior of the micelle. From these observations it was 
concluded that in these model membranes nisin is localised on the surface of the micelles 
with the hydrophobic residues immersed below the surface and the more polar or charged 
residues orientated outwards.   
 
Nisin variants containing fluorescent tryptophan residues at three different positions, 1, 17 
and 32, were used 
2
 to determine the positions of the three tryptophan residues in the 
membrane by measurement of the tryptophan fluorescence quenching by spin labelled lipids 
and to study the insertion step. The C-terminal tryptophan was located near the membrane 
surface whilst the N-terminal tryptophan had the deepest location within the membrane.  
 
Please see: E. Breukink, B de Kruijff; Biochim. Biophys. Acta.; 1999, 1462, 223 
And L. Lins, P. Ducarme, E. Breukink, R. Brasseur; Biochim. Biophys. Acta.; 1999, 
1420, 111 to see Figure 10. 
 
Figure 10: 2 Molecular hydrophobicity potential (MHP) around nisin which is 
represented in creatine phosphokinase (CPK). Green envelopes represent hydrophilic 
potentials and orange/brown envelopes, the hydrophobic ones. Picture adapted from R. 
Brasseur et al. 
67
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1.2.5. Pore formation
 
 
The antimicrobial activity of nisin arises from pore formation in the cytoplasmic membrane 
of the target bacteria. Aggregation of peptides in the membrane results in pore formation and 
this has been demonstrated using model vesicles. 
66 
 
 
1.2.6. Models for nisin membrane interactions 
 
Two mechanisms for pore formation have been postulated: the “Barrel-stave’’ model 71 and 
“wedge’’ model. 72 Nisin has both water solubility and membrane binding properties which 
are required for both models.  
 
When considering pore formation model according to the “barrel-stave” model a hydrophilic 
surface is required for the water soluble nisin monomer. A conformational change is 
postulated to take place after the initial binding of the monomer to the membrane exposing 
hydrophobic sites. Interactions then take place between the hydrophobic lipid cores of the 
membrane with the non-polar side chains of the peptide. A water-filled pore is then formed as 
several nisin molecules aggregate with their hydrophilic side-chains pointing inward. 
 
The “wedge” 72 model suggests the pores are formed by the destabilisation of the lipid bilayer 
as a result of amphiphilic molecules adhering to the surface of the membrane.  
 
Montville and Chen 
73 
proposed two models of barrel-stave and wedge model (Figure 11). 
Both models propose that through some degree of electrostatic interaction nisin initially binds 
to the target membrane where the model shows that N-terminus is initially coming into closer 
proximity to the inner leaf of the membrane. The two models B and C show the binding 
positions of nisin and the proton motive force enhancing (B) and mediating (C) nisin 
insertion and pore formation into the membrane.     
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Please see T. J. Montville, Y. Chen; Appl. Microbiol. Biotechnol.; 1998, 50, 511 to see 
Figure 11. 
 
 
 
 
Figure 11: Models for nisin pore formation. (A) Peptide showing N and C terminal 
domains with hydrophobic face shaded white and hydrophilic face shaded dark. (B) 
Barrel-stave model. (C) Wedge model. Model shows interaction of the C and N terminus 
of nisin with the lipid bilayer, insertion then aggregation to form pores. In both cases of 
the model the hydrophilic face of nisin molecule faces the lumen of the pore. Picture 
adapted from T. J. Montville and Y. Chen. 
73
  
 
1.3. Interaction of nisin with lipid II 
 
An important step forward in understanding the mode of antibacterial action of nisin was the 
discovery that lipid II plays a key role (Figure 12). 
74 
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Figure 12:
 
Structure of lipid II.  
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Lipid II is a component of the cytoplasmic membrane, and is necessary for the biosynthesis 
of the bacterial cell wall. It consists of an undecaprenyl lipid attached to a disaccharide of 
(MurNAc-GlcNAc). A pentapeptide, L-Ala-D-Glu-L-Lys-D-Ala-D-Ala is also attached at the 
MurNAc (Figure 12). 
 
1.3.1. Lipid II-Nisin interaction 
 
Somner and Reynolds 
75
 showed that nisin sensitivity of intact cells decreased when the 
biosynthesis of lipid II was blocked with ramoplanin (Figure 14 step B). The activity of nisin 
was measured by monitoring CF leakage from a model membrane composed of DOPC to 
which increasing amounts of pure lipid II were added. Nisin-induced CF leakage was 
detected at concentration of 1 M in the absence of lipid II, whereas in the presence of lipid II 
the CF leakage was detected at 1nM. 
76
  
 
This indicates that nisin has a high affinity for lipid II, and nisin activity is dependent on lipid 
II concentrations ranging from 0.001 to 0.1 mol %. 
76
 This suggests that different 
concentrations of lipid II in the membrane of different bacteria cause nisin to display diverse 
activity. In addition, accessibility of lipid II for nisin in intact cells should also be considered. 
76
    
1.3.2. Mechanism of nisin-lipid II pore formation 
 
Hasper et al. 
74 
used pyrene fluorescence spectroscopy (performed with Large Unilamellar 
Vesicles of DOPC) and CD (performed with Small Unilamellar Vesicles) to analyse the 
assembly and stability of nisin pores. The assembly of pores were formed from the 
interaction between nisin and lipid II, these pores contained a consistent structure. Maximum 
intensity of the excimer fluorescence was observed which show there are distinct amounts of 
nisin and lipid II in the pores regardless of the concentration of lipid II in the membrane and 
the distribution. Hasper et al. 
74
 also showed that there was an interaction between two 
pyrene-labelled lipid II molecules with one pore complex. There was no discrimination 
between the un-labelled and labelled lipid II during pore formation and that there were four 
molecules of lipid II for a pores complex. Due to a 2:1 nisin/lipid II ratio occurring at the 
excimer fluorescence it suggested that there were 8 nisin molecules and 4 lipid II molecules 
in the pores. 
46 
 
The mechanism of pore formation by nisin can be divided into steps where binding to the 
target membrane is the first step, this is followed by insertion into the lipid phase of the 
membrane which leads to the pore formation. 
2  
 
Hasper et al. 
74 
modelled formation of nisin-lipid II pores in lipid bilayer where complex A 
(Figure 13) 
74
 is formed, by the N-terminal rings A and B binding to the pyrophosphate and 
saccharide regions of lipid II. Meetings of multiple nisin and lipid II molecules at the 
interface of the bilayer form complex B. This is followed by insertion of nisin molecules into 
an orientation with respect to the membrane surface which then forms the stable pore 
complex C (Figure 13). 
74
     
 
 
 
 
Please see: H. E. Hasper, B. De Kruijff, E. Breukink; Biochemistry.; 2004, 43, 11567 to 
see Figure 13. 
 
 
 
Figure 13: Model for the formation of nisin-lipid II pores in the lipid bilayer. (A) Initial 
binding complex between nisin and lipid II. (B) Multiple meeting on surface of bilayer. 
(C) Nisin-lipid II pore (8 nisin grey oval and 4 lipid II white triangle). Picture adapted 
from Hasper et al. 
74
  
  
Stability of the nisin-lipid II pores was investigated, pores containing pyrene-labeled lipid II 
and nisin were challenged with unlabeled lipid II. There was minor decrease in the pyrene 
excimer fluorescence which indicated that the nisin-lipid II pore complexes are very stable 
and the pore complexes stayed intact. Also addition of detergents such as n-octyl-
polyoxyethylene (OPOE)
 74
 which dissolve the membrane did not affect the pore complex. 
Circular dichoroism (CD) measurements confirmed this; upon solubilisation the 
conformation of the pore complex did not change. However addition of a stronger detergent 
sodium dodecylsulfate (SDS) encourages the dissociation of the nisin-lipid II pore 
complexes. 
 
47 
 
I. Wiedemann 
77
 suggested that for the nisin-lipid II interaction a negative surface charge is 
not required.  Instead in a 1:1 stoichiometry the N-terminal of nisin bind to the carbohydrate 
moiety of lipid II. After binding, conformational rearrangement of rings A and B in the N-
terminal of nisin takes place due to the aggregation of nisin-lipid II complex. This is followed 
by the insertion into the membrane of the C-terminal of nisin by the flexible hinge region 
containing ring C. Translocation across the membrane of the C-terminal takes place allowing 
the interaction between nisin and the moiety of lipid II.  
 
1.3.3. Peptidoglycan biosynthesis cycle 
 
Lipid I and lipid II are two intermediates in the peptidoglycan biosynthesis cycle. Figure 14 
shows how the cell wall subunits are transported from within the cell to the outside of the 
cell. Lipid I is synthesised by the UDP-activated amino sugar MurNAc pentapeptide binding 
to the undecaprenylphosphate releasing UMP (Step A). Lipid II is then formed by the 
addition of the second UDP-activated amino sugar GlcNAc to the MurNAc group of lipid I 
and releasing UDP (Step B). Lipid II is then flipped from within the inner leaf of the 
membrane to the outer leaf of the membrane via an unknown mechanism (Step C). Step D 
then couples the two amino sugars and the pentapeptide to the cell wall peptidoglycan. The 
remaining undecaprenylpyrophosphate is transported back to the inner leaf of the membrane 
(Step E), followed by dephosphorylation to undecaprenylphosphate (Step F) where the cycle 
is complete and ready to start again.    
 
 
Figure 14: Schematic presentation of the role of lipid II in the cell wall biosynthesis 
cycle. Picture adapted from D. Nicolau. 
2,
 
78
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Nisin not only forms highly specific pores when it interacts with lipid II but it also inhibits 
peptidoglycan biosynthesis. Lipid II is thought to be used as a docking target by several other 
antibiotics with antimicrobial activity. 
 
Studies have shown that nisin inhibits cell wall synthesis via Lipid II binding 
79
 (Figure 15).
80
 
The cross-linked peptidoglycan network in the bacterial cell wall is prevented from forming 
by the interruption of biosynthesis when lantibiotics bind to lipid I or lipid II precursors. 
Binding prevents access to the lipid precursors by transpeptidase and transglycosylase. 
Another example of an antibiotic that kills bacteria by targeting lipid II is vancomycin which 
binds to the D-Ala-D-Ala moiety of lipid II. 
80
 Like other lantibiotics nisin competes with 
vancomycin lipid II binding. Nisin is effective against some strains resistant to vancomycin 
because it binds to a different region of lipid II. 
6, 81
   
 
 
 
 
 
Please see: B. Ostash, S. Walker; Curr. Opin. Chem. Biol.; 2005, 9, 459 to see Figure 15. 
 
 
 
 
 
 
 
Figure 15: Lipid II a specific target for a range of antimicrobial agents and their 
binding points. Picture adapted from B. Ostash and S. Walker. 
80
 
 
 
 
 
 
49 
 
1.4. Nuclear magnetic resonance studies 
 
Spectrums of nisin A and nisin Z were very similar containing the same three unsaturated 
amino acids dehydroalanine at positions 5 and 33 and dehydrobutyrine at position 2 however 
comparison of the low-field part of the H-NMR shows lack of His 27 resonances and 
additional of an Asn resonance (Figure 16). 
2, 82
 The presence of Asn in nisin Z results in a 
more polar side chain increasing solubility in aqueous solutions.  
 
 
 
 
Please see: J. W. M. Mulders, I. J. Boerrigter, H. S. Rollema, R. J. Siezen, W. M. de 
VOS; Eur. J. Biochem.; 1991, 201, 581 to see Figure 16. 
 
 
 
 
 
 
 
 
Figure 16:
 
NMR analysis of nisin A and nisin Z. (A) 
1
H NMR of nisin A at pH 3.6 (B) 
1
H 
NMR of nisin Z at pH 3.3. Spectra adapted from W. M. De Vos et al. 
17
     
 
The solution structure of nisin has been determined (Figure 17) 
3
 using NMR spectroscopy 
3 
in the presence of dodecylphosphocholine (DPC) and sodium dodecyl sulphate (SDS) 
micelles which mimic the cellular membrane. 
77, 83, 84 
The studies
 
have shown that the 
structure of nisin has two well-defined domains. The N-terminal domain consists of residues 
1-19 and the three lanthionine rings A, B and C. Residues 23-28 form the second domain 
consists of ring D and E and the C-terminal residues. 
66 
The N-terminus of nisin recognises 
and specifically binds to lipid II, which is followed by pore formation by nisin and this is 
mediated by the C-terminus. 
2
 Nisin appears to have a double mode of action where both 
termini appear to participate in antibacterial action. Residues 20-22 are known as the flexible 
50 
 
hinge region that allows rotational movement (Figure 7) and separates the two domains. 
Hinge regions are often found in antimicrobial peptides and affect their activity, though it is 
not clear how. 
 
 
 
 
 
 
 
 
 
Please see: C. Chatterjee, M. Paul, L. Xie, W. A. van der Donk; Chem. Rev.; 2005, 105, 
633 to see Figure 17. 
 
 
 
 
 
 
 
 
 
Figure 17: (A) A NMR structure of nisin in the presence of DPC micelles. 
84
 Here the 
molecule adopts an extended conformation with the N and C termini curling back 
toward each other. turn conformation is enforced by the four amino acid rings B, C, D 
and E, which is also adopted by the residues 21-24 in a non-covalent manner. (B) Same 
view points as in part A with the A ring in blue, B ring in yellow, C ring in cyan and the 
fused D and E rings in orange. Picture adapted from Chatterjee et al. 
3
 
 
Hsu et al. 
81
 used a lipid II variant 3LII, an analogue with a short prenyl tail of three isoprene 
units instead of 11 to determine the structure of the complex of nisin with lipid II in DMSO. 
This analogue was used to eliminate multiple of alkyl peaks and make lipid II more water 
51 
 
soluble. DMSO was used as a membrane mimic due to the dielectric constant  = 47.2 lying 
between water  = 80 and that of the interior of the membrane = 2-4. From NOE spectral 
data two intramolecular hydrogen bonds were identified which involved the amide groups of 
Dhb2 and Abu8 of nisin and the pyrophosphate moiety of 3LII. It was also observed a cage 
like structure was formed due to the N-terminal of nisin folding back onto the first two 
lanthionine rings A and B during binding to 3LII (Figure 18 A).
 81
 All side chains, except the 
part of the lanthionine ring linkage Ala3 and Ala7, reside on the rim of the binding cleft. Five 
intramolecular hydrogen bonds were allowed to be formed between the backbone amides of 
nisin and the pyrophosphate group (Figure 18 B). 
81 
 
 
                
 
Please see: S. T. D. Hsu, E. Breukink, E. Tischenko, M. A. G. Lutters, B. De Kruijff, R. 
Kaptein, A. M. J. J. Bonvin, N. A. J. Van Nuland; Nat. Struct. Mol. Biol.; 2004, 11, 963 
to see Figure 18. 
 
 
 
Figure 18: Structure of nisin 3LII complex. Picture adapted from Hsu et al. 
81 
 
From the structure it can be seen that nisin-lipid II recognition is determined by interaction of 
the N-terminal of nisin with MurNAc, pyrophosphate and the first isoprene in lipid II. This 
explains earlier observations such as: 
  
i) Kuipers 
49
 generated nisin mutants with additional residues at the N-terminus and found 
that this reduces the antimicrobial activity. ii) Lipid II binding affinity of nisin was reduced 
when at the side chain of Ala3, S3T-nisin a extra methyl group was introduced whereas there 
was little effect when a similar addition was carried in position 2, Dhb2. 
77
 iii) Ala5-nisin was 
biologically inactive when ring A was opened by hydrolytic cleavage.  
 
The interface model of the complex explains the 3 observations above. i) Interfacial 
complimentarity may be affected by the extension of the N-terminal as Ile1 side chain of the 
N-terminal is part of the interface (Figure 18 A). ii) Intermolecular hydrogen bond formation 
52 
 
is sterically hindered by the additional methyl group in S3T-nisin (Figure 18 B, green arrow). 
iii) Due to ring opening the rigidity of the structure is lost and the intermolecular hydrogen 
bond between Dha5 and the pyrophosphate moiety is destabilised. 
81 
    
Lipid II is a specific target which nisin uses for its antimicrobial activity and this is found in 
all eubacterial membranes, 
74, 76, 79 
where it transports peptidoglycan subunits. Nisin 
permeabilise the membrane and forms pores when it binds to lipid II, resulting in the collapse 
of the vital ion gradient across the membrane. Lipid II binding also interferes with cell wall 
synthesis as the peptidoglycan transport is disrupted. Thus in order for nisin to act as an 
antibiotic the formation of the pores is not essential but increases the efficiency of bacterial 
killing. 
74
  
 
1.5. Nisin fermentation and isolation 
 
The nisin producing organism Lactococcus lactis subsp. Lactis is cultured in milk or whey, 
63
 
in pH-controlled batch fermentation.  
 
Demirci et al. 
86
 cultured Lactococcus lactis subsp. Lactis in a medium containing glucose, 
yeast extract, peptone, KH2PO4, NaCl and MgSO4.7H2O, per litre of deionised water which 
was adjusted to pH 6.8 with 4 M NaOH. This is then stored at 4 °C and subculturing is 
carried out monthly to maintain viability. 
 
Ardine Z, Sensient Bionutrients and peptone which are less expensive industrial yeast 
extracts were used and the glucose concentration was increased to 80 g/L for the fermentation 
medium. The indicator microorganism Micrococcus luteus (ATCC 10240) was used for 
analysing fermentation samples of nisin. M. luteus was grown in a Micrococcus luteus 
medium containing peptone, yeast extract, glucose and NaCl. M. luteus was maintained in 
Agar slants containing Bacto agar and Micrococcus luteus medium. The stock slants are then 
stored at 4 ºC and subculturing is carried out weekly. 
 
 
They used Celligen Cell Culture fermenter for batch fermentation. Plastic composite support 
discs (PCS) containing defatted soybean flour, polypropylene, yeast extract, soybean hulls 
and bovine albumin was added to the reactor vessel along with PCS rings both different in 
53 
 
size in 430 cm
3
. Everything was sterilised, different media concentrations were used to test, 
glucose and nitrogenous components, mineral salts were added to the reactor after being 
sterilised separately and then inoculation with an overnight culture of L. lactis was carried 
out. The broths from fermentations were agitated without aeration at constant 30 °C and 
controlled pH. Samples were taken and analysed for nisin activity. 
86
  
 
1.6. Actagardine 
 
Actagardine (formerly called gardimycin) is a Type B Class II lantibiotic produced by 
fermentation of Actinoplanes strains ATCC 31048 and ATCC 31049 and has good activity in 
bacterial infections in mice coupled with low acute toxicity. It contains 19 amino acids and 
has a molecular mass of 1873 Daltons. Actagardine has a globular structure which consists of 
two domains that are joined between residues 6 and 7 (Figure 19 and 20).  
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Figure 19: Structure of actagardine. 
 
Three small stranded -sheets are formed by residues 7-8, 9-12 and 17-19, with two parallel 
and one anti parallel strand. One Lan ring is found in the N-terminal domain whilst the C-
terminal domain contains three MeLan rings. The thio-ether bridges impart a large degree of 
rigidity and the two domains are in an L-shaped planar arrangement due to van der Waals 
interaction. 
3
 The thio-ether bridges, Glu11 and Ser2, form a hydrophilic pocket. 
3
 The thio-
ether bridge between residues 14-19 and the backbone amide loop form a second pocket 
(Figure 20). 
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Please see: N. Zimmermann, G. Jung; Eur. J. Biochem.; 1997, 246, 809 and C. 
Chatterjee, M. Paul, L. Xie, W. A. van der Donk; Chem. Rev.; 2005, 105, 633 to see 
Figure 20 
 
 
 
 
 
 
 
 
Figure 20: (A) Stereoview NMR structure of actagardine reported by Jung and 
Zimmermann. 
87
 (B) View of actagardine in the same orientation as A with rings 
highlighted and side chains removed. Ring A in blue making up the first domain, 
domain two is highlighted by magenta formed by ring B (green), ring C (red), and ring 
D (purple). Adapted from Chatterjee et al. 
3
    
 
1.6.1. Lipid II binding 
 
Actagardine also forms a complex with lipid II. This does not result in pore formation but 
results in slow cell lysis by blocking the incorporation of lipid II into peptidoglycan. 
69 
 
 
It is believed that actagardine interferes either during transfer of the pentapeptide to the 
polysaccharide chain after synthesis of the disaccharide or the cross linking stage of the cell 
wall synthesis, as it draws out the growth of UDP-MurNAc-pentapeptide. 
88
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1.6.2. Synthetic modification of actagardine 
 
Malabarba et al. 
89 
synthesised chemical derivatives of actagardine (Figure 21). Selected 
amines were reacted with actagardine in DMF in the presence of diphenylphosphorylazide 
and triethylamine (Table 2). 
89
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Figure 21: Chemical structure of actagardine. 
 
NHCH2CH2NH2                                                 H                                           H                                         10
NH(CH2)4NH2                                         H                                           H                                         10
NH(CH2)3N(CH3)2.HCl                                   H                                            H                                         52
      CH2CH2NH2
N                                                             H                                           H                                         15
      CH2CH2NH2
   
       CH2CH2N(CH3)2   
N                                                             H                                           H                                         10
       CH2CH2N(CH3)2
N N CH3                                        H                                           H                                         43
N N H                                            H                                           H                                          15
N N H                                            H                                         20
N N
H2
C
H                                            H                                         44
NHC2H5                                                NHC2H5                                  H                                        88     
NHCH2COOC2H5                                 NHCH2COOC2H5                   H                                        76
H                                                           H                                             CO(CH2)14CH3                  60
9
10
11
12
13
14
15
16
17
18
19
20
Compound        R                                                 R'                                          R"                                     Yield (%)
 
 
Table 2: 
89
 Derivatives of actagardine. 
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Similar antibacterial activity to that of actagardine was obtained for all compounds apart from 
the N-acyl derivative 20, which showed negligible activity.  
 
1.6.3. Actagardine fermentation and isolation 
 
Actinoplanes liguriae ATCC 31048 strain produce actagardine, 
90 
Actinoplanes liguriae 
ATCC 31048 strains was used to inoculate a seed medium
 
containing agar.  The seed medium 
solution contained starch; peptone, glucose, yeast extract and corn steep liquor in water. The 
medium was first sterilised by autoclaving this was followed by inoculation of the seed stage 
medium with plugs from a culture plate. This was then used to inoculate a nutrient medium 
containing glycerol, casein peptone, K2HPO4, NaCl and MgSO4.7H2O. These cultures were 
incubated followed by isolation of pure actagardine. 
5 
The purification involved passing the 
filtered fermentation broth through a column and then combining the active fractions, 
concentrating in vacuo and then freeze drying. 
 
Actagardine can be extracted as a free acid or as a sodium salt from the culture filtrate due to 
it being an amphoteric peptide with overall negative charge. 
91
 The isolation is carried by an 
extraction of the culture broth with butanol at pH 8. Dialysis of a 10 % aqueous solution of 
the crude material led to purification. 
91
  
 
When the same fermentation process was used with soya meal/mannitol production medium 
instead of the nutrient culture an additional lantibiotic, Ala(0)-actagardine was formed. 
87
 The 
new compound was isolated by solid phase extraction, molecular sieve chromatography and 
preparative HPLC. 
5
 The molecular mass for the new isolated compound was 1960 Dalton 
(Figure 22). It has greater antimicrobial activity than the parent actagardine. 
5 
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Figure 22: Structure of actagardine and the new isolated product Ala(0)-actagardine. 
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1.7. Mersacidin 
 
Mersacidin (Figure 23) (formerly named M87-1551) is isolated from Bacillus HIL Y-85-
54728. 
92
 Mersacidin has significant in vivo efficiency against methicillin-resistant 
Staphylococcus aureus MRSA, 
93 
curing infections in mice
 
and abscesses in rats and also 
removes MRSA in a mouse rhinitis model.  This makes it a potential candidate as a 
therapeutic agent. It is a tetracyclic Type B lantibiotic with broad in vitro activity against 
Gram positive bacteria. It consists of 20 amino acid residues with a molecular weight of 1825 
Dalton. It contains three methyllanthionines, one dehydroalanine and one S-aminovinyl-2-
methylcysteine residue 6 (Figure 1). It carries no overall charge, does not depolarise 
membranes and has hydrophobic properties overall. 
92
 There are three domains formed by the 
thio-ether bridges residues 1-3, 4-12 and 13-20 (Figure 24). 
3
 There are only two charged 
groups, namely Glu17 and the N-terminus, and the sequence consists mainly of neutral side 
chains. In the second domain residues 4-12 contain glycine-rich sequences which gives some 
conformational flexibility whilst the third domain residues 13-20 results in backfolding and 
rigidity of the structure. There are intramolecular hydrogen bonds between domain one 
residues 1-3 and domain three residues 13-20. 
3, 94 
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Figure 23: Structure of mersacidin. 
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Please see: S. T. Hsu, E. Breukink, G. Bierbaum, H.-G. Sahl, B. De Kruijff, R. Kaptein, 
N. A. Van Nuland, A. M. Bonvin; J. Biol. Chem.; 2003, 278, 13110 and C. Chatterjee, M. 
Paul, L. Xie, W. A. van der Donk; Chem. Rev.; 2005, 105, 633 to see Figure 24. 
 
 
 
 
Figure 24: (A) Stereoview structure of mersacidin. (B) View of mersacidin in the same 
orientation of A with rings highlighted and side chains removed. 
95
 Ring A in blue, ring 
B in red, ring C in green and ring D in magenta. Picture adapted from Chatterjee et al. 
3
   
 
1.7.1. Lipid II binding 
 
Like actagardine, mersacidin also inhibits peptidoglycan biosynthesis by binding to lipid II 
blocking access by transglycosylase and transpeptidase enzymes. 
96, 97
 Residues 13-18 of 
domain III of mersacidin, and the disaccharide region and maybe the pyrophosphate moiety 
of lipid II appear to be involved during mersacidin lipid II binding. 
96
 From an NMR study it 
was found that residues 12 and 13 Ala and Abu between rings B and C act as a hinge region 
which allows the charged side chains of mersacidin to interact with lipid II. 
95 
Mersacidin 
does not form pores in the bacterial membrane. 
3 
 
 
1.7.2. Synthetic modification of mersacidin 
 
A mutagenesis approach was used to investigate the structure activity relationship. Mutants 
F3L, S16I and E17A were developed by Szekat 
98
 and were either found to be weakly active 
or inactive. Appleyard et al. 
99 
investigated a large number of mutants consisting of three 
libraries where amino acids were inserted, substituted or deleted (Figure 25 and 26). 
99 
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Please see: A. N. Appleyard, S. Choi, D. M. Read, A. Lightfoot, S. Boakes, A. Hoffmann, 
I. Chopra, G. Bierbaum, B. A. M. Rudd, M. J. Dawson, J. Cortes; Chem. Biol.; 2009, 16, 
490 to see Figure 25. 
 
 
 
 
Figure 25: Mersacidin substitution library, circles represents variants. Pink circles 
represent mersacidin, purple circles are variants produced at high yields and blue 
circles represent variants produced at trace levels. Picture adapted from Appleyard et 
al. 
99 
 
 
 
 
Please see: A. N. Appleyard, S. Choi, D. M. Read, A. Lightfoot, S. Boakes, A. Hoffmann, 
I. Chopra, G. Bierbaum, B. A. M. Rudd, M. J. Dawson, J. Cortes; Chem. Biol.; 2009, 16, 
490 to see Figure 26. 
 
 
 
 
Figure 26: Mersacidin insertion library, arrows show where amino acids were inserted, 
circles are the variants inserted. Pink circles represent mersacidin, purple circles are 
variants produced at high yields and blue circles represent variants produced at trace 
levels. Picture adapted from Appleyard et al. 
99 
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From the study it was discovered that ring A cannot be extended or mutated. However ring B 
is open to both insertion and substitution but it is not flexible at positions near the ring 
forming residues. It was found that mutants with some activity were associated with those of 
ring B but mutants with activity were spread throughout the molecule. Deletion were not 
accepted as products were not formed, suggesting that the biosynthetic enzymes cannot 
process substrates which contain fewer amino acid residues.  It was found that changes to 
Glu17, Leu5 and Ile19 abolished all activity indicating that these residues were vital for 
activity (Figure 27). 
100
 Most variants formed were less active than the parent mersacidin.     
 
 
 
 
 
 
Please see: A. C. Ross, J. C. Vederas; J. Antibiotics.; 2011, 64, 27 to see Figure 27. 
 
 
 
 
 
 
Figure 27: Mutants and structure activity relationship of mersacidin. Active mutants 
are placed above mersacidin structure with inactive below. Insertion of amino acids are 
shown by arrows and residues vital to activity are shown in red bordered lines. Picture 
adapted from Ross and Vederas. 
100 
 
1.7.3. Mersacidin fermentation and isolation 
 
Bacillus sp. was isolated from a soil sample. The first step involved sterilising the seed 
medium containing casamino acid, corn steep liquor, galactose and glycerol in demineralised 
water by autoclaving. The seed stage medium was inoculated with plugs from a culture plate 
with Bacillus sp. This was followed by preparation of the seed culture. 
41 
The second step 
involved sterilising the medium containing sucrose, KH2PO4, Na2HPO4, (NH4)2SO4, Na-
61 
 
glutamate, MgSO4.7H2O, MnSO4.H2O, (NH4)6Mo7O24.4H2O, ZnSO4.7H2O and FeSO4.7H2O 
in a fermenter. This was then inoculated with the seed medium from step 1.  
 
More medium was sterilised in step 3 same as in step 2 and then this was used to inoculate 
with the seed culture from step 2. 
41
     
 
Centrifugation separated the culture broth from the mycelial cake after 45 hr of harvesting. 
Mersacidin was found in the culture filtrate which was passed through a resin column. 
Activity against S. aureus 209P was monitored with the fractions collected, fractions with 
mersacidin was reduced to give crude mersacidin. 
41 
 
Medium pressure liquid chromatography was carried out on crude mersacidin. The eluant 
with mersacidin was reduced and columned again as above giving semi pure sample which 
was purified further by precipitation giving pure mersacidin.          
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
2. Synthesis of lantibiotics 
 
There are advantages in carrying out chemical synthesis of lantibiotics; as this enable changes 
to be made to the peptide sequence of nisin. These changes can include the incorporation of 
additional amino acids, unusual amino acids such as cystathione and changes in the 
stereocentres of the lanthionine. Fluorophores and isotopic labels can be introduced which 
will enable additional NMR studies of lantibiotics such as nisin and give more information on 
the mode of action.  
 
Incorporation of lanthionine as a novel conformational constraint in other biologically active 
peptides leads to peptides with one or more thio-ether bridges. These confer stability to 
proteolytic cleavage, and cannot be reductively cleaved, whereas conformationally 
constrained peptides containing Cys-S-S-Cys bridges are generally not stable in vivo. Due to 
these properties many medicinally related peptides have had lanthionine analogues 
incorporated in them to obtain biologically active thio-ether bridged peptidomimetics. 
101, 102
  
 
Synthesis of lanthionine residues with the correct stereochemistry at the  positions (and  
positions in the case of the -methyl lanthionine) is important and essential. It is also 
important for regioselective cyclisation of the peptide to take place. 
 
There are two approaches which can be considered for the synthesis of lantibiotics, the first 
approach involves making the linear precursor first and then cyclise to form lanthionine or 
methyllanthionine generating the thio-ether bridges. Whilst the second approach involve 
making the key bis-amino acids, lanthionine and methyl lanthionine first and then 
incorporating them into the peptide. 
 
2.1. Solution phase synthesis 
 
Shiba et al. 
103
 synthesised nisin which was identical to the naturally occurring peptide giving 
10 % overall yields. Shiba’s group used solution phase synthesis to assemble the Cys-Cys 
bridged analogues of the individual segments: ring A, ring B, ring C, and rings D and E by 
condensation of the four main segments. Desulfurisation was carried out to convert these 
63 
 
lanthionine bridged segments which was followed by dehydration, forming the Dha and Dhb 
residues. Segment couplings of the protected fragments were than carried out in solution to 
give the desired peptide. 
       
2.1.2. Total synthesis of nisin via desulfurisation 
 
T. Shiba et al. 
103 
first carried out desulfurisation with hexaethylphosphorus triamide to form 
all the thio-ether bridges. This allowed the formation of the optically pure lanthionine by 
selective removal of the sulphur atom from the appropriate cystine. This was an approach 
used for the preparation of lanthionine by Harpp and Gleason. 
104
  
 
2.1.2.1. Desulfurisation of the cystine to form the lanthionine 
 
Harpp and Gleason 
104
 found that aminophosphines can effect selective desulfurisation in 
simple disulfide systems giving monosulfide compounds. However methyl or ethyl ester 
protection was required on cystine derivatives as carboxylic groups react with the 
aminophosphine (Scheme 1). 
104
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R1HN CO2R2
NHR1CO2R2
S
R1HN
CO2R2 NHR1
CO2R2(Et2N)3P
+     (Et2N)3P O 
 
Scheme 1: 
104
 Desulfurisation of cystine to form the lanthionine. R1 = COCF3 or 
CO2CH2C6H5 and R2 = CH3 or C2H5. 
 
When this method was used to desulfurise unsymmetrical substituted disulfides, byproducts 
were obtained (Figure 28). 
S S
S
R2R1
R1 R1 SR1 R2 SR2 R2 
 
Figure 28: Three lanthionine products synthesised from desulfurisation of 
unsymmetrically substituted cystine.  
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This method was adapted by Cavalier-Frontin et al. 
105
 who modified the method in order to 
synthesise the unsymmetrical lanthionine 23 from cyclic cystine 21 (Scheme 2). 
105 
Desulfurisation was carried out on the cyclic cystine where the two amino groups were 
protected with different protecting groups. Saponification of 22 led to the unsymmetrical 
meso-lanthionine 23.  
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Scheme 2: 
105
 Desulfurisation of an unsymmetrical substituted cystine. 
 
2.1.2.2. Synthesis of ring A fragment 
 
Shiba et al. 
103 
had to resolve two problems during the synthesis of nisin; this involved the 
introduction of the dehydramino acids and the formation of the sulfide ring. These problems 
were solved by carrying out desulfurisation of cyclic disulfide peptides as they judged that it 
was easier to form the S-S bond than to carry out cyclisation via the amide bond.
 
   
Shiba et al. 
106 
investigated the methodology for preparing the lanthionine moiety in a cyclic 
peptide. Linear peptide 24 was prepared containing two cysteine residues. 
106
  
 
COOMe
H
HN O
H
HN
O
NHCbz
N
H
O
NH
H H
BocHN
H
O
SAcm
STrt
COOMe
H
HN O
H
HN
O
NHCbz
N
H
O
NH
H H
BocHN
H
O
S
S
24                                                                25
I2/MeOH
      
COOMe
H
HN O
H
HN
O
NHCbz
N
H
O
NH
H H
BocHN
H
O
S
P(Et2N)3
26  
COOH
H
HN O
H
HN
O
N
H
O
NH
H
H2N H
O
S
Meso Lanthionine
     
Ala
Ile Dha
Leu
Ala
S             
COOMe
H
HN O
H
HN
O
N
H
O
NH
H
BocHN
H
O
S
27
H2/Pd
HCHO, NaBH3CN
CH3I/KHCO3
 
 
Scheme 3: Synthesis of protected ring A of nisin via desulfurisation. 
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The peptide was then cyclised to give peptide 25; the oxidation proceeded smoothly to give 
the disulfide product. Tris(diethylamino)phosphine in DMF was used for desulfurisation of 
25 to give peptide 26 without the formation of any dehydroalanyl peptide. The desulfurisation 
step was attempted in other solvents such as CHCl3, THF, dioxane, and benzene however 
these solvents resulted in forming the dehydroalanine derivative as the major product due to 
intramolecular elimination (Scheme 4 b). 
106
 Desulfurisation was followed by removal of 
the Cbz group of the diaminopropionic acid (Dpr) sidechain. N-methylation was then carried 
out immediately. Conversion of the A2pr residue to dehydroalanine was achieved by the 
addition of 1-1.5 equivalent of MeI in DMF in the presence of KHCO3. This gave the desired 
dehydroalanyl peptide 27, ring A of nisin (Scheme 3). 
106
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Scheme 4: 
106 
Mechanism for desulfurisation. 
 
It was important to make sure that dry solvents were used during desulfurisation as otherwise 
side reactions occurred (Figure 29). Solvents used for the desulfurisation of each ring 
depended on the substrate, where DMF was used for the formation of Boc-(ring A)-OMe, 
106 
benzene for Boc-(ring B)-OMe 
107
 and Boc-(ring D and E)-OMe, 
108
 and THF for Boc-(ring 
C)-OMe. 
109
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Figure 29: Mechanism for the competing formation of a phosphoramidate byproduct. 
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2.1.2.3. Synthesis of ring B fragment 
 
Ring B of nisin was synthesised using the above method, by elimination of one sulphur atom 
from the cysteine and threo-3-methyl-D-cysteine sulphide bonds. 
107
 The reaction of ring B of 
nisin (Scheme 5) was carried out in benzene which gave a better yield than it did in DMF.  
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Scheme 5: 
107
 Formation of protected ring B of nisin via desulfurisation.  
 
In order for the desulfurisation of peptide 28 to take place to form ring B (peptide 29); it was 
important that the threo form of methyllanthionine found in wild type nisin was obtained. 
The threo form of methyllanthionine was achieved by keeping the configuration on the -
carbon of threo-3-Methyl-D-cysteine (Scheme 6 a). 
107
 If the mechanism of the reaction 
proceeded via path b, erythro-methyllanthionine will be obtained as a result of the inversion 
of configuration on the -carbon of 3-methylcysteine (Scheme 6 b). 
107
 It was found that path 
a of Scheme 6 takes place, this could possibly be due to a selective nucleophilic attack taking 
place at the sulphur atom of D-cysteine residue because of the steric hindrance of the 3-
methyl group in the threo-3-methyl-D-cysteine. Another reason could be due to the thiolate 
anion of cysteine residue being less stable than the thiolate anion of 3-methylcysteine residue. 
Shiba et al. 
110
 confirmed the formation of threo-methyllanthionine by carrying out amino 
acid analysis of the hydrolyzate of 29. 
110
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Scheme 6: 
107
 Desulfurisation pathways of ring B. 
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2.1.2.4. Synthesis of ring C fragment 
 
The same methodology was used to synthesise ring C of nisin (Scheme 7). The naturally 
occurring threo- -methyl lanthionine residue was again synthesised from threo-3-methyl-D-
cysteine, during desulfurisation the reaction proceeded in the configuration-retaining route. 
109 
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Scheme 7: 
109
 Formation of protected ring C of nisin via desulfurisation. 
 
2.1.2.5. Synthesis of rings D and E fragment 
 
Rings D and E of nisin are the most complicated rings to synthesise, due to the two 
overlapping disulfide bridges of the unique bicyclic structure. Two methods were used to 
synthesise rings D and E. The first method involved a one step desulfurisation, this facilitated 
the formation of the two sulphide rings from the bis-disulfide peptide. The advantage of this 
method is it requires less reaction steps however there is the possibility for rearrangements of 
the rings to take place during the desulfurisation step (Figure 30 method A). 
108
 The second 
method involved a stepwise construction of the two rings (Figure 30 method B). 
108
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Figure 30:
 
Two possible methods for the synthesis of rings D and E. Picture adapted 
from Shiba et al. 
108 
 
The synthesis started with the preparation of linear peptide 32. Iodine oxidation of 32 gave 
the disulfide peptide 33. Deprotection of the S-Trt group was carried out by iodine oxidation 
in the presence of CF3CH2OH in CH2Cl2. 
108
 Dipeptide 33 was then elongated to give 
hexapeptide 34. During this coupling step an active reagent benzotriazole-l-yl diethyl 
phosphate (BDP) was used, this was to avoid the steric influence in cyclic sulfide or disulfide 
peptide which will cause a slow rate in the coupling reaction. During this step the Ts 
protecting group is removed, which has to be reintroduced with tosyl chloride and 
triethylamine once the coupling reaction is complete. 
108
 The second disulfide ring was 
formed by a second iodine oxidation, simultaneously removing the Trt and Acm groups and 
cycling to form peptide 35. Then using P(NEt2)3 in a one step desulfurisation reaction the 
bicyclic sulfide rings 36 were obtained in benzene (Scheme 8). 
108
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 Scheme 8: Protected rings D and E of nisin synthesised by desulfurisation via synthetic 
strategy path A (Figure 30). 
 
For comparison of the two routes, the stepwise construction of the two rings D and E were 
carried out. The cyclic sulfide peptide ring E 37 was obtained after the first desulfurisation of 
disulfide peptide 33 in anhydrous benzene. Elongation was carried out on the cyclic peptide 
to give the hexapeptide 38 this was followed by iodine oxidation of 38, removing the S-Trt 
and S-Acm group and simultaneously forming the bicyclic peptide 39. The desired peptide 36 
ring D was then formed by the second desulfurisation (Scheme 9). 
108
 Both desulfurisation 
steps resulted in very low yields, due to formation of multiple oligomers.     
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Scheme 9: Protected rings D and E of nisin synthesised by desulfurisation via synthetic 
strategy path B (Figure 30). 
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From the two routes it was found that the first route (Scheme 8) 
108
 gave better results. This 
can be concluded from the fact that less reaction steps were required, the yields obtained from 
the desulfurisation were much higher and it was much easier to carry out elongation of the 
peptide. Low yields were obtained by the second route (Scheme 9) due to oligomers being 
produced. 
108
  
 
2.1.2.6. Fragment Coupling 
 
A segment condensation method was used by Shiba et al. 
103
 in the total synthesis of nisin 
(Scheme 10). The five cyclic segments were synthesised separately as described above, 
carbodiimide and copper (I) chloride (II) 
111
 were used to dehydrate the threonine to Dhb of 
segment I (Scheme 11). The segments were then coupled together as shown in Scheme 10.    
 
In the previous study a methyl ester derivative 
107 
was used for the synthesis of ring B 
(Scheme 5), it was found that this decomposes very easily under saponification conditions 
due to which benzyl ester derivatives were preferred. 
103 
The structures of the synthetic 
intermediates were confirmed by comparing with enzymatic (a part of trypsin digestive 
fragment) and BrCN degradation products of natural nisin. 
103
 
 1
H NMR, FAB mass spec and 
retention time in HPLC confirmed that synthetic nisin was identical to natural nisin. 
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Scheme 10: Total synthesis of nisin by coupling the five fragments of nisin. 
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Scheme 11: Dehydration of serine and threonine to Dha and Dhb. 
 
2.2. Biomimetic synthesis of lantibiotics 
 
Individual rings of lantibiotics have been synthesised by different groups using a biomimetic 
approach (Figure 31, Scheme 12). This synthetic approach mimics the lantibiotic biosynthetic 
pathway that takes place by extensive posttranslational modification by specific enzymes 
which catalyses the dehydration of Ser and Thr residues by genes NisB and NisC discussed in 
Chapter 1, Section 1.1.4. Michael addition of cysteine residues to dehydroamino acids lead to 
the formation of thio-ether bridges. Studies on biomimetic additions of cysteine residues to 
Dha and Dhb have shown formation of diastereoisomers as the reaction is not stereospecific. 
112
 Thus the regio- or stereoselectivity of the cyclisation step is difficult to control in the 
absence of the biosynthetic enzymes. 
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Figure 31: Biomimetic synthesis of lanthionine-bridged peptides. 
 
Bradley et al. 
112 
isolated mixtures of diastereoisomers resulting in no stereocontrol 
demonstrating this approach is not stereospecific (Scheme 12). 
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Scheme 12: 
112
 Lanthionine synthesis via Michael addition. 
 
Bradley et al. 
113
 developed a synthetic methodology to allow synthesis of peptides 
containing multiple dehydro amino acids, which can be used for the biomimetic synthesis of 
lantibiotic subunits. Incorporation of multiple dehydro amino acids were achieved by 
synthesising peptides with S-methylcysteine which undergoes oxidation/elimination reaction. 
Dehydroalanine residues were generated within a linear peptide this was followed by a 
Michael addition of cysteine sulfhydryl to form the thio-ether bridge which produced the 
lanthionine bridged cyclic peptides (Scheme 13). 
    
They undertook the synthesis of subunits of subtilin. For example ring B was synthesised 
from peptide 51 (Figure 32). The cyclisation proceeded in 50mM triethylammonium acetate 
(pH 8) (Scheme 13) 
113 
to
 
give the single stereoisomer which was confirmed by NMR and 
HPLC analysis. There was complete consumption of starting material under 10 min shown by 
UV/VIS analysis. The same stereoselectivity was observed for ring E.  
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Scheme 13: 
113
 Biomimetic synthesis of ring B of subtilin. 
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51 = B - ring precursor
54 = E - ring precursor
55 = A - ring precursor 
 
Figure 32: Precursors of rings A, B and E. 
 
In the same way, ring A (Figure 32) was synthesised. Cyclisation was carried out on the 
crude peptide due to the problems of stability of the linear precursor peptide. However, two 
products in a ratio of 3:1 were produced. NMR studies showed the structures to be stereo-
isomers rather than regio-isomers. TOCSY experiments confirmed that each product was a 
single diastereoisomer, and that regioselective Michael addition has occurred on Dha2, giving 
natural regioisomer of the subtilin ring A (Scheme 14) as a mixture of diastereoisomers. 
113
  
 
There was a possibility of the cyclisation taking place at residue 4 however addition to this 
dehydroamino acid was not detected. 
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Scheme 14 
113
 Subtilin ring A. 
 
Zhu et al. 
114 
carried out a biomimetic approach investigating the stereochemistry of (non-
enzymatic) intramolecular Michael additions producing lanthionines and methyllanthionines. 
From the previous studies it has been seen that biomimetic intramolecular conjugate additions 
from cyclic thio-ethers often have the same stereochemistry as those found in lantibiotics. 
75 
 
They attempted to explore the regiochemistry of the formation of rings A and B of nisin by 
the use of solid phase reaction conditions. Dehydroamino acids were incorporated by 
oxidative elimination methodology from selenocysteine derivatives. Zhu et al. 
114 
found that 
the attempt to synthesise rings A and B of nisin did not give the desired product. This was 
due to Cys11 reacting with Dha5 forming a six residue lanthionine ring, forming nisin with 
different rings (Scheme 15). 
114
 Diastereoisomers and constitutional isomers were formed 
which was shown by LC-MS analysis. Resonances of the Dhb vinyl protons were present in 
the product whilst the vinyl protons of Dha were absent. Enzymatic control 
114
 is thus 
required for regioselectivity of the cyclisation reactions. This approach is therefore an 
unsuitable method for multiple thio-ether bridged ring synthesis. 
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Scheme 15:
 114
 Synthesis of rings via biomimetic approach. 
 
In order to probe the receptor binding selectivity of enkephalin mimics, Goodman et al. 
115
 
synthesised a conformationally constrained analogue of enkephalin 62 with a lanthionine ring 
between residues 2 and 5 (Figure 33, Scheme 16) using a biomimetic approach. This peptide 
contains one ring containing one dehydroamino acid and only one diastereoisomer was 
76 
 
obtained which meant the peptide was stereospecific. Michael additions are not normally 
stereoselective however the steric hindrance provided by the solid support adjacent to the SH 
is responsible for the diastereoselectivity of this reaction.       
HO
H NH2
O
HN
H
O
S
H
N
O
N
H
H2NOC H
NH
O
H
62  
Figure 33: Structure of an analogue of enkephalin. 
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Scheme 16: 
115
 Synthesis of enkephalin analogue 62. 
 
2.3. Solid phase synthesis 
 
An alternative approach for the synthesis of both naturally occurring lantibiotics and 
analogues with different sequences and ring sizes is to incorporate suitably protected 
lanthionine derivatives into a precursor linear peptide, using solid phase peptide synthesis. If 
suitable protecting groups are chosen, the lanthionine residue can be selectively deprotected 
77 
 
and the peptide cyclised as required, leading to the synthesis of lanthionine containing 
peptides with complete regio- and stereocontrol. 
 
2.4. Synthesis of lanthionine 
 
2.4.1. -Alanyl cation equivalent 
 
Incorporation of lanthionine building blocks that are orthogonally protected was an 
alternative strategy in synthesising these lantibiotic peptides. Retrosynthetic analysis of 
lanthionine suggests that reaction of a -alanyl cation equivalent and a cysteine thiolate anion 
could be used to form both lanthionine and methyllanthionine (Scheme 17). 
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Scheme 17: Reterosynthesis of lanthionine and methyllanthionine. 
 
A good leaving group at the  position would allow SN2 nucleophilic substitution by cysteine 
to form lanthionine. This includes ring opening of serine -lactones, 
116, 117, 118
 aziridines, 
119, 
120
 cyclic sulfamidates 
121
 and  iodoalanine. 
122, 123, 124 
 
 
2.4.2. Sulfamidates as -alanyl cation equivalent 
 
Nucleophiles can stereo- and regioselectively open sulfamidates, which are useful synthetic 
building blocks for the synthesis of lanthionines. 
121, 125
 Vederas 
121
 obtained stereochemically 
pure orthogonally protected lanthionine 67 and methyllanthionine 71 (Scheme 18), by using 
protected cysteine 68 as a thiol nucleophile which reacts with the cyclic sulfamidate 69 or 72. 
78 
 
Competing elimination reactions can take place by the attack on the sulphur nucleophiles on 
the sulfamidates; this can be prevented by blocking the  positions. 
125 
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Scheme 18: Synthesis of lanthionine and methyllanthionine using cyclic sulfamidate. 
 
Vederas 
121
 first attempted these reactions using Fmoc-Cys-OtBu as a thiol nucleophile which 
gave mixtures of products leading to unsuccessful reactions. This could possibly be due to the 
Fmoc group being unstable under the basic conditions used. Smith and Goodman 
117
 observed 
similar problems when they attempted ring opening of -methyl-D-serine -lactone with 
Fmoc-Cys-OMe and Cs2CO3. 
 
2.4.3. -Bromoalanine derivatives as -alanyl cation equivalent 
 
Zhu and Schmidt’s 102 strategy involved using -bromoalanine derivatives and phase transfer 
catalysis (PTC) to synthesise protected lanthionine. -bromoalanine derivatives have high 
reactivity towards nucleophiles under mild basic conditions.  
 
A quantitative yield of (2S, 6R) meso lanthionine 76 was obtained by coupling bromide 74 
with Boc-Cys-OBn 75. The coupling was carried out in the presence of tetrabutyl ammonium 
hydrogensulfate in ethyl acetate and aqueous solution of NaHCO3 at pH 8.5 (Scheme 19).  
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Scheme 19: Synthesis of lanthionine using -bromoalanine. 
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This strategy did not lead to elimination followed by Michael addition and therefore no trace 
of the opposite diastereoisomer was detected.  
 
Other groups had problems using the above methodology. When VanNieuwenhze 
118
 
attempted synthesising -methyllanthionine via this strategy, byproduct 79 was produced 
(Scheme 20). Protected methyl cysteine 77 was S-alkylated with carbamates similar to 74 to 
give lanthionine 78. The competing elimination reaction was observed due to the reduced 
nucleophilicity of the methyl cysteine which is more sterically hindered. VanNieuwenhze 
118
 
optimised the conditions including the use of aqueous Cs2CO3 however the dehydroalanine 
byproduct was still produced.    
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Scheme 20: Synthesis of lanthionine using bromoalanine. 
 
The nature of the protecting groups present on the cysteine is very important for this reaction. 
N. I. Martin 
126 
used ivDde protecting group to synthesise a tetra orthogonally protected 
lanthionine. An Fmoc protected -bromoalanine was reacted with ivDde-cysteine this 
produced the desired product (Scheme 21). It was found that the nucleophile TMSE protected 
cysteine 83 gave better yields than the allyl protected cysteine 82.   
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Scheme 21: Lanthionine formation via bromoalanine. 
 
Bromination of 86 to synthesise bromoalanine 87 formed the undesired dehydroalanine 
product due to the competing elimination reaction occurring. When mesylation of 86 was 
carried out followed by S-alkylation this resulted in racemisation at the C2 position of the 
lanthionine to give 91 (Scheme 22). 
80 
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Scheme 22: Formation of lanthionine via bromoalanine. 
-chloroalanine was also used as a -alanyl cation equivalent this was reacted with cysteine 
thiolate by Vigneaud et al. 
127 
to synthesise lanthionine. Racemisation of the lanthionine took 
place due to strong base and harsh conditions being used. Dha was formed via the elimination 
reaction followed by Michael addition with cysteine (Scheme 23). 
128
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Scheme 23: Racemisation of lanthionine. 
 
2.4.4. Iodoalanine derivatives as -alanyl cation equivalent 
 
Dugave and Menez 
122
 have shown that trityl protection of -iodoalanine prevents -proton 
abstraction. It can be removed selectively in the presence of other protecting groups and it 
protects the -ester from saponification. The  proton abstraction is prevented due to the 
trityl group being electron donating compared to protecting groups such as Boc. This makes 
the C less acidic preventing dehydration.  
 
The study focused on N-trityl-3-iodoalanine benzyl ester 97 that have good reactivity towards 
heteroatom nucleophiles. Iodide 97 is substituted by L-cysteine to give the lanthionine in 
good yields in the presence of some aziridine (Scheme 24). 
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Scheme 24: Synthesis of lanthionine using iodoalanine. 
 
Iodine substitution with thiolates is a good yielding strategy where the trityl group prevent 
epimerisation of the stereogenic centre, giving the orthogonally protected lanthionine 
stereoselectively. They reported that the 
1
H NMR of
 
the N-trityl iodoalanine 97 and the 
lanthionine 99 had two sets of signals, but attributed this to the presence of two rotamers. 
 
However Tabor et al. 
129
 have shown that the strategy used by Dugave and Menez 
122
 reacting 
alanyl -cation equivalent and cysteine is problematic. Synthesis of iodoalanine using this 
strategy produced two products. The major product synthesised was the undesired 
regioisomer -iodo- -alanine 100 (Figure 34) which may have been formed by the aziridine 
intermediate, and the minor product being the desired  iodoalanine. 
 
TrtHN
I COOAllyl
HA
HB2
HB1
I
TrtHN COOAllyl
HA
HB1
HB2
S
COOtBuTrtHN
H H
COOAllyl
NHFmoc
S
COOHAlocHN
H H
COOAllyl
NHFmoc
AllylOOC S
COOtBu
H
NHFmoc
HB1
HB2TrtHN
HA
100                           101                             102                                           103
                                                                     104  
Figure 34: Structures of desired iodoalanine, lanthionine and undesired iodoalanine and 
lanthionine. 
 
Two isomers were also seen by Dugave and Menez 
122 
when synthesising iodoalanine 101 but 
this again was attributed to the presence of rotameric forms of iodoalanine. Tabor et al. 
129
 
used the published route, 
121
 they reacted the iodoalanine with Fmoc-Cys-OtBu in the 
presence of Cs2CO3 to give lanthionine 102. This was followed by trityl deprotection then 
Aloc protection which were then followed by tert-butyl ester deprotection to give the 
orthogonally protected lanthionine 103. Two sets of signals were observed from the 
1
H NMR 
82 
 
for 102 which was also seen by Dugave and Menez 
122 
however multiple isomers were seen 
after removal of the bulky trityl group and replacement of the Aloc group. After preparative 
HPLC purification two distinct isomers were obtained. The major product was identified as 
being the nor-lanthionine 104 formed from the -iodo- -alanine and the minor product being 
lanthionine 102 (Scheme 31). 
     
2.4.5. Aziridine as -alanyl cation equivalent 
 
Nakajima et al. 
119
 reacted cysteine derivative with aziridine 105 a or methyl substituted 
aziridine 105 b to synthesise lanthionine 107 a and Methyllanthionine 107 b in low yields 
(Scheme 25). 
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Scheme 25: Synthesis of lanthionine from aziridine. 
 
Shiba et al. 
110
 used (2S, 3S) and (2S, 3R)-3-methyl-D-cysteine protected derivatives 108 a 
and 108 b with -chloroalanine 109 in D or L form, to form the meso lanthionine. The 
lanthionine was then treated with hydrogen bromide in glacial acetic acid to synthesise 
methyllanthionine 110 which gave four diastereoisomers (Scheme 26).  
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Scheme 26: Synthesis of methyllanthionine using -chloroalanine. 
 
83 
 
2.4.6. -Lactone as -alanyl cation equivalent 
 
Vederas et al. 
130
 and Goodman et al. 
116
 used protected cysteine residues to open serine -
lactones (Scheme 27) to give lanthionine derivatives in moderate yields. 
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Scheme 27: Synthesis of lanthionine using -lactone. 
 
The advantage of this method is that the opening of the -lactones leads to stereochemically 
pure compounds however the yield obtained was low. Better yields were obtained in the 
synthesis of 3,3-dimethyllanthionine using the same methodology but in the presence of -
methyl-D-serine -lactone 
117
 (Scheme 28).  
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Scheme 28: Synthesis of methyllanthionine using -lactone. 
 
2.5. Solid phase peptide synthesis of lantibiotics 
 
Solid phase peptide synthesis (SPPS) involves the synthesis of a peptide on an insoluble 
support. The advantage of this method is that any unreacted reagents left at the end of each 
synthetic step can be removed by a simple wash procedure. The method relies on having the 
α-amino group protected with an Fmoc group, and any reactive side chains orthogonally 
protected using Boc or tBu protecting groups. The first amino acid is coupled to a linker resin 
by the carboxylic acid. The Fmoc group is then deprotected leaving a free amino group. This 
free amino group is then coupled to a second protected amino acid and this repeats to form a 
sequence. After the desired sequence is produced the peptide is cleaved off the resin (Figure 
35).  
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Figure 35: Solid phase peptide synthesis. 
 
2.5.1. On resin cyclisation 
 
On resin cyclisation is advantageous due to the “pseudodilution” effect. The risks of 
intermolecular reactions are reduced as there are large distances between the growing chains 
on the solid support. 
131
 Usually it is good to use low or medium loading as this increases the 
distance between the growing chains.  
 
2.5.2. Peptide cyclisation on an oxime resin (PCOR) 
 
Polystyrene-bound oxime esters used as supports in SPPS were first developed by DeGrado 
and Kaiser. 
132
 Oxime resins can only be used for Boc methodology as the secondary amines 
used in Fmoc methodology to cleave the Fmoc group can also cleave the growing peptide 
from the oxime resin. 
85 
 
After the synthesis of the linear peptide TFA is used to cleave protecting groups such as Boc 
and tBu, any remaining TFA is neutralised by DIPEA. 
133
 Acetic acid is then used to 
simultaneously catalyse cyclisation followed by cleavage off the peptide from the resin.  
 
Goodman et al. 
101
 synthesised thio-ether bridged analogues of somatostatin using a 
cyclisation method on an oxime resin followed by condensation reaction. They used an 
orthogonally protected lanthionine 116. The peptide synthesis was carried out using Boc 
chemistry and BOP activation. The lanthionine was coupled using BOP and DIPEA. Acetic 
acid catalysis was used to carry out cyclisation after the Boc group was deprotected from the 
lanthionine and then simultaneously release of the peptide from the resin was carried out. 
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Scheme 29: 
101 
Synthesis of sandostatin an analogue of somatostatin.  
 
Deprotection reactions were then carried out in solution, HBr/acetic acid was used to 
deprotect the benzyloxycarbonyl groups from the N-terminus and the bzl groups. Elongation 
of the peptide was carried out by coupling Cbz-DPhe-OH. The methyl ester group was 
hydrolysed and then the remaining protecting groups were deprotected to give 121 (Scheme 
29). 
101
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2.5.3. Orthogonally protected lanthionines 
 
Mustapa and Tabor 
82, 129
 required orthogonally protected lanthionine 103 (Figure 36) for the 
solid phase peptide synthesis of lanthionine containing peptides. They chose to use Dugave 
and Menez 
122
 approach based on the generation of an alanyl β-cation. This route appeared to 
be advantageous as it was direct and high yielding.  
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Figure 36: Structures of lanthionine. 
 
During the synthesis problems occurred due to which a full investigation was carried out on 
the regio and stereo chemical outcome of the reaction between cysteine and iodoalanine.  
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Scheme 30: Orthogonally protected lanthionine. 
 
Nucleophilic reaction is known to be most successful at the β-position of serine when the 
amino group is trityl protected. Serine was therefore converted to 122. This was mesylated to 
give 123 and reacted with NaI to give 101 (Scheme 30). 
82
 From this methodology two 
distinct peaks were observed in the proton NMR of the purified product 101. This was 
attributed by Dugave and Menez 
122
 to two rotameric forms of the iodoalanines being present. 
VT experiments of 102 at temperatures up to 100 
o
C showed no coalescence of the signals, 
which indicated that the two sets of signals seen in the 
1
H NMR spectrum of 102 did not arise 
from the presence of two
 
rotamers.  
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However, it was established that, in fact an intermediate aziridine 124 is formed during the 
synthesis of 101, and under these reaction conditions it reacts further to form 100 (Scheme 
31).
 82 
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Scheme 31: Aziridine formation. 
 
2.5.3.1. Lanthionine synthesis via Mitsunobu reaction 
 
It was found that the reaction of aziridine 124 with Fmoc-Cys-OtBu does not lead to either 
the correct or the incorrect ring-opened product. Therefore it was important to find a way to 
make compound 101 with minimal aziridine formation with no excess I 
–
 present to ring-open 
124 if it is formed. This was done by an alternative synthesis of 101 using the Mitsunobu 
reaction. The reaction is carried out at low temperature making trityl-β-iodoalanine without 
forming the undesired major isomer. This is then used for the synthesis of the protected 
lanthionine (Scheme 32). 
124
  
  
TrtHN COOAllyl
H
OH
TrtHN COOAllyl
H
I
101
MeI, PPh3, DEAD,
CH2Cl2
Fmoc-CysOtBu,
Cs2CO3, DMF
TrtHN
COOAllyl
S
NHFmoc
COOtBu
HH
102
AlocHN
COOAllyl
S
NHFmoc
COOtBu
HH
TFA/CH2Cl2,
Aloc-Cl, 
NaHCO3,
H2O/Dioxane
125
AlocHN
COOAllyl
S
NHFmoc
COOH
HH TFA/CH2Cl2
103
122
 
Scheme 32: 
124
 Orthogonally protected lanthionine. 
 
In this route the production of the undesired regio-isomeric α-iodo-β-alanine was avoided. It 
reduced the formation of aziridine dramatically however there were traces of it during 
purification. Lanthionine 102 was obtained by reaction of 101 with Fmoc-Cys-OtBu in the 
presence of Cs2CO3 giving 102. Removal of the trityl group and replacement with the Aloc 
88 
 
group afforded 125 which were followed by removal of tBu ester to give the desired 
lanthionine 103. 
 
2.5.4. Solid phase peptide synthesis of lantibiotics 
 
Bregant and Tabor 
124 
used Fmoc chemistry to incorporate the orthogonally protected 
lanthionine 103 into an analogue of ring C of nisin. The linear peptide 126 was first 
assembled manually on the resin using HBTU and DIPEA to pre-activate and couple the 
Fmoc protected amino acid. Each amino acid coupling was followed by capping with 
acetylimidazole and deprotected by 20% piperidine in DMF (Scheme 33).
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Scheme 33: Analogue of ring C of nisin. 
 
89 
 
With palladium (0) the Aloc and allyl protecting groups were removed. Intramolecular 
cyclisation was carried out by using PyAOP/HOAt after the removal of Fmoc group. The 
peptide was cleaved off the resin and purified by HPLC.  
 
2.6. Lacticin 3147 
 
Lacticin 3147 is a two-component lantibiotic consisting of two posttranslationally modified 
peptides A1 and A2 (Figure 37). 
134
 The lantibiotics individually are very weak antimicrobial 
peptides, however they have strong antibacterial action synergistically. 
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Figure 37: 
134
 Structures of Lacticin 3147 components A1 and A2. The bis(desmethyl) 
lanthionine analogue (R=H) of lacticin A2 is Lan-A2. 
 
A three component complex is formed, as follows: Lacticin 3147 A1 first binds to lipid II 
135
 
followed by recognition of the complex by A2 resulting in the formation of pores in the cell 
membrane.  
 
Vederas et al. 
134
 used solid phase methods to synthesise an analogue of A2 where the two -
methyllanthionine rings were replaced with lanthionine rings forming bis(desmethyl) lacticin 
3147 Lan-A2 (Figure 37), using orthogonally protected lanthionine 103.  
 
103 was first attached to chlorotrityl chloride resin by reacting partially capped resin with 
lanthionine and DIPEA to give 129. A low loading resin (0.16 mmol g
-1
) was used to prevent 
any intermolecular coupling and crosslinking complications which could otherwise take place 
after the deprotection of the carboxyl and amino group of the lanthionine. Fmoc peptide 
90 
 
synthesis was carried out for the elongation of the peptide to obtain 130 using PyBOP 
coupling reagent. Deprotection of Aloc/allyl protecting groups were carried out using Tabor 
et al‘s 86 methodology using [Pd(PPh3)4] and PhSiH3. Once the Aloc and allyl groups of 130 
were deprotected, Fmoc deprotection followed by cyclisation using PyBOP/HOBt was 
carried out to give ring C of 131. The linear sequence was continued followed by another 
Aloc/allyl deprotection to give ring B 132. The same methodology was used to synthesise 
ring A giving 133 and then further elongation was carried out by SPPS. Residues 1-5 135 was 
synthesised in solution which was then coupled to the peptide followed by cleavage of the 
peptide of the resin to give Lan-A2 (Scheme 34). 
110  
 
Removal of the methyl groups prevented biological activity thus losing its independent 
antimicrobial activity.  
 
2.7. Lactocin S 
 
Lactocin, a 37 residue lantibiotic, 
136 
is isolated from Lactobacillus Sakei. Vederas et al. 
136 
recently presented the synthesis of the natural lantibiotic. Amino acid 136 was synthesised in 
solution, whilst the rest of the residues 3-37 were synthesised on solid support using Fmoc 
SPPS. They coupled the orthogonally protected lanthionine to the 2-chlorotrityl chloride 
resin. The linear sequence was carried out followed by Fmoc deprotection, Aloc/allyl 
deprotection using [Pd(PPh3)4] and PhSiH3, and then cyclisation with PyBOP and HOBt to 
give ring B. Elongation between rings A and B were completed by SPPS which included 
coupling a second Aloc/allyl lanthionine which was deprotected after Fmoc deprotection and 
then cyclised to give ring A. Further elongation was carried out giving peptide 140 to which 
136 was coupled. The peptide was then cleaved to give lactocin S (Scheme 35). 
136
  
 
The inhibition growth of Pediococcus acidlactici was similar for both the natural and 
synthetic peptide lactocin S however there was no antibacterial activity against L. Sakei L45 
the producer organism by either peptide.   
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Scheme 34: 
110
 Synthesis of lacticin. 
92 
 
BocHN
O
N
H O
OH
136  
 
O
O
FmocHN
S
NHAloc
O
AllylO
1. SPPS
2. Pd(PPh3)4, PhSiH3
3. 20 % Piperidine
O
O
S
NH2
O
HO
Ala
HisHisLys
Ala
NH2
PyBOP, HOBt, NMM,
DMF, 2 x 2 hr
O
O
Ala
HisHisLys
Ala
D-AlaH2N
S
**
*
*
* *
1. SPPS
2. Lanthionine, PyBOP,  HOBt, NMM
3. SPPS
4. Pd(PPh3)4, PhSiH3
5. 20 % Piperidine/DMF
6. PyBOP, HOBt, NMM, 2 x 3 hr
7. SPPS
O
O
Ala
His
His
Lys
Ala
D-Ala
S
*
* *
Tyr
Lys
Phe
Ala
Gly
AlaValAsp
D-Ala
S
Tyr
Leu
Val
D-Ala
Ala
Thr
Pro
Leu
Leu
Glu
Met
Leu Val
D-Ala
Ala
Val
Ala
Val
D-Ala
*
*
*
*
*
*
Pro
NH2
3
10
20
30
37
B
B
A
1. 136, PyBOP, HOBt, NMM, 2 x 3 hr
2. TFA/H2O/anisole (95/2.5/2.5 %), 2 hr
O
O
Ala
His
His
Lys
Ala
D-Ala
S
*
* *
Tyr
Lys
Phe
Ala
Gly
AlaValAsp
D-Ala
S
Tyr
Leu
Val
D-Ala
Ala
Thr
Pro
Leu
Leu
Glu
Met
Leu Val
D-Ala
Ala
Val
Ala
Val
D-Ala
*
*
*
*
*
*
Pro3
10
20
30
37
B
A
Dhb
O
O
137                                                         138                                                        139
140
Lactocin S
 
 
Scheme 35: 
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 Synthesis of lactocin S. 
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2.8. Project outline 
 
The initial aim of this project was to prepare hybrid lantibiotics by a combination of novel 
peptide synthesis techniques and bioengineering. Complementary techniques of solid phase 
peptide synthesis and biosynthesis would have been used to produce hybrid lantibiotics. The 
C-terminal of nisin (the pore forming region) produced by solid phase synthesis, would have 
been coupled with the lipid II binding lantibiotic mercasidin or actagardine, produced by 
fermentation.  
 
This would give further insights of the role of each subsection of the original molecule; it 
may also lead to discovery of more potent and selective antibacterials, and may lead to hybrid 
lantibiotics.  
 
Therefore it was important to synthesise an analogue of rings D and E of nisin 141 residues 
22-29 (Figure 38, 39) using protected lanthionine building blocks. The synthesis of 
orthogonally protected lanthionines, 103 and 169 was initially required.  
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The aim was then to incorporate both protected lanthionines in a linear peptide precursor by 
solid phase synthesis. Deprotection of the two protecting groups of the first lanthionine, 
followed by on-resin cyclisation would then be carried out selectively with the protecting 
groups on the second lanthionine unaffected. In addition, the protecting groups for both 
lanthionines had to be stable to both acid and base (Figure 39).  
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Figure 38: Analogue of rings D and E of nisin. 
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Figure 39: Strategy for synthesising rings D and E. 
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3. Synthesis of orthogonally protected lanthionine 
residues 
 
This chapter focuses on the synthesis of the orthogonally protected lanthionine 103 
containing Aloc/allyl protecting groups and the orthogonally protected lanthionine 169 
containing Teoc/TMSE protecting groups. The synthesis of an analogue of the overlapping 
rings D and E of nisin, using these lanthionine building blocks, will be discussed in chapter 4.  
 
3.1. (Aloc, allyl) / (Fmoc, OH) lanthionine 103  
 
S
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O O
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O
O
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Stable to Acid,Base
and TBAF
H H
O O
Alloc    =
Allyl     =
 
 
3.1.1. Aloc/allyl lanthionine residue  
 
To synthesise (Aloc, allyl) / (Fmoc, OH) lanthionine 103, the route developed by Bregant and 
Tabor, 
124
 via -iodoalanine 101, was used. Scheme 36 shows the planned route for the 
synthesis of (Aloc, allyl) / (Fmoc, OH) lanthionine which will be discussed in this section. 
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Scheme 36: Planned route for the (Aloc, allyl) / (Fmoc, OH) lanthionine. 
 
3.1.1.1. Synthesis of protected cysteine 
 
To synthesise the protected cysteine 90 three different reactions were carried out. The 
reactions involved the synthesis of tert-butyl protected cysteine which was followed by Fmoc 
protection and then cleavage of the disulfide bond. 
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Scheme 37: Synthesis of Fmoc-Cys-OtBu. 
 
L-cystine was converted to the bis-tert-butyl ester using tert-butyl acetate (Scheme 37). 
Purification was not required at this stage as 
1
H NMR showed that the product 145 obtained 
was pure. It was important to make sure that the next reaction was carried out quickly to 
avoid degradation of the compound which was visible by the change of colour.   
 
Perchloric acid has a pKa of -7.0 and is therefore highly corrosive, furthermore there is a high 
risk of explosion of metal perchlorates. For a safer approach the protection of the carboxylic 
acids were first attempted using sulphuric acid. 
137
 However previous work 
137
 in the group 
had shown that the thiol group was also protected in the reaction giving 149 (Scheme 38).  
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Scheme 38: Synthesis of thiol protected cysteine. 
 
M. F. A. Groussier 
137
 then attempted the reaction with S-tert-butylthiocysteine. Here the 
thiol group was first protected to avoid tBu protection of the thiol. tBu protection of the acid 
was then carried out this was followed by Fmoc protection of the free amine. These steps 
proceeded in high yields; however the final step involving the disulfide cleavage to give the 
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free thiol gave low yields. One of the major problems in this step was the formation of tert-
butyl thiol as a byproduct which was difficult to separate during purification (Scheme 39).   
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Scheme 39: Synthesis of Fmoc-Cys-OtBu. 
 
The free amine of t-butyl protected cysteine was Fmoc protected with Fmoc-Cl in the 
presence of N-methylmorpholine (Scheme 37). Recrystallisation from CH2Cl2: methanol did 
not give the pure product 146. Instead 
1
H NMR spectroscopy showed the presence of Fm-OH 
which recrystallised from the quenching of the excess reagent. Due to this purification by 
flash column chromatography was carried out in hexane and ether.  
 
The final reaction involved the cleavage of the disulfide bond of cystine with tributyl 
phosphine (Scheme 37). It was found that addition of excess water after the addition of 
tributyl phosphine made the cleavage step more effective. The reaction was described as “wet 
THF” by Dugave and Menez 122 however it was found that higher yields were produced with 
a large excess of water in a ratio of 9:1 THF: water. The mechanism below shows how water 
plays a key role in this reaction (Figure 40). Product 90 was obtained as a white solid after 
purification by flash column chromatography. 
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Figure 40: Mechanism for the disulfide cleavage. 
 
3.1.1.2. Synthesis of iodoalanine 
 
In order to synthesise the protected lanthionine, β-iodoalanine 101 was also required. The 
iodoalanine was synthesised from D-serine using experimental procedures developed 
previously. 
82, 124, 129 Synthesis of the β-iodoalanine also involved 3 reactions, trityl protection 
of the amino group, allyl protection of the carboxylic group and the synthesis of the desired 
iodoalanine via Mitsunobu reaction. 
 
3.1.1.2.1. Synthesis of trityl serine 
 
OH
H2N COOH
H
OTMS
TMSHN COOTMS
H
OTMS
H2N COOTMS
H
MeOH (1 equiv)
Et3N (1 equiv),
Trt-Cl (1 equiv),
20 hr
OH
TrtHN COOH
H
CH2Cl2,
Me3SiCl (3.1 equiv), 
20 min,
Et3N (3.1 equiv), 45 min
143
88 %
0 oC,
 
Scheme 40: Synthesis of trityl serine. 
 
The synthetic route to the iodoalanine required the carboxylic acid and the amino group to be 
differentially protected. The ‘one pot’ approach of Barlos et al. 138 was used to selectively 
protect the amine with a trityl group in the presence of the -OH and carboxylic groups. In this 
reaction all functional groups are initially protected with trimethylsilyl chloride. This was 
followed by selective deprotection of the amine using 1 equiv of methanol, followed by 
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addition of the trityl group to the free amine. The final step of the reaction involved addition 
of excess triethylamine and methanol. This was to remove the trimethylsilyl group from the 
carboxylic acid and alcohol. 
 
3.1.1.2.2. Synthesis of allyl iodoalanine 
 
OH
TrtHN COOH
H
143
MeOH,
CsCO3 (0.5 equiv),
15 min
OH
TrtHN COO  Cs
H DMF,
Allyl bromide (0.95 equiv),
14 hr
OH
TrtHN
H
O
O
122
73 %
CH2Cl2,
PPh3 (1.5 equiv), 10 min,
- 10 oC, DEAD (1.5 equiv),
1 min,
MeI (1.5 (equiv), - 2 oC, 3 hr
I
O
O
N
H
Ph
PhPh
101
45 %  
Scheme 41: Synthesis of iodoalanine 101. 
 
The next step involved esterification of 143 to give 122. Addition of allyl bromide to the salt 
resulted in allyl protection of the carboxylic acid (Scheme 41) in good yield. 
139 1
H NMR 
spectroscopy showed the product to be pure and therefore no further purification was carried 
out. Other methods such as using triethylamine as a base were previously explored however 
these only give yields less than 50 %. 
140
  
 
The key intermediate N-trityl- -iodo alanine 101 was formed by carrying out a Mitsunobu 
reaction from the alcohol 122 directly from the protected serine. In order to avoid synthesis of 
the undesired α-iodo- alanine 82 Mitsunobu reaction was carried out (section 2.5.3, Scheme 
31). 
 
The reaction proceeded under inert conditions and at low temperature. The temperature was 
kept stable using an ethanol bath refrigerated by a cryostat. Purification was carried out 
immediately to avoid aziridine formation, where the whole reaction mixture was directly 
filtered by flash column chromatography in hexane and ethyl acetate. Traces of aziridine 
101 
 
were seen in tiny amounts in the 
1
H NMR spectra. This was simply due to difficulty in 
separating iodoalanine and aziridine during purification.  
 
The reaction was found to be very low yielding, after several attempts 45 % yield was 
obtained compared to the literature yield 72 %. 
124 
This may possibly be due to the reaction 
not going to completion. Starting material 122 (Scheme 41) was easily separated by column 
chromatography which can be reused. Long reaction times and the use of polar solvents 
during purification led to the formation of the undesired aziridine. In order to minimise this 
undesirable effect, the reaction was stopped after 3 hr and a high ratio of 20: 1 hexane: ethyl 
acetate was used for the flash column chromatography.   
 
3.1.1.3. Synthesis of (Aloc, allyl / Fmoc, OH) Lanthionine 103 
+
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Cs2CO3 (0.5 equiv), 
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Scheme 42: (Aloc, allyl) / (Fmoc, OH) lanthionine. 
 
Using the published method 
124
 coupling of the protected cysteine and iodoalanine was 
carried out under inert atmosphere which led to the synthesis of lanthionine 102. 
Intermediates 90 and 101 (Scheme 42) were dissolved in DMF, followed by addition of dry 
Cs2CO3. It was very important to use very dry Cs2CO3 to avoid any Fmoc deprotection from 
the cysteine. 
116
 It was also important to carry out an extraction once the reaction was 
complete, again to avoid Fmoc deprotection. 
 
102 
 
An Aloc group was then required in the place of the trityl group. The synthetic pathway 
required the cleavage of the trityl group and replacement with an Aloc group. The 
substitution was carried out in a ‘one pot’ reaction.  
 
The trityl deprotection was carried out using TFA and triethylsilane (TES) in CH2Cl2. Here 
the TES traps the triphenylmethyl carbocation by acting as a scavenger and preventing any 
reverse reactions. 10 % TFA was used for the trityl removal which was not sufficient for the 
t-butyl deprotection. After an extraction, the reaction was carried out in dioxane and sodium 
bicarbonate; this was followed by addition of allyl chloroformate to protect the free amine 
(Scheme 42). After purification 64 % yield was obtained. TLC and 
1
H NMR spectroscopy 
showed that the reaction did not go to completion which explains the yield obtained. One 
reason could have been due to the pH of the solution being slightly acidic and not basic 
before the addition of allyl chloroformate.  
 
Many problems have been encountered in obtaining good yields. The solutions to the 
problems were carried out and the yield has been improved from initial 18 % to a 
reproducible 64 %. This involved carrying out the reaction under inert atmosphere, under 
argon and ensuring that the trityl group has been removed completely. It was also important 
that the mixture was between pH 7 and pH 8 before the addition of allyl chloroformate and 
cold temperature was essential for the reaction. Strict repetition of these precautions led to 
reproducible yields. 
 
The final step to synthesising the orthogonally protected lanthionine involved removing the 
tert-butyl group. Cleavage of the tert-butyl group was carried out using 50 % TFA in CH2Cl2 
over 3 hr and the product purified using reverse phase column chromatography, overall 
giving 69 % product. The material was then ready for incorporation into solid phase peptide 
synthesis with the desired orthogonal protecting groups in place. 
 
In summary (Aloc, allyl / Fmoc, OH) lanthionine 103 has been synthesised using the 
published procedure, 
124
 ready for incorporation into cyclic peptides using solid phase peptide 
synthesis.  
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3.2. Second lanthionine 
 
SES     =
TMSE      =
Fmoc
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Stable to acid, 
base and Pd(PPh3)4
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O
HN
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O
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O
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Figure 41: Structure of initial second lanthionine. 
 
The original aim of the project involved synthesising the second orthogonally protected 
lanthionine 153 containing 2-trimethylsilanyl-ethanesulfonic acid amide (SES) and 2-
trimethylsilanyl-ethyl ester (TMSE) protecting groups (Figure 41, Scheme 43). Silyl-based 
protecting groups are orthogonal to Aloc and allyl protecting groups. The purpose of 
choosing these protecting groups was to avoid deprotection of the protecting groups of the 
second lanthionine when Aloc and allyl deprotection was carried out. These silyl groups are 
stable to acid, base and Pd(PPh3)4, and they are selectively removed by F
-
, for example using 
tetrabutyl ammonium fluoride (TBAF). 
 
Synthesis of lanthionine 153 was planned to follow the same reaction sequence as the 
synthesis of lanthionine 103. It was envisaged that Iodoalanine 101 and cysteine 90 would be 
coupled, as before to give lanthionine 102. This would be followed by the replacement of the 
trityl group with an SES protecting group. Scheme 43 shows the planned route to the 
synthesis of the second lanthionine. 
 
SESHN
S
COOtBu
NHFmoc
COOAllyl
SESHN
S
COOtBu
NHFmoc
COOTMSE
SESHN
S
COOH
NHFmoc
COOTMSE
Orthogonally protected
Lanthionine 153
TrtHN
S
COOtBu
NHFmoc
COOAllyl
102 154
155153
H
H H
HH
H
H
H
 
Scheme 43: Planned route for synthesis of (SES, TMSE) / (Fmoc, OH) lanthionine 153. 
104 
 
3.2.1. Synthesis of 2-trimethylsilanyl-ethanesulfonyl chloride  
 
In order to synthesise the second orthogonally protected lanthionine containing the SES and 
TMSE protecting groups, it was necessary to synthesise the SES-Cl reagent, as this was not 
commercially available at the start of the project. The procedure of Weinreb 
141 
and Bregant, 
142
 using 2-(trimethylsilyl)ethane sulfonic acid sodium salt, was used to synthesise SES-Cl 
(Scheme 44). 
 
S
(H3C)3Si Cl
O O
15 min, 0 oC,
Thionyl Chloride, 0 oC, 20 min, 
DMF, 0 oC, 20 min 157
S
(H3C)3Si ONa
O O
80 %
156
 
Scheme 44: Synthesis of SES-Cl. 
 
Purification was attempted via distillation using a hot oil bath with the aid of a heat gun to 
separate the product and any remaining SOCl2. This was a problem for small scale reactions 
due to charring of the small amount of crude 157. Distillation was therefore carried out using 
a hot water bath and vacuum to give 157. Confirmation of the product was obtained by mass 
spectrometry, a peak was seen at m/z 257 [M + K]
+
. 
1
H NMR indicated the presence of 
residual DMF in the product. Attempts to remove this in vacuo led to problems, as during the 
removal of DMF an impurity was formed. Longer exposure to vacuum increased the intensity 
of the impurity peaks.  
 
The mechanism for the formation of SES-Cl by DMF catalysed reaction of the sulfonate with 
thionyl chloride is shown below (Figure 42). 
 
N
ClH
MeMe
S
(H3C)3Si
O
O
O
N
H
Me Me
S
(H3C)3Si
O
O
O + Cl
Cl
S
(H3C)3Si
O
O
Cl
157  
Figure 42: Mechanism for the formation of SES-Cl. 
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3.2.2. Synthesis of (SES, allyl) / (Fmoc, tBu) lanthionine 
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Scheme 45: Synthesis of (SES, allyl) / (Fmoc, tBu) lanthionine. 
 
With SES-Cl in hand, the synthesis of the second orthogonally protected lanthionine was 
attempted. This involved replacing the trityl group of the common intermediate 102 with the 
SES group. Several attempts were carried out to synthesise 154 using SES-Cl 157 (Table 3). 
 
In the first attempt on (Table 3, entry 1) the desired product was not synthesised, instead from 
1
H NMR spectroscopy, peaks correlating to the free amine 158 were observed.  
 
The second attempt involved reversing the order of addition, adding 2 equivalents of 
triethylamine followed by the addition of SES-Cl 157 in DMF (Table 3, entry 2). The desired 
product 154 was synthesised in 30 % yield along with the intermediate 158 in 44 % yields. 
The procedure was repeated a couple of times but the yields were variable and low. The 
reaction was attempted using 5 equivalents of SES-Cl rather than 1.5 equivalents (Table 3, 
entry 3), which gave 38 % yield, this was the best yield obtained by far however it was not 
reproducible.  
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Entry Trityl 
deprotection
/ Time 
Reaction 
solvents 
Base (equiv) SES-
Cl, 157 
(equiv) 
Reaction time 
/ temperature 
Product 
Isolated 
154 (%)  
Byproduct 
Isolated 
158 (%)     159 (%) 
1 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2) 
(1.5)  1 hr, 0 °C,  24 
hr, 5 °C 
-  38 % - 
2 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2) 
(1.5)  1 hr, 0 °C,  
24 hr, 5 °C 
30 % 44 % - 
3 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2) 
(5) 1 hr, , 0 °C,  
24 hr, 5 °C
 
 
38 % - - 
4 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2) 
(2.6) 1 hr 30 min, 
0 °C, 
1 hr 30 min, 
 5 °C, 
40 min, RT 
27 % 
 
 
45 % - 
5 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(3) 
(1.5) 24 hr, 5 °C - - 35 % 
6 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(3) 
(1.5) 24 hr, 5 °C NR * NR * NR * 
7 TFA/TES/ 
CH2Cl2, 4 hr 
1,4-Dioxane Sodium 
bicarbonate, 
(4)  
(3) 24 hr, 4 °C 26 % - - 
8 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2) 
Triethylamine, 
(2) 
(5) 
 
(5) 
3 hr, RT 
1 hr 30 min, 
RT 
35 % - - 
9 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(1.5) 
(1.6) 5 hr, 0 °C – 
RT 
12 % - - 
10 TFA/TES/ 
CH2Cl2, 4 hr 
Benzene AgCN, (1.5) (1.5) 22 hr, 60 °C - 30 % - 
11 TFA/TES/ 
CH2Cl2, 4 hr 
Acetonitrile 4-methoxy 
pyridine-N-
oxide hydrate, 
(6) 
(2)  24 hr, RT 19 % - - 
* NR : No Reaction 
Table 3: Conditions used for the synthesis of (SES, allyl) / (Fmoc, tBu) lanthionine. 
 
When 2.6 equivalents of SES-Cl were used (Table 3, entry 4), mass spectrometry and COSY 
NMR confirmed that the product was obtained in 27 % and 
1
H NMR indicated that 
intermediate 158 was isolated. Increasing the equivalents of triethylamine (Table 3, entry 5) 
resulted in base-catalysed cleavage of the Fmoc group giving 159. Hence the number of 
equivalents of the triethylamine could not be increased.  
 
There was a possibility that the low yield could be due to traces of TFA being present from 
the deprotection of the trityl group. Once excess toluene was added and removed in vacuo 3 
times followed by CH2Cl2. The residue was dissolved in CH2Cl2 and stirred with sodium 
bicarbonate for 1 hr 30 min (Table 3, entry 6). This was to remove any traces of TFA which 
could be present. The procedure for placing the SES group was the same as (Table 3, entry 
5), after purification it was discovered only starting material 102 was isolated in 90 % yield. 
107 
 
The reaction was also attempted using identical conditions to those used for the synthesis of 
(Aloc, allyl) / (Fmoc, tBu) lanthionine 125 (Table 3, entry 7). However this did not improve 
the yield, with a maximum of 26 % yield obtained. 
 
Conditions from Table 3, entry 8 were then attempted this gave 35 % yield however this was 
not reproducible. Only 12 % yield was obtained when the reaction was carried out using 
conditions from Table 3, entry 9. 
  
After several attempts of using previously prepared SES-Cl, SES-Cl became commercially 
available. All previous attempts were then repeated using the commercially available 
material. It was envisaged that the impurities that may appear due to removing DMF might 
have caused the poor yields. However this was not the case, as the reactions using the 
commercially available SES-Cl also gave very poor yields. Moreover, the 
1
H NMR spectrum 
of the commercially available reagent also showed several impurities.  
 
3.2.3. Trial protection of Met-OMe with SES-Cl 
 
SES protection of (H, allyl) / (Fmoc, tBu) lanthionine 158 does occur however in poor yields. 
To optimise protection of the free amines with SES-Cl, reactions were carried out on L-
methionine methyl ester 160 using both the commercially available SES-Cl and 157. 
 
O
O
S
NH2
H Cl
DMF,
SES-Cl,  (3 equiv),
Et3N (2 equiv),
5 hr
O
O
S
NH
S
O
O
Si
160 161
71%  
Scheme 46: Synthesis of SES-Met-OMe. 
 
Initially, L-methionine methyl ester hydrochloride 160 was dissolved in DMF; SES-Cl was 
added, followed by 2 equiv triethylamine (Scheme 46, Table 4, entry 1). The desired product 
161 was isolated in 71 % yield. Better yields were obtained when only 2 equiv of 
triethylamine was added to the reaction to synthesise 161 (Table 4, entry 1) compared to the 
synthesis of 154 (Table 3, Entry 1, 2, 3 and 4).  
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After concluding that triethylamine was not the best condition to use, attempts were carried 
out to install the SES protecting group using other conditions. Hale 
143
 found that the use of 
AgCN to introduce the SES group gave higher yields compared to the traditional amine 
catalysed protocols which lead to slower and more problematic issues of side reactions. 
 
Entry Reaction 
solvent 
Base (equiv) SES-Cl, 
157 
(equiv) 
Reaction time 
/ temperature 
Product 
Isolated 
161 (%) 
1 DMF Triethylamine, 
(2) 
(3) 5 hr, RT 71 % 
2 Benzene AgCN, (1) (1.5) 22 hr, 75 °C 42 % 
3 Acetonitrile 4-methoxy 
pyridine-N-
oxide hydrate, 
(6) 
(1.5) 24 hr, RT 45 % 
 
Table 4: Conditions used for the synthesis of SES-Met-OMe 
 
Therefore these conditions were tested on Met-OMe.HCl (Table 4, entry 2); however the 
product was isolated in only 42 % yield.  
 
The reaction was then attempted on lanthionine 102 (Table 3, entry 10). Two different 
fractions collected from chromatography were analysed. From 
1
H NMR it was observed that 
starting material 102 was isolated where the trityl group did not deprotect after exposure to 
TFA, TES and CH2Cl2. The second fraction showed intermediate 158 was synthesised. The 
two observations indicated that the reaction between the free amine and SES-Cl did not take 
place. The failure of this reaction could be due to steric hindrance or due to partial 
deprotection of the trityl group taking place. 
 
160 and 6 equivalents of 4-methoxy pyridine-N-oxide hydrate 162 were reacted in 
acetonitrile. 
144 
2 equivalents of SES-Cl were added (Table 4, entry 3) and the product 161 
was isolated by flash column chromatography in 45 % yield. 
 
The protocol was then attempted on lanthionine 102. After trityl deprotection of 102, the 
residual amine 158 and 4-methoxy pyridine-N-oxide hydrate 162 were dissolved in dry 
acetonitrile, SES-Cl was added and stirred for 24 hr. The reaction was quenched with 
saturated sodium bicarbonate which was extracted with CH2Cl2. The product was isolated via 
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flash column chromatography giving 154 in 19 % yield (Table 3, entry 11). The mechanism 
of the reaction can be seen in Figure 43. 
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Figure 43: Mechanism of SES protection. 
 
Van der Laan et al. 
144
 obtained 75 % yield for the protection of their compound. When the 
same conditions were used on methionine 45 % yield was obtained and only 19 % for the 
lanthionine. The reaction did not proceed very well possibly due to steric hindrance. 
 
From the reactions above it can be concluded that maybe the SES-Cl reagent is not reactive 
enough to be used as a protecting group for this particular amine. Also increasing the number 
of equivalents of triethylamine was problematic as this caused deprotection of the Fmoc 
group forming 159. Various reactions with different conditions were carried out, however all 
yields obtained were very poor. 
 
3.2.4. Boc Lanthionine 
 
Changes in the protecting groups were considered to avoid deprotection of the Fmoc group 
and low yield reactions. The amino group was Boc protected instead of Fmoc protection 
(Scheme 47).  
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Scheme 47: Second planned route for the (SES, TMSE) / (Fmoc, OH) lanthionine. 
 
3.2.4.1. Synthesis of (Trt, allyl) / (Boc, tBu) lanthionine 
 
O
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HN
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HN
102 163
Piperidine (20 %) , 
CH2Cl2 (80 %),
30 min,
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Scheme 48: Removal of the Fmoc group and protection with Boc group. 
 
Entry Fmoc 
deprotection 
solvents / Time 
Reaction 
solvent 
Base (equiv) Boc 
anhydride 
(equiv) 
Reaction time 
/ temperature 
Product 
Isolated  
163 (%) 
Byproduct 
Isolated 
168 (%) 
1 20% piperidine 
in CH2Cl2, 30 
min 
CH2Cl2 Sodium 
bicarbonate, 
(1.3) 
(1.3) 30 min, RT 
4 hr, RT 
 
3 % 
 
 
65 % 
2 20% piperidine 
in CH2Cl2, 30 
min 
DMF Triethylamine, 
(1.3) 
(1.3)  
4 hr, RT 
 
56 % 
 
- 
 
Table 5: Conditions used for the synthesis of (Trt, allyl) / (Boc, tBu) lanthionine. 
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Fmoc deprotection was carried out followed by Boc protection to give product 163 in only 3 
% which meant very little Boc protection took place, starting material 102 was also isolated 
in 20 % and the free amine 168 (Table 5, entry 1).  
 
Boc protection was attempted again but in DMF instead of CH2Cl2, and triethylamine was 
used rather than sodium bicarbonate (Scheme 48, Table 5, entry 2). It was found that the 
reaction works better in DMF then it does in CH2Cl2; the product was isolated in 56 % yield. 
Next SES protection on the amino group of the lanthionine 163 was carried out. 
 
3.2.4.2. Synthesis of (SES, allyl) / (Boc, tBu) lanthionine  
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Scheme 49: SES protection. 
 
After trityl deprotection, the residue was suspended in DMF to which SES-Cl was added and 
cooled to 0 ºC. Triethylamine was added and the reaction was stirred for 24 hr; further SES-
Cl and triethylamine was then added and the reaction was stirred for a further 7 hr. After 
purification 54 % yield of the desired product was obtained (Scheme 49). Comparison of the 
yields obtained by Boc and Fmoc protection, indicated that Boc protection increased the yield 
of the desired product. 
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3.2.5. Synthesis of Boc and tBu protected cysteine 
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Scheme 50: tBu and Boc protected cystine. 
 
Large amounts of Fmoc-Cl were used for the protection of the amino groups of the cysteine 
(Scheme 37). Fmoc deprotection of lanthionine 163 is required followed by protection with 
Boc group (Scheme 48), before SES protection can be carried out. In order to avoid using 
Fmoc-Cl which would be a waste during scale up and time consuming, synthesis of the Boc 
and tBu protected cysteine was carried out (Scheme 50). Compound 145 was synthesised 
from 144 using previous experimental conditions (Scheme 37). 145 were then dissolved in 
THF to which Boc anhydride was added followed by triethylamine (Scheme 50). A yield of 
98 % was obtained.  
 
Trial reactions were carried out to cleave the disulfide bond, the same conditions used for the 
formation of 90 was used (Scheme 37). From mass spectrometry and 
1
H NMR it was seen 
that mainly the starting material was recovered. The product was isolated but at a very low 
yield along with oxidised tributylphosphine (Appendix 1).  
 
At this point the SES-Cl became unavailable from the commercial suppliers and due to the 
difficulties encountered in either synthesising pure SES-Cl or in finding a reliable supplier of 
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pure SES-Cl it was decided to investigate the use of alternative silyl protecting groups for the 
-NH2. 
 
3.2.6. New silyl protecting groups 
 
O
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S
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For protection of the amino and carboxylic acid moieties, (trimethylsilyl)ethoxycarbonyl 
(Teoc) and trimethylsilylethyl (TMSE) groups were used repectively, because TBAF can 
easily remove these silyl-based protecting groups under mild conditions and at a neutral pH. 
Two reagents, 4-nitrophenyl 2-(trimethylsilyl)ethyl carbonate (Teoc-ONp) 170 and 1-[2-
(Trimethylsilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione (Teoc-OSu) 171 were used to install 
the Teoc protecting group. 
 
NO2
OO
O
170 171
N
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Si
Si
 
 
The protections were attempted on both (Trt, allyl) / (Boc, tBu) lanthionine 163 and (Trt, 
allyl) / (Fmoc, tBu) lanthionine 102 as outlined on the planned route (Scheme 51). Each 
reaction will be discussed separately in this section. 
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Scheme 51: Planned route for the (Teoc, TMSE) / (Fmoc, OH) and (Teoc, TMSE) / (Boc, 
OH) lanthionines. 
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3.2.6.1. Synthesis of (Teoc, allyl) / (Boc, tBu) lanthionine 
 
S
HN
HNO
O
Si
S
HN
HNO
O
Si
O
O
Si
O
OHN
O
O
S
OO
HN
O
OHN
O
O
S
OO
HN
102
163
56 %
Piperidine (20 %), CH2Cl2 (80 %),
30 min,
Boc2O (1.3 equiv),
Et3N (1.3 equiv),
4 hr
TFA (10 %), TES (5 %), 
CH2Cl2 (75 %), 4 hr,
H2O, Dioxane, Et3N (1.5 equiv),
Carbonic acid 4-nitro-phenyl ester 
2-trimethylsilanyl-ethyl ester (1.5 equiv)
OO
O
O
O
O
172
17 %
OO
O
O
177
41 %
H H
H
H H
H H
H
+
 
 
Scheme 52: Removal of the trityl group and protection with Teoc group of Boc 
lanthionine.  
 
Lanthionine 102 was used as a common intermediate, from which different protecting groups 
were put in place. The Fmoc group of 102 was deprotected giving a free amino group; this 
was then protected using Boc anhydride to give 163 (Scheme 52). The reaction was carried 
out in distilled water and Teoc-ONp 170 was used for Teoc protection (Table 6, entry 1). 17 
% yield was obtained for the synthesis of the desired product, it was also noticed that a 
second compound was formed. The Boc group deprotected giving a free amino group; this 
was then protected by ester 170 giving 177 in 41 % yields. The same results were obtained 
when the reaction was repeated.    
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Entry Trityl 
deprotection / 
Time 
Reaction 
solvents 
Base (equiv) Protecting group 
Teoc-ONp   Teoc-ONSu 
170 (equiv)   171 (equiv) 
Reaction time 
/ temperature 
Product 
Isolated 
172 (%) 
Byproduct 
Isolated 
177 (%) 
1 TFA/TES/ 
CH2Cl2, 4 hr 
H2O / 
1,4- 
dioxane 
aq. sodium 
bicarbonate, 
(4) 
(2) - Cool to 0 °C, 
18 hr, ≤ 4 °C 
17 % 41 % 
2 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2 drops) 
(2) - 24 hr, RT NR *
 
NR * 
3 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(2), dioxane 
(2) - 24 hr, RT - < 10 % **
 
4 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), dioxane 
(2) - 24 hr, RT - < 10 % ** 
5 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(1.5), dioxane 
(1.5) - 24 hr, RT 17 % - 
6 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(2), dioxane 
- (2) 18 hr ≤ 4 °C - < 10 % ** 
7 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), dioxane 
- (2) 18 h at ≤ 4 °C 14 % - 
8 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(1.5), dioxane 
- (1.5) 24 hr, RT 10 % - 
9 TFA/TES/ 
CH2Cl2, 4 hr 
H2O / 
1,4- 
dioxane 
aq. sodium 
bicarbonate, 
(4) 
- (2) Cool to 0 °C, 
18 hr, ≤ 4 °C 
14 % 
 
< 10 % ** 
* NR: No Reaction 
** < 10 %:  Identified by mass spec but not isolated 
Table 6: Conditions used for the synthesis of (Teoc, allyl) / (Boc, tBu) lanthionine. 
 
The reaction was attempted in DMF with 2 drops of triethylamine and Teoc-ONp (Table 6, 
entry 2). From NMR and mass spectrometry it was found that the reaction did not occur. This 
was obviously due to lack of base used. 
 
The approach of Shute and Rich 
145 
was then attempted. The reaction was carried out in 
water, with 2 equivalents of triethylamine diluted in 1,4-dioxane. The increased equivalents 
of triethylamine deprotected the Boc group followed by protection with the carbonate 170, 
giving 177 (Table 6, entry 3). The reaction was repeated in DMF (Table 6, entry 4); this also 
led to the formation of compound 177. When the reaction was attempted with 1.5 equivalents 
of triethylamine a very low yield of the desired product 172 was obtained (Table 6, entry 5). 
 
Byproduct 177 was also obtained when the reaction was carried out in water, with 2 
equivalents of triethylamine in dioxane and 2 equivalents of Teoc-ONSu 171 (Table 6, entry 
6). The reaction was repeated (Table 6, entry 7) by suspending the residue in DMF; again 177 
was formed and the desired product 172 was formed in only 14% yield. 
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Use of low equivalents of triethylamine and protecting group 171 led to very low yields 
(Table 6, entry 8). 
 
Table 6, entry 1 shows that when sodium bicarbonate was used some reaction occurred 
forming the desired product 172 in 17 %. The reaction was attempted again using the same 
conditions however in the presence of the second protecting reagent 171 (Table 6, entry 9). 
From NMR and mass spectrometry it was seen that the product was obtained in only 14 % 
yield however the same problem arose where the Boc group deprotected and then protection 
with the Teoc group took place giving 177. 
 
The conditions developed earlier for Aloc protection did not deprotect the Fmoc group unless 
excess sodium bicarbonate is used. It was therefore decided to carry out attempts on Fmoc 
protected lanthionine 102 to find a suitable route. 
  
3.2.6.2. Synthesis of (Teoc, allyl) / (Fmoc, tBu) lanthionine 
 
O
OHN
O
O
S
OO
HN
102
TFA (10 %), TES (5 %), 
CH2Cl2 (75 %), 4 hr,
    
1,4-dioxane, 
NaHCO3 (4 equiv),
Carbonic acid 4-nitro-phenyl ester 
2-trimethylsilanyl-ethyl ester (2 equiv),
24 hr
O
OHN
O
O
S
OO
HN
175
23 %
O
O
SiH HH H
 
Scheme 53: Removal of the trityl group and protection with Teoc group of Fmoc 
lanthionine. 
 
The reaction was first attempted using sodium bicarbonate (Scheme 53, Table 7, entry 1). 
After trityl deprotection the residue was dissolved in dioxane, aqueous sodium bicarbonate 
was added followed by the protecting reagent. This did not show any improvement in the 
yields. However there was no Fmoc deprotection. 
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Entry Trityl 
deprotection 
/ Time 
Reaction 
solvents 
Base (equiv) Protecting group  
Teoc-ONp Teoc-ONSu 
    170 (%)     171 (%) 
Reaction time 
/ temperature 
Product 
Isolated 
175 (%) 
1 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
aq. sodium 
bicarbonate, (4) 
 (2) - 24 hr, RT 23 % 
2 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
aq. sodium 
bicarbonate, (4) 
 (2) - Cool to 0 °C,  
24 hr at RT 
14 % 
3 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
Triethylamine, 
(0.5), dioxane, 
 
 Triethylamine, 
(0.5), dioxane 
 (2) - 2 hr, RT 
 
 
24 hr, RT 
21 % 
4 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(0.5), dioxane,  
 
 Triethylamine, 
(0.5), dioxane 
 (2) - 2 hr, RT 
 
 
24 hr  RT 
21 % 
5 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(0.5), dioxane  
 
 Triethylamine, 
(0.5), dioxane 
-  (2) 2 hr, RT, 
 
 
24 hr, RT 
21 % 
6 TFA/TES/ 
CH2Cl2, 4 hr 
1,4-
dioxane 
aq. sodium 
bicarbonate, (4) 
-  (1) 24 hr, RT 23 % 
7 TFA/TES/ 
CH2Cl2, 4 hr 
1,4-
dioxane 
aq. sodium 
bicarbonate, (4), 
Triethylamine, 
(couple of 
drops) 
-  (2) Cool to 0 °C, 
24 hr, RT 
2 % 
8 TFA/TES/ 
CH2Cl2, 4 hr 
1,4-
dioxane 
aq. sodium 
bicarbonate, (4) 
-  (2) Cool to 0 °C, 
24 hr, RT 
31 % 
9 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(0.5), dioxane,  
 
 Triethylamine, 
(0.5), dioxane 
-  (2) 
 
 
 (2)  
3 hr 30 min, 
RT, 
 
 24 hr, RT 
25 % 
10 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
aq. sodium 
bicarbonate, 
(4.6) 
- (2) Cool to 0 °C, 
24 hr in 
freezer, 
 5 hr,  0 °C 
50 % 
11 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
aq. sodium 
bicarbonate, (5) 
-  (2.5) Cool to 0 °C, 
24 hr in 
freezer,  
5 hr, 0 °C – 
RT 
83 % 
 
Table 7: Conditions used for the synthesis of (Teoc, allyl) / (Fmoc, tBu) lanthionine. 
 
Table 7, entry 1 and Table 7, entry 2 show attempts where the conditions used were the same 
apart from the temperature of the reaction mixture before the addition of the ester. The 
reaction mixture of Table 7, entry 2 was cooled to 0 °C before the addition of the ester. 
Comparison of the two reactions showed that there was a reduction in the yield, indicating 
that lower temperature may not be appropriate. 
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The reaction in 1,4-dioxane, with triethylamine and the protecting reagent 170 (Table 7, 
Entry 3) gave a yield of only 21 %. Similar yields were obtained when the reaction was 
repeated. When the reaction was carried out in water with diluted triethylamine in 1,4 
dioxane (Table 7, entry 4) there was no difference in the yield.  
 
Conditions similar to Table 7, entry 4 were used, and instead of ester 170, ester 171 was used 
(Table 7, entry 5). The yield obtained was similar to that of Table 7, entry 4.  
 
Table 7, entry 6 gave the product in 23 % yield when the reaction was carried out in 1,4-
dioxane using 1 equivalents of 171. Only 2 % of the product was obtained when the reaction 
was carried out using similar conditions to Table 7, entry 7, however the reaction mixture 
was cooled to 0 
º
C before 171 and triethylamine were added. The low yield obtained may 
have been due to traces of TFA being present in the residue after the removal of the trityl 
group preventing the reaction from proceeding. 
 
To observe whether there was a difference in using triethylamine or not, a reaction was 
carried out using the similar conditions to Table 7, entry 7 but without any use of 
triethylamine (Table 7, entry 8). The results showed there was an increase in the yield to 31 
%, when the reaction was repeated 38 % yield was obtained.  
 
The protecting reagent was added twice (Table 7, entry 9) to see how this affects the reaction. 
The reaction was carried out in H2O after trityl deprotection, 0.5 equiv triethylamine in 1,4-
dioxane was added followed by Teoc-ONSu 171. Further 0.5 equiv triethylamine in 1,4-
dioxane and Teoc-ONSu were added after 3 hr 30 min. The yield obtained was 25 % which 
was still very low.  
 
Better yields were obtained using Teoc-ONSu 171 and therefore it was decided 171 would be 
a better reagent to use compared to Teoc-ONp 170. 
 
Comparing all the yields, the best yield obtained was 38 % from carrying out the Teoc 
protection using the conditions from Table 7, entry 8. The reaction was repeated again with 
slight modifications, once 171 was added the reaction was left in the freezer overnight. The 
reaction was then stirred at 0 ºC for 5 hr (Table 7, entry 10). 50 % yield was obtained which 
was promising compared to the yields which were previously obtained. 
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The reaction was repeated again using similar conditions where the reaction was stirred at 0 
°C to room temperature for 5 hr instead of maintaining the reaction at 0 °C. This gave 83 % 
yield, and these optimised conditions were therefore used (Table 7, entry 11). 
 
3.2.6.3.        Removal of the allyl group and protection with TMSE 
 
Pd(PPh3)4 (10 %), NDMBA (5 equiv),
CHCl3, 3 hr,
    
CH3CN,
pyridine (1 equiv),
2-(Trimethylsilyl)ethanol (1.5 equiv),  
0 oC, N',N'-dicyclohexylcarbodiimide 
(1.2 eqiuv), 24 hr
O
OHN
O
O
S
OO
HN
175
O
O
Si
O
OHN
O
O
S
OO
Si
HN
176
O
O
SiH HH H
 
 
Scheme 54: Synthesis of (Teoc, TMSE) / (Fmoc, tBu) lanthionine. 
 
The next step involved deprotecting the allyl group and then protecting with a TMSE group 
(Scheme 54). Lanthionine 175 was dissolved in a solution of tetrakis(triphenyl 
phosphine)Palladium(0) catalyst (Pd(PPh3)4) and 1,3-dimethylbarbituric acid (NDMBA) 
78, 
146, 147
 in chloroform which was stirred for 3 hr. 
 
From mass spectrometry a clean peak was observed at 653 [M + Na]
+
 (Appendix 2) this 
indicates that allyl deprotection had taken place. However from the crude 
1
H NMR a broad H 
peak was not observed for the free OH, also the allyl peaks were still present (Appendix 3).  
 
Without any purification DCC coupling was then carried out to protect the free acid with a 
TMSE group.  
 
Mass spectrometry showed a clean peak at m/z 753 [M + Na]
+
 confirming that the reaction 
has proceeded (Appendix 4). From 
1
H NMR peaks corresponding to the hydrogen of the 
desired product were observed. However it was noticed that the desired compound was co-
eluting with a compound containing peaks corresponding to an allyl group (Appendix 5). 
Mass spectrometry did not detect any other molecular weight that may refer to the allyl group 
other than the molecular weight of the product. Also only one spot was seen by TLC. It was 
concluded that the allyl group was deprotected and the lanthionine was successfully TMSE 
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protected. It was assumed the allyl group that was deprotected, had further reacted to give a 
different compound that co-elutes with the desired product (Appendix 6).   
 
When the reaction was attempted again using the same conditions, purification was carried 
out after the allyl deprotection. The allyl peaks were still co-eluting with the intermediate. 
Once TMSE protection was carried out and the reaction was complete, after purification it 
was noticed the same purification issue occurred. The next step involved tert-butyl 
deprotection and then purification by reverse phase chromatography. It was hoped that all 
allyl impurities present which were not removed by flash column chromatography would be 
removed by reverse phase chromatography in the subsequent step. 
 
3.2.6.4. Synthesis of (Teoc, TMSE) / (Fmoc, OH) lanthionine  
 
TFA (50 %), 
CH2Cl2 (50 %)
O
OHN
O
O
S
OO
Si
HN
176
O
O
Si
O
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O
S
OO
Si
HN
169
O
O
Si HHH H
 
 
Scheme 55: Removal of the tBu group to give (Teoc, TMSE) / (Fmoc, OH) lanthionine. 
 
The final step to synthesising the second orthogonally protected lanthionine was by removing 
the tert-butyl group. The tert-butyl group was removed by 50 % TFA in CH2Cl2 over 3 hr and 
purified using reverse phase chromatography. Mass spectrometry confirmed that the reaction 
had taken place, also from the mass spectrum it was observed that there was TMSE 
deprotection giving another byproduct. 
1
H NMR showed the presence of the allyl peaks co-
eluting with the product.  
 
Further purification was carried out, analytical HPLC was carried out (Appendix 7) to find 
the right method to separate the compounds. 10- 60 % acetonitrile over 35 min separated out 
1 major peak at 23.5 min along with 14 other small peaks. From preparative HPLC a big peak 
was observed at 29 min and a broad peak at 34 min representing the product (Appendix 8). 
1
H NMR showed that the product was not pure, separation between the compounds co-eluting 
with the product were separated however the product picked up other impurities. Due to the 
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small quantity of the sample and the number of peaks present, further purifications by HPLC 
were not carried out. 
 
3.2.7. New synthetic route to (Teoc, TMSE) / (Fmoc, OH) 
lanthionine 
 
Since there were issues with the purification above the synthetic route was changed (Scheme 
56). This route overcomes the problem of the compound co-eluting with the final product as 
the allyl protecting group was eliminated from the synthetic route. Scheme 56 shows the 
planned route for the synthesis of the second orthogonally protected lanthionine. 
 
OBzl
BocHN COOH
OBzl
BocHN COOTMSE
OH
BocHN COOTMSE
OH
TrtHN COOTMSE
S
COOH
H2N S
NH2
COOH
S
COOtBu
H2N S
NH2
COOtBu
S
COOtBu
FmocHN
S
NHFmoc
COOtBu
SH
FmocHN COOtBu
TrtHN
S
COOtBu
NHFmoc
COOTMSE
TeocHN
S
COOtBu
NHFmoc
COOTMSE
H
H
H
H
I
TrtHN COOTMSE
H
TeocHN
S
COOH
NHFmoc
COOTMSE
OH
H2N COOTMSE
H
H
H
H
H
H
H
178
179
180
181
182
183
144
145
146
90
184
176
Orthogonally 
Prottected
Lanthionine 169  
 
Scheme 56: Planned route for the second orthogonally protected lanthionine. 
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The original synthetic route was used to synthesise the protected cysteine 90 ready for the 
coupling with the iodoalanine (Scheme 56, 36, conditions Scheme 37). The route to 
synthesise the iodoalanine was completely changed. The new route started from the 
commercially available Boc-(D)Ser(Bn)-OH 178 (Scheme 56). 
 
3.2.7.1. TMSE protection of Boc-(D)-Ser(Bn)-OH 
 
O N
H
O
O
OH
O
O N
H
O
O
O
Si
O
178 179
80%
DMAP (0.15 equiv),
THF, 
0 oC,
 
2-(Trimethylsilyl)eyhanol (2 equiv),
DCC (1.3 equiv), 96 hr
HH
 
Scheme 57: TMSE protection of Boc-(D)Ser(Bn)-OH.   
 
The first step involved the protection of the carboxylic functional group of the serine. Instead 
of TMSE protecting the carboxylic group at the end of the synthetic route just before the tert-
butyl deprotection as in Scheme 54, TMSE protection was carried out in the first reaction of 
the synthetic route. The reason behind this decision was to avoid the purification issue which 
had been faced with the conditions previously used (Section 3.2.6.3, Scheme 54).  
 
Samy et al. 
148
 used DCC for a similar coupling, with DMAP as a nucleophilic catalyst. 3-
Benzyloxy-2-tert-butoxycarbonylamino-propionic acid 178 was used and DCC coupling was 
used to give 179 (Scheme 57). After purification 80 % yield was achieved which was 
promising as literature 
148
 showed yield obtained for TMSE protection of carboxylic group of 
Boc, methyl and benzyl protected threonine was 56 %. 
 
3.2.7.2. Benzyl deprotection of Boc-(D)Ser(Bn)-TMSE 
 
O N
H
O
O
O
HO
O N
H
O
O
O
Si
O
180179
Pd/C (10 %),
H2,
Ethanol, 5 hr
x
Si
H
H
 
 
Scheme 58: Benzyl deprotection of Boc-(D)Ser(Bn)-TMSE. 
124 
 
The next step was to deprotect the benzyl group by hydrogenation, Compound 179 was 
dissolved and 10 % Palladium catalyst on carbon was suspended in ethanol and stirred under 
hydrogen (Scheme 58). Literature precedent suggests placing hydrogen under atmospheric 
pressure for 5 hr and then filter through a pad of Celite. 
148
 However these conditions did not 
work for deprotecting the benzyl group of 179.  
 
O N
H
O
O
O
HO
O N
H
O
O
O
Si
O
180
87 %
179
Pd/C (10 %),
H2,
EtOH, 48 hr
Si
H
H
 
Scheme 59: Benzyl deprotection of Boc-(D)Ser(Bn)-TMSE. 
 
When the reaction was repeated again for 24 hr under hydrogen at atmospheric pressure, with 
refill of hydrogen and addition of more catalyst 53 % yield was obtained. This proved the 
hypothesis to be correct where longer exposure to hydrogen leads to the reaction proceeding. 
The reaction was repeated again for 48 hr (Scheme 59), where the hydrogen was refilled and 
two further portions of the catalyst were added; this increased the yield to 87 %.  
 
3.2.7.3. Boc deprotection of Boc-(D)Ser-TMSE 
 
The next step was to deprotect the Boc group. Boc protected serine 180 was stirred in a 
solution of trifluroacetic acid (95 %), triisopropylsilane (2.5 %) and water (2.5 %) for 2 hr. 
TIPS was used as a scavenger in the reaction. From mass spectrometry it was observed that 
the desired product was not obtained. 
O N
H
O
O
O
HO
H2N
O
O
Si
HO
180 181 
49 %
TFA (50 %), 
CH2Cl2  (50 %),
     
1 hr
Si
H H
 
Scheme 60: Boc deprotection of Boc-(D)Ser-TMSE. 
 
The reaction was repeated again, this time starting material 180 was stirred in a solution of 50 
% TFA and 50 % CH2Cl2 for 1 hr. After purification by flash column chromatography the 
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product was isolated in 49 % yield (Scheme 60). The yield was slightly low, and a higher 
yield would be preferred however it was acceptable at this stage.  
 
HO N
H
O
O
O
HO
O N
H
O
O
O
Si
O
181
47 %
179
Pd/C (10 %),
H2,
EtOH, 103 hr Si
H H
H2N
O
O
Si
O
185
61.5 %
H
TFA (50 %), 
TES (2 %), 
DCM (48 %), 4.5 hr
 
Scheme 61: Synthesis of TMSE serine. 
 
It was later found that a higher yield was obtained when the Boc group was deprotected first 
followed by hydrogenation to deprotect the benzyl group (Scheme 61). This made the 
purification step much easier as aqueous work up was not required, flash column 
chromatography gave the pure product. Previously aqueous work up was carried out after 
Boc deprotection, due to the presence of free amine and OH this made the work up difficult 
(Scheme 60).  
 
3.2.7.4. Trityl protection of TMSE serine  
 
H2N
O
O
Si
HO
181
DMF,
Et3N (1 equiv),
Trt-Cl (1 equiv),
20 hr
N
H O
O
Si
182
OH
H2N
O
O
Si
O
HN
O
O
Si
O
186187
+
+
H
H H
H
 
Scheme 62: Synthesis of the trityl, TMSE serine and the byproducts. 
 
In order to prepare the iodoalanine from serine both the carboxylic acid and the amino groups 
had to be protected. Boc deprotection gives a free amine, which must then be protected with a 
trityl group. Amino acid 181 was dissolved in DMF, triethylamine was added followed by 
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triphenylmethylchloride and then stirred for 20 hr (Scheme 62). Due to the NH2 being more 
reactive then the OH group it was assumed that the reaction will take place at NH2 and 
therefore trityl protection will take place. Mass spectrometry showed a peak at m/z 470 [M + 
Na]
+
 which indicated the product was isolated which was also indicated by
 1
H NMR.  
 
When HMBC NMR was carried out it was observed that both the OH and the NH functional 
groups were protected with the trityl group. This was also confirmed when the mass spectrum 
was analysed again, a peak at m/z 722 (187 + H) was observed which corresponds to both 
OH and NH group being protected with the trityl group. From the HMBC NMR a 3 bond 
correlation is observed where carbon 5 (5C) is coupling to the 2 hydrogens on carbon 4 
(4CH2). This indicates that the O is protected with the trityl group. Another 3 bond 
correlation is also observed where the carbon 1 (1C) is coupling to the hydrogen on carbon 3 
(3CH) (Figure 44). 
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Figure 44: HMBC NMR showing the protection of OH and NH with trityl group. 
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Scheme 63: Trityl protection of TMSE serine. 
 
A second attempt was carried out, the original procedure for the synthesis of 143 (Scheme 
40) was used. The two functional groups were protected first and then selective deprotection 
of the TMS group on the amine was carried out which was then protected with the trityl 
group. This was to avoid protecting both functional groups with trityl group as Scheme 62.  
 
The Boc group was deprotected in 50 % TFA, 49 % CH2Cl2 and 1% TIPS. Protection of both 
functional groups OH and NH2 were carried out by trimethylsilyl chloride (TMS). Selective 
deprotection of the amine was carried out by adding anhydrous methanol. This was followed 
by triethylamine then triphenylmethyl chloride for the protection of the amine with the trityl 
group (Scheme 63). The removal of the TMS group on the alcohol was achieved with excess 
methanol and triethylamine. From the mass spectrum a peak at m/z 470 corresponding to 182 
[M + Na]
+
 and peaks at m/z 526 and 542 corresponding to 188 [M + Na]
+
 and 188 [M + K]
+
 
were observed. This indicated that a mixture of the product 182 and the intermediate 188 
containing the TMS group on the alcohol was obtained. Proton NMR confirmed the presence 
of the mixture of both compounds.  
 
The oily residue containing a mixture of the two compounds was redissolved in excess 
methanol and triethylamine at 0 °C and stirred at room temperature for 1 hr to remove the 
TMS group. Compound isolated after purification still contained a mixture of both the 
product and the intermediate. The reaction was repeated again and the same was observed. 
On the third attempt after purification the product was isolated in only 12 % yield.  
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Another attempt involved purification of the crude material after Boc deprotection by flash 
column chromatography. This was followed by protection of the OH and NH2 groups with 
TMS then selective deprotection was carried out followed by trityl protection using 
conditions in Scheme 63. After workup and purification product 182 was isolated in 43 %.  
 
It was therefore important to purify the intermediate after Boc deprotection and then to 
protect both alcohol and amino functional groups then carry out selective deprotection 
followed by trityl protection to give the desired product.     
 
The intermediate 188 was observed repeatedly during this reaction. The problem was solved 
by carrying out a deprotection of the TMS group. Evans et al. 
149
 used NaHCO3 in methanol 
at room temperature to deprotect TMS group, this was attempted on compound 188 which 
gave product 182. An attempt was carried out where after trityl protection the crude 
containing a mixture of 182 and 188 was stirred in methanol with NaHCO3. It was discovered 
that purification was required before deprotection of the TMS group in order to ensure the 
reaction proceeds to give 182.  
 
3.2.7.5. Synthesis of TMSE iodoalanine 
 
N
H O
O
Si
182
OH
PPh3 (1.5 equiv),
CH2Cl2, 10 min,
-10 oC,
DEAD (1.5 equiv), 5 min,
MeI (1.5 equiv),
6 hr, - 2 oC
N
H O
O
Si
183
47 %
I
H H
 
 
Scheme 64: Synthesis of TMSE, trityl iodoalanine. 
 
Trityl protected serine 182 and triphenylphosphine were dissolved in dry CH2Cl2 and cooled 
to -10 °C. DEAD was added followed by iodomethane and the reaction was stirred for 3 hr. 7 
% yield was obtained however when the reaction was repeated again and left stirring for 6 hr 
the yield increased to 47 % (Scheme 64).  
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3.2.7.6. Synthesis of (Trt, TMSE) / (Fmoc, tBu) lanthionine 
 
DMF,
CsCO3 (0.5 equiv),
2 hr,
    
CsCO3 (0.5 equiv),
2 hr
N
H O
O
Si
183
I
+
O
OHN
O
O
S
OO
Si
HN
184
39 %
H HH
90
NH
O
O
O
O
SH
 
 
Scheme 65: Synthesis of (Trt, TMSE) / (Fmoc, tBu) lanthionine. 
 
The next step was to synthesise the lanthionine by coupling the iodoalanine and cysteine. 183 
and 90 were dissolved in DMF; caesium carbonate was added and the reaction mixture was 
stirred for 2 hr. Further caesium carbonate was added and stirring contained for further 2 hr 
(Scheme 65).  
 
It was important to ensure that the caesium carbonate was dry to avoid any Fmoc 
deprotection. It was also found that 0.5 equivalents of caesium carbonate followed by another 
portion of 0.5 equivalents of caesium carbonate after 2 hr of first addition gave higher yields. 
Splitting caesium carbonate into two portions also prevented Fmoc deprotection compared to 
the addition of 1 equivalent of caesium carbonate all at once. After purification a mixture of 
two compounds were observed from proton NMR and TLC. It contained the desired product 
184 but it was difficult to work out what the second compound was. It was thought that mass 
spectrometry may help to find out what the second compound was, however there was no 
observations of peaks corresponding to another compound. 
 
On the second attempt after purification by flash column chromatography the product was 
separated from the impurities in the crude giving a yield of 39 %. 
    
In the presence of a non-nucleophilic base there was no dehydroalanine elimination by 
product formation. This was due to the trityl group on the free amine which prevented -
proton abstraction.   
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3.2.7.7. Synthesis of (Teoc, TMSE) / (Fmoc, tBu) lanthionine 
 
TFA (10 %), TES (5 %),
CH2Cl2 (75 %), 4 hr,
1,4-Dioxane,
    
    
NaHCO3 (4 equiv),
0 oC,
Teoc (2 equiv), 
freezer overnight,
0 oC - RT, 5 hr
O
OHN
O
O
S
OO
Si
HN
184
O
OHN
O
O
S
OO
Si
HN
176
12 %
O
O
SiH HH H
 
 
Scheme 66: Removal of the trityl group and protection with Teoc group 
 
In order to synthesise the desired second orthogonally protected lanthionine, replacement of 
the trityl group with Teoc group was required. This was one step before the end of the 
synthesis. The optimised conditions from Table 7, entry 11 were used (Scheme 66). After 
purification by flash column chromatography a mixture of two compounds were obtained, 
one of which was the desired product.  
 
Due to only 30 mg being obtained purification was carried out by preparative HPLC. An 
analytical HPLC (Appendix 9) was carried out to see the number of peaks present. There was 
one major peak at 26.7 min along with 7 other small peaks. The product separated at 27.51 
min on the preparative HPLC (Appendix 10). Mass spectrometry showed peaks at m/z 753 
and 769 corresponding to 176, [M + Na]
+
 and [M + K]
+
 confirmed by a proton NMR 
(Appendix 11) giving 12 % yield. Third peak at m/z 702 represents the second compound, 
possibly [M + Na]
+
 or [M + K]
+
. 
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3.2.7.8. Formation of byproducts during synthesis of (Teoc, TMSE) / 
(Fmoc, OH) lanthionine  
 
TFA (50 %),
CH2Cl2 (50%), 3 hr
O
OHN
OH
O
S
OO
Si
HN
169
O
O
Si
O
OHN
O
O
S
OO
Si
HN
176
O
O
Si
X
O
OHN
OH
O
S
OHO
HN
190
42 %
O
O
Si
O
OHN
OH
O
S
OO
Si
H2N
189
+
H H
HH
H H
HH
 
 
Scheme 67: Synthesis of byproducts during tBu deprotection. 
 
The last step involved the deprotection of the tert-butyl group in TFA and CH2Cl2, for 3 hr to 
give 169 ready for incorporation into solid phase peptide synthesis (Scheme 67). Reverse 
phase chromatography was then carried out to obtain pure product 169.  
 
During this reaction unexpected results were obtained. The desired product 169 was not 
synthesised. 
1
H NMR and mass spectrometry showed that byproducts 189 and 190 were 
formed.  
 
It was possible that during purification deprotection of the Teoc and TMSE groups may have 
taken place, due to the use of saturated sodium bicarbonate in the reverse phase 
chromatography. The reaction was repeated, and the purification was carried out in water and 
acetonitrile. Unfortunately the same two byproducts were observed. 
 
It was also possible that the deprotection of the Teoc and TMSE groups were taking place 
after the reaction when the TFA and CH2Cl2 solution were removed, in vacuo. As more 
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volatile CH2Cl2 is removed first, the concentration of TFA increases. In order to confirm this, 
the reaction was then attempted again. 
 
The reaction was repeated in deuterated TFA and deuterated CH2Cl2, and the reaction was 
monitored by 
1
H NMR. 
1
H NMR of the reaction samples were taken at 10 min, 30 min, 1 hr, 
2 hr and 3 hr. From the NMR it was seen that the deprotection was taking place during the 
reaction itself (Appendices 12-16). This was unexpected because Teoc and TMSE protecting 
groups theoretically should be stable to acid and base. However Wood et al. 
150
 used excess 
TFA to deprotect (trimethylsilyl)ethyl ester to afford the free carboxylic functional group. 
 
This represented a major problem, if the tert-butyl group could not be selectively deprotected 
in the presence of Teoc and TMSE protecting groups. In order to solve this problem there 
were two options. 
 
The first was to find an alternative way of deprotecting the tert-butyl group using different 
conditions. This could be done by using thermitase catalysed deprotection of the tert-butyl 
moiety using esterases biocatalyst enzymes which Schmidt et al. used, 
151
 esterase are an 
advantage to use because they are stable in organic solvents. Schultz et al. 
152
 also carried out 
enzymatic cleavage of the tert-butyl group in a thermitase-catalysed reaction. Gmeiner et al. 
153
 used HOAc/iPrOH/H2O to hydrolyze the tert-butyl ester. This method was not selected 
due to the particular enzymes not being readily available. 
 
The second option was to change the protecting groups. Having spent a lot of time putting the 
Teoc and TMSE groups in place and finding good conditions it was felt to be wise to change 
the tert-butyl protecting group. This required finding different protecting groups which can 
be selectively deprotected in the presence of Teoc and TMSE protecting groups. Scheme 68 
shows the planned route to the second orthogonally protected lanthionine with Teoc, TMSE, 
Fmoc, Tce groups.  
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Scheme 68: Planned route for the (Teoc, TMSE) / (Fmoc, OH) lanthionine. 
 
The synthesis of 183 from 178 was carried out as before with one modification the order of 
one reaction was changed. Problems were encountered when 181 was synthesised yields 
produced previously were not reproducible. This was due to the work up of the reaction. Due 
to the free carboxylic acid and a free amine during aqueous workup it was difficult to extract 
the product out of the aqueous phase. Changing the solvents and pH did not have an effect. 
Purification was carried out straight after the reaction solvent was reduced in vacuo without 
any extraction this also did not make any difference, the compound isolated was still low in 
yield with the presence of impurities. Due to this the order of the reaction was slightly 
changed. After TMSE protection, the Boc group of 179 was deprotected and then purified to 
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give 185. Hydrogenation was then carried out to remove the benzyl group giving 181, this 
eliminated any aqueous workup as no TFA was used at this stage. The reaction was filtered 
and reduced followed by purification.   
HO
Cl
Cl
Cl
196  
Instead of tert-butyl ester, 2,2,2-trichloroethyl ester 196 was used for the carboxy protecting 
group. Out of many other protecting groups available for amino acids Tce was selected 
because of its facile removal using mild conditions with zinc dust whereas base hydrolysis is 
required for alkyl esters. Woodward et al. 
154 
used trichloroethyl ester in the synthesis of 
cephalosporin C as a protecting group.    
 
3.2.7.9. (Fmoc-Cys-OTce)2 
O
H
N
O
O O
S S
HN
O
O
O
O
192
87. 4 %
Cl
Cl
Cl
Cl Cl
Cl
O
H
N
O
O OH
S S
HN
O
O
O
OH
191
Toluene sulphonic acid (2.3 equi),
benzene,
2,2,2-trichloroethanol (4.7 equiv),
110 oC, Dean stark, 24 hr
 
Scheme 69: Tce protection of cystine. 
 
The tert-butyl group of 146 was deprotected in TFA and CH2Cl2. Then Jou et al’s approach 
155
 was used where the residue was dissolved in CH2Cl2 to which TceOH was added followed 
by DMAP and DCC (Table 8, entry 1). 18 % yield was obtained the product was not pure 
after purification due to urea being present. 
 
Bogers et al‘s approach 156 was used where they synthesised the opposite isomer. The free 
amine of Cystine 144 was first Fmoc protected using Fmoc-Cl in THF-Water 1:1 in the 
presence of NaOH. HOBt, TceOH and DCC were used (Table 8, entry 2). Only 2.7 % was 
obtained compared to 63 % yield obtained by Boger et al. 
156
 It was very difficult to remove 
urea, after two flash column chromatography the urea was still present. 
135 
 
Entry Compound 
 
144 146  191  
Tertbutyl 
deprotection / 
Time 
Fmoc 
protection 
reagents,  
(equiv) / 
Time 
Reaction 
solvent 
Reagents 
(equiv) 
TceOH 
196 
(equiv) 
Reaction time 
/ temperature 
Product 
Isolated 
192 (%) 
1 - X - TFA/ 
CH2Cl2, 4 hr 
- CH2Cl2 DMAP (0.4), 
DCC (2.2),  
 
DMAP (0.4) 
(2.2) 
 
 
(2.2) 
  
    0 °C - RT,  
24 hr, RT, 
24 hr, RT 
18 % 
2 X - - - NaOH (4.2),  
THF – H2O, 
Fmoc-Cl 
(2.1), RT, 14 
hr 
Pyridine HOBt (2.9), 
 
DCC (2.3) 
(3.45)   
 
 - 20 °C, 24 hr 
2.7 % 
3 - X - TFA/ 
CH2Cl2, 4 hr 
- CH2Cl2 DMAP (0.4), 
DCC (6), 
 
DMAP (0.4) 
(3) 
 
 
(3) 
 
0 °C - RT 
24 hr, RT 
    24 hr, RT 
25.3 % 
4 - X - TFA/ 
CH2Cl2, 4 hr 
- Pyridine HOBt (9), 
 
DCC (9.9) 
(11.6)  
 
- 20 °C, 24 hr 
44.4 % 
5 - - X - - Pyridine HOBt (8.4), 
DCC (8.4), 
2 x HOBt (8.4), 
DCC (8.4) 
(9.35) 
 
(2 x 
9.35) 
 
 
- 20 °C, 24 hr 
- 20 °C 
2 x 24 hr  
 
17.7 % 
6 - - X - - CH2Cl2 DMAP (0.47), 
DCC (8.4), 
 
2 x DMAP 
(0.47), 
DCC (8.4) 
(9.35) 
 
 
(2 x 
9.35) 
 
0 °C - RT 
24 hr, RT 
2 x 24 hr, RT 
 
 
26 % 
7 - - X - - CH2Cl2 DMAP (0.47), 
EDCI-polymer 
(2),  
 
DMAP (0.24), 
EDCI-polymer 
(2)  
(9.35) 
 
 
 
(9.35) 
 
 
0 °C 
48 hr, RT  
 
72 hr, RT 
3.9 % 
8 - - X - - CH2Cl2 DMAP (0.4), 
EDCI (2.2),  
 
DMAP (0.4) 
(4) 
 
 
(4) 
0 °C  
24 hr, RT 
 
24 h at RT 
NR * 
9 - - X - - DMF N-hydroxy 
Succinimide (2), 
EDCI.HCl (2), 
N-hydroxy 
Succinimide (2), 
EDCI.HCl (2) 
(4) 
 
 
 
(4) 
 
24 hr, RT 
 
 
 
24 h at RT 
32.7 % 
10 - - X - - Toluene Toluene-4- 
Sulphonic acid 
(2.4) 
(2.4) 
 
   (2.4) 
140 °C, 5 hr 
  
 140 °C, 24 hr 
60 % 
11 - - X - - Benzene Toluene-4- 
Sulphonic acid 
(2.4) 
(2.4) 
 
(2.4)  
80 - 105 °C, 5 
hr 
80 - 105 °C, 5 
hr 
87.4 % 
* NR: No Reaction 
Table 8: Conditions used for Tce protection. 
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Due to the poor yield, Jou et al’s approach 155 was carried out again (Table 8, entry 3) using 
different number of equivalents. Increasing the number of equivalence of DCC and TceOH 
increased the yield by only 7 %. 
 
Table 8, entry 4 shows an increase of the yield to 44.4 % when Bogers et al‘s 156 approach 
was attempted. Having seen this increase commercially available 191 was used. Here 9.35 
equivalence of TceOH, 8.4 equivalence of HOBt and 8.4 equivalence of DCC was used. 
Surprisingly this did not increase the yield (Table 8, entry 5). The reaction was repeated using 
Jou et al’s approach 155 (Table 8, entry 6), this also did not have much effect on the yield. 
There may have been increase on the yield if an increased DMAP equivalence was used, 
however to avoid Fmoc deprotection only catalytic amounts were used. 
 
The best yield obtained was 44.4 % (Table 8, entry 4) which was acceptable at this stage in 
order to continue with the next reaction. The problem encountered in this reaction was the 
presence of urea, different solvent systems were used however it was unsuccessful to separate 
the product and the urea by purification. 
 
To avoid impure 192 polymer-bound EDC was used for the protection in the presence of 
DMAP and TceOH. A mass spectrum of the reaction showed the protection of only one acid. 
Further TceOH, DMAP and EDC-polymer was added however after purification only 3.9 % 
of 192 were obtained. This low yield was expected, due to the resin bound EDC which was 
likely to decrease the reaction. When the reaction was attempted with EDCI using Rademann 
et al 
157
 and Vallinayagam et al’s approach 158 to protect the carboxylic functional groups 
(Table 8, entry 8), no products were formed.    
 
EDCI.HCl was then used in order to overcome the problem of urea. It was believed since the 
compound was a hydrochloride the urea would remain in the aqueous layer during aqueous 
workup (Table 8, entry 9). However after purification from 
1
H NMR it was observed that the 
urea was still present.  
 
Hoyem et al. 
159
 used Dean-Stark conditions to couple Tce protecting groups to their diacid. 
191 were dissolved in toluene in the presence of toluene-4-sulphonic acid, TceOH was added 
and the reaction was refluxed at 140 °C with a Dean-Stark trap (Table 8, entry 10). After 
work up and purification 60 % yield of the pure product was obtained which was good 
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considering the low yields and impure products previously obtained. This approach solved 
the problem of urea being present in the product as DCC or EDCI was not used. To improve 
the yield the reaction was attempted in Benzene which increased the yield to 87.4 %.   
 
3.2.7.10. Fmoc-Cys-OTce   
 
O
H
N
O
O O
S S
HN
O
O
O
O
192
THF,
PPh3 (4.4 equiv), 
2-mercaptoethanol 
(4.8 equiv) / water (10 equiv),
50 oC, 5 hr
193
98 %
O
O
N
H
O
O
SH
ClCl
Cl
Cl
Cl
Cl
Cl
Cl
Cl
 
 
Scheme 70: Disulfide cleavage. 
 
Reduction of the disulfide precursor was carried out in THF with mercaptoethanol. It was 
found that the addition of excess water after the addition of triphenylphosphine made the 
cleavage step more effective. 
156
  
 
3.2.7.11. Synthesis of (Trt, TMSE) / (Fmoc, Tce) lanthionine 
 
DMF,
CsCO3 (0.5 equiv), 2 hr,
CsCO3 (0.5 equiv), 2 hr
N
H O
O
Si
183
I
+
O
OHN
O
O
S
OO
Si
HN
194
58 %
193
O
O
N
H
O
O
SH
Cl
Cl
Cl
Cl
Cl
Cl
H H
 
Scheme 71: Synthesis of (Trt, TMSE) / (Fmoc, Tce) lanthionine. 
 
A similar approach to 102 was used to prepare 194. Intermediates 183 and 193 (Scheme 71) 
were dissolved in DMF this was followed by addition of dry Cs2CO3. The lanthionine was 
obtained in 58 % yield. 
 
The next steps were to replace the trityl group with the Teoc group then deprotect the Tce 
protecting group to give the free carboxylic acid. Before these reactions were carried out, a 
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trial reaction of the deprotection of the Tce group was attempted to ensure it can be 
selectively deprotected in the presence of TMSE. 
 
Due to the problems previously described while deprotecting tert-butyl ester when the 
Teoc/TMSE protecting groups were also deprotected, trial reactions were carried with Tce 
protection to see if this can be selectively deprotected in the presence of Teoc and TMSE 
groups.  
 
3.2.7.12. Synthesis of (Trt, TMSE) / (Fmoc, OH) lanthionine 
  
O
OHN
OH
O
S
OO
Si
H2N
189
45 %
H H
THF,
Zinc dust (36 equiv), 
NH4OAc (1 M),
RT, 24 hr
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O
O
S
OO
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OH
O
S
OO
Si
HN
197
21 %
H HH H
+
 
 
Scheme 72: Deprotection of the Tce group. 
 
Reductive removal of the 2,2,2-trichloroethyl group with zinc dust in ammonium acetate gave 
the acid 197. Jou et al. 
155 
used zinc dust for Tce deprotection, this approach was adapted. 194 
were dissolved in THF to which zinc dust was added followed by 1 M ammonium acetate. 
After purification via flash column chromatography 197 was obtained in 21 % yield. From 
1
H 
NMR and mass spectroscopy it was discovered that compound 189 was also synthesised in 
45 % yield (Scheme 72). This showed that Zinc dust with ammonium acetate deprotected the 
trityl protecting group along with the trichloroethyl group. At this stage this was not a 
problem, as the trityl group would be deprotected and protected with a Teoc group. The 
concern was whether the TMSE group was affected during Tce deprotection. Mass spec and 
1
H NMR confirmed that the Tce protecting group deprotected selectively in the presence of 
the TMSE group.  
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3.2.7.13. Synthesis of (Teoc, TMSE) / Fmoc, OH) lanthionine 
 
O
OHN
OH
O
S
OO
Si
H2N
189
O
OHN
OH
O
S
OO
Si
HNO
O
Si1,4-Dioxane,
NaHCO3 (4 equiv),
0 oC,
Teoc (19.9 equiv),     
Freezer overnight,
0 oC - RT, 5 hr 169
64.4 %
H HH H
 
 
Scheme 73: Protection of the free amine of lanthionine with Teoc. 
 
Deprotection of the trityl group saves a synthetic step giving the intermediate 189. Conditions 
from Table 7, entry 11 were used on 189, after purification product 169 was obtained in 64 % 
yield (Scheme 73).  
 
At this point the second orthogonally protected lanthionine was obtained with a free 
carboxylic group ready for incorporation into solid phase peptide synthesis. When the 
reaction was repeated the yield was not reproducible. 
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O
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DMAP (catalytic),
Teoc (4.9 equiv),     
Freezer overnight,
RT, 24 hr
169
24.3 %
H HH H
+
 
 
Scheme 74: Teoc protection to give the second orthogonally protected lanthionine. 
 
The coupling of Teoc was then attempted using DMAP as catalytic amount. 189 were 
dissolved in 1,4-dioxane, DMAP was added in catalytic amount followed by Teoc. After 
purification it was found that the reaction did not go to completion giving 65 % starting 
material. Longer reaction time did not increase the yield. Increasing the DMAP increased 
Teoc protection however it resulted in Fmoc deprotection. 
 
The reaction was then attempted on 194 where Teoc protection was carried out first and then 
Tce deprotection. 
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3.2.7.14. (Teoc, TMSE) / (Fmoc, OH) lanthionine 
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HN
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O
Si
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TFA (10 %), TES (5 %), 
CH2Cl2 (75 %), 4 hr,
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DMAP 91 equiv),
Teoc (4.9 equiv),     
RT, 24 hr
H HH H
 
 
Scheme 75: Removal of the trityl group and protection with Teoc group. 
 
R. Shute and D. Rich’s 145 used triethylamine as their base in their reaction for Teoc 
protection. Scheme 75 shows the use of DMAP as the nucleophilic catalyst. Product 195 was 
obtained as clear oil in 66 % yield.  
 
The Tce protecting group was then deprotected to give 169 when the reaction was stirred in 
THF with zinc dust and 1 M ammonium acetate for 24 hr (Scheme 76), proton and carbon 
NMR can be seen in the Appendix 17 and 18. This second orthogonally protected lanthionine 
was ready for incorporation into solid phase peptide synthesis.  
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Scheme 76: Deprotection of the Tce group to give the second orthogonally protected 
lanthionine. 
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3.3. Summary 
 
(Aloc, allyl / Fmoc, OH) lanthionine 103 has been synthesised using the published procedure. 
124
 
 
Due to low yielding reactions from SES protected lanthionine 154 an alternative protecting 
group Teoc was chosen. New synthetic routes were adapted where the TMSE group was 
protected to give 179 during the first synthetic step of lanthionine formation. This eliminated 
the use of allyl protected serine 122 which otherwise led to issues on purification when the 
allyl group was replaced with a TMSE group from 175 to 176 at the end of the synthetic 
route.  
 
Tce protecting group was used as an alternative to tert-butyl protecting group. This was to 
ensure that the Teoc and TMSE groups do not fall apart during the selective deprotection of 
Tce to give the free carboxylic acid 169 from 195. This however was the problem when the 
tert-butyl protecting group was deprotected from 176.  
 
An efficient and good yielding pathway has been developed to synthesise the Teoc, TMSE 
orthogonally protected lanthionine 169 which was produced in 300 mg routinely in 40 % 
yield. 
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4. Solid phase peptide synthesis of rings D and E of 
nisin 
 
To synthesise an analogue of rings D and E of nisin two orthogonally protected lanthionine 
residues 103 and 169 were required. The first, 103, has one amine and one carboxylic acid 
protected with Aloc and allyl groups respectively and the other amine with an Fmoc group. 
The second orthogonally protected lanthionine 169 has one amine and one carboxylic acid 
protected with Teoc and TMSE groups respectively and the other amine with an Fmoc group 
(Figure 45). The synthesis of these protected lanthionines was discussed in Chapter 3.  
 
AlocHN
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COOAllyl NHFmoc
HH
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S
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HH
S
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103                                                                   169
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Ala
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Ala His
Ala Ser
S
S
D
E
Ala His Ala Ser
Trt tBu
S
AllocHN COOAllyl
S
Lanthionine 169
Lanthionine 103
FmocHN
TeocHN
COOTMSE
Rings D and E of nisin
Stable to Pd o,
piperidine
Selective cleavage
with TBAF
Selective cleavage
with Pd o
2
1
Cylisation to form ring E
Cylisation to form ring D
Stable to TBAF ,
piperidine
 
 
Figure 45: Strategy to synthesising an analogue of nisin rings D and E. 
 
4.1. SPPS methodologies 
 
There are two commonly used methodologies for SPPS, Merrifield SPPS and Fmoc/tBu 
SPPS. tert-Butoxycarbonyl (Boc) is used as a temporary protecting group in Merrifield SPPS. 
The Boc group is on the N-terminus which is cleaved using neat TFA. Benzyl - derived 
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protecting groups are used as the permanent protecting groups on reactive side chains, these 
are removed using HF. The disadvantage of this approach was the use of HF, which is very 
corrosive and capable of dissolving many materials including glass, for this reason special 
glassware was required. The second approach uses Fmoc and tert-butyl groups as the 
temporary and permanent protecting groups respectively. The Fmoc group is used to protect 
the  amino group and is removed using a mild base, usually piperidine. 
160
 Acid labile 
protecting groups are used as the side chain protecting groups and these are cleaved with 
TFA during the end of the peptide synthesis. As these milder conditions are used compared to 
the Merrifield approach the second approach is found to be more convenient and easier to 
handle (Figure 35). This explains why lanthionine 103 and 169 are Fmoc protected.   
 
4.2. Coupling reagents 
 
There are a large number of coupling reagents for peptide synthesis. In this work HBTU has 
been used for amino acid coupling and PyAOP/HOAt has been used for the cyclisation steps. 
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Figure 46: Mechanism for coupling using HOAt and HOBT esters. 
 
1-Hydroxy-7-azabenzotriazole (HOAt) 
161, 162
 and PyAOP 
161, 163
 are better cyclisation 
reagents compared with DCC giving high yielding reactions and reducing racemisation 
during coupling and cyclisation. Racemisation takes place during cyclisation when HBTU 
164
 
is used; however HBTU is a very efficient cyclisation reagent. The decrease in racemisation 
by the use of HOAt and PyAOP is due to hydrogen bonding of the nitrogen from the fused 
pyridine ring with the incoming amine, which allows for greater stabilisation for the overall 
negative charge of the leaving group (Figure 46). PyAOP side products are also known to be 
unreactive and relatively harmless, as compared to carcinogenic byproducts of BOP or AOP. 
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4.3. Model Peptide 
 
4.3.1. Met-His-Met-Ser 
 
Synthesis of a model peptide containing residues H-Met-His-Met-Ser-OH 198 was chosen, 
this was to be familiar with SPPS. The residues were chosen according to the C-terminus that 
would be synthesised however the lanthionine residues were replaced with the methionine 
residues. 
 
Highly acid labile NovaSyn TGT alcohol resin was chosen, preloaded with Ser(tBu) with a 
loading of 0.19 mmol g
-1
. The peptide synthesis was carried out on a Merrifield Bubbler 
using standard solid phase peptide synthesis techniques.  
 
Fmoc deprotections of all the coupled amino acids were completed using 20 % piperidine in 
DMF this leads to comprehensive cleavage of the Fmoc group, whilst all the coupling of the 
amino acids were carried out using standard coupling reagents HBTU and DIPEA.  
 
The peptide synthesis was carried out using a Merrifield Bubbler (Experimental, Figure 74).  
Fmoc deprotection was carried out using 20 % piperidine in DMF bubbling with argon for 20 
min, the solution was then removed. The resin was washed 6 times with DMF, during which 
time the amino acid was activated for 20 min. The activating solution was made up with 4 
equivalents of the amino acid, 4 equivalents of HBTU in 1 mL of DMF and 4 equivalents of 
DIPEA. After The solution was added to the resin and bubbled for 30 min, the solution was 
then removed, followed by washings 6 times with DMF. The procedure was repeated to 
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couple Fmoc-Met-OH, Fmoc-His(Trt)-OH and Fmoc-Met-OH each coupling was followed 
by Fmoc deprotection. The final Fmoc deprotection was carried out to give 198 (Scheme 77).  
 
Kaiser tests 
165
 were carried out after each Fmoc deprotection steps and after each coupling 
steps, which showed that each reaction proceeded well. The final step involved the 
deprotection of side chain protecting groups and the cleavage of the peptide from the resin 
using a cocktail solution of TFA (94 %), H2O (2.5 %), TIPS (1 %) and EDT (2.5 %). The 
cocktail was added to the resin and bubbled for 3 hr, the solution was collected by flushing 
out and then the resin was washed twice with TFA. The TFA cocktail was reduced in vacuo 
and the peptide precipitated using cold ether, the solvent was removed in vacuo and the 
residue was redissolved in water and freeze dried to give the crude product 198 as small 
brown crystals. 
 
The crude peptide was characterised by LCMS which gave a peak at m/z 505 corresponding 
to [M + H]
+
, along with with the presence of other peaks. Analytical HPLC showed that there 
were traces of several peaks (Appendix 19 a). Purification via preparative HPLC confirmed 
the presence of the same peptide in two fractions affording the desired linear peptide 198 
with a yield of 22% (Scheme 77). After purification a peak corresponding to the desired 
product was observed by mass spectroscopy using electrospray positive mode (ESI+) 
(Appendix 19 b). 
1
H NMR experiments were carried out in CD3OD, however the compound 
was observed to still contain impurities. 
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Scheme 77: Solid phase peptide synthesis of the model peptide. 
 
 
After preliminary investigation of the model peptide methodology, analogue of ring D and 
ring E of nisin were each synthesised separately containing a single lanthionine bridge.  
 
4.4. Synthesis of an analogue of ring E of nisin 
 
An analogue of ring E of nisin was synthesised, containing a single lanthionine bridge, and 
with a methionine residue substituted for the second lanthionine at the fourth amino acid 
(Scheme 78). As previously NovaSyn TGT resin was used, preloaded with Ser(tBu). (Aloc, 
allyl / Fmoc) protected lanthionine 103 was used to prepare the analogue of ring E of nisin, 
and it was envisaged that standard coupling conditions would be used to incorporate 103 into 
a linear resin-bound precursor 206.  
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Scheme 78: Synthesis of an analogue of ring E of nisin. 
 
The first attempt in synthesising analogue of ring E of nisin was carried out using a 
Merrifield bubbler (Experimental, Figure 74). The resin was placed in a bubbler in which 
argon was bubbled vigorously to make sure the resin is constantly moving. All addition of 
reagents for Fmoc deprotection, coupling of amino acids and washes after each synthetic step 
were carried out manually. All standard amino acids were activated for 20 min before being 
added to the resin in the Merrifield bubbler, Kaiser tests were carried out after each synthetic 
step. The detailed procedure is described in the Experimental chapter. 
 
148 
 
The first step involved the deprotection of the Fmoc group of serine using 20 % piperidine 
over 20 min followed by washes with DMF to give 200, Kaiser test showed purple colour a 
positive result indicating Fmoc deprotection has taken place. Lanthionine 103 activated over 
20 min was added for coupling, the resin was bubbled for 30 min, followed by washing in 
DMF to give 204. A yellow colour was obtained from the Kaiser test indicating coupling has 
taken place. Fmoc deprotection was carried out to give 205 followed by coupling with 
activated Fmoc-His(Trt)-OH, Fmoc deprotection of Histidine and then coupling of activated 
Fmoc-Met-OH to give 206.  
 
Selective deprotection of the Aloc and allyl protecting groups of the lanthionine were carried 
out using tetrakis(triphenylphosphine)Palladium (0) catalyst Pd(PPh3)4 and 1,3-dimethyl 
barbituric acid (NDMBA). 
78, 146, 147, 166 
A solution of Pd(PPh3)4 0.5 equivalents and 10 
equivalents of barbituric acid were dissolved in DMF: chloroform which were gently heated. 
Since Pd(PPh3)4 was both light and heat sensitive, fume hood lights were switched off, flask 
containing the solution was covered in foil, and when the flask was heated it was ensured that 
the colour did not change from yellow to orange. The solution was added to the resin in the 
Merrifield bubbler, the bubbler was wrapped in foil to avoid any light entering and the 
reaction was carried out for 2 hr, it was made sure that the solution added was a nice yellow 
colour which indicates that the palladium has not gone off. 
 
Figure 47 shows the mechanism of the deprotection of the Aloc and allyl protecting groups 
using palladium catalyst and NMM, where the resonance stabilisation of the carboxylate and 
carbamate activates the -allyl palladium complex formed. This is then trapped by a known 
mild nucleophile N-Methylmorpholine (NMM). 
167 
It was found that barbituric acid gives a 
better result than NMM due to which barbituric acid was used. 
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Figure 47 Mechanism for allyl deprotection. 
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The deprotection was followed by washes by DMF, DIPEA 0.5 % v/v in DMF, DMF, sodium 
diethyldithiocarbamate trihydrate 0.5 % w/v in DMF, followed by the final washes with 
DMF. This was to ensure that the palladium catalyst was scavenged off the resin, where the 
DIPEA acts as a base to the barbituric acid and cleans everything whilst sodium 
diethyldithiocarbamate trihydrate acts as a ligand to the palladium. The qualitative Kaiser test 
was observed to be purple. 
 
The Fmoc group on the methionine was deprotected and this was followed by cyclisation of 
ring E (Scheme 78) using PyAOP, HOAt and DIPEA for 1 hr to give the intermediate 208 
(Scheme 78). Coupling of the activated Fmoc-Ala-OH was carried out followed by 
deprotection of the Fmoc group of alanine, followed by the cleavage of the peptide from the 
resin to give 209.  
 
From mass spectrometry the molecular weight for the peptide was visible at m/z 639 [M + 
Na]
+
 along with a peak corresponding to an oxidised peptide. The oxidation could have been 
possibly due to contact with air as the bubbler was not sealed. The peptide was not visible 
when analytical HPLC was carried out this was due to the absence of aromatic groups 
therefore purification was not carried out on the preparative HPLC.  
 
A second attempt was carried out using a Syro peptide synthesiser using a 2 mL syringe. In 
this attempt the Fmoc group from the alanine was not deprotected (Figure 48) to ensure easy 
purification via HPLC. Modifications in the reaction conditions during this attempt involved 
using 40 % piperidine for Fmoc deprotection and HOAt and PyAOP reagents during the 
lanthionine coupling instead of HBTU. The oxidised peptide was synthesised again. It was 
difficult to separate the oxidised peptide from the desired product which led to two peptides 
being isolated. From the structure it can be seen there was a possibility of oxidation of either 
the Met or Lan residues. However in this case only one sulphur atom had been oxidised and 
this was confirmed from mass spectrometry. Further NMR experiments were not carried out 
to distinguish which sulphur had been oxidised so it was difficult to predict from a 
1
H NMR 
at this stage which sulphur had oxidised. 
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Figure 48: Structures of the desired peptide and the oxidised peptides. 
 
The synthesis was repeated again using the MultiSyroTech peptide synthesiser. Highly acid 
labile NovaSyn TGT alcohol resin were used, this was to ensure easy cleavage of the peptide 
off the resin when using 94 % TFA. The resin was preloaded with Serine which was tert-
butyl protected with a loading of 0.19 mmol g
-1
. This low loading was used to prevent any 
cross linking between functional groups on the same resin taking place at 207 between the 
free amine of the lanthionine and the free carboxylic group of the lanthionine. This low 
loading also helps to prevent any aggregation of the peptide during the synthesis, which 
might interfere with any subsequent reactions. These aggregations that may take place with 
the solid support or with itself could be due to the hydrophobic effects or hydrogen bonding.  
 
The first step in the solid phase peptide synthesis involved Fmoc deprotection of serine using 
40 % piperidine in DMF for 30 min. In order to ensure good coupling of the lanthionine 
Fmoc deprotection was carried out twice on serine followed by washes with DMF after each 
deprotection. After each synthetic reaction the resin was washed 6 times with DMF to 
remove any unreacted reagents. Amino acids were not required to be activated in advance 
when the peptide synthesiser was used. Once the amino acid was added to the resin followed 
by the coupling reagents the amino acid was activated on the resin, hence the reaction time 
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was longer. All additions of standard amino acids, reagents and washes were carried out 
automatically. 
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Figure 49: Mechanism of peptide coupling using PyAOP and HOAt. 
 
Lanthionine coupling was carried out manually in the presence of PyAOP, HOAt (Scheme 
79) and DIPEA for 1 hr 15 min. The syringe was sealed with an argon balloon attached, the 
sealing’s were to make sure the amino acid in solution was not drained or leaked out. Once 
the reaction time was complete all sealing were removed and the syringe was placed back on 
the synthesiser.  
 
The Fmoc group of the lanthionine was then deprotected with 40 % piperidine over 30 min 
followed by washes with DMF, this was followed by coupling of Fmoc-His(Trt)-OH using 
less reactive coupling reagents HBTU and DIPEA over 1 hr 15 min. Fmoc deprotection was 
carried out on the histidine followed by coupling of Fmoc-Met-OH to give 206 (Scheme 79). 
 
In order to check Fmoc deprotection and coupling of amino acids were taking place, Kaiser 
tests were carried out after each synthetic step. 
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The next step involved selective deprotection of the Aloc and allyl protecting groups from the 
lanthionine using (Pd(PPh3)4 and 1,3-dimethyl barbituric acid. 
78, 146, 147, 166
 The solution was 
prepared as previously mentioned. Precautions involved carrying out the reaction manually; 
the syringe was sealed from the bottom with a cap and top with a bung, and covered with foil 
to prevent light entering. Balloon filled with argon attached to a needle was pierced into the 
syringe. The solution was added manually to the resin in the syringe and the syringe was then 
placed back onto the synthesiser and reacted for 2 hr.   
 
The deprotection was followed by DMF washes 6 times, DIPEA 0.5 % in v/v in DMF 6 
times, DMF 6 times followed by sodium diethyldithiocarbamate trihydrate 0.5 % w/v in 
DMF 8 times and the final washes with 6 times DMF. This was to ensure that the palladium 
catalyst was scavenged off the resin, where the DIPEA acts as a base to the barbituric acid 
and cleans everything whilst sodium diethyldithiocarbamate trihydrate acts as a ligand to the 
palladium.  
 
The Fmoc group on the methionine was then deprotected and this was followed by 
cyclisation of ring E (Scheme 79) using PyAOP, HOAt and DIPEA for 1 hr and 30 min to 
give the intermediate 208 (Scheme 79). Additions of reagents during the cyclisation step were 
carried out manually and the syringe was again sealed to avoid the loss of any solution. 
Kaiser tests were negative after each coupling and positive after each deprotection.  
 
Using standard amino acid coupling conditions alanine was coupled, after which the peptide 
was cleaved off the resin using a cocktail of TFA (94 %), ethanedithiol (2.5 %), water (2.5 
%) and triisopropylsilane (1 %). The resin was left in solution for 3 hr, after which the 
solution was collected and the resin was washed twice with TFA. The procedure not only 
cleaves the peptide off the resin but also leads to the cleavage of the side chain permanent 
protecting groups that are orthogonally protected to the Fmoc, Aloc and allyl protecting 
groups. TFA cocktail were collected in a Falcon tube, resin washed with neat TFA was also 
collected in the same Falcon tube, the peptide was precipitated using cold ether, centrifuged 
and then the ether layer was decanted. The procedure was repeated five times, the peptide 
was then redissolved in water which was freeze dried.  
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Scheme 79: Synthesis of an analogue of ring E of nisin. 
 
The crude product obtained from freeze drying was a cream solid, 12.3 mg of the crude 
peptide was obtained from a theoretical yield of 22 mg. Mass spectrometry confirmed the 
molecular weight of the peptide at m/z 839 [ M + H ]
+
. Analytical HPLC showed 3 major 
peaks along with minor peaks using a gradient of 10 – 60 % acetonitrile over 30 min with the 
product appearing at RT 16.80. An assumption of where the product appears was assisted by 
LCMS which showed the first peak to be the actual peptide. When a purity test was carried 
out on the crude on the LCMS it was found to be 26.3 % pure (Figure 50). It was possible to 
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get better purer sample (Appendix 20) where 68 % purity was obtained during a third attempt 
using the same procedure discussed however this was not reproducible.  
 
Synthesis of oxidised peptides was avoided during this and the third attempt. In these two 
attempts strict precautions were carried out compared to the second attempt. It was ensured 
that the syringe was sealed with argon balloon during lanthionine coupling, Aloc / allyl 
deprotection and cyclisation steps.  
Product
[M + H]+ = 839
 
Figure 50: Crude LCMS of an analogue of ring E of nisin before purification 
 
Purification via preparative HPLC using a linear gradient of 10 % – 60 % acetonitrile in 
water over 40 min isolated the pure peptide in 1.7 mg at 22.3 min (Figure 51). Mass 
spectrometry and 
1
H NMR (Figure 52) showed a clean peptide, this was confirmed by 
analytical HPLC which showed one peak at RT 16.80 corresponding to the peptide (Figure 
53). 
Product
 
Figure 51: Preparative HPLC trace of an analogue of ring E of nisin , RT 22.3 min; 
H2O/0.5 % TFA and acetonitrile/0.5 % TFA at a gradient of 10 % - 60 % acetonitrile 
over 40 min. 
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Figure 52: (a)  
 
 
 
Figure 52: (b)  
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Figure 52: (d) 
 
Figure 52:  (a) MALDI mass spec, (b) accurate mass spec, (c) proton NMR, (d) COSY 
NMR of an analogue of ring E of nisin. 
 
The 
1
H NMR was assigned with the help of a 2D NMR spectra, chemical shifts were 
compared with a list of chemical shifts for protons of standard amino acids. 
168
 protons 
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of lanthionine were the interesting assignments belonging to this peptide. Assignments of 
standard amino acids in the peptide were carried out first, chemical shifts for the proton of 
lanthionine was difficult to visualise from a 1D NMR. When cross coupling were assigned in 
a 2D NMR, coupling peaks were noticed hiding under the water residual peak, which cross 
coupled between itself and the protons of lanthionine (Figure 52, (d)). Full characterisation 
was carried out on 210 and all the NMR experiments can be found in the Appendices 21-24. 
 
 
Figure 53: Analytical HPLC trace of an analogue of ring E of nisin, RT 16.8 min; A: 
H2O/0.5 % TFA; B: acetonitrile/0.5% TFA; B gradient 10 % - 60 % B over 30 min. 
 
It has also been found that once the peptide was cleaved off the resin it requires to be purified 
straight away otherwise the peptide starts degrading. Figure 54 shows an analytical HPLC 
trace after cleavage and Figure 55 shows an analytical HPLC when the peptide started 
degrading. 
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Figure 54: Analytical HPLC trace after cleavage of the analogue ring E of nisin. A: 
H2O/0.5 % TFA; B: acetonitrile/0.5% TFA; B gradient 10 % - 60 % B over 30 min. 
 
 
Figure 55: Analytical HPLC trace of an analogue of ring E of nisin when the peptide 
started degrading. Analytical was carried out 7 days after cleaving. A: H2O/0.5 % TFA; 
B: acetonitrile/0.5% TFA; B gradient 10 % - 60 % B over 30 min. 
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Figure 56: Structures of an analogue of ring E of nisin showing proton and carbon 
chemical shifts. 
 
4.5. Synthesis of an analogue of ring D of nisin 
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Scheme 80: Synthesis of a linear peptide of an analogue of ring D of nisin. 
 
The synthesis of an analogue of ring D of nisin was then attempted with the second 
orthogonally protected lanthionine 169. 169 was incorporated as the second amino acid, and 
substituting a methionine residue as the third amino acid in place for the other lanthionine 
(Scheme 80). An analogue of ring D of nisin was synthesised with a single lanthionine bridge 
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using NovaSyn TGT resin, preloaded with His(Trt) with the  amino group Fmoc protected. 
(Teoc, TMSE / Fmoc) protected lanthionine 169 was used to prepare the analogue of ring D 
of nisin.  
 
Synthesis of ring D was carried out using a Syro peptide synthesiser using a 2 mL syringe. As 
previously described all additions of amino acids, reagents and washes were carried out 
automatically, however the lanthionine coupling, Teoc and TMSE deprotection and the 
cyclisation step were carried out manually. 
 
As ring E the first step involved Fmoc deprotection of histidine using 40 % piperidine in 
DMF for 30 min to give 214. The procedure was repeated twice to ensure good coupling of 
the lanthionine. After each Fmoc deprotection the resin was washed 6 times with DMF. 
Throughout the synthesis, after each reaction the resin was washed 6 times with DMF to 
remove any unreacted reagents. Teoc and TMSE lanthionine coupling was carried out in the 
presence of PyAOP, HOAt and DIPEA for 1 hr 15 min giving 215. 
 
The Fmoc group of the lanthionine was then deprotected followed by washing the resin with 
DMF, this was followed by coupling of Fmoc-Met-OH using HBTU and DIPEA. Fmoc 
deprotection was carried out on the methionine followed by coupling of Fmoc-Ala-OH to 
give the linear resin-bound precursor 217.  
 
The next step involved selective deprotection of the Teoc and TMSE protecting groups from 
the lanthionine using tetrabutylammonium fluoride (TBAF). Sieber 
169
 has previously used 
2.1 M TBAF to deprotect the TMSE groups. Marlowe 
170
 used 1.0 M TBAF in DMF to 
deprotect the TMSE group of a peptide on resin, the method was adapted from Ukei and 
Amemiya 
171
 where they used 0.1 M TBAF in DMF to deprotect the Fmoc group of their 
peptide. This meant during Teoc and TMSE deprotection it was probable that the Fmoc was 
also deprotected. 100 equivalents of TBAF was dissolved in DMF, the solution was added to 
the resin in the syringe and reacted for 1 hr. After the reaction the resin was washed 10 times 
with DMF to remove any unreacted reagents. However, to ensure that Fmoc deprotection was 
complete, the usual deprotection with 40 % piperidine was carried out. 
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Figure 57 shows the mechanism of the deprotection of the Teoc and TMSE protecting groups 
using TBAF. Nucleophiles that are strongly electronegative are effective nucleophiles for 
silicon which form strong bonds with the silicon upon reaction. The reaction of TBAF occurs 
via a pentacovalent silicon centre led by a nucleophilic attack of fluoride anion; this is 
permitted due to hybridisation with the vacant d-orbitals of silicon. Figure 57 shows the 
mechanism of the deprotection of the Fmoc group. 
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Figure 57: Mechanism for TMSE deprotection. 
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Figure 58: Mechanism for Fmoc deprotection. 
 
After Fmoc deprotection of the alanine residue, cyclisation of 217, to give ring D was carried 
out using PyAOP, HOAt and DIPEA for 1 hr and 30 min giving intermediate 219 (Scheme 
81). Again PyAOP and HOAt were used due to it being more powerful coupling reagent 
(Figure 49).  
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Scheme 81: Synthesis of an analogue of ring D of nisin. 
 
Using standard amino acid coupling conditions Fmoc-Lys(Boc)-OH was coupled, after which 
the permanent acid labile side chain protecting groups (Trityl and Boc) were cleaved from the 
cyclic peptide by TFA in the presence of a scavenger. The cleavage of the peptide off the 
resin and the deprotection of the side chain protecting groups were carried out in a one pot 
reaction using a cocktail solution containing TFA, ethanedithiol, water and triisopropylsilane. 
Once the TFA cocktail was reduced to a minimum volume in vacuo, the peptide was 
precipitated using cold ether, centrifuged and then the ether layer was decanted, this 
procedure was repeated 5 times. The peptide residue was then redissolved in water and freeze 
dried.  
 
18.0 mg of the crude peptide was obtained from a theoretical yield of 17.5 mg as a cream 
solid. Mass spectrometry showed the molecular weight of the peptide at m/z 880 [M + H]
+ 
(Figure 59). Analytical HPLC showed 2 major peaks along with minor peaks when a gradient 
of 15 – 40 % acetonitrile over 35 min was used with the product appearing at RT 21.55 
(Figure 60).  
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M + H
880
RMM 879
 
 
Figure 59: Mass spectrum of an analogue of ring D of nisin. 
Product
 
Figure 60: Analytical trace of the crude sample of an analogue of ring D of nisin. A: 
H2O/0.5 % TFA; B: acetonitrile/0.5 % TFA; B gradient 15 % - 40 % over 30 min. 
 
Purification via preparative HPLC using a linear gradient of 15 % – 40 % acetonitrile in 
water over 40 min isolated the pure peptide at 14.4 min giving 1.0 mg (Figure 61). Mass 
spectrometry and proton NMR (Figure 62) showed a clean peptide, this was confirmed by 
analytical HPLC which showed a single peak at RT 16.60 corresponding to the peptide when 
a gradient of 10 - 60 % acetonitrile over 30 min was used (Figure 63). 
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Figure 61: Preparative HPLC trace of an analogue of ring D of nisin. RT 14.1 min; A: 
H2O/0.5 % TFA; B: acetonitrile/0.5 % TFA; B gradient 15 % - 40 % over 30 min. 
 
 
Figure 62 (a) 
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A 2D NMR was carried out to help characterise the proton NMR this was followed by full 
characterisation of 220 (Appendices 25-29). 
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Figure 62: (a) Accurate mass, (b) proton NMR (c) COSY NMR of an analogue of ring D 
of nisin.  
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Figure 63: Analytical HPLC trace of an analogue of ring D of nisin. A: H2O/0.5 % TFA; 
B: acetonitrile/0.5 % TFA; B gradient 10 % - 60 % over 30 min. 
 
Purification of the peptide was carried out straight away to avoid any decomposition and 
oxidation. The peptide was easily separated from the impurities. 
 
The Fmoc group from the lysine was not deprotected to ensure easy purification via 
preparative HPLC and to correlate the 
1
H NMR spectra of an analogue of ring D of nisin with 
the 
1
H NMR spectra of an analogue of ring E of nisin.  
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Figure 64: Structures of an analogue of ring D of nisin showing proton and carbon 
chemical shifts. 
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4.6. Synthesis of an analogue of rings D and E of nisin 
 
After preliminary investigation of the methodology for the synthesis of the two individual 
rings, ring D and ring E, bicyclic peptide was then attempted. An analogue of ring D and E of 
nisin was synthesised containing two overlapping lanthionine bridges. The two distinct 
lanthionine residues with protecting groups orthogonal to each other were used: (Aloc, allyl) /  
(Fmoc) protected lanthionine 103 was used to prepare analogue of ring E of nisin and (Teoc, 
TMSE) / (Fmoc) protected lanthionine 169 was used to prepare analogue of ring D of nisin.  
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Scheme 82: Synthesis of the linear peptide of an analogue of the overlapping rings D 
and E of nisin.  
 
NovaSyn TGT resin, preloaded with Fmoc-Ser(tBu), was used. Again the low loading resin 
was used to prevent any cross linking between functional groups on the same resin and this 
approach had been successful when synthesising the individual rings D and E. 
 
The synthesis of the linear peptide 221 was carried on the peptide synthesiser. The resin was 
washed 6 times with DMF after each synthetic steps. The Fmoc group of serine was 
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deprotected using piperidine, this was repeated twice to ensure complete deprotection. The 
coupling of 103 was carried out in the presence of PyAOP, HOAt and DIPEA over 1 hr 30 
min. The reagents were added manually, making sure the syringe was well sealed to avoid 
losing any of the lanthionine amino acid solution. Addition of the second lanthionine 169, 
deprotection of the protecting groups of both lanthionine and cyclisations were also carried 
out manually. Additions of all other standard amino acids, reagents and washes were done 
automatically.  
 
The Fmoc group of lanthionine 103 was deprotected over 30 min followed by washings with 
DMF, this was followed by coupling of Fmoc-His(Trt)-OH using HBTU and DIPEA over 1 
hr 15 min. Fmoc deprotection was carried out on the histidine followed by coupling of Fmoc 
protected second lanthionine 169 to give 221 (Scheme 82). 
 
The next step involved selective deprotection of Aloc and allyl protecting groups from 
lanthionine 103 using (Pd(PPh3)4 and 1,3-dimethyl barbituric acid, using the same method 
which was previously used for the synthesis of the analogue of ring E 210. After all the 
washes the Fmoc group of the second lanthionine 169 was deprotected which was followed 
by cyclisation forming ring E (Scheme 83) using PyAOP, HOAt and DIPEA over 1 hr and 30 
min to give the resin-bound intermediate 223. Standard amino acid coupling conditions were 
used to couple Fmoc-Ala-OH to give 224. 
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Scheme 83: Synthesis of the analogue of the overlapping rings D and E of nisin. 
 
The next step involved selective deprotection of the Teoc and TMSE protecting groups from 
the lanthionine using TBAF. The solution was added to the syringe and reacted for 1 hr. After 
washes with DMF the base labile N -Fmoc protecting group of alanine was deprotected by 
piperidine, and cyclisation of ring D (Scheme 83) was carried out using PyAOP, HOAt and 
DIPEA for 1 hr and 30 min to give the intermediate 226. Fmoc-Lys-OH was then coupled 
followed by cleavage of the permanent protecting groups on the peptide and cleavage from 
the resin to give 141 (Scheme 83).  
 
The crude peptide obtained from freeze drying was a cream solid, 26.4 mg of crude peptide 
was obtained from a theoretical yield of 21.15 mg. Mass spectrometry showed the molecular 
weight of the peptide at m/z 1008 [ M + H ]
+ 
(Figure 65).  
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M + H+
RMM = 1007
 
 
Figure 65: Crude mass spectrum of the analogue of rings D and E of nisin. 
 
Analytical HPLC of crude peptide showed a hump with two slightly distinguished peaks 
along with many small peaks when a gradient of 15 % - 50 % acetonitrile was used (Figure 
66). Different gradients were used in an attempt to obtain a good separation however this was 
not successful. 
 
 
Figure 66: Crude analytical HPLC trace of the analogue of rings D and E of nisin. A: 
H2O/0.5 % TFA; B: acetonitrile/0.5 % TFA; B gradient 15 % - 50 % over 30 min. 
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A test preparative HPLC was carried out to see whether a separation could be observed 
during purification. Fractions were collected every 3 to 5 min, and mass spec was carried out 
on each fraction to identify where the product was. From the mass spectrums it was 
discovered that the product was in fraction 22.33 – 27.58 min (Figure 67) however no peaks 
could be distinguished on the HPLC spectra. 
 
Figure 67: Test preparative HPLC trace of an analogue of rings D and E of nisin. A: 
H2O/0.5 % TFA; B: acetonitrile/0.5 % TFA; B gradient 15 % - 50 % over 35 min. Trace 
in red shows absorption at 214 and trace in blue show absorption at 254. 
 
The crude sample was put through preparative HPLC in couple of runs, when the time 
reached 22 min the fractions were collected every min until 28 min to find the retention time 
of the product. From these runs mass spectrum (Appendix 30) showed that the product comes 
between 26.1 – 27.0 min. A proton NMR was carried out. From 1H NMR it was hard to 
assign peaks however it was observed that the product was present, the Fmoc group was 
clearly visible. Also where the and protons of the amino acid residues should be present, 
peaks were obtained however they were broad and overlapping which made the assignments 
impossible. 
 
From analytical HPLC it was seen that the sample obtained was much cleaner compared to 
that of the crude. A sharp peak was seen along with a slightly broad peak which was very 
promising (Appendix 31). 
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An attempt was carried out to separate the above two peaks, the peptide was dissolved in 50 
% EtOH and 50 % H2O which was then centrifuged. The solvent was decanted and the 
procedure repeated. LCMS was carried out using a gradient of 10 % - 90 % acetnoitrile with 
0.1 % TFA to see whether the product was present in the supernatant. A nice peak of the 
product was present along with another unknown peak, LCMS of the pellet sample also 
showed the product however there was less of a hump in the supernatant sample compared to 
the pellet sample (Appendix 32). 
 
Analytical HPLC trace of the pure sample after the third purification showed a sharper peak 
however the hump was still present (Figure 68). A 
1
H NMR was attempted with this sample, 
however there was insufficient material to obtain an assignable spectra. 
 
 
Figure 68: Analytical HPLC trace after the third purification. A: H2O/0.5 % TFA; B: 
acetonitrile/0.5 % TFA; B gradient 10 % - 90 % over 30 min. 
 
Synthesis of the analogue 141 rings D and E of nisin was attempted again using the same 
procedure as previously described. The mass spectrum obtained from the crude peptide 
showed a single product (Figure 69), however HPLC revealed that this was not the case. 
Analytical HPLC proved to be much better, two peaks could be distinguished and were better 
resolved (Appendix 33). 
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Product
 
 
Figure 69: Mass spectrum of rings D and E of nisin obtained from the second attempt.  
 
During the first attempt when, purification was carried out, 80 % of the material was lost 
during preparative HPLC. To avoid this huge loss a Varian Bond-Elute C18 column was 
used. Here the column was first washed with 100 % methanol then with 100 % water to 
saturate the column. The crude peptide was dissolved in minimum amount of water and 
loaded onto the column, the solvent was collected as flow through and then the column was 
loaded with 100 % water. Table 9 shows the eluant conditions for the fractions collected 
during the column. 0.1 % TFA in acetonitrile was used to wash the column. Mass 
spectrometry showed that the product was removed from the column and collected in fraction 
16 (Table 9, Fraction 16), an analytical trace can be seen in the appendices (Appendix 34).      
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Fraction Water (%) Methanol (%) Acetonitrile (%) 
 
TFA (%) 
Flow through - - - - 
1 100 0 - - 
2 95 5 - - 
3 90 10 - - 
4 85 15 - - 
5 80 20 - - 
6 75 25 - - 
7 70 30 - - 
8 65 35 - - 
9 60 40 - - 
10 50 50 - - 
11 40 60 - - 
12 30 70 - - 
13 20 80 - - 
14 10 90 - - 
15 0 100 - - 
16 - - 99.9  0.1 
 
Table 9: Eluant conditions for overlapping rings D and E peptide purification. 
 
Fraction 16 obtained from the C18 column was then analysed by LCMS. From mass 
spectrum it was observed the product was present in the sample so purifcation of this sample 
was attempted through LCMS where fractions were collected. The trace showed two peaks, a 
sharp peak and a slightly broad peak which were partially seperated (Figure 70). 
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Figure 70: Purification by LCMS, trace observed during purification.  
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The fractions collected during LCMS purifcation were freeze dried to give a cream fluffy 
solid in low yield. However, the spectra observed were not clean due to which it was difficult 
to assign peaks. Due to the lack of material further purification was not carried out. 
 
Third synthesis of the analogue 141 rings D and E of nisin was attempted using the same 
procedure as previously described. 
 
Purifications via preparative HPLC were problematic because of the tailing of impurities 
which led to a hump this was observed from the first attempt, C18 SPE columns were 
therfore used in the second attempt. C18 SPE columns were also used for purification from 
the third synthesis. This attempt involved carrying out a two stage purification procedure 
using C18 SPE column. It was discovered in the previous purification attempt that the 
product was collected when acetonitrile was used instead of methanol. The column therefore 
was saturated with acetonitrile followed by water. Once the crude sample solution was loaded 
onto the 100 mg column the eluant was collected as a flow through, Table 10 shows the 
eluant used for the purification.  
 
Fraction 
Water (%), 0.15 
(%) TFA  
Acetonitrile (%),   
0.15 (%) TFA Water (%) 
Flow through - - - 
1 - - 100 
2 95 5 - 
3 90 10 - 
4 85 15 - 
5 80 20 - 
6 75 25 - 
7 70 30 - 
8 65 35 - 
9 60 40 - 
10 50 50 - 
11 40 60 - 
12 30 70 - 
13 20 80 - 
14 10 90 - 
15 0 100 - 
 
Table 10: Eluant conditions for overlapping rings D and E purification. 
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After freeze drying mass spectrometry were carried out on all the fractions that were 
collected. The peptide eluted in fraction  6 (Table 10, Fraction 6), analytical trace showed a 
sharp peak with a much smaller hump compared to previous spectras (Figure 71), however 
NMR obtained showed broad peaks. Analytical HPLC were carried out on all the fractions 
that were collected, mass spectrometry clearly tied in with the analytical. Most of the 
fractions showed a hump with the same peak which was representing an impurity. 
 
 
Figure 71: Analytical trace of fraction 6 collected at 25 % acetonitrile. A: H2O/0.5 % 
TFA; B: acetonitrile/0.5 % TFA; B gradient 10 % - 60 % over 30 min. 
 
A second purification was carried out on the fraction 6 (Table 10) collected at 25 % 
acetonitrile, Bond-Elute C18 column with a capacity of 50 mgs was used. The elutant used 
were both deuterated water and acetonitrile in 0.15 % TFA (Table 11), fractions were directly 
collected into NMR tubes, this was to avoid transferring samples which may have led to 
sample loss.  
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Fraction 
Water (%), 0.15 
(%) TFA  
 Acetonitrile (%),   
0.15 % TFA 
Flow through - - 
1 83 17 
2 81 19 
3 79 21 
4 77 23 
5 75 25 
6 73 27 
7 71 29 
8 60 40 
9 50 50 
10 40 60 
11 30 70 
12 20 80 
13 10 90 
14 0 100 
15 0 100 
 
Table 11: Eluant conditions for purifications of overlapping rings D and E. 
 
Mass spectrum analysis indicated majority of the product was obtained in fraction 4 (Table 
11) in less than 0.1 mg, and a slightly better analytical trace was obtained (Figure 72).  
 
 
Figure 72: Analytical trace of product 141 after second SPE column collected in fraction 
4 (23 % acetonitrile). A: H2O/0.5 % TFA; B: acetonitrile/0.5 % TFA; B gradient 10 % - 
60 % over 30 min. 
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Figure 73: Proton NMR of an analogue of rings D and E of nisin. 
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NMR experiments were carried out on the sample, different solvents such as D2O, deuterated 
acetonitrile, deuterated TFA, and deuterated methanol were used. NMR’s obtained for the 
peptide from different solvents were all similar with very broad peaks. The best 
1
H NMR 
obtained was in D4-Methanol (Figure 73) however this itself was very difficult to assign. 
There was still presence of impurities this possibly could be PEG which has also come 
through during the cleavage step which is causing the hump in the analytical HPLC trace and 
also causing the peaks of the proton NMR to be broad. Another possibility could be due to 
the aggregation of the peptide or conformational constrainsts of the peptide however this 
should not broaden the Fmoc group.   
 
The sample had very poor solubility properties which made it very difficut to get all samples 
in solution. There was very little sample with traces of impurities which was large compared 
with the sample. Also there was not enough sample for a 2D NMR due to these reason it was 
difficult to assign peaks. 
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4.7. Conclusion 
 
The orthogonally protected bis-amino acid (Teoc, TMSE) / Fmoc lanthionine 169 has been 
successfully synthesised. The synthetic route has been optimised, permitting the necessary 
scale up required for ensuing solid phase peptide synthesis has been successful (Chapter 3). 
 
Using a quadruply orthogonal protecting group strategy, analogue of the overlapping rings D 
and E of nisin has been synthesised. An analogue of the ring E has been synthesised for the 
first time using previous developed (Aloc, allyl) / Fmoc lanthionine 103 (Chapter 3). An 
analogue of the ring D has also been successfully synthesised for the first time using newly 
developed (Teoc, TMSE) / Fmoc lanthionine 169 (Chapter 3).  
 
Having the two lanthionines 103 and 169 with protecting groups orthogonal to each other and 
also to the transient Fmoc and permanent tBu/Boc protecting groups enabled first solid phase 
peptide synthesis of an analogue of rings D and E of nisin 141.  
  
Purification of individual rings D and E were carried out without any problems and full 
characterisation were obtained. In the case of the overlapping rings the mass recovery was 
good however the purification was poor. Possible reasons could be as a result of aggregation 
of the peptide, slowly interconverting conformers or possibly due to isolating PEG from the 
resin/linker during the cleavage step, and another main issue was poor solublity.  
 
Rings D and E of nisin both contain methyl lanthionine, however due to time constraints it 
was not possible to further develop this chemistry to give the required orthogonally protected 
methyl lanthionine building blocks. 
 
In conclusion an effective methodology for the solid phase peptide synthesis of peptides 
containing overlapping lanthionine rings has been developed. 
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4.8. Future work 
 
Although the analogue 141 of the overlapping rings D and E has been synthesised, further 
work is necessary to optimise the purification conditions. It will be necessary to repeat the 
synthesis using different resins and linkers, as it is possible that impurities from the final 
cleavage steps are causing the problem in purification. Removal of the Fmoc group prior to 
purification to give a more hydrophilic peptide will also be attempted.  
 
Further work on SPE column will be carried out to optimise conditions for the purification of 
the overlapping rings, to get better results other techniques such as gel filtration may be 
carried out along with SPE columns. 
 
Finally, with larger quantities of pure peptide in hand, a full structural analysis by NMR will 
be possible, followed by bioconjugation to mersacidin and actagardine to afford hybrid 
lantibiotics. 
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5. Validation  
 
Validation involves establishing documented evidence of a specific process which provide 
assurance that the process will reliably and constantly produce a product that meets the 
determined properties, specifications and quality attributes when manufacturing. This will 
include health and safety, quality and efficacy. 
 
5.1. Introduction 
 
The work presented in this thesis show that Aloc, allyl / Fmoc lanthionine 103 has been 
synthesised using the published procedure, 
124 
and an efficient and good yielding pathway has 
been developed to synthesise the Teoc, TMSE / Fmoc lanthionine 169 in a small scale. These 
amino acids were incorporated into cyclic peptides using solid phase peptide synthesis and 
therefore an effective methodology has been developed for the solid phase peptide synthesis 
of peptides containing the overlapping lanthionine rings in a small scale. 
 
Prior to the synthesis of these two final amino acids there are multiple reaction steps which 
have their own regulatory requirements for performance qualification, process design, 
process performance qualification, installation qualification, operational qualification and 
process operation. The regulatory requirements concerned to biopharmaceutical manufacture 
are very strict and the requirements for the synthesis of the two amino acids and the peptide 
in the biopharmaceuticals will be discussed. 
  
It is important to satisfy regulatory requirements on health and safety and produce efficient 
and economically viable products where the process step operates correctly within the 
process limits, and the performance objectives are met reliably and consistently during 
manufacturing. Analysis will be carried out to confirm product quality is achieved under the 
regulatory of FDA (USA) and MCA (EU/UK).  
 
This chapter will discuss two scenarios: 
1. Batch synthesis of the two orthogonally protected lanthionines  
2. Automated synthesis of the overlapping rings D and E peptide  
in an industrial context and suggestions in marketing of the peptide. The specific objectives 
include: 
                                                 
 This chapter is included as part of the UCL requirement for the award of the EngD degree. 
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- Validation required to be carried out on design, installation, operation, process, 
systems, performance qualification, cleaning and purification for the synthesis of the 
two amino acids and the peptide.  
- Validation and evaluation of industrial implementations  
 
5.2. Validation of lanthionines 103 and 169  
 
5.2.1. Design qualification 
 
The synthetic route to the two unusual amino acids 103 and 169 requires to be checked to 
ensure the protocols are successful and meet the process design requirements for the desired 
compounds. This then leads to the lanthionines ready for incorporation into solid phase 
peptide synthesis eliminating the formation of by-products such as 189 and 190 (Chapter 3) 
during manufacturing.  
 
At the design stage the synthetic process specifications include the chemical reagents selected 
for the reactions, mass, volumes and equivalence of the reagents, where the reagents are 
purchased from, reaction conditions (i.e. inert atmosphere), temperature, time and pH, 
reaction work up and type of purification method. Operating equipment such as the column 
size, diameter, flasks size, glassware (such as round bottom flasks, syringes, measuring 
cylinders, reflux condenser, chromatography columns), magnetic stirrer, hot plates, ice baths, 
thermometer, and Syro peptide synthesiser and a centrifuge (Chapter 3 and 6). It is important 
to ensure that during this stage that all critical reactions are monitored and characterised, and 
that the critical parameters affecting the process and its key quality attributes are identified 
and considered. 
 
Before operating at the large manufacturing scale, a pilot plant scale process would be carried 
out for the synthesis of the two lanthionines to ensure that the process is robust and likely to 
be successful at the larger scale. Small scale reactions (Chapter 3) have enabled an 
understanding of how to control undesired compounds, understand the process and discover 
the product impurities. The product qualities of the lanthionines were primarily determined 
by NMR, mass spectrometry and optical rotation. The effectiveness of the process designs 
has been confirmed from the small scale reactions carried out during the synthesis of 
lanthionine 103 and 169.   
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5.2.2. Installation qualification 
 
Performing an installation qualification verifies that all equipment are built and installed per 
design specifications. For small scale reactions the assembling of the equipment were very 
simple, installation qualification was not required at this stage. An argon cylinder was already 
connected to a dual manifold schlenk line containing several ports located in the fume hood. 
This dual manifold schlenk line has the second manifold connected to a high vacuum pump. 
The magnetic stirrer and hot plate employs a rotating magnetic field and means for heating 
the reaction, which also did not require any installation.   
  
                                           
At large scale, reactors with impellers will be required for efficient mixing. Therefore, 
overhead-stirring with screw impellers may be essential to obtain satisfactory results at pilot-
plant scale and large scale, where agitation rates of 220 - 500 rpm will be more than 
adequate.  It will also be important to ensure that large argon cylinders or tanks are directly 
connected to large scale reactors to avoid exposure of oxygen to reactions which require inert 
conditions. In-process control requirements such as temperature and pH will require installing 
for critical Mitsunobu and Aloc protection reactions. At larger scale more complicated valves 
will be required for the addition of reagents and solvents and clean-in-phase.  
 
5.2.3. Operation / Cleaning validation 
 
Thorough cleaning will be carried out on all glassware to ensure all remnants of prior 
contaminating materials are removed. Glassware/reactors will be cleaned manually to remove 
contaminants and then rinsed with de-ionised water. This will be followed by the process 
which includes cleaning-in-place. All manually cleaned glassware will be placed in an 
automated dishwasher at 80 ºC. Once the cleaning-in-place process is complete, 
glassware/reactors will then be rinsed with acetone and placed in an oven at 100 ºC for 24 hr.  
 
Glassware that are not clean from the cleaning-in-place process; a second process will be 
carried out involving cleaning-out-of-place process, where manual cleaning will be 
supplemented, followed by cleaning-in-place process.  
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Inspection of glassware will be carried out to ensure the cleaning method is correct, mass 
spectrum of clean glassware can be carried out; if impurities are present in the spectrum then 
contaminants are present on the glassware. If this problem occurs then the temperature set for 
cleaning-in-place process will be raised higher, and the washing detergent will be changed. 
 
 Equipment
Clean Equipment
Sampling
3 consequtive runs
Washer protocol
Manual wash protocol
Mass spec:
Cleaning Agent
Contaminants from 
reaction
All results are within parameters
Cleaning  procedures are performed in 
normal process parameters
Prove hold times  
 
5.2.4. Process and factors affecting product quality  
 
The use of the orthogonally protected lanthionine as crucial building-blocks for solid phase 
peptide synthesis (Chapter 4) may be of benefit to industrial applications. These orthogonally 
protected lanthionines show potential for the production of biopharmaceuticals, such as for 
the synthesis of other overlapping peptides such as cinnamycin. The qualities of the 
lanthionines were confirmed by the yield, mass spectrometry and NMR (Chapter 3 and 6).  
 
Synthesis of the two lanthionines and the procedure for the synthesis can be seen in Chapter 3 
and 6 (Scheme 36 and 68). It is important to ensure that the starting materials are pure. 
Sampling of the starting materials was carried out by NMR to confirm the purity of the 
commercially purchased reagents. 
 
tert-Butyl protected cystine 145 and Tce protected cystine 192 are both key starting materials 
in the synthesis of the orthogonally protected lanthionines 103 and 169, and the ability to 
obtain kilogram quantities of 145 and 192 was important for the total synthesis. It is 
important to ensure that perchloric acid is added dropwise in the presence of a glass shield for 
safety precautions; due to perchloric acid being explosive this may be a safety issue for the 
operation of large scale reaction processes. Experimental technique during perchloric acid 
reaction involves the reaction to be carried out in Pyrex glass but in the case of large-scale, 
reactor vessels made of chemically pure titanium or 316 stainless steel is required with 
efficient impellers for liquid reaction. A well-ventilated room, with forced draft and non-
combustible construction is also required. Tce protection of the carboxylic acids for the 
synthesis of 192 may also be problematic during large-scale reactions due to the 
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carcinogenicity and highly flammable properties of benzene. Due to perchlorate and benzene 
these reaction steps may need modifying when large-scale reactions are carried out. An 
alternative safer approach may need to be investigated for the protection of the carboxylic 
acids as in both cases, the solvent and acid will be utilised as industrially-unfriendly 
chemicals.  
 
The Mitsunobu reaction is a critical reaction and critical process parameters needs to be 
considered. This is considered as the first part of performance qualification as this will have 
an impact on the product quality. The temperature requires to be maintained at -2 ºC to make 
sure high yields of the product are obtained. Good temperature monitoring is required. In the 
case of small scale reactions a cryostat was used to maintain the temperature. During large 
scale it will have to be ensured that temperature sensors are installed which will alert if there 
are any changes to the temperature.  
 
Another critical reaction is the Aloc protection of lanthionine 103 it is important to ensure the 
pH is between pH 7 and pH 8 before addition of the allyl chloroformate. During the small-
scale reaction the pH was easily monitored using pH paper. A pH sensor will be required for 
large-scale reaction processes where the sensor will need to be directly connected to the 
large-scale reactor.  
 
The final critical reaction involves the hydrogenation reaction to deprotect the benzyl group 
of 185 to give 181. Safety aspects of using hydrogen gas would likely lead to scale-up safety 
issues and therefore might cause difficulties for industrial synthesis making this protocol 
unsuitable for larger scale use, which means an alternative may be required. However the 
requirements for large scale would include using a pressure reactor vessel with efficient 
impellers for gas-liquid reaction. The selection of the pressure vessel will have to be made 
keeping in mind the cleanability & product impurity profile. Degree of agitation, pressure, 
temperature ratings and space availability. The vessel will be required to have features such 
as optimum utilisation of gas, reliable containment of gas and the product of the reaction. The 
vessel must have high vacuum capability via dry seal pumps or utility vacuum via liquid ring 
pumps. Once the reaction is complete gases are vented through local scrubbers to ensure 
complete destruction of any hazardous or flammable vapours.  
 
The remaining protocols (typically 10- 13 steps) are industrially amenable since the reagents 
used are of minimal toxicity risk and the reaction proceeds in benign solvents and at 0 ºC to 
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ambient temperatures. The ease of the chemistry involved in these reactions makes these 
protocols suitable for further scale up activities. The protocols designed achieve the desired 
and intended results reliably and reproducibly meeting critical quality acceptance criteria. 
Large scale reactions will include carrying out reactions in 500 - 700 g scale in order to 
obtain large amounts of lanthionines, which are ready for incorporation into solid phase 
peptide synthesis. 
 
From the small scale reactions design qualification (DQ), installation qualification (IQ), 
operational qualification (OQ) and performance qualification (PQ) have been checked and 
proved to be successful. 
 
Product: Products synthesised will be kept in vials under inert conditions and stored in fridges 
to avoid any by-products from forming and any contamination taking place. 
 
Process environment: Reactions will be carried out at room temperature or as stated in the 
protocol e.g. Mitsunobu. Light will not affect the reaction process, temperature will not affect 
reaction rates other than those reaction stated to be kept at certain temperatures e.g. the 
Mitsunobu reaction. 
 
5.2.5. Purification validation 
 
Validation is required on purification to ensure that it is capable to remove impurities. This is 
the third part of performance qualification which reduces impurities and contaminants. 
Purification will be performed by column chromatography. 
 
Depending on the quantity of materials column dimension will vary. Standard flash column 
chromatography and reverse-phase chromatography will be carried out for purification. After 
each chromatography silica waste will be placed in a container which will be disposed to a 
contractor and clean in-place will be used. Purification methods have been optimised during 
small scale reactions, solvents and gradient has been selected for each reaction to provide 
pure sample, Rf values for each compound has been confirmed (Chapter 6). 
 
Columns will be packed with silica gel with a length of 15 cm however the diameter will 
depend on the column dimension. It will be ensured that no air bubbles are formed inside the 
pack to avoid dead space or change in the flow rate thus leading to changes in the output of 
the compounds. Air pressure will be used which will be maintained manually.  
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Column Equilibration
Loading
Washing
Elution
Column packing
Column Performance
ProductIsolation
 
 
Purification by chromatography was easily handled during small scale it may be an issue 
when large scale products need to be purified. Modification of purification by column 
chromatography may be investigated to find alternative methods for purifications such as 
recrystallisation to save time, cost and volume of solvents during large scale. However 
modification will be avoided on purification on lanthionines 103 and 169 by reverse phase 
chromatography.  
 
5.3. Validation of an analogue of the overlapping rings D and E of nisin 
141 
Peptide
reactors
Amino acid 
reactors
Reagents
bottles
Robotic arms
Three way valve
Vortex 
speed
 
5.3.1. Design qualification, installation qualification, operational qualification and 
purification 
 
Syro I an automated, computer controlled peptide synthesiser will be used to synthesise the 
overlapping rings D and E of nisin which is based on a one arm pipetting robot. The robotic 
arm contains a pipette tip that is connected to a pump with a tube and a three way valve. The 
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robotic arms can sample reagents in bottles or reactors and deliver to its chosen reactor.  
There is one Type U reactor block accepting 2, 5 and 10 mL reactors (syringes) and the 
vortex will guarantee optimal mixing of the reactants. All containers, reactors, and bottles are 
equipped with inert gas. Digital injection pumps allow injection of samples, and solution into 
the reactor. The Syro peptide synthesiser and the centrifuge do not require the facility design 
aspect as both equipments are already up and running. This is to confirm that the equipments 
are operating accurately to suit the specifications of the process. This includes the vortex of 
the peptide synthesiser, speed of the centrifuge and the speed of the stirrer plate therefore 
installation qualification is not required at this stage as the equipment is already set up and 
running. Operational qualification was carried out to ensure that the correct speed was used 
for the agitation during peptide synthesis.  
 
A small-scale reaction was carried out to obtain the specifications for the process. The 
program was set up in order to synthesise the desired peptide. Calculation for all amino acids, 
solvents and peptide sequence were carried out using Syro xp software. From this small-scale 
reaction it was confirmed all parameters were accomplished to give the desired peptide 141.  
 
The second part of performance qualification involves demonstrating that the manufacturing 
process is consistent. Reactions will be carried out at manufacturing scale using the protocols 
of small-scale peptide synthesis which confirm DQ, IQ, OQ and PQ where the objectives 
were met and all of these were analysed. Commercially available amino acids will be 
purchased to save time.  
  
Batch production will be carried out to synthesise the overlapping rings on the automated 
peptide synthesiser. This requires a simple process validation, where there is no temperature 
mapping, 10 peptides will be synthesised in one go, disposable reactor vessel (syringe) will 
be used to place the resin linker. The use of disposable reactor vessel reduces the cost load, 
allows process and validation development prototyping, reduce validation loads and allow 
scale down. It is a single use throw away, which is chemically clean and sterile.  
 
All reagents and amino acids will be weighed out when the resin is being soaked in DMF. 
Solvents will be prepared and delivered into the bottles, and the amino acids will be placed in 
the vials and placed in the rack. The synthesis will be carried out under inert conditions.  
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The critical step during the peptide synthesis is the first Fmoc deprotection of the amino acid 
loaded on the resin. In order to ensure that deprotection takes place, Fmoc deprotection will 
be carried out twice. The other critical parameters are the lanthionine coupling, deprotection 
of the protecting groups of the lanthionine and cyclisation of the rings. These steps will be 
carried out manually to ensure that extra care is given.  
 
Purification of the peptide will be carried out using in house Preparative HPLC which again 
will not require facility design qualification as the equipment is already installed and running. 
Another purification method will include using Bond-Elute SPE columns which will be 
purchased commercially, this will also reduce validation. Issues on purification (Chapter 4) 
were encountered during small-scale reactions and so an alternative method may be required 
during manufacturing scale.  
 
5.4. Industrial implementation 
 
The purpose to synthesising an analogue of rings D and E of nisin was to develop a 
methodology to cyclise complicated overlapping rings in a peptide. It is assumed that this 
peptide may have biological activity however it is unknown. It will be a benefit to industries 
if this peptide has antibacterial activity and therefore manufacturing in a large scale will be 
necessary before marketing the analogue of rings D and E of nisin.  
 
It is important to demonstrate to the industrial companies the biological activity of peptide 
141 therefore scaled down pilot plant is required to be carried out which allows the company 
to quickly evaluate the potential benefits of the product to their company. Industrial 
manufacture is essential once the approval by the management team is confirmed for the 
capital investment of an analogue of rings D and E of nisin 141. Planned time scale for the 
manufacturing synthesis can be seen below for the two lanthionines and the final peptide.  
 
10 or more years ago manufacturing of peptide therapeutic containing >30 amino acids were 
stated as being difficult and expensive. 
172
 High production cost of US $75-100 per gram per 
amino acid residue 
173
 associated with synthetic peptides in the pharmaceutical industry is 
correct however only when the production is carried out in a few kilo grams. When 
production is carried out in a pilot plant capacity of 100 kg per year the cost should drop to 
$7.5-10 and to $1 per gram per amino acid residue when the production is carried out in a 
multi-tonne per year. 
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The industrial manufacture will include requirements of: 
- 2 large reactors with sensors allowing automated monitoring of pH and temperatures, 
direct connection of gas cylinders for inert conditions.  
- Rotary evaporators which can efficiently and gently remove large volumes of solvents 
from samples by evaporation.  
- Cost-effective production scale chromatography 
- Automated peptide synthesiser, power supply, all reagents, solvents, amino acids  
- Electricity, water and finally the resin.  
 
The set up cost depending on all equipments and reagents at 400-700 kg ranges from 
$238350 - $588004 (£150000 - £370000).  
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Planned timeline for the synthesis of the two orthogonally protected lanthionine 
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A number of issues need to be considered and developments of alternative methods are 
required which may otherwise cause a barrier to manufacturing at industrial scale. These 
include the change in reaction solvent benzene, perchloric acid, hydrogenation reaction 
(Chapter 3 and 6) and the issues of purification of the final peptide (Chapter 4 and 6).   
 
In summary this chapter has evaluated and justified manufacturing of analogue of rings D and 
E of nisin 141 at industrial scale. A review on design, installation, operation, process, 
systems, performance qualification, cleaning and purification for the synthesis of the two 
amino acids and the peptide were carried out.   
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Planned timeline for the synthesis of the overlapping rings D and E of nisin 
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6. Experimental 
6.1. Characterisation procedures and instrumentation 
Unless specified all reagents were obtained from chemical suppliers with no further 
purification. THF and CH2Cl2 were dried over anhydrous alumina columns, 
174
 moisture 
levels were usually <15 ppm by Karl Fischer titration. Anhydrous methanol, anhydrous 
benzene and anhydrous triethylamine were purchased from Sigma-Aldrich in Sure/Seal™ 
bottles. Water was HPLC grade or distilled. Ether refers to diethyl ether and brine to 
saturated sodium chloride solution in water. Ethanol refers to ethanol 96 % v/v unless 
otherwise stated. Petroleum ether refers to petroleum ether 40- 60 %. 
 
1
H and 
13
C NMR spectra were recorded on Bruker AVANCE III 600 (600 MHz), Avance 500 
(500 MHz), Varian VXR 400 (400 MHz) and Bruker AC300 (300 MHz) spectrometers, using 
CDCl3 and CD3OD solvents.  The chemical shifts (δ) were given in ppm units relative to 
tetramethylsilane, and coupling constants (J) are measured in Hertz. Proton 
1
H NMR 
multiplicities are shown as s (singlet), d (doublet), t (triplet), m (multiplet), dd (doublet of 
doublet), bs (broad singlet), bd (broad doublet), bt (broad triplet) and bm (broad multiplet). 
13
C signals were assigned from DEPT, HSQC and HMBC spectra.  
 
Electrospray mass spectra were recorded on a Thermo Finnegan MAT 900XP and high 
resolution electrospray mass spectra on a Waters LCT Premier XE spectrometer. MALDI-
TOF mass spectra were recorded on a Waters Micromass MX instrument. LCMS on a Waters 
Aquity UPLC – SQD instrument. FAB mass spectra were recorded using a VG70-SE mass 
spectrometer. 
 
Melting points were determined using a Gallenkamp instrument. 
 
The cryostat used was a Radleys Huber TC50E. Optical rotation measurements were all 
measured at 25 °C on a Perkin-Elmer model 343 polarimeter. IR spectra were recorded on a 
Perkin-Elmer Spectrum 100 FT-IR spectrometer in chloroform and methanol solutions.  
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Thin layer chromatography was performed on Fluka silica gel with fluorescent indicator (254 
nm); layer thickness 0.2 mm. The spots were visualised with U.V. light, and also by dipping 
in: ninhydrin in ethanol; bromocresol green; potassium permanganate; and PMA, as 
appropriate. Normal flash column chromatography was carried out using silica gel with 
particle size < 60 μm. Reverse phase TLC was carried out on Merck RP-F254 plates. Silanized 
silica60 gel purchased from BDH was used for reverse phase chromatography. Reverse phase 
chromatography was carried out as follows the compound was dissolved in the minimum 
amount of acetonitrile. This solution was then diluted approximately 10-fold with saturated 
aqueous sodium bicarbonate solution 20 % to give an emulsion. The column was loaded with 
the emulsion and collected as flow through. 20 % bicarbonate solution was used as the eluant 
for one column width followed by one column width of 10 % acetonitrile in 20 % bicarbonate 
solution, then 20 % acetonitrile followed by two column width of 30 % acetonitrile followed 
by 40 %.  TLC was carried out in an eluant made up of 40 % acetonitrile in 20 % bicarbonate, 
and observed using U.V. light. Acetonitrile was removed in vacuo, concentrated HCl was 
added to the collected fraction containing the product to reach pH 3 or below followed by 
addition of NaCl and CH2Cl2. Extraction was carried out using CH2Cl2 or chloroform. 
 
All amino acids, coupling reagents and resins were purchased from Novabiochem or 
Perseptive Biosystems. Peptides were synthesized using a Syro I multiple peptide synthesiser 
(MultiSynTech GmbH) using solid phase peptide Fmoc strategy. Most steps were carried out 
using automated synthesiser protocols, however lanthionine coupling steps, orthogonal 
deprotection steps with Pd(PPh3)4 or TBAF, and on-resin cyclisation steps with PyAOP and 
HOAt were carried out manually. 
   
A qualitative Kaiser test
 165, 175
 was carried out to check for the presence of free amines as 
follows. The resin was manually washed with CH2Cl2 to remove traces of DMF, eliminating 
any effects from possible interfering impurities. Several resin beads were removed and placed 
in an Eppendorf vial, and 4 drops of each Kaiser test solution were added, in order from 
solution 1 to 3, and heated at 110 °C for 5 min. A purple/red/blue colour indicates a positive 
Kaiser test, indicating the presence of free amines, while a clear yellow solution indicated a 
negative result. 
Solution 1: KCN (2 ml, 0.001 M) in pyridine (98 mL) 
Solution 2: Ninhydrin (5 % w/v) in t-butanol 
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Solution 3: Phenol (80 % v/v) in t-butanol 
 
Peptides were purified by preparative reverse phase HPLC and analysed by analytical reverse 
phase HPLC, with aqueous TFA (0.1 % v/v) and acetonitrile (with 0.1 % TFA, v/v) as 
solvents. Preparative HPLC was carried out with Varian Prostar 210 instrument with a 
Galaxy chromatography workstation. A Wide Pore C18, 25 cm x 21.2 mm, 10 m column 
was used. Analytical HPLC was carried out on Varian Prostar 410 instrument with a Star 
chromatography workstation. A Wide Pore C18, 25 cm x 4.6 mm, 10 m and Onyx 
Monolithic C18, 100 x 3.0 mm columns were used.    
 
Bond Elute C18 Solid Phase Extraction (SPE) columns (Agilent) were used for peptide 
purification (of rings D and E). 
 
Thermo Finnigan Surveyor LCMS LCQ DECA XP plus HPLC C18 column Agilent 
technologies was used for mass spectrometry and separation. 
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6.2. Experimental section 
 
(R,R)-Cystine bis-tert-butyl ester 145 
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H2N
O O
S
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Hazard 
Metal perchlorates are explosive, and as a safety precaution this reaction was carried out 
behind a blast shield. 
 
L-cystine 144 (10 g, 82 mmol) was suspended in perchloric acid (70 % v/v, 15.6 mL, 259 
mmol, 4 equiv) and tert-butyl acetate (100 mL) was added to the slurry. Two immiscible 
layers were formed which disappeared on stirring. The reaction was carried out at room 
temperature, after 2 hr a white precipitate appeared in solution. The reaction mixture was 
stirred for a further 72 hr after which it was cooled in an ice bath for 30 min. Sodium 
hydroxide (2 M, aq) was slowly added until the solution reached pH 11. The product was 
extracted with ether (6 x 100 mL) and ethyl acetate (6 x 100 mL) the organic layers were 
combined and dried over anhydrous sodium sulphate. Removal of solvents in vacuo yielded 
the title product 145 as pale yellow oil, identical by NMR to the literature. 
123
   
 
Yield: 5.22 g, 14. 8 mmol, 36 %; 
NMR: δH (300 MHz, CDCl3), 3.66 (2 H, dd, J = 7.8, 4.5 Hz, 2 x CHCH2S), 3.10 (2 H, dd, J = 
13.4, 4.5 Hz, CHCHHS), 2.84 (2 H, dd, J = 13.4, 7.8 Hz, 2 x CHCHHS), 1.44 (18 H, s 2 x 
CO2C(CH3)3). 
 
NN’-Bis(9-fluorenylmethoxycarbonyl)-(R,R)-cystine bis-tert-butyl ester 146 177 
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Diamine 145 (5.22 g, 14 mmol) and 9-fluorenylmethoxycarbonyl chloride (7.67 g, 29.6 
mmol, 2 equiv) were dissolved in THF (152 mL). The reaction was cooled in an ice bath, and 
NMM (3.26 mL, 29.6 mmol, 2 equiv) was added dropwise. The reaction went cloudy yellow 
and the resulting mixture was stirred for 3 hr. Ethyl acetate (400 mL) was added and the 
mixture was washed with potassium hydrogen sulphate (5 %, aq. w/v, 4 x 100 mL) and water 
(3 x 100 mL). The organic layer was dried over anhydrous sodium sulphate and the solvent 
removed in vacuo yielding yellow oil. Purification via flash column chromatography (hexane: 
ether, 2:1) gave the title product 146 as white foam, identical by NMR and mp to the 
literature. 
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Yield: 6.1 g, 7.66 mmol, 53 %; 
Rf: 0.1 (Hexane:Ether; 2:1); 
Mp: 148 - 152 º C (lit.
 123
 151.5 – 152 ºC); 
NMR: δH (300 MHz, CDCl3), 7.74 (4 H, dd, J = 7.6 Hz, Ar), 7.57 (4 H, dd, J = 7.3 Hz, Ar), 
7.40 (4 H, bt, J = 7.5 Hz, Ar), 7.29 (4 H, dd, J = 7.6 Hz, Ar), 5.73 (4 H, bd, J = 7.7 Hz, NH), 
4.57 (2 H, m, CHCH2S), 4.35 (4 H, bm, CHcCH2O), 4.22 (2 H, bm, Hc), 3.28 (2 H, bm, 
CHCH2S), 3.13 (2 H, bm, CHCH2S), 1.47 (18 H, s, CO2C(CH3)3); 
MS: (ES
+
), C44H48N2O8S2, m/z: 819.4 [M + Na]
+
. 
 
N-9-fluorenylmethoxycarbonyl-(R)-cystine bis-tert-butyl ester 90 
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A solution of N,N’-bis(9-fluorenylmethoxycarbonyl)-(R,R)-cystine bis-tert-butyl ester 146 
(6.1 g, 7.8 mmol) in dry THF (150 mL) was treated with tributylphosphine (3.8 mL, 15 
mmol). The mixture was stirred for 2 min after which water (distilled, 7.7 mL, 428 mmol, 56 
equiv) was added. The reaction was stirred for a further 2 hr. The mixture was concentrated 
in vacuo and dissolved in ethyl acetate (300 mL). The solution was washed with citric acid 
(10 % aq. w/v, 300 mL) and then brine (300 mL). The organic layer was dried over 
anhydrous sodium sulphate and the solvent removed in vacuo to yield pale yellow oil. 
Purification via flash column chromatography (hexane: ether, 2:1) yielded the title product 90 
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as an extremely viscous oil which solidified to give a white solid 90, identical by NMR to the 
literature. 
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Yield: 3.5 g, 8.77 mmol, 57 %;  
Rf: 0.3 (Hexane: Ether; 2:1); 
NMR: δH (300 MHz, CDCl3), 7.76 (2 H, d, J = 7.4 Hz, Ar), 7.61 (2 H, d, J = 7.3 Hz, Ar), 
7.41 (2 H, t, J = 7.3 Hz, Ar), 7.3 (2 H, t, J = 7.4 Hz, Ar), 5.68 (1 H, d, J = 7.1 Hz, NH), 4.52- 
4.61 (1 H, bm, CHCH2S), 4.41 (2 H, bm, CHcCH2O), 4.23 (1 H, t, J = 6.8 Hz, Hc), 2.99 (2 H, 
m, CHCH2S), 1.50 (9 H, s, CO2C(CH3)3).   
 
N-Triphenylmethyl-(R)-serine 143
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Trimethylsilylchloride (37.4 mL, 292 mmol, 3.1 equiv) was added to a suspension of R-serine 
(10 g, 95 mmol) in CH2Cl2 (133 mL) under argon. The mixture was heated under reflux for 
20 min and then cooled to room temperature. Triethylamine (41.1 mL, 294 mmol, 3.1 equiv) 
was then added after which the reaction was heated under reflux for 45 min. The mixture was 
then allowed to cool to room temperature and then cooled in an ice bath to 0 ºC. Methanol 
(anhydrous, 3.85 mL, 92 mmol, 1 equiv) was then added, and the mixture was allowed to 
reach room temperature. Triethylamine (13.2 mL, 95 mmol, 1 equiv) was added, followed by 
triphenylmethylchloride (26.5 g, 95.2 mmol, 1 equiv) and the reaction was stirred for 20 hr. 
 
Excess triethylamine (30 mL) and methanol (150 mL) were then added until the white solids 
dissolved. The solvents were removed in vacuo yielding a mixture of yellow and white 
crystals which was partitioned between ethyl acetate (400 mL) and citric acid (5 % aq. w/v, 4 
x 50 mL) pre-cooled to 4 ºC. The organic layer was washed with sodium hydroxide (2 M, 5 x 
50 mL) and water (3 x 100 mL). The aqueous layers were combined, washed with ethyl 
acetate (300 mL) and neutralised with glacial acetic acid at 0 ºC. The precipitated product 
was extracted with ethyl acetate (4 x 100 mL) and the organic layer was dried over anhydrous 
sodium sulphate. Removal of solvent under pressure yielded the title product 143 as a white 
solid identified by mass spectrometry, identical by NMR to the literature. 
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201 
 
Yield: 29.2 g, 84.1 mmol, 88 %; 
NMR: δH (300 MHz, CDCl3), 7.48 (6 H, m, Trt), 7.25 (9 H, m, Trt), 3.17 (1 H, dd, J = 11.0, 
6.8 Hz, CHCH2OH), 3.09 (1 H, m, CHCH2OH), 2.81 (1 H, dd, J = 11.0, 4.5 Hz, CHCH2OH); 
MS: (ES
+
), C22H21NO3, m/z: 370 [M + Na]
+
.  
 
N-Triphenylmethyl-(S)-serine allyl ester 122 
123 
 
Ph N
H
O
O
OH
PhPh H
 
 
N-Triphenylmethyl-(R)-serine 143 (6 g, 17 mmol) was dissolved in methanol (170 mL). 
Caesium carbonate (2.81 g, 8.6 mmol, 0.5 equiv) was added and the solution was stirred for 
15 min before being concentrated in vacuo. The resulting caesium salt was then dissolved in 
DMF (170 mL), allyl bromide (1.98 mL, 16 mmol, 0.95 equiv) was added dropwise at room 
temperature and the reaction was stirred for 14 hr. Ethyl acetate (44 mL) was then added to 
the mixture. The mixture was washed with aqueous citric acid (5 % w/v, 5 x 100 mL) 
precooled to 4 ºC. The organic layer was dried over anhydrous magnesium sulphate, 
concentrated in vacuo, and purified by flash column chromatography (CH2Cl2: MeOH, 20:1) 
to give the title product 122 as cream oil, identical by NMR to the literature. 
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Yield: 4.91 g, 12.6 mmol, 73 %; 
Rf: 0.59 (CH2Cl2: MeOH; 20:1);   
NMR: δH (500 MHz, CDCl3), 7.47 (6 H, m, Trt), 7.25 (6 H, m, Trt), 7.16 (3 H, m, Trt), 5.68 
(1 H, m, CH2CH=CH2), 5.16 (1 H, dd, J = 10.5, 1.4 Hz, CH2CH=CH2), 5.11 (1 H, m, 
CH2CH=CH2), 4.2 (1 H, dd, J = 10.2, 5.8 Hz, CH2CH=CH2), 4.09 (1 H, dd, J = 10.2, 4.3 Hz, 
CH2CH=CH2), 3.71 (1 H, m, H ), 3.57 (2 H, m, CH2β). 
 
N-Triphenylmethyl-β-iodo-(S)-serine allyl ester 101 124 
 
I
O
O
N
H
Ph
PhPh H
 
 
N-Triphenylmethyl-(R)-alanine allyl ester 122 (3.68 g, 9.4 mmol) was dissolved in dry 
CH2Cl2 (9.5 mL) at room temperature in the presence of triphenylphosphine (3.75 g, 14.2 
202 
 
mmol, 1.5 equiv). After 10 min, the reaction mixture was cooled to -10 ºC using an 
acetone/ice bath. Diethylazodicarboxylate (2.25 mL, 14.4 mmol, 1.5 equiv) was then added 
dropwise to the reaction over 1 min. After further 5 min, this was followed by the careful 
addition of iodomethane (8.89 mL, 14.2 mmol, 1.5 equiv). The reaction was kept at -2 ºC 
over 3 hr using an ethanol bath refrigerated by a cryostat. 
 
The reaction mixture was directly filtered by flash column chromatography, beginning with 
20:1 hexane: ethyl actate reducing to 10:1 until the removal of the title product 101 obtained 
as a clear oil, identical by NMR to the literature. 
124
 A 4:1 eluant was then used to collect the 
starting material 122. 
 
Yield: 1.11 g, 2.23 mmol, 23 %; 
Rf: 0.31 (Hexane: Ethyl acetate; 10:1); 
NMR: δH (300 MHz, CDCl3), 7.51 (6 H, m, Trt), 7.24 (9 H, m, Trt), 5.71 (1 H, m, 
CH2CH=CH2), 5.23 (1 H, 2 dd, J = 12.4, 1.4 Hz, CH2CH=CH2), 5.17 (1 H, m, CH2CH=CH2), 
4.21 (1 H, dd, J = 13.0, 5.9 Hz, CH2CH=CH2), 4.11 (1 H, dd, J = 4.7, 1.2 Hz, CH2CH=CH2), 
3.49 (1 H, bm, H ), 3.32 (1 H, dd, J = 9.8, 3.5 Hz CH2I), 3.18 (1 H, dd, J = 9.8, 2.9 Hz CH2I). 
 
3-(R)-2-tert-Butoxycarbonyl-2-(fluoren-9-ylmethoxcarbonylamino)ethylsulfanyl)-(S)-
(allyloxycarbonylamino)propionic acid allyl ester 102 
123 
 
'' B-side'' (R)
'' A-side'' (S)
O
OHN
O
O
S
OO
HN
HH
 
 
N-9-fluorenylmethoxycarbonyl-(R)-cystine bis-tert-butyl ester 90 (1.67 g, 4.18 mmol) and N-
triphenylmethyl-β-iodo-(S)-alanine allyl ester 101 (2.08 g, 4.18 mmol, 1 equiv) were 
dissolved in DMF (68 mL) under inert conditions. Cs2CO3 (0.68 g, 2.09 mmol, 0.5 equiv) 
dried in a dessicator overnight was added over 2 min and the reaction was stirred for 2 hr. 
Further dry Cs2CO3 (0.68 g, 2.09 mmol, 0.5 equiv) was added over 1 min and the reaction 
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was stirred for a further 2 hr. Excess ethyl acetate (600 mL) was added and the mixture was 
washed with cold citric acid (5 % w/v aq, 300 mL) followed by distilled water (10 x 250 mL). 
The ethyl acetate layer was dried over anhydrous sodium sulphate and concentrated in vacuo. 
Purification was carried out by flash column chromatography (hexane: EtOAc, 4:1) to give 
the title product 102 as a white fluffy solid, identical by NMR to the literature. 
123, 124
  
 
Yield: 1.12 g, 1.45 mmol, 67 %; 
Rf: 2.5 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (600 MHz, CDCl3), 7.77-7.16 (23 H, m, Ar), 5.63 (1 H, m, CH2CH=CH2), 5.62 (1 
H, d, J = 7.9 Hz, NHFmoc), 5.18 (1 H, dd, J = 17.3, 1.4 Hz, CH2CH=CH2), 5.14 (1 H, m, 
CH2CH=CH2), 4.49 (1 H, m, H  B side), 4.35 (2 H, m, CH2Fmoc), 4.22 (1 H, t, J = 7.1 Hz, 
CHFmoc), 4.15 (1 H, dd, J = 13.1, 7.3, 5.8 Hz, CH2CH=CH2), 3.97 (1 H, dd, J = 13.1, 7.2, 
5.9 Hz, CH2CH=CH2), 3.54 (1 H, m, H  A side), 2.88 (4 H, m, CH2 β A and B sides), 1.56 (1 
H, s, NHTrt), 1.47 (9 H, s, tBu). 
 
3-(R)-2-tert-Butoxycarbonyl-2-(fluoren-9-ylmethoxcarbonylamino)ethylsulfanyl)-(S)-
(allyloxycarbonylamino)propionic acid allyl ester 125 
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3-(R)-2-tert-Butoxycarbonyl-2-(fluoren-9-ylmethoxcarbonylamino)ethylsulfanyl)-(S)-
(allyloxycarbonylamino)propionic acid allyl ester 102 (0.2 g, 0.26 mmol) was treated with a 
solution of TFA (10 %, 0.4 mL), triethylsilane (TES) (5 %, 0.2 mL) and CH2Cl2 (3.2 mL) 
under argon for 4 hr. Excess CH2Cl2 (350 mL) was then added. The organic layer was 
washed with saturated sodium bicarbonate (300 mL) and brine (300 mL), dried over 
anhydrous sodium sulphate, and concentrated in vacuo. The residue was dissolved in 1,4-
dioxane (3.2 mL) and a solution of sodium bicarbonate (0.1 g, 1.19 mmol, 4.5 equiv) in water 
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was added (3.2 mL). The resulting mixture was cooled to 0 ºC and allyl chloroformate (0.065 
mL, 0.61 mmol, 2.3 equiv) was added. The mixture was left for 18 hr at ≤ 4 ºC. Excess 
CH2Cl2 (500 mL) was added and the organic layer was washed with saturated sodium 
bicarbonate (300 mL) and brine (300 mL). The organic layer was dried over anhydrous 
sodium sulphate, concentrated in vacuo, and purified by flash column chromatography 
(hexane: EtOAc, 4:1) to give the title product 125 as a clear viscous oil, identical by NMR 
and mass spec to the literature. 
124
  
 
Yield: 0.094 g, 0.15 mmol, 64 %; 
Rf: 0.18 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (300 MHz, CDCl3), 7.76 (2 H, d, J = 7.4 Hz, Ar), 7.61 (2 H, d, J = 7.3 Hz, Ar), 
7.39 (2 H, t, J = 7.4 Hz, Ar), 7.32 (2 H, t, J = 6.7 Hz, Ar), 5.91 (2 H, m, CH2CH=CH2 Aloc 
and allyl), 5.88 (1 H, d, J = 5.7 Hz, NHFmoc), 5.84 (1 H, d, J = 5.5 Hz, NH Aloc), 5.33 (2 H, 
m, CH2CH=CH2 allyl), 5.26 (2 H, m, CH2CH=CH2 Aloc), 4.63 (3 H, m, CH2CH=CH2 allyl 
and H  A side), 4.58 (2 H, m, CH2CH=CH2 Aloc), 4.51 (1 H, m, H  B side), 4.39 (2 H, m, 
CH2Fmoc), 4.24 (1 H, t, J = 7.0 Hz, HcFmoc), 3.03 (4 H, m, CH2 β A and B sides), 1.48 (9 H, 
s, tBu); 
MS: (ES
+
), C32H38N2O8S, m/z: 633 [M + Na]
+
.
   
 
3-(S)-(2-Allyloxycarbonyl-2-allyloxycarbonylamino-ethylsulfanyl)-(R)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid 103 
124 
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3-(R)-2-tert-Butoxycarbonyl-2-(fluoren-9-ylmethoxcarbonylamino)ethylsulfanyl)-(S)-
(allyloxycarbonylamino)propionic acid allyl ester 125 (0.96 g, 1.57 mmol) was treated with a 
mixture of trifluoroacetic acid (TFA) (1.92 mL) and CH2Cl2 (1.92 mL) (1:1), the resulting 
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mixture was stirred for 3 hr. The solvents were then removed under high vacuum. Removal 
of TFA was helped by several additions of toluene (3 x 100 mL) followed by evaporation. 
Traces of TFA were removed by purifying the crude mixture by reverse phase 
chromatography. Acetonitrile was removed under high vacuum. Concentrated sulphuric acid 
was added to bring the aqueous layer to pH 2 and sodium chloride was added until saturation 
was reached. The product was extracted from the aqueous layer with chloroform. The organic 
layer was then dried over anhydrous sodium sulphate and concentrated in vacuo to give the 
title product 103 as a white fluffy solid, identical by NMR, 
13
C NMR and mass spec to the 
literature. 
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Yield: 0.60 g, 1.05 mmol, 69 %; 
Rf: 0.35 [AcCN (40 %): Sat NaHCO3] reverse phase TLC; 
NMR: δH (600 MHz, CD3OD), 7.79 (2 H, d, J = 7.6 Hz, Ar), 7.70 (2 H, d, J = 7.3 Hz, Ar), 
7.38 (2 H, t, J = 7.4 Hz, Ar), 7.31 (2 H, t, J = 7.4 Hz, Ar), 5.91 (2 H, m, CH2CH=CH2 allyl 
and Aloc), 5.29 (2 H, m, CH2CH=CH2 allyl), 5.18 (2 H, m, CH2CH=CH2 Aloc), 4.61 (2 H, m, 
CH2CH=CH2 allyl), 4.60 (2 H, m, CH2CH=CH2 Aloc), 4.44 (1 H, m, H  A side), 4.40 (1 H, 
m, H  B side), 4.35 (2 H, m, CH2Fmoc), 4.24 (1 H, t, J = 7.2 Hz, HcFmoc), 3.31 - 2.93 (4 H, 
m, CH2 β A and B sides); 
NMR: δC (150 MHz, CD3OD), 173.8 (C17), 171.9 (C25), 158.5 (C15), 158.3 (C21), 145.2 (CAr), 
142.5 (CAr), 134.1 (C23), 133.1 (C27), 128.7 (CAr), 128.2 (CAr), 126.3 (CAr), 120.9 (CAr), 118.8 
(C24), 117.6 (C28), 68.2 (C14), 67.4 (C22 or C26), 67.0 (C26 or C22), 56.0 (C16 or C20), 55.6 (C20 
or C16), 48.3 (C1), 35.3 (C19 or C18), 35.1 (C19 or C18); 
MS: (ES
+
), C28H30N2O8S, m/z: 577.58 [M + Na]
+
.  
 
2-(Trimethylsilanyl)-ethanesulfonyl chloride 157 
141, 142 
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4
2
3
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Si Cl
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2-(Trimethylsilyl)ethane sulfonic acid sodium salt 156 (1 g, 4.9 mmol) was stirred and cooled 
down to 0 ºC for 15 min without any solvents under inert conditions. At this temperature, 
thionyl chloride (2.75 mL, 37.6 mmol, 7.7 equiv) was added dropwise with continuous 
stirring over 20 min. The SO2 generated was allowed to evacuate through a Pasteur pipette. 
DMF (0.013 mL) was slowly added via a syringe resulting in a substantial increase in the 
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evolution of SO2. The solution was stirred for an additional 20 min at 0 ºC during which time 
evolution of SO2 ceased. The reaction mixture was warmed to room temperature and stirred 
overnight, resulting in a white precipitate. The reaction mixture was then concentrated in 
vacuo. The resulting white paste was diluted with hexane (2 x 25 mL) and the removal of 
residual SOCl2 and hexane were carried out in vacuo. The semi solid obtained was then 
mixed to hexane and the slurry was filtered through a pad of Celite. Several hexane washings 
of the solid were carried out and the combined filtrate was then concentrated affording 2-
(trimethylsilanyl)-ethanesulfonyl chloride 157 as a brown liquid. The 
1
H NMR showed peaks 
for 157, identical to the literature 
142
 however signals for an unidentified impurity (impurities) 
were observed.      
 
Kugelrohr distillation was attempted at 85 - 100 ºC at 0.3 - 0.5 mm however at this 
temperature the compound charred.  
 
Yield: 0.85 g, 3.93 mmol, 80 %; 
NMR: δH (300 MHz, CDCl3), 3.58 (2 H, m, CH2SO2), 1.27 (2 H, m, CH2TMS), 0.04 (9 H, s, 
Si(CH3)3), Impurities: 3.36 (2 H, s, DMF), 3.12 (2 H, s, DMF), 2.98 (4 H, m), 1.05 (4 H, m);  
NMR: δC (150 Mz, CDCl3), 63.50 (C5), 12.01 (C4), -1.87 (C1, 2, 3);  
MS: (ES
+
), C5H13ClO2SSi, m/z: 255 [M + K]
+
;  
IR: νmax 2955, 1366, 1252, 1173 cm
-1
. 
 
(S)-3-[2-Allyloxycarbonyl-2-(2-trimethylsilanyl-ethanesulfonylamino)-ethylsulfanyl]-(R)-2-
(fluoren-9-ylmethoxcarbonylamino)-propionic acid tert-butyl ester 154 
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Entry Trityl 
deprotection
/ Time 
Reaction 
solvents 
Base (equiv), 
/ 
Temperature 
SES-Cl, 
157 
(equiv), 
°C 
Reaction time 
/ temperature 
Product 
Isolated 
154 (%)  
Byproduct 
Isolated 
158 (%)     159 (%) 
1 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), 0 °C  
(1.5),  
0 °C 
 1 hr, 0 °C,  24 
hr, 5 °C 
-  38 % - 
2 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), 0 °C 
(1.5),  
0 °C 
 1 hr, 0 °C,  
24 hr, 5 °C 
30 % 44 % - 
3 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), 0 °C 
(5), 0 °C 1 hr, , 0 °C,  
24 hr, 5 °C
 
 
38 % - - 
4 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), 0 °C 
(2.6),  
0 °C 
1 hr 30 min, 
0 °C, 
1 hr 30 min, 
 5 °C, 
40 min, RT 
27 % 
 
 
45 % - 
5 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(3), 0 °C 
(1.5),  
0 °C 
24 hr, 5 °C - - 35 % 
6 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(3), 0 °C 
(1.5),  
0 °C 
24 hr, 5 °C NR * NR * NR * 
7 TFA/TES/ 
CH2Cl2, 4 hr 
1,4-Dioxane Sodium 
bicarbonate, 
(4), RT 
(3), 
0 °C 
24 hr, 4 °C 26 % - - 
8 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), 0 °C 
Triethylamine, 
(2), RT 
(5), 0 °C, 
 
(5), RT 
3 hr, RT 
1 hr 30 min, 
RT 
35 % - - 
9 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(1.5), 0 °C 
(1.6), 
RT 
5 hr, 0 °C – 
RT 
12 % - - 
10 TFA/TES/ 
CH2Cl2, 4 hr 
Benzene AgCN, (1.5), 
RT 
(1.5), RT 22 hr, 60 °C - 30 % - 
11 TFA/TES/ 
CH2Cl2, 4 hr 
Acetonitrile 4-methoxy 
pyridine-N-
oxide hydrate, 
(6), RT 
(2), RT  24 hr, RT 19 % - - 
* NR: No Reaction 
Optimised experiments 
 
General procedure 
 
3-(R)-2-tert-Butoxycarbonyl-2-(fluoren-9-ylmethoxcarbonylamino)ethylsulfanyl)-(S)-
(allyloxycarbonylamino)propionic acid allyl ester 102 was treated with a solution of TFA (10 
%, 0.4 mL), triethylsilane (TES) (5 %, 0.2 mL) and CH2Cl2 (3.2 mL) under argon for 4 hr. 
Excess toluene was added and removed in vacuo 3 times, followed by addition of CH2Cl2 and 
then concentration in vacuo. The residue was then suspended in the appropriate solvent and 
the base was added followed by the addition of the SES-Cl at the required temperature. The 
equivalent number of reagents, the reaction time, and temperature of the reaction and the 
addition of further reagents were carried out and maintained according to the optimised 
experiments table above.  
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- Entry 9 involved the addition of SES-Cl first, followed by the addition of the base at 0 ºC. 
All reaction mixtures were diluted in excess ethyl acetate (except entry 11 which was diluted 
in CH2Cl2), the layer was washed 3 times with aqueous citric acid (5 %) and then with brine. 
The organic layer was dried over anhydrous magnesium sulphate and concentrated in vacuo. 
This afforded a crude oil which was purified via flash column chromatography on silica gel 
(hexane: EtOAc, 4:1) to give the title product 154 as a clear viscous oil. 
 
Rf: 0.2 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (300 MHz, CDCl3), 7.76 (2 H, d, J = 7.4 Hz, Ar), 7.62 (2 H, d, J = 7.1 Hz, Ar), 
7.40 (2 H, t, J = 7.4 Hz, Ar), 7.32 (2 H, t, J = 7.4 Hz, Ar), 5.87 (1 H, m, CH2CH=CH2), 5.70 
(1 H, d, J = 7.4 Hz NHFmoc), 5.45 (1 H, d, J = 8.7 Hz, NHSES), 5.29 (2 H, m, 
CH2CH=CH2), 4.64 (2 H, m, CH2CH=CH2), 4.50 (1 H, m, H  B side), 4.39 (3 H, m, 
CH2Fmoc and H  A side), 4.23 (1 H, t, J = 7.0 Hz, CHFmoc), 3.08 (2 H, m, CH2 A side), 
2.98 (2 H, m, CH2SO2), 2.91 (2 H, m, CH2 β B sides), 1.48 (9 H, s, CH3 tBu), 1.12 (2 H, m, 
CH2TMS), 0.02 (9 H, s, Si(CH3)3);  
NMR: δC (125 MHz, CDCl3), 173.1 (C25), 158.3 (C15), 146.2 (CAr), 143.7 (C27), 133.6 (CAr), 
130.1 (CAr), 129.5 (CAr ), 127.6 (CAr), 122.4 (C28), 85.6 (C17), 69.7 (C14), 68.7 (C26), 58.5 
(C21), 57.2 (C24), 52.8 (C29), 49.5 (C30), 39.5 (C1), 32.1 (C23, 22), 30.4 (C18, 19, 20), 12.8 (Si), 0.4 
(C31, 32, 33);  
IR νmax: 3400, 3010, 2999, 2810, 1700, 1510 cm
-1
;  
HRMS: cald (ES
-
), m/z: Found [M + H]
+
, 691.25293; C33H47N2O8SiS2, requires 691.25430;
 
(ES
+
), C33H46N2O8SiS2, m/z: 713 [M + Na]
+
;  
[α]20 D = - 7.5 (c 6.5 mg/mL, CHCl3);  
(ES
+
), 158 C28H34O6N2S, m/z: 549 [M + Na]
+
; (ES
+
), 159 C18H36O6N2S, m/z: 491 [M + Na]
+
, 
178 [Fmoc].  
 
4-Methylsulfanyl-2-(2-trimethylsilanyl-ethanesulfonylamino)-butyric acid methyl ester 161 
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Entry Reaction 
solvent 
Base (equiv), 
Temperature 
SES-Cl, 
157 
(equiv), °C 
Reaction time / 
temperature 
Product Isolated 
161 (%) 
1 DMF Triethylamine, 
(2), RT 
(3), RT 5 hr, RT 71 % 
2 Benzene AgCN, (1), 
RT 
(1.5), RT 22 hr, 75 °C 42 % 
3 Acetonitrile 4-methoxy 
pyridine-N-
oxide hydrate, 
(6), RT 
(1.5), RT 24 hr, RT 45 % 
 
Optimised experiments 
 
General procedure 
 
SES-Cl was added to a stirring solution containing methionine hydrochloride ester 160 and 
the selected base in the appropriate solvent as mentioned in the table above.  
- The base in Entry 1 was added after the addition of SES-Cl. 
The equivalent number of reagents, the reaction time and the temperature of the reaction were 
carried out and maintained according to the table above. The mixture was diluted in excess 
organic solvent (Entry 1: ethyl acetate and Entry 3: CH2Cl2). The organic layer was washed 
with saturated NaHCO3 then with brine. The organic layer was dried over anhydrous 
magnesium sulphate and concentrated in vacuo this afforded a crude oil. 
The reaction mixture of Entry 2 was filtered through Celite and then washed with ethyl 
acetate, the filtrate was then concentrated in vacuo. 
The residues of all Entries were purified via flash column chromatography (hexane: EtOAc, 
4:1) on silica gel to give the title product 161 as a clear oil.  
 
Rf: 0.62 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (500 MHz, CDCl3), 4.21 (1 H, m, NHCHCH2), 3.74 (3 H, s, OCH3), 2.91 (2 H, m, 
CH2CH2SCH3), 2.58 (2 H, m, CH2SO2), 2.06 (4 H, m, CH2SCH3 and CH2CH2SCH3), 1.92 (1 
H, m, CH2CH2SCH3), 1.00 (2 H, m, (H3C)3SiCH2CH2), 0.00 (9H, s, Si(CH3)3);  
NMR: δC (125 MHz, CDCl3), 172.8 (C5), 54.9 (C4), 52.9 (C6), 49.9 (C7), 32.3 (C3), 29.9 (C2), 
15.3 (C1), 10.4 (C8), -1.87 (C9, 10, 11);  
HRMS: cald (ES
-
), m/z: Found [M - H]
-
, 326.0932; C11H24NO4SiS2, requires 326.0916.
 
(ES
+
), C11H25NO4SiS2, m/z: 350 [M + Na]
+
;  
IR νmax: 3276, 2953, 1744, 1435, 1323 cm
-1
;  
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[α]20 D = -1.6 (c 11.2 mg/mL, CHCl3).  
 
(S)-2-[Allyloxycarbonyl-2-(trityl-amino)-ethylsulfanyl]-(R)-2-tert-butoxycarbonylamino-
propionic acid tert-butyl ester 163 
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Entry Fmoc 
deprotection 
solvents / Time 
Reaction 
solvent 
Base (equiv), 
Temperature 
Boc 
anhydride 
(equiv), °C 
Reaction time 
/ temperature 
Product 
Isolated  
163 (%) 
Byproduct 
Isolated 
168 (%) 
1 20% piperidine 
in CH2Cl2, 30 
min 
CH2Cl2 Sodium 
bicarbonate, 
(1.3), RT 
(1.3), RT 30 min, RT 
4 hr, RT 
 
3 % 
 
 
65 % 
2 20% piperidine 
in CH2Cl2, 30 
min 
DMF Triethylamine, 
(1.3), RT 
(1.3), RT  
4 hr, RT 
 
56 % 
 
- 
 
Optimised experiments 
 
General procedure 
 
3-(R)-2-tert-Butoxycarbonyl-2-(fluoren-9-ylmethoxcarbonylamino)ethylsulfanyl)-(S)-
(allyloxycarbonylamino)propionic acid allyl ester 102 was added to a solution of piperidine 
(20 %) in CH2Cl2. The solution was removed in vacuo and the residue was redissolved in the 
appropriate. Di-tert-butyl dicarbonate (1.3 equiv) was added to the solution and (stirred for 
30 min, Entry 1) this was followed by addition of the base (1.3 equiv). The mixture was 
stirred for 4 hr at room temperature. The reaction mixture of Entry 1 was concentrated in 
vacuo. Whilst the mixture of Entry 2 was diluted in excess CH2Cl2 and the layer was washed 
with saturated sodium bicarbonate followed by brine. The organic layer was dried over 
anhydrous magnesium sulphate and concentrated in vacuo. The crude of both entries were 
purified by flash column chromatography (hexane: EtOAC, 9:1) on silica gel to give the title 
product 163. 
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Rf: 0.53 (Hexane: Ethyl acetate; 4:1); 
    : 0.19 (Hexane: Ethyl acetate; 9:1); 
NMR: δH (500 MHz, CDCl3), 7.54 (6 H, d, J = 8.6 Hz, Trt), 7.27 (6 H, m, Trt), 7.18 (3 H, m, 
Trt), 5.71 (1 H, m, CH2CH=CH2), 5.36 (1 H, d, J = 7.6 Hz, NHBoc), 5.17 (2 H, m, 
CH2CH=CH2), 4.40 (1H ,m, H  B side), 4.13 (1 H, dd, J = 13.0, 6.0 Hz, CH2CH=CH2), 3.99 
(1 H, dd, J = 13.1, 6.0 Hz, CH2CH =CH2), 3.56 (1 H, bm, H  A side), 2.9 (3 H, m, Hβ), 2.79 
(1 H, m, Hβ), 1.56 (1 H, s, NHTrt), 1.47 (18 H, s, tBu);  
NMR: δC (125 MHz, CDCl3), 173.1 (C21), 170.0 (C28), 155.3 (C33), 145.8 (CAr), 131.9 (C23), 
128.8 (CAr), 127.8 (CAr), 126.8 (CAr), 118.6 (C24), 82.5 (C32), 79.9 (C34), 71.3 (C22), 65.7 (C7), 
56.4 (C27), 54.0 (C20), 38.3 (C25), 35.7 (C26), 28.4 (C29, 30, 31), 28.1 (C35, 36, 37);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 669.2983; C37H46N2O6NaS, requires 669.2974;
 
(ES
+
), C37H46N2O6S, m/z: 669 [M + Na]
+
;   
IR νmax: 2977, 1714, 1492, 1367 cm
-1
;  
[α]20 D = - 6.0 (c 10.6 mg/mL, CHCl3);  
1
H NMR was not carried out on the byproduct 168, byproduct was identified by mass spec 
(ES
+
), 161 C32H38N2O4S, 569 [M + Na]
+
. 
 
(S)-3-[2-Allyloxycarbonyl-2-(2-trimethylsilanyl-ethanesulfonylamino)-ethylsulfanyl]-(R)-2-
tert-butoxycarbonylamino-propionic acid tert-butyl ester 164 
 
 
'' B-side'' (R)
'' A-side'' (S)
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A solution of TFA (0.05 mL, 5 %), triethylsilane (0.025 mL, 2.5 %) and CH2Cl2 (0.93 mL, 
92.5 %) was added to (S)-2-[Allyloxycarbonyl-2-(trityl-amino)-ethylsulfanyl]-(R)-2-tert-
butoxycarbonylamino-propionic acid tert-butyl ester 163 (0.47 g, 0.72 mmol) and stirred for 
4 hr. The mixture was concentrated in vacuo, removal of TFA was helped by several 
additions of toluene (3 x 100 mL) and CH2Cl2 evaporation. The residue was dissolved in 
DMF (2 mL), SES-Cl 157 (0.058 mL, 0.31 mmol, 0.4 equiv) was added and then cooled to 0 
ºC. Triethylamine (0.032 mL, 0.25 mmol, 0.35 equiv) was added and stirred for 24 hr. 
Further SES-Cl 157 (0.058 mL, 0.31 mmol, 0.4 equiv) was added and triethylamine (0.032 
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mL, 0.25 mmol, 0.35 equiv) was added and stirred for 7 hr. The mixture was then diluted in 
excess CH2Cl2 and the organic layer was washed with citric acid (5 %) and then with brine. 
The organic layer was dried over anhydrous magnesium sulphate and concentrated in vacuo. 
Purification was carried out by flash column chromatography (hexane: EtOAc, 9:1) to give 
the title product 164 as a clear oil. 
    
Yield: 0.023 g, 0.040 mmol, 54 %;  
Rf: 0.13 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (500 MHz, CDCl3), 5.92 (1 H, m, CH2CH=CH2), 5.72 (1 H, d, J = 7.5 Hz, 
NHSES), 5.56 (1 H, d, J = 7.0 Hz, NHBoc), 5.29 (2 H, m, CH2CH=CH2), 4.72 (1 H, d, J = 
5.8 Hz, H  B side), 4.68 (2 H, m, CH2CH=CH2), 4.45 (2 H, m, CH2SO2), 3.41 (1 H, m, H
  A side), 3.02 (4 H, m, 2 CH2 β A and B side), 1.46 (18 H, d, J = 6.6 Hz, tBu), 1.09 (2 H, m, 
CH2Si), 0.03 (9 H, s, Si(CH3)3); 
NMR: δC (150 MHz, CDCl3), 169.4 (C7, 19), 155.1 (C14), 129.8 (C9), 128.0 (C10), 78.8 (C20), 
68.9 (C15), 63.3 (C8), 53.5 (C13), 51.6 (C6), 46.2 (C5), 29.8 (C11, 12), 28.4 (C21, 22, 23), 27.7 (C16, 
17, 18), 9.83 (C4), -1.70 (C1, 2, 3);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 591.2178; C23H44N2O8NaSiS2, requires 591.2206;
 
(ES
+
), C23H44N2O8NaSiS2, m/z: 591 [M + Na]
+
;  
IR νmax: 2954, 1718, 1329 cm
-1
;  
[α]20 D = - 3.1 (c 5.8 mg/mL, CHCl3).  
 
2-tert-Butoxycarbonylamino-3-(2-tert-butoxycarbonyl-2-tert-butoxycarbonylamino-
ethyldisulfanyl)-propionic acid tert-butyl ester 166 
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(R,R)-cystine bis-tert-butyl ester 145 (0.88 g, 2.51 mmol) was dissolved in THF. Di-tert-butyl 
dicarbonate (1.65 g, 7.56 mmol, 3 equiv) was added to the solution, this was followed by 
triethylamine (1.05 mL, 7.55 mmol, 3 equiv) and the reaction was left stirring for 4 hr. The 
mixture was diluted in excess CH2Cl2 and washed with saturated NaHCO3 and brine, the 
organic layer was then dried over anhydrous magnesium sulphate and concentrated in vacuo. 
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The crude was purified by flash column chromatography (hexane: EtOAc, 9:1) to give the 
title product 166 as a yellow viscous oil, identical by NMR to the literature. 
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Yield: 1.37 g, 2.48 mmol, 98 %; 
Rf: 0.39 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (600 MHz, CDCl3), 5.35 (2 H, d, J = 6.9 Hz, NH), 4.45 (2 H, m, 2 x CHCH2S), 
3.20 (2 H, dd, J = 13.8, 4.6 Hz, CHCH2S), 3.12 (2 H, dd, J = 13.7, 5.5 Hz, CHCH2S), 1.47 
(18 H, s, 2 x (CH3)3), 1.44 (18 H, s, 2 x (CH3)3);  
NMR: δC (150 MHz, CDCl3), 169.0 (C7, 20), 155.1 (C5, 15), 82.8 (C8, 21), 80.1 (C4, 16), 53.7 (C6, 
14), 42.2 (C12, 13), 28.4 (C9, 10, 11, 22, 23, 24), 28.1 (C1, 2, 3, 17, 18, 19);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 575.24437; C24H44N2O8NaS, requires 575.24366;
 
(ES
+
), C24H44N2O8S, m/z: 575 [M + Na]
+
;  
IR νmax: 2980, 1710, 1498, 1368, 1216 cm
-1
. 
 
2-tert-Butoxycarbonylamino-3-(2-tert-butoxycarbonyl-2-tert-butoxycarbonylamino-
ethyldisulfanyl)-propionic acid tert-butyl ester 167 
122 
 
10
12
9
8
7
6
5
4
3 2
1
11
SH
HN
O
O
OO
 
 
2-tert-Butoxycarbonylamino-3-(2-tert-butoxycarbonyl-2-tert-butoxycarbonylamino-
ethyldisulfanyl)-propionic acid tert-butyl ester 166 (0.39 g, 0.71 mmol) in dry THF (20 mL) 
was treated with tributylphosphine (0.31 mL, 1.55 mmol, 2 equiv). The mixture was stirred 
for 2 min after which water (distilled, 0.62 mL, 34.4 mmol, 56 equiv) was added. The 
reaction mixture was stirred for further 2 hr. The mixture was then concentrated in vacuo and 
dissolved in ethyl acetate (150 mL). The solution was washed with citric acid (10 % aq. w/v, 
100 mL) and then brine (100 mL). The organic layer was dried over anhydrous sodium 
sulphate and the solvent was removed under reduced pressure to yield pale yellow oil. 
Purification via flash column chromatography (Petroleum ether: Diethyl ether, 9:1 then to 
5:1) yielded the starting material, oxidised tributylphosphine O=PBu3 (Appendix 1) and the 
title product 167 as pale yellow oil with, identical by NMR to the literature. 
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Yield: 0.01 g, 0.036 mmol, 5 %; 
Rf: 0.46 (Petroleum ether: Diethyl ether; 2:1); 
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NMR: δH (600 MHz, CDCl3), 5.39 (1 H, d, J = 6.5 Hz, NH), 4.46 (1 H, m, CHCH2S), 2.95 (2 
H, m, CHCH2S), 1.48 (9 H, s, (CH3)3), 1.44 (9 H, s, (CH3)3), 1.35 (1 H, t, J = 8.8 Hz, 
CH2SH);  
NMR: δC (150 MHz, CDCl3), 169.4 (C8), 155.2 (C5), 82.9 (C9), 80.6 (C4), 55.1 (C6), 28.2 
(C10, 11, 12), 28.1 (C1, 2, 3), 27.9 (C7);  
HRMS: cald (ES
+
), m/z: Found [M + H]
+
, 278.14288; C12H24NO4NS, requires 278.14260;
 
(ES
+
), C12H24NO4S, m/z: 278 [M + H]
+
; 
 
IR νmax: 2979, 1715, 1498, 1367, 1249 cm
-1
;  
[α]20 D = + 8.2 (c 8.0 mg/mL, CHCl3).  
 
(R)-3-(2-tert-Butoxycarbonyl-2-tert-butoxycarbonylamino-ethylsulfanyl)-(S)-2-(2-
trimethylsilanyl-ethoxycarbonylamino)-propionic acid allyl ester 172 
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Entry Trityl 
deprotection / 
Time 
Reaction 
solvents 
Base (equiv), 
Temperature 
Protecting group 
Teoc-ONp   Teoc-ONSu 
170 (equiv)   171 (equiv) 
       °C                 °C 
Reaction time 
/ temperature 
Product 
Isolated 
172 (%) 
Byproduct 
Isolated 
177 (%) 
1 TFA/TES/ 
CH2Cl2, 4 hr 
H2O / 
1,4- 
dioxane 
aq. sodium 
bicarbonate, 
(4), RT 
(2), 0 °C -  18 hr, ≤ 4 °C 17 % 41 % 
2 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2 drops), RT 
(2), RT - 24 hr, RT NR * NR * 
3 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(2), dioxane, 
RT 
(2), RT - 24 hr, RT - < 10 % 
** 
4 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), dioxane, 
RT 
(2), RT - 24 hr, RT - < 10 % 
** 
5 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(1.5), dioxane, 
RT 
(1.5), RT - 24 hr, RT 17 % - 
6 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(2), dioxane, 
RT 
- (2), 0 °C 18 hr ≤ 4 °C - < 10 % 
** 
7 TFA/TES/ 
CH2Cl2, 4 hr 
DMF Triethylamine, 
(2), dioxane, 
RT 
- (2), 0 °C 18 h at ≤ 4 °C 14 % - 
8 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(1.5), dioxane, 
RT 
- (1.5), RT 24 hr, RT 10 % - 
9 TFA/TES/ 
CH2Cl2, 4 hr 
H2O / 
1,4- 
dioxane 
aq. sodium 
bicarbonate, 
(4), RT 
- (2), 0 °C  18 hr, ≤ 4 °C 14 % 
 
< 10 % 
** 
* NR: No Reaction 
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** < 10 %:  Identified by mass spec but not isolated 
 
Optimised experiments 
 
General procedure 
 
(S)-2-[Allyloxycarbonyl-2-(trityl-amino)-ethylsulfanyl]-(R)-2-tert-butoxycarbonylamino-
propionic acid tert-butyl ester 163 was treated with a solution of TFA (10 %, 0.4 mL), 
triethylsilane (TES) (5 %, 0.2 mL) and CH2Cl2 (3.2 mL) under argon for 4 hr. Excess CH2Cl2 
(100 mL) was then added. The organic layer was washed with saturated sodium bicarbonate 
(50 mL) and brine (50 mL), dried over anhydrous sodium sulphate, and then concentrated in 
vacuo. The residue was suspended in the appropriate solvent and then the base was added 
followed by the addition of the protecting reagent at the required temperature. The 
equivalents of reagents, the reaction time and the temperature of the reaction were carried out 
and maintained according to the optimised experiments table above. Excess CH2Cl2 (150 mL) 
was added and the mixture was washed with saturated sodium bicarbonate (80 mL) and brine 
(80 mL). The organic layer was dried over anhydrous sodium sulphate, concentrated in 
vacuo, and purified by flash column chromatography (hexane: EtOAC, 9:1) to give the title 
product 172 and undesired product 177 identified by mass spec.  
 
Desired product 
 
Rf: 0.39 (Hexane: Ethyl acetate; 4:1); 
HRMS: cald (ES
+
), m/z: Found [M + H]
+
, 548.2590; C24H44N2O8SiS, requires 548.2588;  
IR νmax: 2925, 1592, 1499, 1320 cm
-1
; 
[α]20 D = + 12.4 (c 2.7 mg/mL, CHCl3);  
 
Byproduct 
 
Rf: 0.13 (Hexane: Ethyl acetate; 4:1); 
HRMS: 177 cald (ES
+
), m/z: Found [M + Na]
+
  615.2570; C25H48N2O8NaSi2S, requires 
615.2568;
 
(ES
+
), C25H48N2O8Si2S, m/z: 615 [M + Na]
+
. 
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(S)-3-[2-Allyloxycarbonyl-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-(R)-
2-(9H-fluoren-9-ylmethoxycarbonylamino)-propionic acid tert-butyl ester 175 
 
'' B-side'' (R)
'' A-side'' (S)
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Entry Trityl 
deprotection 
/ Time 
Reaction 
solvents 
Base (equiv), 
Temperature 
Protecting group 
Teoc-ONp Teoc-ONSu  
  170 (%)          171 (%) 
      °C                   °C 
Reaction 
time / 
temperature 
Product 
Isolated 175 
(%) 
1 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
aq. sodium 
bicarbonate, (4), 
RT 
 (2), RT - 24 hr, RT 23 % 
2 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
aq. sodium 
bicarbonate, (4), 
RT 
 (2), 0 °C -    24 hr, RT 14 % 
3 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
Triethylamine, 
(0.5), dioxane, 
RT, 
 Triethylamine, 
(0.5), dioxane, 
RT 
 (2), RT - 2 hr, RT 
 
 
24 hr, RT 
21 % 
4 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(0.5), dioxane, 
RT,  
 Triethylamine, 
(0.5), dioxane, 
RT 
 (2), RT - 2 hr, RT 
 
 
24 hr  RT 
21 % 
5 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(0.5), dioxane, 
RT,  
 Triethylamine, 
(0.5), dioxane, 
RT 
-  (2), RT 2 hr, RT, 
 
 
24 hr, RT 
21 % 
6 TFA/TES/ 
CH2Cl2, 4 hr 
1,4-
dioxane 
aq. sodium 
bicarbonate, (4), 
RT 
-  (1), RT 24 hr, RT 23 % 
7 TFA/TES/ 
CH2Cl2, 4 hr 
1,4-
dioxane 
aq. sodium 
bicarbonate, (4), 
RT, 
Triethylamine, 
(couple of 
drops), 0 °C 
-  (2),  
0 °C 
 24 hr, RT 2 % 
8 TFA/TES/ 
CH2Cl2, 4 hr 
1,4-
dioxane 
aq. sodium 
bicarbonate, (4), 
RT 
-  (2),  
0 °C 
   24 hr, RT 31 % 
9 TFA/TES/ 
CH2Cl2, 4 hr 
H2O Triethylamine, 
(0.5), dioxane, 
-  (2), RT 
 
3 hr 30 min, 
RT, 
25 % 
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RT,  
 Triethylamine, 
(0.5), dioxane, 
RT 
 
 (2), RT  
 
 24 hr, RT 
10 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
aq. sodium 
bicarbonate, 
(4.6), RT 
- (2),  
0 °C 
 24 hr in 
freezer, 
 5 hr,  0 °C 
50 % 
11 TFA/TES/ 
CH2Cl2, 4 hr 
1,4- 
dioxane 
aq. sodium 
bicarbonate, (5), 
RT 
-  (2.5),  
0 °C 
 24 hr in 
freezer,  
5 hr, 0 °C – 
RT 
83 % 
 
Optimised experiments 
 
General procedure 
 
3-(R)-2-tert-Butoxycarbonyl-2-(fluoren-9-ylmethoxcarbonylamino)ethylsulfanyl)-(S)-
(allyloxycarbonylamino)propionic acid allyl ester 102 was treated with a solution of TFA (10 
%, 0.4 mL), triethylsilane (TES) (5 %, 0.2 mL) and CH2Cl2 (3.2 mL) under argon for 4 hr. 
Excess CH2Cl2 (100 mL) was then added. The organic layer was washed with saturated 
sodium bicarbonate (50 mL) and brine (50 mL), dried over anhydrous sodium sulphate, and 
then concentrated in vacuo. The residue was suspended in the appropriate solvent and then 
the base was added followed by the addition of the protecting reagent at the required 
temperature. The equivalents of reagents, the reaction time, and temperature of the reaction 
and the addition of further reagents were carried out and maintained according to the 
optimised experiments table above. Excess CH2Cl2 (150 mL) was added and the mixture was 
washed with saturated sodium bicarbonate (80 mL) and brine (80 mL). The organic layer was 
dried over anhydrous sodium sulphate, concentrated in vacuo, and purified by flash column 
chromatography (hexane: EtOAC, 9:1) to give the title product 175 as a clear oil. 
 
Rf: 0.45 (Hexane: Ethyl acetate; 9:1); 
NMR: δH (500 MHz, CDCl3), 7.76 (2 H, d, J = 7.5 Hz, Ar), 7.62 (2 H, d, J = 5.4 Hz, Ar), 
7.39 (2 H, t, J = 7.4 Hz, Ar), 7.38 (2 H, t, J = 7.4 Hz, Ar), 5.86 (1 H, m, CH2CH=CH2), 5.81 
(1 H, d, J = 7.1 Hz, NHFmoc), 5.58 (1 H, d, J = 5.2 Hz, NHTeoc), 5.28 (2 H, m, 
CH2CH=CH2), 4.63 (3 H, m, J = 5.8 Hz, CH2CH=CH2 and H  A side), 4.49 (1 H, m, H  B 
side), 4.38 (2 H, m, CH2Fmoc), 4.24 (1 H, t, J = 7.3 Hz, CHFmoc), 4.16 (2 H, t, J = 8.6 Hz, 
CH2OCO), 3.02 (4 H, m, CH2 β A and B side), 1.48 (9 H, s, tBu), 0.97 (2 H, bt, J = 8.6 Hz, 
CH2TMS), 0.01 (9 H, s, Si(CH3)3); 
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NMR: δC (125 MHz, CDCl3), 170.0 (C25), 169.4 (C17), 156.0 (C15), 155.9 (C29), 143.9 (CAr), 
143.8 (CAr), 141.4 (C27), 131.4 (CAr), 127.8 (CAr), 127.2 (CAr), 125.6 (CAr), 120.1 (C28), 67.3 
(C18), 66.4 (C14), 63.7 (C26), 60.5 (C16), 54.4 (C24), 53.9 (C30), 47.2 (C8), 35.9 (C22, 23), 28.1 
(C19, 20, 21), 14.2 (C31), -1.23 (C32, 33, 34);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 693.2605; C34H46N2O8NaSiS, requires 693.2642.
 
(ES
+
), C34H46N2O8SiS, m/z: 693 [M + Na]
+
;  
IR νmax: 2952, 1715, 1519 cm
-1
; 
[α]20 D = - 5.2 (c 8.5 mg/mL, CHCl3).  
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-
(S)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid tert-butyl 
ester 176 
'' B-side'' (R)
'' A-side'' (S)
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(S)-3-[2-Allyloxycarbonyl-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-(R)-2-
(9H-fluoren-9-ylmethoxycarbonylamino)-propionic acid tert-butyl ester 175 (0.17 g, 0.25 
mmol) was dissolved in a solution of tetrakis-triphenyl phosphine, Pd(PPh3)4 (10 % w/v, 
0.017 g, 0.014 mmol), 1,3-dimethylbirbaturic acid (0.020 g, 0.128 mmol, 5 equiv) in CHCl3 
(1 mL) and the reaction was stirred for 3 hr. The mixture was diluted in excess ethyl acetate 
which was washed with brine and then with distilled water. The organic layer was dried over 
anhydrous sodium sulphate, filtered and concentrated in vacuo (mass spec and NMR in 
Appendix 2 and 3). The residue was then dissolved in acetonitrile (2 mL). To the solution dry 
pyridine (0.02 mL, 1 equiv) and 2-(trimethylsilanyl)ethanol (0.054 mL, 0.37 mmol, 1.5 
equiv) was added. The mixture was cooled to 0 ºC then N’,N’-dicyclohexylcarbodiimide 
(0.06 g, 0.29 mmol, 1.2 equiv) was added and the reaction mixture was stirred overnight at 
room temperature under inert conditions. The DCU precipitate was removed by filtration and 
washed with ethyl acetate, the filtrate was then removed in vacuo. The resulting oily residue 
was redissolved in ethyl acetate and washed with saturated sodium bicarbonate and water. 
The organic layer was dried over anhydrous sodium sulphate, concentrated in vacuo, and 
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purified by flash column chromatography (hexane: EtOAc, 9:1) to give the title product 176 
as a clear viscous oil.    
 
Yield: 0.095 g, 0.130 mmol, 51 %;  
Rf: 0.34 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (500 MHz, CDCl3), 7.75 (2 H, d, J = 7.5 Hz, Ar), 7.62 (2 H, bt, J = 6.4 Hz, Ar), 
7.39 (2 H, t, J = 7.5 Hz, Ar), 7.31 (2 H, t, J = 7.5 Hz, Ar), 5.82 (1 H, d, J = 7.4 Hz, 
NHFmoc), 4.58 (1 H, m, NHTeoc), 4.50 (1 H, m, H  B side), 4.36 (2 H, m, CH2Fmoc), 4.24 
(2 H, m, CHFmoc and H  A side), 4.16 (4 H, m, 2 x Si(CH3)3CH2CH2), 3.01 (4 H, m, CH2 β 
A and B side), 1.45 (9 H, s, tBu), 0.98 (4 H, m, 2 x Si(CH3)3CH2CH2), 0.03 (18 H, d, J = 4.4 
Hz, 2 x Si(CH3)3), co-eluting with 5.50 (1 H, m, allyl impurity), 5.12 (4 H, m, allyl impurity), 
2.71 (2 H, d, J = 7.5 Hz, allyl impurity), (Appendix 5); 
NMR: δC (125 MHz, CDCl3), 168 (C17, 25), 156.0 (C15, 31), 143.8 (CAr), 141.0 (CAr), 127.8 
(CAr), 127.2 (CAr), 125.3 (CAr), 83.2 (C18), 67.4 (C14), 64.5 (C26), 54.5 (C16), 54.0 (C24, 32), 
47.2 (C13), 36.1 (C22, 23), 28.1 (C19, 20, 21), 17.7 (C27), 17.5 (C33) -1.44 (C28, 29, 30, 34, 35, 36); 
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 753.3058; C36H54N2O8NaSi2S, requires 753.3037;
 
(ES
+
), C36H54N2O8Si2S, m/z: 753 [M + Na]
+ 
(Appendix 4).   
*Sample not pure. 
 
3-[2-tert-Butoxycarbonyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethylsulfanyl]-2-(2-
trimethylsilanyl-ethoxycarbonylamino)-propionic acid 
 
'' B-side'' (R)
'' A-side'' (S)
O
OHN
O
O
S
OHO
HNO
O
Si H H
 
 
(S)-3-[2-Allyloxycarbonyl-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-(R)-2-
(9H-fluoren-9-ylmethoxycarbonylamino)-propionic acid tert-butyl ester 175 (0.17 g, 0.25 
mmol) was dissolved in a solution of tetrakis-triphenyl phosphine, Pd(PPh3)4 (10 % w/v, 
0.017 g, 0.014 mmol), 1,3-dimethylbarbituric acid (0.020 g, 0.128 mmol, 5 equiv) in CHCl3 
(1 mL) and stirred for 3 hr. Excess ethyl acetate was added to the reaction mixture, and the 
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resulting organic layer was washed with brine, followed by distilled water. The organic layer 
was dried over anhydrous sodium sulphate, filtered and concentrated in vacuo to give 3-[2-
tert-butoxycarbonyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethylsulfanyl]-2-(2-
trimethylsilanyl-ethoxycarbonylamino)-propionic acid. 
  
NMR: δH (500 MHz, CDCl3), 7.87 (2 H, d, J = 7.4 Hz, Ar), 7.72 (2 H, bd, J = 7.5 Hz, Ar), 
7.36 (2 H, t, J = 7.3 Hz, Ar), 7.28 (2 H, t, J = 7.5 Hz, Ar), 6.01 (1 H, bd, J = 7.3 Hz, 
NHFmoc), 5.72 (1 H, bd, J = 7.3 Hz, NHTeoc), 4.42 (1 H, m, H  B side), 4.34 (2 H, m, 
CHFmoc and H  A side), 4.20 (2 H, t, J = 7.2 Hz, CH2Fmoc), 4.12 (2 H, m, CH2OCO), 3.00 
(4 H, m, CH2 β A and B side), 1.46 (9 H, s, tBu), 0.94 (2 H, t, CH2TMS), 0.00 (9 H, s, 
Si(CH3)3), co-eluting with 5.49 (1 H, m, allyl impurity), 5.27 (4 H, m, allyl impurity), 2.71 (2 
H, d, J = 7.5 Hz, allyl impurity), (Appendix 3);
MS: (ES
+
), C31H42N2O8SiS, m/z: 653 [M + Na]
+ 
(Appendix 2).   
*Sample not pure. 
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-
(S)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid 169 
 
'' B-side'' (R)
'' A-side'' (S)
O
OHN
OH
O
S
OO
Si
HNO
O
Si H H
 
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-
(S)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid tert-butyl ester 
176 (0.27 g, 0.36 mmol) was treated with a solution of TFA (1 mL) and CH2Cl2 (1 mL) and 
the mixture was stirred for 3 hr. The reaction mixture was concentrated in vacuo with toluene 
(100 mL), this was added to aid the removal of TFA. Purification was completed by reverse-
phase column chromatography in acetonitrile and saturated NaHCO3, gradient 0 % - 40 % 
actonitrile in 100 % - 60 % (20 % NaHCO3) saturated NaHCO3. The acetonitrile was 
removed under vacuum. Concentrated sulphuric acid was added to bring the aqueous layer to 
pH 2 and sodium chloride was added until saturation was reached. The product was extracted 
from the aqueous layer with chloroform. The organic layer was then dried over anhydrous 
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sodium sulphate and concentrated in vacuo to give the title product 169 followed by 
preparative HPLC.  
Yield: 0.071 g, 0.105 mmol, 28 %;  
Rf: 0.13 (AgCN ((40 %): Sat. NaHCO3) Reverse phase TLC; 
NMR: δH (500 MHz, CDCl3), 7.73 (2 H, d, J = 7.2 Hz, Ar), 7.69 (2 H, m, Ar), 7.32 (2 H, bt, 
J = 7.35 Hz, Ar), 7.24 (2 H, t, J = 7.7 Hz, Ar), 6.48 (1 H, bs, NHFmoc), 4.61 (1 H, bs, 
NHTeoc), 4.39 (2 H, m, H  B side and CHFmoc), 4.40 - 4.11 (7 H, m, CH2Fmoc, H  A side 
and 2 x Si(CH3)3CH2CH2), 3.27 (4 H, m, CH2 β A and B side), 0.86 (4 H, m, 2 x 
Si(CH3)3CH2CH2), 0.04 (9 H, s, Si(CH3)3), -0.07 (9 H, s, Si(CH3)3), co-eluting with 5.29 (1 
H, m, allyl), 5.06 (2 H, m, allyl), 2.71 (2 H, d, J = 7.5 Hz, allyl), (Appendix 6);
MS: (ES
+
), C32H46N2O8Si2S, m/z: 675 [M + H]
+
;    
Analytical HPLC: (Wide Pore C18); RT 23.35; A: H2O/0.5 % TFA; B: acetonitrile/0.5% 
TFA; gradient 10 % - 60 % B over 35 min (Appendix 7);  
Preparative HPLC: (Wide Pore C18) in H2O/0.5 % TFA and acetonitrile/0.5 % TFA at a 
gradient of 10 % - 60 % acetonitrile over 45 min to give 162, which eluted at 34 min 
(Appendix 8). 
*Sample not pure. 
 
(R)-3-Benzyloxy-2-tert-butoxycarbonylamino-propionic acid (2-trimethylsilanyl)ethyl ester 
179 
O N
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Boc-D-Serine(Bzl)-OH 178 (2.30 g, 7.79 mmol) and 4-(dimethylamino)pyridine (DMAP) 
(0.155 g, 1.27 mmol, 0.15 equiv) were dissolved in dry THF (32 mL) and cooled to 0 ºC 
under nitrogen. 2-Trimethylsilylethanol (2.43 mL, 16.9 mmol, 2 equiv) was added dropwise, 
followed by 1,3-dicyclohexylcarbodiimide (2.27 g, 11.0 mmol, 1.3 equiv) in one portion, the 
solution was allowed to reach room temperature and stirred for 36 hr. After 36 hr the mixture 
was filtered, washed with ethyl acetate and the filtrate was concentrated in vacuo. The residue 
was redissolved in ethyl acetate. The organic layer was washed with saturated sodium 
bicarbonate (200 mL) and brine (200 mL), and then dried over anhydrous magnesium 
sulphate and the solvent was removed in vacuo. Flash column chromatography (hexane: 
EtOAc, 9:1) was carried out to give the title product 179 as a clear oil. 
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Yield: 2.7 g, 6.83 mmol, 80 %;  
Rf: 0.5 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (500 MHz, CDCl3), 7.73-7.25 (5 H, m, Ar), 5.40 (1 H, d, J = 8.6 Hz, BocHNCH), 
4.53 (1 H, d, J = 12.2 Hz, ArCH2OCH2CH), 4.46 (1 H, d, J = 12.2 Hz, ArCH2OCH2CH), 4.39 
(1 H, m, ArCH2OCH2CH), 4.22 (2 H, m, CH2CO2CH2CH2Si(CH3)3), 3.86 (1 H, dd, J = 9.4, 
3.0 Hz, ArCH2OCH2CH), 3.68 (1 H, dd, J = 9.4, 3.0 Hz, ArCH2OCH2CH), 1.44 (9 H, s, 
Boc), 0.96 (2 H, m, J = 8.9, 8.3 Hz, CH2SiCH3)3), 0.02 (9 H, s, Si(CH3)3);  
NMR: δC (125 MHz, CDCl3), 170.8 (C15), 155.6 (C10), 137.7 (CAr), 129.7 (CAr), 128.4 (CAr), 
127.6 (CAr), 79.8 (C11), 73.3 (C7), 70.1 (C8), 63.9 (C16), 54.2 (C9), 28.3 (C12, 13, 14), 17.4 (C17), 
-1.45 (C18, 19, 20);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 418.1855; C20H33NO3NaSi, requires 418.1848;
 
(ES
+
), C20H33NO3Si, m/z: 418 [M + Na]
+
;  
IR νmax: 3447, 2953, 2119, 1721, 1717, 1497 cm
-1
;  
[α]20 D = - 7.6 (c 10 mg/mL, CHCl3).  
 
(R)-2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid (2-trimethylsilanyl)ethyl ester 
180 
O N
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(R)-3-Benzyloxy-2-tert-butoxycarbonylamino-propionic acid (2-trimethylsilanyl)ethyl ester 
179 (2.47 g, 6.25 mmol) was dissolved in ethanol (80 mL), Pd/C (10 %, 0.5 g) was added to 
the mixture. The suspension was placed under a hydrogen atmosphere and stirred at 
atmospheric pressure for 24 hr. Further Pd/C (10 %, 0.5 g) was added and the hydrogen re-
charged; the suspension was stirred for a further 7 hr. A further Pd/C (10 %, 0.5 g) was added 
and the suspension was stirred for 24 hr. A final portion of Pd/C (10 %, 0.5 g) was added, the 
hydrogen re-charged, and the suspension was stirred for a further 48 hr. The mixture was 
filtered through a pad of Celite, rinsing several times with ethyl acetate. The combined 
filtrates were concentrated in vacuo and the title product 180 was isolated as a clear oil by 
flash column chromatography (hexane: EtOAc, 9:1) on silica gel. 
 
Yield: 1.76 g, 5.77 mmol, 87 %;  
Rf: 0.17 (Hexane: Ethyl acetate; 9:1); 
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      0.71 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (500 MHz, CDCl3), 5.47 (1 H, d, J = 4.4 Hz, BocNHCH), 4.32 (1 H, m, 
BocNHCHOH), 4.24 (2 H, m, Si(CH3)3CH2CH2CO2), 3.90 (2 H, m, BocNHCHCH2OH), 
2.56 (1 H, bs, OH), 1.43 (9 H, s, Boc), 1.00 (2 H, t, J = 5.1 Hz, Si(CH3)3CH2CH2TMS), 0.02 
(9 H, s, Si(CH3)3);  
NMR: δC (125 MHz, CDCl3), 170.9 (C6), 155.8 (C9), 80.2 (C10), 64.3 (C8), 60.5 (C5), 55.9 
(C7), 28.3 (C11, 12, 13), 14.2 (C4), -1.49 (C1, 2, 3);  
HRMS: cald (ES
+
), m/z: Found [M + H]
+
, 306.1739, C13H28NO5Si, requires 306.1736;
 
(ES
+
), 
C13H27NO5Si, m/z: 306 [M + H]
+
;  
IR νmax: 2954, 1717, 1497, 1366 cm
-1
;  
[α]20 D = - 8.3 (c 9.9 mg/mL, CHCl3).  
 
(R)-2-Amino-3-hydroxy-propionic acid (2-trimethylsilanyl)ethyl ester 181 
 
H2N
O
O
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Condition 1 
 
(R)-2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid (2-trimethylsilanyl)ethyl ester 
180 (0.2 g, 0.65 mmol) was treated with a solution of TFA (1 mL) and CH2Cl2 (1 mL) and 
the reaction mixture was stirred for 1 hr. The reaction mixture was then concentrated in 
vacuo, excess toluene was added and removed in vacuo, this was repeated 2 times followed 
by CH2Cl2. The title product 181 was isolated by flash column chromatography on silica gel 
as colourless oil. Column was loaded with (MeOH: CH2Cl2, 2:98) followed by (MeOH: 
CH2Cl2, 5:95). 
 
Yield: 0.066 g, 0.32 mmol, 49 %;  
Rf: 0.25 (MeOH: CH2Cl2; 10:90). 
 
Condition 2 
(R)-2-Amino-3-benzyloxy-propionic acid (2-trimethylsilanyl)ethyl ester 185 (0.26 g, 0.90 
mmol) was dissolved in ethanol, Pd/C (10 %, 0.06 g) was then added to the mixture. The 
suspension was placed under a hydrogen atmosphere and stirred at atmospheric pressure for 
24 hr. Further Pd/C (10 %, 0.06 g) was added and the hydrogen re-charged; the suspension 
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was stirred for a further 7 hr. A further portion of Pd/C (10 %, 0.06 g) was added and the 
suspension was stirred for 24 hr. A final portion of Pd/C (10 %, 0.06 g) was added, the 
hydrogen re-charged, and the suspension was stirred for a further 48 hr. The mixture was 
filtered through a pad of Celite, rinsing several times with ethyl acetate. The combined 
filtrates were concentrated in vacuo and the title product 181 was isolated by flash column 
chromatography on silica gel (CH2Cl2: MeOH, 95:5) as a colourless oil. 
 
Yield:  0.057 g, 0.27 mmol, 47 %; 
Rf: 0.6 (CH2Cl2: MeOH; 20:80); 
NMR: δH (500 MHz, CD3OD), 4.29 (2 H, m, CO2CH2CH2Si(CH3)3), 3.92 (3 H, m, 
NHCHCH2OH), 1.05 (2 H, m, CH2Si(CH3)3), 0.04 (9 H, s, Si(CH3)3);  
NMR: δC (125 MHz, CD3OD), 170.9 (C3), 65.6 (C1), 62.0 (C4), 56.5 (C2), 18.2 (C5), -1.40 
(C6, 7, 8);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 228.1040; C8H19NO3NaSi, requires 228.1032;
 
(ES
+
), C8H19NO3Si, m/z: 228 [M + Na]
+
;  
IR νmax: 3235, 2954, 1736, 1640, cm
-1
;  
[α]20 D = - 41.0 (c 7.3 mg/mL, MeOH).  
 
(R)-2-Amino-3-benzyloxy-propionic acid (2-trimethylsilanyl)ethyl ester 185 
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(R)-3-Benzyloxy-2-tert-butoxycarbonylamino-propionic acid (2-trimethylsilanyl)ethyl ester 
179 (0.58 g, 1.47 mmol) was treated with a solution of TFA (1 mL), TIPS (0.04 mL) and 
CH2Cl2 (0.98 mL), and the reaction was stirred for 4.5 hr under argon. Excess CH2Cl2 (200 
mL) was added and the organic layer was washed with saturated NaHCO3 (200 mL) and 
brine (200 mL). The organic layer was dried over anhydrous magnesium sulphate and 
concentrated in vacuo. The title product 185 was isolated as colourless oil by flash column 
chromatography on silica gel (CH2Cl2: MeOH, 95:5). 
 
Yield: 0.266 g, 0.91 mmol, 62 %;  
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Rf: 0.37 (MeOH: CH2Cl2; 10:90); 
NMR: δH (500 MHz, CDCl3), 7.31 (5 H, m, Ar), 4.55 (1 H, d, J = 12.1 Hz, ArCH2OCH2), 
4.51 (1 H, d, J = 12.1 Hz, ArCH2OCH2), 4.21 (2 H, m, CH2CH2Si(CH3)3), 3.72 (1 H, dd, J = 
9.0, 5.2 Hz, ArCH2OCH2CH), 3.69 (1 H, dd, J = 9.0, 3.8 Hz, ArCH2OCH2CH), 3.61 (1 H, dd, 
J = 5.0, 3.8 Hz, ArCH2OCH2CH) 0.97 (2 H, m, CH2CH2Si(CH3)3), 0.03 (9 H, s, Si(CH3)3); 
NMR: δC (150 MHz, CDCl3), 173.9 (C10), 137.9 (CAr), 128.7 (CAr), 127.9 (CAr), 127.6 (CAr), 
72.70 (C7), 71.98 (C8), 64.02 (C11), 55.24 (C9,), 17.50 (C12), -1.39 (C13, 14, 15);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 318.15092; C15H25NO3NaSi, requires 318.15013;
 
(ES
+
), C15H25NO3Si, m/z: 318 [M + Na]
+
;  
IR νmax:  3384, 2952, 1735, 1454, 1250 cm
-1
;  
[α]20 D = + 1.3 (c 15.0 mg/mL, CHCl3). 
  
(R)-3-Hydroxy-2-(triphenylmethylamino)-propionic acid (2-trimethylsilanyl)ethyl ester 182 
N
H
O
O
Si
OH
25
26
27
24
23
22
21
20
7
14
19
18
17
16 15
8
1312
11
10
9
5
1
6
4
3
2
H
 
 
Entry SM Boc 
deprotection / 
Time 
Reaction 
solvents 
Base (equiv), 
Temperature 
TMS-Cl, 
(equiv), 
°C 
Trt-Cl 
(equiv), 
°C 
Reaction 
time, / 
°C 
Product 
Isolated 
182 (%) 
Byproduct 
Isolated % 
186   187  
188 
1 180 TFA / TIPS / 
CH2Cl2, 4 hr 
DMF Triethylamine 
(1), RT 
- (1), RT 24 hr, RT - Observ
ed by 
MS 
- 
2 180 TFA / TIPS / 
CH2Cl2, 2 hr 
CH2Cl2 Triethylamine, 
(2), RT, 
MeOH, (1), 
0 °C, 
Triethylamine, 
(1), RT, 
 
(2), RT (1), RT Reflux, 
20 min, 
Reflux, 
45 min, 
24 hr, RT 
 
10 % - - 20 
% 
3 180 TFA / TIPS / 
CH2Cl2, 1 hr 
30 min 
THF Triethylamine, 
(2), RT, 
MeOH, (1), 
0 °C, 
Triethylamine, 
(1), RT, 
 
(2), RT (1), RT Reflux, 
20 min, 
Reflux, 
45 min, 
24 hr, RT 
 
12 % - - 15 
% 
4 181 - CH2Cl2 Triethylamine, 
(2), RT, 
MeOH, (1), 
0 °C, 
Triethylamine, 
(1), RT, 
 
(2), RT - Reflux, 
20 min, 
Reflux, 
45 min, 
24 hr, RT 
 
43 % - - 20 
% 
Optimised experiments 
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General procedure 
 
(R)-2-tert-Butoxycarbonylamino-3-hydroxy-propionic acid (2-trimethylsilanyl)ethyl ester 
180 (0.1 g, 0.32 mmol) was treated with TFA (50 %, 0.5 mL), CH2Cl2 (49 %, 0.49 mL) and 
TIPS (1 %, 0.01 mL), for the time specified in the table above. Excess toluene was added and 
removed in vacuo 3 times, followed by addition of CH2Cl2 and then concentration in vacuo 
(Entries 1, 2 and 3). Residue (Entry 1, 2, and 3), -Amino-3-hydroxy-propionic acid 2-
trimethylsilanyl-ethyl ester 181 (Entry 4) were suspended in the appropriate solvent (Table 
above). 
- Entry 1: triphenylmethyl chloride (1 equiv) was added followed by triethylamine (1 equiv) 
and the mixture was stirred for 20 hr, the reaction solvent was removed under vacuum.  
- Entry 2, 3 and 4: Trimethylsilylchloride (2 equiv) was added to the suspension under argon. 
The mixture was refluxed for 20 min and then cooled to room temperature. Triethylamine (2 
equiv) was then added after which the reaction was refluxed for 45 min. The mixture was 
then allowed to cool to room temperature and then cooled in an ice bath to 0 ºC. Methanol 
(anhydrous, 1 equiv) was then added and the mixture was allowed to reach room temperature. 
Triethylamine (1 equiv) was added followed by triphenylmethylchloride (1 equiv), and the 
reaction was stirred for a further 24 hr at room temperature. 
 
Excess triethylamine (10 mL) and methanol (60 mL) were then added until white solid 
dissolved. The solvent was removed in vacuo yielding a mixture of yellow and white crystals 
which was partitioned between ethyl acetate (100 mL) and citric acid (5 % aq, w/v, 50 mL) 
precooled to 0 ºC. The organic layer was dried over anhydrous sodium sulphate. The product 
182 was isolated as colourless oil by flash column chromatography in (CH2Cl2: MeOH, 98:2). 
  
Rf: 0.28 (MeOH: CH2Cl2; 1:9); 
NMR: δH (500 MHz, CDCl3), 7.50 (6 H, m, Trt), 7.28 (6 H, m, Trt), 7.20 (3 H, m, Trt), 3.80 
(1 H, m, TrtNHCHCH2OH), 3.70 (2 H, m, CO2CH2CH2Si(CH3)3), 3.51 (2 H, m, 
TrtNHCHCH2OH), 0.79 (2 H, m, CH2Si(CH3)3), 0.01 (9 H, s, Si(CH3)3);  
NMR: δC (125 MHz, CDCl3), 173.7 (C22), 145.8 (CAr), 128.7 (CAr), 128.0 (CAr), 126.4 (CAr), 
71.1 (C7), 64.9 ( C21 or C23), 63.5 (C21 or C23), 57.9 (C20), 17.3 (C24), -1.49 (C25, 26, 27);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 470.2115; C27H33NO3NaSi, requires 470.2127;
 
(ES
+
), C27H33NO3NaSi, m/z: 470 M + Na;  
IR νmax: 3465, 2952, 1726, 1597 cm
-1
;   
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[α]20 D = - 0.6 (c 8.6 mg/mL, CHCl3).  
 
(S)-3-Iodo-2-(triphenylmethylamino)-propionic acid (2-trimethylsilanyl)ethyl ester 183 
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Optimised experiments 
 
General procedure 
 
(R)-3-Hydroxy-2-(triphenylmethylamino)-propionic acid (2-trimethylsilanyl)ethyl ester 182 
was dissolved in dry CH2Cl2 (4 mL) at room temperature in the presence of 
triphenylphosphine (1.5 equiv). After 10 min, the reaction mixture was cooled to -10 ºC using 
an acetone/ice bath. Diethylazodicarboxylate (1.5 equiv) was then added dropwise to the 
reaction over 1 min. After further 5 min, this was followed by the careful addition of 
iodomethane (1.5 equiv). The reaction was kept at -2 ºC for the time above using an ethanol 
bath refrigerated by a cryostat. 
 
The reaction mixture was directly filtered by flash column chromatography, beginning with 
20: 1 hexane: EtOAc reducing to 10:1 until the removal of the title product 183 was collected 
as a colourless oil. A 4:1 eluant was then used to collect the starting material 182 in 50 % 
yield. 
 
Rf: 0.15 (Hexane: Ethyl acetate; 15:1); 
NMR: δH (600 MHz, CDCl3), 7.50 (6 H, m, Trt), 7.33 (6 H, m, Trt), 7.18 (3 H, m, Trt), 3.78 
(1 H, td, J = 5.8 Hz, CO2CH2CH2Si(CH3)3), 3.68 (1 H, td, J = 5.8 Hz, CO2CH2CH2Si(CH3)3), 
Entry Reaction 
solvent 
PPh3 (equiv), 
Temperature 
DEAD 
(equiv), / 
°C 
MeI 
(equiv), 
/ °C 
Reaction 
time, / °C 
Product 
Isolated 
183 (%) 
1 CH2Cl2 (1.5), RT (1.5), 
-10 °C 
(1.5), 
-10 °C 
3 hr, -2 
°C 
8.6 % 
2 CH2Cl2 (1.5), RT (1.5), 
-10 °C 
(1.5), 
-10 °C 
6 hr, -2 
°C 
47 % 
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3.43 (1 H, m, TrtNHCHCH2I), 3.31 (1 H, dd, J = 9.8, 3.4 Hz, TrtNHCHCH2I), 3.18 (1 H, dd, 
J = 9.8, 6.8 Hz, TrtNHCHCH2I), 2.90 (1 H, d, J = 9.4 Hz, NH), 0.85 (2 H, m, CH2Si(CH3)3), 
0.01 (9 H, s, Si(CH3)3);  
NMR: δC (125 MHz, CDCl3), 172.4 (C22), 145.7 (CAr), 128.7 (CAr), 128.1 (CAr), 126.7 (CAr), 
71.2 (C7), 63.7 (C23), 56.2 (C20), 14.2 (C24), 10.3 (C21), -1.40 (C25, 26, 27);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 580.113105; C27H32INO2NaSi, requires 
580.11447;
 
(ES
+
), C27H32INO2Si, m/z: 580 [M + Na];  
IR νmax: 3058, 2952, 1730, 1596, 1490, 1448 cm
-1
;  
[α]20 D = - 8.1 (c 5.2 mg/mL, CHCl3).  
    
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[(S)-2-(2-trimethylsilanyl-
ethoxycarbonyl)-2-(triphenylmethylamino)-ethylsulfanyl]-propionic acid tert-butyl ester 
184 
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N-9-fluorenylmethoxycarbonyl-(R)-cystine bis-tert-butyl ester 90 (0.09 g, 0.24 mmol) and 
(S)-3-Iodo-2-(triphenylmethylamino)-propionic acid (2-trimethylsilanyl)ethyl ester 183 (0.13 
g, 0.24 mmol, 1 equiv) were dissolved in DMF (10 mL) under argon. Dry Cs2CO3 (0.038 g, 
0.12 mmol, 0.5 equiv) was added over 2 min and the reaction was stirred for 2 hr. Further dry 
Cs2CO3 (0.038 g, 0.12 mmol, 0.5 equiv) was added over 1 min and the reaction was stirred 
for a further 2 hr. Excess ethyl acetate (200 mL) was added and the mixture was washed with 
cold citric acid (5 % w/v aq, 100 mL) and distilled water (5 x 50 mL). The ethyl acetate layer 
was dried over anhydrous sodium sulphate and concentrated in vacuo. Purification was 
carried out by flash column chromatography (hexane: EtOAc, 50:1 followed by 25:1) to give 
the title product 184 as a white foam. 
 
Yield: 0.078 g, 0.094 mmol, 39 %; 
Rf: 0.37 (Hexane: Ethyl acetate; 4:1); 
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NMR: δH (500 MHz, CDCl3), 7.77-7.15 (23 H, m, Ar), 5.66 (1 H, d, J = 7.9 Hz, NHFmoc), 
5.60 (1 H, d, J = 7.4 Hz, NHTrt), 4.50 (1 H, m, H B side), 4.36 (2 H, m, CH2Fmoc), 4.24 (1 
H, t, J = 7.0 Hz, CHFmoc), 3.72 (2 H, m, CH2CH2Si), 3.61 (2 H, m, CH2CH2Si), 3.51 (1 H, 
m, H  A side), 3.00 (4 H, CH2 β A and B side), 1.48 (9 H, s, tBu), 0.77 (2 H, m, CH2CH2Si), 
0.00 (9 H, s, Si(CH3)3; 
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 851.3513; C49H56N2O6NaSiS, requires 851.3526;
 
(ES
+
), C49H56N2O6NaSiS, m/z: 851 [M + Na]
+
. 
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-
(S)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid tert-butyl 
ester 176 
'' B-side'' (R)
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(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[(S)-2-(2-trimethylsilanyl-
ethoxycarbonyl)-2-(triphenylmethylamino)-ethylsulfanyl]-propionic acid tert-butyl ester 184 
(0.08 g, 0.09 mmol) was treated with TFA (10 %, 0.2 mL), triethylsilane (TES) (5 %, 0.1 mL 
and CH2Cl2 (85 %, 1.7 mL), the mixture was stirred under argon for 4 hr. Excess CH2Cl2 
(100 mL) was added and the organic layer was washed with saturated sodium bicarbonate (50 
mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulphate, filtered 
and concentrated in vacuo. The residue was dissolved in 1,4-dioxane (2 mL) and then a 
solution of sodium bicarbonate (0.04 g, 0.47 mmol, 4 equiv) in water (2 mL) was added to 
the mixture. The resulting mixture was cooled to 0 ºC, Carbonic acid 2,5-dioxo-pyrrolidin-1-
yl ester 2-trimethylsilanyl-ethyl ester 171 (0.07 g, 0.026 mmol, 2 equiv) was added. The 
reaction was left in the freezer for 24 hr and then stirred at 0 ºC to room temperature for 5 hr. 
Excess CH2Cl2 (100 mL) was added and the organic layer was washed with saturated sodium 
bicarbonate (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium 
sulphate, concentrated in vacuo, and purified by flash column chromatography (hexane: 
EtOAc, 10:1 and then 3:1). This was followed by purification by preparative HPLC to give 
176 as colourless oil.  
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Yield: 0.008 g, 0.011 mmol, 12 %; 
Rf: 0.18 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (500 MHz, CDCl3), 7.91-7.28 (8 H, m, Ar), 5.81 (1 H, d, J = 7.3 Hz, NHFmoc), 
5.54 (1 H, d, J = 7.8 Hz, NHTeoc), 4.54 (2 H, m, H B side and CHFmoc), 4.35 (2 H, d, J = 
7.0 Hz, CH2Fmoc), 4.24 (1 H, m, H  A side), 4.20 (4 H, m, 2 x CH2CH2Si(CH3)3), 3.12 (4 H, 
m, CH2 β A and B side), 1.47 (9 H, s, tBu), 0.99 (4 H, m, 2 x CH2TMS), 0.09 (18 H, s, 2 x 
Si(CH3)3), (Appendix 11);  
NMR: δC (150  MHz, CDCl3), 170.8 (C17), 168 (C8), 156.3 (C6), 156.0 (C22), 143.8 (CAr), 
141.0 (CAr), 127.8 (CAr), 127.2 (CAr), 125.3 (CAr), 83.2 (C18), 67.4 (C23), 64.5 (C5 or 9), 163.7 
C5 or 9), 54.5 (C16), 54.0 (C7), 47.2 (C24), 37.4 (C14 or 15), 36.1 (C14 or 15), 28.1 (C19, 20, 21), 
17.7 (C4 or 10), 17.5 (C4 or 10), -1.44 (C1, 2, 3, 11, 12, 13);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 753.3052; C36H54N2O8NaSi2S, requires 753.3037;
 
(ES
+
), C36H54N2O8Si2S, m/z: 769 [M + K]
+
;  
IR νmax: 2953, 1720, 1511, 1340 cm
-1
;  
[α]20 D = - 9.3 (c 6.0 mg/mL, CHCl3);  
Analytical HPLC: (Wide Pore C18), RT 26.7; A: H2O/0.5 % TFA; B: isopropanol /0.5% 
TFA; gradient 10 % - 90 % B over 35 min (Appendix 9); 
Preparative HPLC: (Wide Pore C18), in H2O/0.5 % TFA and isopropanol/0.5 % TFA at a 
gradient of 10 % - 90 % isopropanol over 35 min to give the title product which eluted at 27.5 
min (Appendix 10). 
 
 (S)-3-[2-Amino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethylsulfanyl]-(R)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid 189 
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Condition 1 
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-
(S)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid tert-butyl ester 
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176 (0.26 g, 0.36 mmol) was treated with a solution of TFA (1 mL) and CH2Cl2 (1 mL), the 
resulting mixture was stirred for 3 hr at room temperature. The mixture was concentrated in 
vacuo, removal of TFA was helped by several additions of toluene (3 x 100 mL) followed by 
evaporation. Purification was completed by reverse-phase column chromatography in 
acetonitrile and saturated NaHCO3, gradient 0 % - 40 % actonitrile in 100 % - 60 % (20 % 
NaHCO3) saturated NaHCO3. Acetonitrile was removed under vacuum. Concentrated 
sulphuric acid was added until saturation was reached and the product was extracted from the 
aqueous layer with chloroform. The organic layer was then dried over anhydrous sodium 
sulphate and concentrated in vacuo to give the title product 189 as colourless oil.  
 
Yield: 0.087 g, 0.16 mmol, 42 %; 
Rf : 0.01 [AcCN (40 %): Sat NaHCO3] reverse phase TLC; 
NMR: δH (600 MHz, CD3OD), 7.79 (2 H, d, J = 7.6 Hz, Ar), 7.67 (2 H, d, J = 7.4 Hz, Ar), 
7.39 (2 H, t, J = 7.4 Hz, Ar), 7.31 (2 H, t, J = 7.4, Hz, Ar), 4.42 (1 H, m, CH2Fmoc), 4.29 (1 
H, m, CH2Fmoc), 4.23 (4 H, m, CHFmoc, H  B side and CH2CH2Si), 3.92 (1 H, m, H  A 
side), 3.08 (2 H, m, CH2 β), 2.93 (2 H, m, CH2 β), 1.00 (2 H, m, CH2CH2Si(CH3)3), 0.02 (9 
H, s, Si(CH3)3); 
NMR: δC (150 MHz, CD3OD), 180 (C11), 163.3 (C2), 158.4 (C12), 145.6 (CAr), 142.5 (C Ar), 
128.8 (CAr), 128.2 (CAr), 126.2 (CAr), 68.0 (C13), 65.6 (C3), 57.3 (C14), 54.5 (C1), 47.9 (C10), 
39.0 (C8, 9), 18.3 (C4), -1.42 (C5, 6, 7);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 553.1805; C26H34N2O6NaSiS, requires 553.1805;
 
(ES
+
), C26H34N2O6NaSiS, m/z: 553 [M + Na]
+
;  
IR νmax: 3355, 1690, 1410 cm
-1
;  
[α]20 D = - 4.4 (c 5.5, MeOH). 
  
Condition 2 
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-
(S)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid tert-butyl ester 
176 (0.029 g, 0.040 mmol) was treated with a solution of TFA (0.3 mL) and deuteriated 
CH2Cl2 (0.7 mL), the mixture was stirred for 3 hr at room temperature. Proton NMRs were 
taken when the solution was added to the starting material (Appendix 12), then at 10 min 
(Appendix 13), 1 hr (Appendix 14), 2 hr (Appendix 15) and 3 hr (Appendix 16). The product 
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was extracted from the aqueous layer with chloroform (50 mL) washed with water (8 x 25 
mL) followed by brine (25 mL), isolating 3 products as crude in 4.1 mgs. 
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Si H H
  
 
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 653.2329; C31H42N2O8NaSiS, requires 653.2329;
 
(ES
+
), C31H42N2O8SiS, m/z: 653 [M + Na]
+
.  
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+
), C26H34N2O6SiS, m/z: 553 [M + Na]
+
.  
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NMR: δH (500 MHz, CD3OD), 7.93 (2 H, m, Ar), 7.71 (2 H, d, J = 7.5 Hz, Ar), 7.37 (2 H, t, J 
= 7.4 Hz, Ar), 7.30 (2 H, t, J = 7.3 Hz, Ar), 4.36 (1 H, m, H  B side), 4.23 (5 H, m, 
CH2Fmoc, CHFmoc and CH2CH2Si), 3.82 (1 H, m, H  A side), 3.11-2.82 (4 H, m, CH2  A 
and B sides), 1.35 (9 H, s, tBu), 1.03 (2 H, m, CH2CH2Si(CH3)3), 0.00 (9 H, s, Si(CH3)3);  
(ES
+
), C30H42N2O6SiS, m/z: 609 [M + Na]
+
.  
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(S)-3-[2-Carboxy-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-(R)-2-(9H-
fluoren-9-ylmethoxycarbonylamino)-propionic acid 190 
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(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-
(S)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid tert-butyl ester 
176 (0.26 g, 0.36 mmol) was treated with a solution of TFA (1 mL) and CH2Cl2 (1 mL), the 
resulting mixture was stirred for 3 hr. The mixture was concentrated in vacuo, removal of 
TFA was helped by several additions of toluene (3 x 100 mL) followed by evaporation. 
Purification was completed by reverse-phase column chromatography in acetonitrile and 
saturated NaHCO3, gradient 0 % - 40 % actonitrile in 100 % - 60 % (20 % NaHCO3) 
saturated NaHCO3. Acetonitrile was removed under vacuum. Concentrated sulphuric acid 
was added until saturation was reached and the product was extracted from the aqueous layer 
with chloroform. The organic layer was then dried over anhydrous sodium sulphate and 
concentrated in vacuo to give the title product 190 as yellow foam. 
 
NMR: δH (600 MHz, CD3OD), 7.83 (2 H, m, Ar), 7.67 (3 H, m, Ar), 7.42 (2 H, m, Ar), 7.35 
(1 H, m, Ar), 4.21-4.42 (7 H, m, CH2Fmoc, CHFmoc and H  B side, H A side and 
CH2CH2Si), 3.15 (2 H, m, CH2 β), 2.94 (2 H, m, CH2 β), 1.09 (2 H, m, CH2CH2Si(CH3)3), 
0.02 (9 H, s, Si(CH3)3); 
NMR: δC (150 MHz, CD3OD), 169.2 (C8, 12), 158.7 (C6, 13), 145.2 (CAr), 142.3 (CAr), 128.8 
(CAr), 128.7 (CAr), 126.2 (CAr), 68.2 (C14), 66.5 (C7, 11), 53.6 (C5), 37.7 (C15), 33.3 (C9, 10), 
18.2 (C4), -1.65 (C1, 2, 3);  
HRMS: cald (ES
+
), m/z: Found [M + H]
+
, 575.1883; C27H35N2O8SiS, requires 575.1862; 
(ES
+
), C27H34N2O8SiS, m/z: 575 [M + H]
+
.  
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(Fmoc-Cys-OH)2 191 
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N’,N’-Bis(9-fluorenylmethoxycarbonyl)-(R,R)-cystine bis-tert-butyl ester 146 (3.00 g, 3.7 
mmol) was treated with a solution of TFA (6 mL) and CH2Cl2 (1 mL), the mixture was stirred 
for 3 hr. The product was concentrated in vacuo and left in a freeze dryer overnight. Yellow 
fluffy foam was isolated. 
 
Rf: 0.11 (CH2Cl2: MeOH; 15:1); 
NMR: δH (600 MHz, CD3OD ), 7.76 (4 H, m, Ar), 7.65 (4 H, d, J = 7.5 Hz, Ar), 7.35 (4 H, m 
Ar), 7.28 (4 H, t, J = 7.4 Hz, Ar), 4.54 (2 H, m, H  A and B side) 4.29 (4 H, m, 
CHCH2Fmoc), 4.19 (2 H, t, J = 7.2 Hz, CHCH2Fmoc), 3.28 (2 H, d, J = 4.2 Hz, CH2 β), 3.02 
(2 H, dd, J = 13.8, 4.4 Hz, CH2 β); 
NMR: δC (150 MHz, CD3OD), 174.0 (C3), 158.5 (C4), 145.2 (CAr), 142.5 (CAr), 128.7 (CAr), 
128.2 (CAr), 126.3 (CAr), 68.2 (C5), 54.6 (C2), 48.3 (C6), 41.0 (C1);  
HRMS: cald (ES
-
), m/z: Found [M – H]-, 683.1476; C36H31N2O8S2, requires 683.1522;  
(ES
-
), C36H32N2O8S2, m/z: 683 [M – H]
-
;  
IR νmax: 3390, 3010, 2159, 1720, 1524 cm
-1
;  
[α]25 D = + -79.6 (c 8.9 mg/mL, MeOH). 
 
(Fmoc-Cys-OTce)2 192 
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Entry Compound 
 
144 146  191 
Tertbutyl 
deprotection / 
Time 
Fmoc 
protection 
reagents,  
(equiv) / 
Time 
Reaction 
solvent 
Reagents 
(equiv), 
Temperature 
TceOH 
196 
(equiv), 
°C 
Reaction time 
/ temperature 
Product 
Isolated 
192 (%) 
1 - X - TFA/ 
CH2Cl2, 4 hr 
- CH2Cl2 DMAP (0.4), 
RT, 
DCC (2.2), 0 
°C, 
DMAP (0.4), 
0 °C 
(2.2), 
RT, 
 
 
 
(2.2), RT 
 
 
0 °C - RT, 
24 hr, RT, 
24 hr, RT 
18 % 
2 X - - - NaOH (4.2), 
THF – H2O, 
Fmoc-Cl 
(2.1), RT, 14 
hr 
Pyridine HOBt (2.9), 
RT, 
 
DCC (2.3), - 
20 °C 
(3.45), 
RT 
 
 
- 20 °C, 24 hr 
2.7 % 
3 - X - TFA/ 
CH2Cl2, 4 hr 
- CH2Cl2 DMAP (0.4), 
RT, 
DCC (6), 
0 °C, 
DMAP (0.4), 
RT 
(3), RT, 
 
 
 
(3), RT 
 
 
0 °C – RT, 
24 hr, RT, 
24 hr, RT 
25.3 % 
4 - X - TFA/ 
CH2Cl2, 4 hr 
- Pyridine HOBt (9), RT, 
 
DCC (9.9), - 
20 °C 
(11.6), 
RT 
 
 
- 20 °C, 24 hr 
44.4 % 
5 - - X - - Pyridine HOBt (8.4), 
RT, 
DCC (8.4), - 
20 °C, 
2 x HOBt 
(8.4), - 20 °C, 
DCC (8.4), - 
20 °C 
(9.35), 
RT, 
 
(2 x 
9.35), - 
20 °C, 
 
 
 
 
- 20 °C, 24 hr, 
- 20 °C, 
2 x 24 hr 
 
17.7 % 
6 - - X - - CH2Cl2 DMAP (0.47), 
RT 
DCC (8.4), 
0 °C, 
2 x DMAP 
(0.47), RT, 
DCC (8.4) 
(9.35), 
RT, 
 
 
(2 x 
9.35), RT 
 
 
0 °C – RT, 
24 hr, RT, 
2 x 24 hr, RT 
 
 
26 % 
7 - - X - - CH2Cl2 DMAP (0.47), 
RT, 
EDCI-polymer 
(2), 0 °C, 
DMAP (0.24), 
RT, 
EDCI-polymer 
(2), RT 
(9.35), 
RT, 
 
 
(9.35), 
RT 
 
 
 
0 °C, 
48 hr, RT 
 
72 hr, RT 
3.9 % 
8 - - X 
 
 
- - CH2Cl2 DMAP (0.4), 
0 °C, 
EDCI (2.2), 
0 °C, 
DMAP (0.4), 
RT 
(4), RT, 
 
 
 
(4), RT 
0 °C, 
 
24 hr, RT, 
 
24 h at RT 
NR * 
9 - - X - - DMF N-hydroxy 
Succinimide 
(2), RT, 
EDCI.HCl (2), 
RT, 
(4), RT, 
 
 
 
(4), RT 
24 hr, RT, 
 
 
 
24 h at RT 
32.7 % 
236 
 
N-hydroxy 
Succinimide 
(2), RT, 
EDCI.HCl (2), 
RT 
 
10 - - X - - Toluene Toluene-4- 
Sulphonic acid 
(2.4), RT 
(2.4), 
RT, 
 
(2.4), 
140 °C 
140 °C, 5 hr, 
 
140 °C, 24 hr 
60 % 
11 - - X - - Benzene Toluene-4- 
Sulphonic acid 
(2.4), RT 
(2.4), 
RT, 
 
(2.4), 80 
- 105 °C 
80 - 105 °C, 
5 hr, 
80 - 105 °C, 5 
hr 
87.4 % 
* NR: No reaction  
Optimised experiments 
 
General procedure 
 
Entry 1, 3, 4, 5, 6, 7, 8 and 9 
N’,N’-bis(fluorenylmethoxycarbonyl)-(R,R)-cystine-bis-tert-butyl ester 146 (Entry 1, 3 and 
4) was treated with a solution of trifluroacetic acid (TFA) (1 mL) and CH2Cl2 (1 mL), the 
mixture was stirred for 4 hr at room temperature. The solvent was reduced in vacuo to give 
fluffy cream solid. Residue (Entry 1, 3, 4), 3-[2-carboxy-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-ethyldisulfanyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino) 
propionic acid (Fmoc-Cys-OH)2 191 (Entry 5, 6, 7, 8 and 9) was dissolved at room 
temperature in the appropriate solution (Table above) containing 2,2,2-trichloroethanol 196 
and the correct reagent (DMAP or HOBt) in the appropriate solvent. The temperature of the 
reaction was attained according to the table above this was followed by the addition of the 
coupling reagent (DCC, EDC-polymer bound, EDCI or EDCI.HCl). The number of 
equivalents of the reagents, time and temperature of the reaction, and the addition of further 
reagents were maintained and carried out as stated in the table above. After the reaction time 
was complete the white precipitate of DCU was removed by filtration and the filtrate was 
concentrated in vacuo (Entry 1, 3, 4, 5, 6 and 7). An extraction was then carried out.  
 
Entry 1, 3, 6  
The residue was taken up in organic solvent (200 mL) Entry 1 and 3 in chloroform, Entry 6 in 
EtOAc, the organic layer was washed with 10 % citric acid (2 x 50 mL) and then brine (2 x 
50 mL).  
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Entry 4 and 5 
The residue was diluted with Ethyl acetate (100 mL) and the organic phase was washed with 
1 M aqueous HCl (100 mL) and then brine (50 mL). 
Entry 7, 8 and 9 
Excess CH2Cl2 (100 mL) was added and the organic layer was washed with H2O (5 x 50 mL) 
and then brine (50 mL). 
Drying and filtration of each entries followed by solvent removal gave white solid, this was 
purified by flash column chromatography (hexane: EtOAc 9:1) giving the title product 192 as 
white solid. 
 
Entry 2 
A solution of L-cystine 144 (2.5 g, 10.4 mmols) and NaOH (1.76 g, 44 mmol) in 300 mL of 
THF – H2O (1: 1) was treated with FmocCl (5.7 g, 22.1 mmol, 2.1 equiv) and the reaction 
mixture was stirred at 25 ºC for 14 hr. The reaction mixture was diluted with water (250 mL) 
and washed with CHCl3 (3 x 250 mL). The aqueous phase was acidified with the addition of 
6 M aqueous HCl (250 mL) and extracted with CHCl3. The combined organic phases were 
dried over anhydrous sodium sulphate, filtered and concentrated in vacuo. The residue was 
dissolved in pyridine (100 mL), HOBt (4.2 g, 31.07 mmols, 2.9 equiv) and 2,2,2-
trichloroethanol (3.45 mL, 35.9 mmols, 3.45 equiv) were added. The mixture was cooled to - 
20 ºC and treated with DCC (5 g, 24.2 mmols, 2.3 equiv). The resulting mixture was stirred at 
- 20 ºC under argon for 24 hr. The white precipitate of DCU was removed by filtration and 
the filtrate was concentrated in vacuo. The residue was diluted with ethyl acetate (500 mL) 
and the organic phase was washed with 1 M aqueous HCl (500 mL), saturated aqueous 
NaHCO3 (500 mL) and brine (250 mL). The organic phase was dried, filtered and 
concentrated in vacuo. Purification by flash column chromatography on silica gel (hexane: 
EtOAc, 80:20) afforded the title product 192 as a white solid. 
 
Entry 10 and 11 
156
 
2,2,2-trichloroethanol 196 was added to a solution containing the commercially available 
(Fmoc-Cys-OH)2 191 and toluene-4-sulphonic acid (2.4 equiv) in the correct solvent (315 
mL). The reaction was heated under reflux with a Dean-Stark trap attached for 24 hr. 
157
 The 
temperature of the reaction and the equivalents of 2,2,2-trichloroethanol 196 were maintained 
and used as reported in the table above. After 24 hr the reaction was cooled to 0 ºC and any 
unreacted acid was removed by filtration. The reaction solvent was removed in vacuo and the 
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residue was dissolved in chloroform (500 mL) and washed with H2O (4 x 150 mL) and brine 
(150 mL). The crude product was purified by flash column chromatography (hexane: EtOAc 
9:1 followed by CH2Cl2: MeOH 98:2) to give the title product 192 as a white powder, 
identical by NMR with the literature. 
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Rf: 0.6 (Hexane: Ethyl acetate; 2:1); 
NMR: δH (600 MHz, CDCl3), 7.75 (4 H, d, J = 7.4 Hz, Ar), 7.58 (4 H, d, J = 7.2 Hz, Ar), 
7.39 (4 H, t, J = 7.3 Hz, Ar), 7.29 (4 H, t, J = 7.3 Hz, Ar), 5.72 (2 H, d, J = 8.0 Hz, NH), 4.83 
(2 H, m, CHCH2S), 4.79 (2 H, d, J = 11.8 Hz, CH2Cl3), 4.74 (2 H, d, J = 11.8 Hz, CH2Cl3), 
4.41 (4 H, m, CHCH2Fmoc), 4.21 (2 H, t, J = 6.8 Hz, CHCH2Fmoc), 3.26 (4 H, m, 
CHCH2S);  
NMR: δC (150 MHz, CDCl3), 169.1 (C17), 155.7 (C15), 143.7 (CAr), 141.4 (CAr), 127.9 (CAr), 
127.2 (CAr), 125.2 (CAr), 120.2 (CAr), 94.3 (C19), 74.9 (C18), 67.5 (C14), 53.5 (C16), 47.1 (C1), 
40.8 (C20);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 966.9785; C40H34N2O8NaS2Cl6, requires 
966.9745; (ES
+
), C40H34N2O8S2Cl6, m/z: 969 [M + Na]
+
;  
IR νmax: 2970, 1770, 1580, 1447 cm
-1
;  
[α]20 D = - 10.7 (c 1.4 mg/mL, CHCl3).  
 
Fmoc-Cys-OTce 193 
156
 
SH
HN
O
O
O
O
Cl
Cl
Cl
1
8
7 6 5
4
3
2
Ha
Hb
Hb'
Ha'Ha'
Hb'
Hb
Ha
16
15
14
13
1211
10
9
19
18
17
20
H
 
 
(Fmoc-Cys-OTce)2 192 (0.061 g, 0.064 mmol) in THF was treated with triphenylphosphine 
(0.075 g, 0.28 mmol, 4.4 equiv), 2-mercaptoethanol (0.022 mL, 0.31 mmol, 4.8 equiv) and 
water (0.011 mL, 0.6 mmol, 10 equiv), the reaction mixture was stirred at 50 ºC for 5 hr 
before being concentrated in vacuo. Purification by flash column chromatography (hexane: 
EtOAc, 9:1) afforded the title product 193 as a white solid, identical by NMR with the 
literature. 
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Yield: 0.060 g, 0.12 mmol, 98 %; 
Rf: 0.23 (Hexane: Ethyl acetate; 9:1); 
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NMR: δH (600 MHz, CDCl3), 7.77 (2 H, d, J = 7.6 Hz, Ar), 7.61 (2 H, d, J = 7.4 Hz, Ar), 
7.41 (2 H, t, J = 7.4 Hz, Ar), 7.33 (2 H, m, Ar), 5.72 (1 H, d, J = 8.0 Hz, NH), 4.92 (1 H, d, J 
= 11.9 Hz, CH2Cl3), 4.83 (1 H, m, CHCH2S), 4.72 (1 H, d, J = 11.9 Hz, CH2CCl3 ), 4.45 (2 H, 
d, J = 6.9 Hz, CHCH2OFmoc), 4.24 (1 H, t, J = 6.9 Hz, CHCH2OFmoc), 3.14 (1 H, m,  
CHCH2S), 3.03 (1 H, m, CHCH2S), 1.46 (1 H, t, J = 9.1 Hz, SH);  
NMR: δC (150 MHz, CDCl3), 168.8 (C18), 155.7 (C3), 143.8 (CAr), 141.4 (CAr), 127.9 (CAr), 
127.2 (CAr), 125.2 (CAr), 120.2 (CAr), 94.3 (C20), 74.7 (C19), 67.2 (C4), 55.5 (C2), 47.2 (C5), 
27.5 (C1);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 495.99270; C20H18NO4NaSCl3, requires 
495.99198; (ES
+
), C20H18NO4SCl3, m/z: 496 [M + Na]
+
;  
IR νmax: 2953, 1733, 1454 cm
-1
;  
[α]20 D = - 2.4 (c 17.3 mg/mL, CHCl3).  
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-(S)-[2-(2-trimethylsilanyl-
ethoxycarbonyl)-2-(trityl-amino)-ethylsulfanyl]-propionic acid 2,2,2-trichloro-ethyl ester 
194 
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Fmoc-Cys-OTce 193 (0.077 g, 0.16 mmol) and (S)-3-iodo-2-(triphenylmethylamino)-
propionic acid (2-trimethylsilanyl)ethyl ester 183 (0.091 g, 0.16 mmol, 1 equiv) were 
dissolved in DMF 93 mL) under argon. Dry Cs2CO3 (0.003 g, 0.079 mmol, 0.5 equiv) was 
added over 2 min and the reaction was stirred for 2 hr. Further dry Cs2CO3 (0.003 g, 0.079 
mmol, 0.5 equiv) was added over 1 min and the reaction was stirred for a further 2 hr. Excess 
ethyl acetate (200 mL) was added and the mixture was washed with cold citric acid (5 %, 200 
mL) and distilled water (8 x 100 mL). The organic layer was dried over anhydrous sodium 
sulphate and concentrated in vacuo. Purification was carried out by flash column 
chromatography (hexane: EtOAc, 15:1) to give the title product 194 as a white fluffy solid. 
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M. pt. 54 ºC; 
Yield: 0.086 g, 0.095 mmol, 58 %; 
Rf: 0.5 (Hexane: Ethyl acetate; 4:1); 
NMR:δH (600 MHz, CDCl3), 7.77 (2 H, d, J = 7.5 Hz, Ar), 7.62 (2 H, t, J = 8.1 Hz, Ar), 7.49 
(6 H, m, Ar), 7.40 (2 H, m, Ar), 7.32-7.21 (8 H, m, Ar), 7.17 (3 H, m, Ar), 5.72 (1 H, d, J = 
8.3 Hz, NHFmoc), 4.83 (1 H, d, J = 11.9 Hz, CH2CCl3), 4.75 (1 H, m, H  B side), 4.71 (1 H, 
d, J = 11.9 Hz, CH2CCl3), 4.39 (2 H, m, CH2Fmoc), 4.23 (2 H, t, J = 7.2 Hz, CHFmoc), 3.74 
(1 H, m, CH2CH2Si(CH3)3), 3.59 (1 H, m, CH2CH2Si(CH3)3), 3.50 (1 H, m, H  A side), 3.12 
(1 H, dd, J = 13.9, 4.6 Hz, Hβ), 3.00 (1 H, dd, J = 13.9, 6.4 Hz, Hβ), 2.91 (1 H, dd, J = 13.4, 
4.6 Hz, Hβ), 2.8 (1 H, m, NHTrt), 2.74 (1 H, dd, J = 13.9, 7.7 Hz, Hβ), 0.76 (2 H, m, 
CH2CH2Si(CH3)3, -0.01 (9 H, s, Si(CH3)3; 
NMR: δC (150 MHz, CDCl3), 173.6 (C21 or 45), 169.4 (C21 or 45), 155.9 (C30), 145.7 (CAr), 
143.8 (CAr), 141.4 (CAr), 128.9 (CAr), 128.2 (CAr), 128.1 (CAr), 127.2 (CAr), 126.7 (CAr),  
125.3 (CAr), 120.1 (CAr), 94.4 (C47), 74.7 (C46), 71.3 (C1), 67.6 (C31), 63.5 (C22), 56.4 (C20), 
53.7 (C29), 47.2 (C32), 37.74 (C27), 34.69 (C28), 17.5 (C23), -1.4 (C24, 25, 26);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 925.2056; C47H49N2O6NaSiSCl3, requires 
925.2044;
 
(ES
+
), C47H49N2O6SiSCl3, m/z: 925 [M + Na]
+
;  
IR νmax: 3325, 2953, 1764, 1718, 1600, 1512, 1448 cm
-1
;  
[α]20 D = - 32.9 (c 10.0 mg/mL, CHCl3).  
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-2-
(trityl-amino)-ethylsulfanyl]-propionic acid 197 
 
'' B-side'' (R)
'' A-side'' (S)
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Zinc dust (0.086 g, 0.504 mmol, 36 equiv) was added portionwise to a solution of (R)-2-(9H-
Fluoren-9-ylmethoxycarbonylamino)-3-(S)-[2-(2-trimethylsilanyl-ethoxycarbonyl)-2-(trityl-
amino)-ethylsulfanyl]-propionic acid 2,2,2-trichloro-ethyl ester 194 (0.033 g, 0.037 mmol) in 
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THF (1.6 mL), followed by the addition of 1 M aqueous NH4OAc solution (0.28 mL). The 
mixture was stirred vigorously under nitrogen for 24 hr at room temperature. After filtration 
and solvent removal the residue was taken up in chloroform (50 mL) and washed with 
saturated aqueous NaCl solution (2 x 20 mL). The organic layer was dried over anhydrous 
magnesium sulphate, after drying and filtration followed by solvent removal, the crude was 
obtained as oil. This was purified by flash column chromatography (gradient, CH2Cl2: 
MeOH, 98:2 to 95:5) giving the title product 197 as oil. 
 
Yield: 0.006 g, 7.7
-03 
mmol, 21 %; 
Rf: 0.61 (CH2Cl2: MeOH; 90:10); 
NMR: δH (600 MHz, CD3OD), 7.77 (2 H, d, J = 7.4 Hz, Ar), 7.64 (2 H, dd, J = 12.0, 6.4 Hz, 
Ar), 7.47 (5 H, d, J = 7.6 Hz, Ar), 7.38 (3 H, m, Ar), 7.30-7.21 (8 H, m, Ar), 7.15 (3 H, t, J = 
7.26 Hz, Ar), 5.15 (1 H, bs, NHFmoc), 4.63 (1 H, bs, NHTrt), 4.35 (2 H, m, CH2Fmoc), 4.24 
(2 H, m, CHFmoc and H B side), 3.70 (1 H, m, CH2CH2Si(CH3)3), 3.59 (1 H, m, 
CH2CH2Si(CH3)3), 3.45 (1 H, m, H  A side), 3.05 (1 H, dd, J = 13.2, 4.8 Hz, Hβ), 2.91 (1 H, 
dd, J = 14.4, 6.0 Hz, Hβ), 2.82 (1 H, dd, J = 15.0, 9.0 Hz, Hβ), 2.74 (1 H, dd, J = 13.8, 7.2 Hz, 
Hβ), 0.75 (2 H, m, CH2CH2Si(CH3)3, -0.03 (9 H, s, Si(CH3)3; 
NMR: δC (150 MHz, CD3OD), 171.6 (C45), 172.9 (C 21), 158.3 (C30), 147.2 (CAr), 145.3 
(CAr), 142.5 (CAr), 129.9 (CAr), 128.9 (CAr), 128.7 (CAr), 128.2 (CAr), 127.5 (CAr), 126.4 (CAr), 
72.3 (C7), 68.2 (C31), 64.3 (C22), 61.4 (C20), 54.8 (C29), 30.6 (C32), 23.7 (C27), 20.8 (C28), 14.4 
(C23), -1.54 (C24, 25, 26);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 795.2861; C45H48N2O6NaSiS, requires 795.2900;
 
(ES
+
), C45H48N2O6SiS, m/z: 795 [M + Na]
+
;  
IR νmax: 3292, 2800, 1611, 1400 cm
-1
;  
[α]22 D = - 18.2 (c 3.1 mg/mL, MeOH).  
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(S)-3-[2-Amino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethylsulfanyl]-(R)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid 189 
 
'' B-side'' (R)
'' A-side'' (S)
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Zinc dust (0.086 g, 0.504 mmol, 36 equiv) was added portionwise to a solution of (R)-2-(9H-
Fluoren-9-ylmethoxycarbonylamino)-3-(S)-[2-(2-trimethylsilanyl-ethoxycarbonyl)-2-(trityl-
amino)-ethylsulfanyl]-propionic acid 2,2,2-trichloro-ethyl ester 194 (0.033 g, 0.037 mmol) in 
THF (1.6 mL), followed by the addition of 1 M aqueous NH4OAc solution (0.28 mL). The 
mixture was stirred vigorously under nitrogen for 24 hr at room temperature. After filtration 
and solvent removal the residue was taken up in chloroform (50 mL) and washed with 
saturated aqueous NaCl solution (2 x 20 mL). The organic layer was dried over anhydrous 
magnesium sulphate, after drying and filtration followed by solvent removal, the crude was 
obtained as oil. This was purified by flash column chromatography (gradient, CH2Cl2: 
MeOH, 98:2 to 95:5) giving the title product 189 as oil. 
 
Yield: 0.0089 g, 0.016 mmol, 45 %; 
Rf: 0.08 (CH2Cl2: MeOH: 85:15); 
NMR: δH (600 MHz, CD3OD), 7.79 (2 H, d, J = 7.6 Hz, Ar), 7.67 (2 H, d, J = 7.4 Hz, Ar), 
7.39 (2 H, t, J = 7.4 Hz, Ar), 7.31 (2 H, t, J = 7.4 Hz, Ar), 4.42 (1 H, m, CH2Fmoc), 4.29 (1 
H, m, CH2Fmoc), 4.23 (4 H, m, CHFmoc, H  B side and CH2CH2Si), 3.92 (1 H, m, H  A 
side), 3.08 (2 H, m, CH2 β), 2.93 (2 H, m, CH2 β), 1.00 (2 H, m, CH2CH2Si(CH3)3), 0.02 (9 
H, s, Si(CH3)3); 
NMR: δC (150 MHz, CD3OD), 180 (C11), 163.3 (C2), 158.4 (C12), 145.6 (CAr), 142.5 (C Ar), 
128.8 (CAr), 128.2 (CAr), 126.2 (CAr), 68.0 (C13), 65.6 (C3), 57.3 (C14), 54.5 (C1), 47.9 (C10), 
39.0 (C8, 9), 18.3 (C4), -1.42 (C5, 6, 7);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 553.1805; C26H34N2O6NaSiS, requires 553.1805;
 
(ES
+
), C26H34N2O6NaSiS, m/z: 553 [M + Na]
+
;  
IR νmax: 3355, 1690, 1410 cm
-1
;  
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[α]20 D = - 4.4 (c 5.5, MeOH). 
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[(S)-2-(2-trimethylsilanyl-
ethoxycarbonyl)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid 
169 
'' B-side'' (R)
'' A-side'' (S)
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Entry Reaction 
solvents 
Base (equiv), 
Temperature 
Protecting 
group  
171 (%), °C               
Reaction time / 
temperature 
Product 
Isolated 
169 (%) 
1 1,4- 
dioxane 
aq. sodium 
bicarbonate, (4), 
RT 
 (19.9), 0 °C 
 
 
24 hr in freezer 
 
5 hr, 0 °C - RT 
64 % 
2 1,4- 
dioxane 
DMAP, (cat), 
RT 
(4.9), RT    24 hr, RT 24 % 
 
Optimised experiments 
 
General procedure 
 
(S)-3-[2-Amino-2-(2-trimethylsilanyl-ethoxycarbonyl)-ethylsulfanyl]-(R)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid 189 was dissolved in 1,4-dioxane. The correct base 
was added followed by the addition of carbonic acid 2,5-dioxo-pyrrolidin-1-yl ester 2-
trimethylsilanyl-ethyl ester 171 at the required temperature. The equivalents of the protecting 
reagent, reaction time and the temperature of the reaction were carried out and maintained 
according to the table above. After the reaction time was complete excess chloroform (50 
mL) was added and the organic layer was washed with water (2 x 30 mL). The organic layer 
was dried over anhydrous magnesium sulphate, concentrated in vacuo, and purified by flash 
column chromatography (CH2Cl2: MeOH, 98:2) to give the title product 169 as white foam. 
 
Rf: 0.37 (CH2Cl2: MeOH; 90:10); 
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NMR: δH (600 MHz, CD3OD), 7.77 (2 H, d, J = 7.6 Hz, Ar), 7.67 (2 H, d, J = 7.3 Hz, Ar), 
7.37 (2 H, t, J = 7.4 Hz, Ar), 7.29 (2 H, t, J = 7.4 Hz, Ar), 4.40 (1 H, m, CHFmoc), 4.36 (1 H, 
m, H  A side), 4.26 (3 H, m, CH2Fmoc and H B side), 4.15 (4 H, m, 2 x CH2CH2Si(CH3)3), 
3.11 (1 H, dd, J = 13.8, 4.3 Hz, Hβ), 3.02 (1 H, dd, J = 13.8, 5.2 Hz, Hβ), 2.93 (2 H, m, Hβ), 
0.94 (4 H, m, 2 x CH2CH2Si(CH3)3), 0.00 (18 H, d, J = 2.4 Hz, Si(CH3)3); 
NMR: δC (150 MHz, CD3OD), 178.3 (C17), 172.6 (C8), 158.7 (C6), 158.4 (C18), 145.3 (CAr), 
142.5 (CAr), 128.7 (CAr), 128.2 (CAr), 126.4 (CAr), 121.0 (CAr), 68.2 (C19), 64.8 (C5 or 9), 64.4 
(C5 or 9),  57.1 (C7 or 16), 55.7 (C7 or 16), 48.4 (C20 signal obscured by CD3OD), 36.7 (C14 or 
15), 35.3 (C14 or 15), 18.5 (C4 or 10), 18.2 (C4 or 10), -1.40 (C1, 2, 3, 11, 12, 13);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 697.2405; C32H46N2O8NaSi2S, requires 697.2411;
 
(ES
+
), C32H46N2O8Si2S, m/z: 697 [M + Na]
+
;  
IR νmax: 3300 (broad), 2954, 1716, 1593, 1418 cm
-1
;  
[α]25 D = + 2.2 (c 10.0 mg/mL, MeOH).  
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[(S)-2-(2-trimethylsilanyl-
ethoxycarbonyl)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid 
2,2,2-trichloro-ethyl ester 195 
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'' A-side'' (S)
O
OHN
O
O
S
OO
NH
Si
24
23
22 21 20
19
18
1716
15
14
13
1211
10
9
8
7
6
5
4
3
2
1
25
26
Ha
Hb
Hb'
Ha'Ha'
Hb'
Hb
Ha
O
O
Si
32
27
28
29
30
31
Cl
Cl
Cl
34
33H H
 
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-2-
(trityl-amino)-ethylsulfanyl]-propionic acid 2,2,2-trichloro-ethyl ester 194 (0.102 g, 0.112 
mmol) was treated with TFA (0.4 mL), TES (0.2 mL) and CH2Cl2 (3.4 mL), the mixture was 
stirred under argon for 24 hr. Excess chloroform (100 mL) was added and the organic layer 
was washed with sodium bicarbonate (50 mL) and brine (50 mL). The organic layer was 
dried over anhydrous magnesium sulphate, filtered and concentrated in vacuo. The residue 
was dissolved in 1,4-dioxane (3.4 mL), DMAP (0.013 g, 0.112 mmol, 1 equiv) was added 
followed by carbonic acid 2,5-dioxo-pyrrolidin-1-yl ester 2-trimethylsilanyl-ethyl ester 171 
(0.143 g, 0.551 mmol, 4.9 equiv). The reaction was left to stir at room temperature for 24 hr. 
Excess Chloroform (50 mL) was added and the organic layer was washed with brine (2 x 30 
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mL). The organic layer was dried over anhydrous magnesium sulphate, concentrated in 
vacuo, and purified by flash column chromatography (hexane: EtOAc, 9:1 then 4:1) to give 
the title product 195 as a clear oil. 
 
Yield; 0.06 g, 0.07 mmol, 66 %; 
Rf: 0.36 (Hexane: Ethyl acetate; 4:1); 
NMR: δH (600 MHz, CDCl3), 7.76 (2 H, d, J = 7.5 Hz, Ar), 7.63(2 H, m, Ar), 7.40 (2 H, m, 
Ar), 7.31 (2 H, m, Ar), 5.95 (1 H, d, J = 7.9 Hz, NHTeoc), 5.48 (1 H, d, J = 7.4 Hz, 
NHFmoc), 4.86 (1 H, d, J =11.82 Hz, CH2CCl3), 4.76 (2 H, m, CH2CCl3 and H  B side), 4.55 
(1 H, m, H  A side), 4.41 (2 H, m, CH2Fmoc), 4.19 (5 H, m, CHFmoc and 2 x 
CH2CH2Si(CH3)3), 3.11 (3 H, m, Hβ), 2.96 (1 H, dd, J = 13.9, 5.8 Hz, Hβ), 0.98 (4 H, m, 2 x 
CH2CH2Si(CH3)3), 0.02 (18 H, d, J = 7.7 Hz, Si(CH3)3); 
NMR: δC (150 MHz, CDCl3), 170.6 (C17), 169.2 (C8), 156.3 (C6), 155.9 (C18), 143.8 (CAr), 
141.4 (CAr), 127.9 (CAr), 127.2 (CAr), 125.3 (CAr), 120.1 (CAr), 94.3 (C34), 74.7 (C33),  67.5 
(C19), 64.6 (C5, or 9), 63.9 (C5 or 9), 53.9 (C16), 47.1 (C20),  36.2 (C7), 35.8 (C14 or 15), 35.4 (C14 
or 15), 17.7 (C4, or 10), 17.5 (C4, or 10), -1.37 (C1, 2, 3, 11, 12, 13);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 829.1566; C34H48N2O8Cl3NaSi2S, requires 
829.1553;
 
(ES
+
), C34H48N2O8Cl3Si2S, m/z: [M + Na]
+
;  
IR νmax: 2954, 1709, 1509, 1337 cm
-1
;  
[α]25 D = - 8.8 (c 4.9 mg/mL, CHCl3).  
 
(R)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[(S)-2-(2-trimethylsilanyl-
ethoxycarbonyl)-2-(2-trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid 
169 
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Zinc dust (0.017 g, 2.7 mmol, 36 equiv) was added portionwise to a solution of  (R)-2-(9H-
Fluoren-9-ylmethoxycarbonylamino)-3-[(S)-2-(2-trimethylsilanyl-ethoxycarbonyl)-2-(2-
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trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid 2,2,2-trichloro-ethyl 
ester 195 (0.06 g, 0.075 mmol) in THF (6 mL), followed by the addition of 1 M aqueous 
NH4OAc solution (0.56 mL). The mixture was stirred vigorously under nitrogen for 24 hr at 
room temperature. After filtration and solvent removal the residue was taken up in 
chloroform (10 mL) and washed with saturated aqueous NaCl solution (2 x 50 mL). The 
organic layer was dried over anhydrous magnesium sulphate, after drying and filtration 
followed by solvent removal, the crude was obtained as oil. This was purified by flash 
column chromatography (gradient, CH2Cl2: MeOH, 98:2 to 95:5) giving the title product 169 
as white foam. 
 
M. pt. 59 º C; 
Yield: 0.02 g, 0.029 mmol, 40 %; 
Rf: 0.37 (CH2Cl2: MeOH; 90:10); 
NMR: δH (600 MHz, CD3OD), 7.77 (2 H, d, J = 7.6 Hz, Ar), 7.67 (2 H, d, J = 7.3 Hz, Ar), 
7.37 (2 H, t, J = 7.4 Hz, Ar), 7.29 (2 H, t, J = 7.4 Hz, Ar), 4.40 (1 H, m, CHFmoc), 4.36 (1 H, 
m, H A side), 4.26 (3 H, m, CH2Fmoc and H B side), 4.15 (4 H, m, 2 x CH2CH2Si(CH3)3), 
3.11 (1 H, dd, J = 13.8, 4.3 Hz, Hβ), 3.02 (1 H, dd, J = 13.8, 5.2 Hz, Hβ), 2.93 (2 H, m, Hβ), 
0.94 (4 H, m, 2 x CH2CH2Si(CH3)3), 0.00 (18 H, d, J = 2.4 Hz, Si(CH3)3), (Appendix 17); 
NMR: δC (150 MHz, CD3OD), 178.3 (C17), 172.6 (C8), 158.7 (C6), 158.4 (C18), 145.3 (CAr), 
142.5 (CAr), 128.7 (CAr), 128.2 (CAr), 126.4 (CAr), 121.0 (CAr), 68.2 (C19), 64.8 (C5 or 9), 64.4 
(C5 or 9),  57.1 (C7 or 16), 55.7 (C7 or 16), 48.4 (C20 signal obscured by CD3OD), 36.7 (C14 or 
15), 35.3 (C14 or 15), 18.5 (C4 or 10), 18.2 (C4 or 10), -1.40 (C1, 2, 3, 11, 12, 13), (Appendix 18);  
HRMS: cald (ES
+
), m/z: Found [M + Na]
+
, 697.2405; C32H46N2O8NaSi2S, requires 697.2411;
 
(ES
+
), C32H46N2O8Si2S, m/z: 697 [M + Na]
+
;  
IR νmax: 3300 (broad), 2954, 1716, 1593, 1418 cm
-1
;  
[α]25 D = + 2.2 (c 10.0 mg/mL, MeOH).  
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Synthesis of Model Peptide 198 
OH
OH
O
N
H
O
HN
S
O
HN
H2N
S
O
N
HN
Molecular Weight : 504
 
Peptide 198 was synthesised manually on a Merrifield bubbler using solid phase peptide 
Fmoc strategy. Fmoc-Ser(tBu)-NovaSyn TGT resin (0.2 g 0.038 mmol) was suspended in 
DMF (5 mL) for 1 hr on a Merrifield bubbler. The terminal Fmoc group was removed by 
treatment with piperidine (20 % piperidine in DMF, 2 mL) with Ar bubbling for 20 min, 
followed by thorough washing with DMF (6 x 4 mL). A qualitative Kaiser test showed a 
positive result. 
 
Fmoc-Met-OH (0.056 g, 0.15 mmol, 4 equiv) in DMF (2 mL) was then activated under inert 
conditions, in a separate flask, with a solution of HBTU in DMF (0.058 g, 0.15 mmol, 4 
equiv, 1 mL of DMF) and DIPEA (0.026 mL, 4 equiv) for 20 min. The activated amino acid 
solution was then added to the resin and Ar was bubbled for 30 min. The coupling solution 
was removed and the resin was washed with DMF (6 x 4 mL). A qualitative Kaiser test 
showed a negative result. The terminal Fmoc group was removed with piperidine (20 % 
piperidine in DMF, 2 mL) with Ar bubbling for 20 min, followed by thorough washing with 
DMF (6 x 4 mL). A qualitative Kaiser test showed a positive result. 
 
Fmoc-His(Trt)-OH (0.094 g, 0.15 mmol, 4 equiv) was then activated under inert conditions, 
in a separate flask, with a solution of HBTU in DMF (0.058 g, 0.15 mmol, 4 equiv, 1 mL of 
DMF) and DIPEA (0.026 mL, 4 equiv) for 20 min. The activated amino acid solution was 
then added to the resin with Ar bubbling for 30 min. The coupling solution was removed and 
the resin was washed with DMF (6 x 4 mL). A qualitative Kaiser test showed a negative 
result. The terminal Fmoc group was removed with piperidine (20 % Piperidine in DMF, 2 
mL) with Ar bubbling for 20 min, followed by thorough washing with DMF (6 x 4 mL). A 
qualitative Kaiser test showed a positive result. 
 
Fmoc-Met-OH (0.056 g, 0.15 mmol, 4 equiv) in DMF (2 mL) was then activated under inert 
conditions, in a separate flask, with a solution of HBTU in DMF (0.058 g, 0.15 mmol, 4 
equiv, 1 mL of DMF) and DIPEA (0.026 mL, 4 equiv) for 20 min. The activated amino acid 
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solution was then added to the resin with Ar bubbling for 30 min. The coupling solution was 
removed and the resin was washed with DMF (6 x 4 mL). A qualitative Kaiser test showed a 
negative result.  
 
Removal of the terminal Fmoc group with 20 % piperidine in DMF (2 mL) with Ar bubbling 
for 20 min was followed by washing with DMF (6 x 4 mL). A qualitative Kaiser test showed 
a positive result. Cleavage of the peptide from the solid support was carried out by 
successively bubbling the resin with a solution of TFA (94 %), H2O (2.5 %), TIPS (1 %) and 
EDT (2.5 %) for 3 hr. The cleavage cocktail were collected in a flask, the resin was washed 
with pure TFA and collected in the cleaved cocktail flask. TFA was removed under high 
vacuum to a minimum amount after which ether was added to precipitate the product, the 
solvent was removed under high vacuum. This was repeated twice. The precipitate was 
redissolved in water and the solution freeze dried overnight which yielded the crude peptide 
(42 mg).  
 
The resulting mixture was then purified via preparative reverse-phase HPLC monitoring at 
214 nm. Purification was performed at a flow rate 15 mL min
-1 
using a linear gradient in H2O 
and CH3CN (90 %: 10 % for 10 min then increased to 10 %: 90 % over 30 min), the peptide 
eluted at 17.8 min. The CH3CN was removed under vacuum, and the peptide solution was 
freeze dried. Freeze drying yielded the peptide 198 as clear oil (4 mg, 7.9 x 10
-3
 mmol, 21 
%).  
(ES+)
+
, C19H32N6O6S2, m/z: [M+H]
+
 = 505.   
Analytical HPLC (Wide Pore C18) RT 18.8 min; A: H2O/0.5 % TFA; B: acetonitrile/0.5% 
TFA; gradient 10 % - 60 % B over 30 min. 
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Figure 74: Merrifield bubbler. 
 
Synthesis of an analogue of ring E of nisin 203 
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Peptide 209 was synthesised manually on a Merrifield bubbler using solid phase peptide 
Fmoc strategy. Fmoc-Ser(tBu)-NovaSyn TGT resin (0.2 g 0.038 mmol) was suspended in 
DMF (5 mL) for 1 hr on a Merrifield bubbler. The terminal Fmoc group was removed by 
treatment with piperidine (20 % piperidine in DMF, 2 mL) with Ar bubbling for 20 min, 
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followed by thorough washing with DMF (6 x 4 mL). A qualitative Kaiser test showed a 
positive result. 
 
Lanthionine 103 (0.084 g, 0.13 mmol, 4 equiv) in DMF (2 mL) was then activated under inert 
conditions, in a separate flask, with a solution of HBTU in DMF (0.058 g, 0.15 mmol, 4 
equiv, 1 mL of DMF) and DIPEA (0.026 mL, 4 equiv) for 20 min. The activated amino acid 
solution was then added to the resin with Ar bubbling for 30 min. The coupling solution was 
removed and the resin was washed with DMF (6 x 4 mL). A qualitative Kaiser test showed a 
negative result. The terminal Fmoc group of 103 was removed with piperidine (20 % 
piperidine in DMF, 2 mL) with Ar bubbling for 20 min, followed by thorough washing with 
DMF (6 x 4 mL). A qualitative Kaiser test showed a positive result. 
 
Fmoc-His(Trt)-OH (0.094 g, 0.15 mmol, 4 equiv) was then activated under inert conditions, 
in a separate flask, with a solution of HBTU in DMF (0.058 g, 0.15 mmol, 4 equiv, 1 mL of 
DMF) and DIPEA (0.026 mL, 4 equiv) for 20 min. The activated amino acid solution was 
then added to the resin with Ar bubbling for 30 min. The coupling solution was removed and 
the resin was washed with DMF (6 x 4 mL). A qualitative Kaiser test showed a negative 
result. The terminal Fmoc group of histidine was removed with piperidine (20 % piperidine 
in DMF, 2 mL) with Ar bubbling for 20 min, followed by thorough washing with DMF (6 x 4 
mL). A qualitative Kaiser test showed a positive result. 
 
Fmoc-Met-OH (0.056 g, 0.15 mmol, 4 equiv) in DMF (2 mL) was then activated under inert 
conditions, in a separate flask, with a solution of HBTU in DMF (0.058 g, 0.15 mmol, 4 
equiv, 1 mL of DMF) and DIPEA (0.026 mL, 4 equiv) for 20 min. The activated amino acid 
solution was then added to the resin with Ar bubbling for 30 min. The coupling solution was 
removed and the resin was washed with DMF (6 x 4 mL). A qualitative Kaiser test showed a 
negative result.  
 
Before the cyclisation step, the fully protected, resin bound peptide 206 was treated with 
tetrakis(triphenylphosphine)Palladium (0) (0.043 g, 0.037 mmol, 0.5 equiv) which was 
dissolved in  previously dissolved 1,3-dimethyl barbituric acid (0.059 g, 0.37 mmol, 10 
equiv) in a mixture of DMF/CHCl3 (1:1, volume 1.5/1.5 mL, total volume 3 mL) by gentle 
heating. The mixture was gently bubbled with Ar for 2 hr in the dark. The resin was then 
washed successively with DMF (6 x 4 mL) followed by a solution of DIPEA in DMF (0.5% 
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v/v, 5 x 4 mL) followed by further washing with DMF (6 x 4 mL). It was then washed with 
sodium diethyldithiocarbamate trihydrate in DMF (0.5% w/v, 5 x 4 mL) followed by a final 
washing with DMF (6 x 4 mL). The qualitative Kaiser test was purple. Removal of the 
terminal Fmoc group of methionine with 20 % piperidine in DMF (2 mL) with Ar bubbling 
for 20 min was followed by washing with DMF (6 x 4 mL), leading to the cyclization 
substrate. During Fmoc deprotection the cyclization reagents were prepared. HOAt (0.026 g, 
0.18 mmol, 5 equiv) was dissolved in DMF (1 mL) and mixed with a solution of PyAOP 
(0.099 g, 0.18 mmol, 5 equiv) dissolved in DMF (1 mL). The mixture was added to the 
Merrifield bubbler containing the resin, this was followed by addition of DIPEA (0.066 mL, 
0.38 mmol, 10 equiv) and left bubbling under Ar for 1 hr. The resin was then washed with 
DMF (6 x 4 mL), Kaiser test showed a dark purple colour.      
 
Fmoc-Ala-OH (0.047 g, 0.15 mmol, 4 equiv) in DMF (2 mL) was then activated under inert 
conditions, in a separate flask, with a solution of HBTU in DMF (0.058 g, 0.15 mmol, 4 
equiv, 1 mL of DMF) and DIPEA (0.026 mL, 4 equiv) for 20 min. The activated amino acid 
solution was then added to the resin with Ar bubbling for 30 min. The coupling solution was 
removed and the resin was washed with DMF (6 x 4 mL). A qualitative Kaiser test showed a 
negative result.   
 
Removal of the terminal Fmoc group of alanine with 20 % piperidine in DMF (2 mL) with Ar 
bubbling for 20 min was followed by washing with DMF (6 x 4 mL). A qualitative Kaiser 
test showed a positive result. Cleavage of the peptide from the solid support was carried out 
by successively bubbling the resin with a solution of TFA (94 %), H2O (2.5 %), TIPS (1 %) 
and EDT (2.5 %) for 3 hr. The cleavage cocktail were collected in a flask, the resin was 
washed with pure TFA and collected in the cleaved cocktail flask. TFA was removed under 
high vacuum to a minimum amount after which ether was added until the peptide 
precipitated, the solvent was then removed under high vacuum this was repeated twice. The 
precipitate was redissolved in water and the solution freeze dried overnight, yielding the 
crude peptide 209 (8.2 mg).  
 
(ES+), C23H36N8O8S2, m/z: [M+Na]
+
 = 639, [M oxidised] = 634. 
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Synthesis of an Fmoc protected analogue of ring E of nisin 210 
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Linear resin-bound peptide 206 
Peptide 210 was synthesised on a MultiSynTech Syro Peptide Synthesiser (Model MP-60) 
using solid phase peptide Fmoc strategy. Fmoc-Ser(tBu)-NovaSyn TGT resin (0.120 g, 0.22 
mmol/g, 0.026 mmol) was suspended in DMF (5 mL) for 1 hr in a 2 mL syringe in order to 
pre-swell the resin followed by thorough washing with DMF (6 x 1.2 mL). The terminal 
Fmoc group was removed by treatment with piperidine (40 % in DMF, 2 mL) with Ar 
bubbling for 30 min, this was repeated again followed by thorough washing with DMF (6 x 
0.9 mL). A qualitative Kaiser test showed a positive result. 
 
3-(2-Allyloxycarbonyl-2-allyloxycarbonylamino-ethylsulfanyl)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid 103 (0.0585 g, 0.12 mmol, 4 equiv), HOAt (0.017 
g, 0.13 mmol, 4 equiv) and PyAOP (0.068 g, 0.13 mmol, 4 equiv) were dissolved in DMF (1 
mL). The mixture was added to the syringe containing the resin, followed by DIPEA (0.045 
mL, 0.25 mmol, 8 equiv) and the mixture was bubbled with Ar for 1 hr 30 min. The coupling 
solution was removed and the resin was washed with DMF (6 x 0.9 mL). A qualitative Kaiser 
test showed a negative result. The terminal Fmoc group was removed with piperidine (40 % 
in DMF, 2 mL) with Ar bubbling for 30 min, followed by thorough washing with DMF (6 x 
0.9 mL). A qualitative Kaiser test showed a positive result. 
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Fmoc-His(Trt)-OH (0.16 g, 0.26 mmol, 10 equiv) and HBTU (0.10 g, 0.26 mmol, 10 equiv) 
were dissolved in DMF (1 mL). The mixture was added to the resin followed by DIPEA 
(0.091 mL, 0.53 mmol, 20 equiv) and bubbled with Ar for 1 hr 15. The coupling solution was 
removed and the resin was washed with DMF (6 x 0.9 mL). A qualitative Kaiser test showed 
a negative result. The terminal Fmoc group was removed with piperidine (40 % in DMF, 2 
mL) with Ar bubbling for 30 min, followed by thorough washing with DMF (6 x 0.9 mL). A 
qualitative Kaiser test showed a positive result. 
 
Fmoc-Met-OH (0.09 g, 0.26 mmol, 10 equiv) and HBTU (0.10 g, 0.26 mmol, 10 equiv) were 
dissolved in DMF (1 mL). The mixture was added to the resin followed by DIPEA (0.091 
mL, 0.53 mmol, 20 equiv) and bubbled with Ar for 1 hr 15 min. The coupling solution was 
removed and the resin was washed with DMF (6 x 0.9 mL) to give the resin-bound peptide 
206. A qualitative Kaiser test showed a negative result. 
  
Deprotection and cyclisation to give cyclic resin-bound peptide 208 
Before the cyclisation step, the fully protected, resin bound peptide was treated with a 
solution of 1,3-Dimethylbarbituric acid (NDMBA) (0.041 g, 0.26 mmol, 10 equiv) dissolved 
in a mixture of DMF/CHCl3 (1:1, volume 0.5/0.5 mL, total volume 1 mL). 
Tetrakis(triphenylphosphine)palladium (0) (0.013 g, 0.011 mmol, 0.5 equiv) was then added 
and the mixture heated gently to completely dissolve the palladium reagent. The solution was 
added to the fully protected, resin bound peptide 206, and the mixture was gently bubbled 
with Ar for 2 hr in the dark. The resin was then washed successively with DMF (6 x 0.9 mL) 
followed by a solution of DIPEA in DMF (0.5 % v/v, 6 x 1 mL) followed by further washing 
with DMF (6 x 0.9 mL). It was then washed with sodium diethyldithiocarbamate trihydrate in 
DMF (0.5 % w/v, 8 x 1 mL) followed by final washing with DMF (6 x 0.9 mL). The 
qualitative Kaiser test was purple. Removal of the terminal Fmoc group with piperidine (40 
% in DMF, 2 mL) with Ar bubbling for 30 min was followed by washing with DMF (6 x 0.9 
mL). 
 
During Fmoc deprotection the cyclization reagents were prepared. HOAt (0.018 g, 0.13 
mmol, 5 equiv) was dissolved in DMF (1 mL) and mixed with a solution of PyAOP (0.069 g, 
0.13 mmol, 5 equiv) dissolved in DMF (1 mL). The mixture was added to the syringe 
containing the resin peptide, this was followed by addition of DIPEA (0.044 mL, 0.25 mmol, 
10 equiv). The mixture was bubbled with Ar for 1 hr 15 min. The resin was then washed with 
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DMF (6 x 0.9 mL), giving the cyclised resin-bound peptide 208. The Kaiser test showed a 
dark purple colour.      
 
Chain elongation to give ring E analogue 210 
Fmoc-Ala-OH (0.081 g, 0.20 mmol, 10 equiv) and HBTU (0.10 g, 0.26 mmol, 10 equiv) 
were dissolved in DMF (1 mL). The mixture was added to the resin, followed by DIPEA 
(0.091 mL, 0.53 mmol, 20 equiv) and gently bubbled with Ar for 1 hr 15 min. The coupling 
solution was removed and the resin was washed with DMF (6 x 0.9 mL). A qualitative Kaiser 
test showed a negative result.   
 
In order to cleave the peptide from the solid support and remove the side-chain protecting 
groups, a solution of TFA (94 %), H2O (2.5 %), TIPS (1 %) and EDT (2.5 %) was added to 
the resin and gently bubbled with Ar for 3 hr. The cleavage cocktail solution was collected in 
a Falcon tube. The resin was washed again with TFA and the washings were added to the 
cleavage cocktail. Diethyl ether was added until the crude peptide precipitated. The solution 
was centrifuged at 4000 rpm for 7 min at 4 ºC after which the ether layer was decanted. The 
centrifuging and decanting process was repeated, washing on each occasion with diethyl 
ether (5 x 13 mL). The precipitate was redissolved in water and the mixture freeze dried 
overnight, yielding the crude peptide (16.7 mg). The peptide was purified by preparative 
HPLC (Wide Pore C18) in H2O/0.5 % TFA and acetonitrile/0.5 % TFA at a gradient of 10 % 
- 60 % acetonitrile over 30 min to give peptide 210, which eluted at 22.3 min. 
 
Yield: 1.8 mg, 2.14
-03
 mmol, 8.2%; 
Analytical HPLC (Wide Pore C18) RT 16.8 min; A: H2O/0.5 % TFA; B: acetonitrile/0.5% 
TFA; gradient 10 % - 60 % B over 30 min. 
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NMR: δH (500MHz, CD3OD), 8.75 (1 H, s, Histidine 2H), 7.79 (2 H, d, J = 7.5 Hz, Fmoc 
Ar), 7.64 (2 H, t, J = 7.2 Hz, Fmoc Ar), 7.38 (2 H, dd, J = 14.7, 7.3 Hz, Fmoc Ar), 7.28 (3 H, 
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m, Fmoc Ar + His 4H), Lan CH7, 12 peaks obscured by residual H2O (but visible in COSY) 
4.44 (1 H, t, J = 4.0 Hz,  Ser H5), 4.35 (2 H, d, J = 6.5 Hz, CH2Fmoc H19, 20), 4.25 (1 H, m, 
CHFmoc H21), 4.21 (1 H, m, α His H40), 4.10 (1 H, t, J = 7.3 Hz, α Met H31), 4.00 (1 H, q, J = 
7.0 Hz, α Ala H14), 3.90 (1 H, dd, J = 11.3, 4.7 Hz, β Ser H3 or H4), 3.80 (1 H, dd, J = 11.3, 
3.7 Hz, β Ser H4 or H4), 3.62 (1 H, m,  His H41 or H42), 3.48 (1 H, dd, J = 7.0, 14.1 Hz,   
Lan H8 or H9 or H10 or H11), 3.10 (1 H, dd, J = 14.4, 3.3 Hz, β Lan H8 or H9 or H10 or H11), 
3.04 (1 H, dd, J = 14.4, 3.3 Hz,  Lan H8 or H9 or H10 or H11), 2.98 (1 H, dd, J = 15.3, 9.8 Hz, 
 Lan H8 or H9 or H10 or H11), 2.84 (1 H, t, J = 12.6 Hz, β His H41 or H42), 2.17 (2 H, m, γ Met 
H34, 35), 1.84 (1 H, m, β Met H32 or H33), 1.78 (3 H, s, Met H36, 37, 38), 1.72 (1 H, m, β Met 
H32 or H33), 1.37 (2 H, d, J = 7.0 Hz, β Ala H15, 16, 17), Assignments are carried out on 1-d and 
2-d spectras (Figure 52 c and d, Chapter 4, Appendix 21); 
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NMR: δC (150 MHz, CD3OD), 176.0 (C1), 174.3 (CONH), 174.1 (CONH), 172.4 (CONH), 
172.1 (CONH), 163.1 (CONH), 158.8 (C12), 145.2 (CAr), 142.7 (CAr), 135.1 (C38),  132.2 
(C36), 128.8 (CAr), 128.2 (CAr), 126.4 (CAr), 120.9 (CAr), 118.2 (C37), 68.3 (C13), 66.9 (C5 or 8), 
62.8 (C3), 56.7 (C28), 56.3 (C2), 55.1 (C14), 52.8 (C10), 52.6 (C5 or C8), 47.9 (C34), 39.6 (C35), 
37.0 (C6 or 7), 33.1 (C29), 31.2 (C30), 26.8 (C6, or 7), 16.7 (C31), 15.2 (C11), (Appendices 21-
24);  
HRMS: (ES
-
), m/z: Found: 837.2654 [M-H]
-
. C38H45N8O10S2 requires 837.2700 (Figure 52 b, 
Chapter 4); 
MALDI-TOF, C38H46N8O10S2, m/z: 839.55 [M + H]
+
, (Figure 52 b, Chapter 4). 
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Synthesis of an analogue of ring D of nisin 220 
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Linear resin-bound peptide 217 
Peptide 220 was synthesised on a MultiSynTech Syro Peptide Synthesiser (Model MP-60) 
using solid phase peptide Fmoc strategy. Fmoc-His(Trt)-NovaSyn TGT resin (0.100 g 0.20 
mmol/g, 0.020 mmol) was suspended in DMF (5 mL) for 1 hr in a 2 mL syringe in order to 
pre-swell the resin followed by thorough washing with DMF (6 x 1.2 mL). The terminal 
Fmoc group was removed by treatment with piperidine (40 % in DMF, 2 mL) with Ar 
bubbling for 30 min, followed by thorough washing with DMF (6 x 1.2 mL). 
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-2-(2-
trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid 169 (0.0539 g, 0.079 
mmol, 4 equiv), HOAt (0.013 g, 0.099 mmol, 4 equiv) and PyAOP (0.051 g, 0.098 mmol, 4 
equiv) were dissolved in DMF (1 mL) and added to the syringe containing the resin. DIPEA 
(0.034 mL, 0.20 mmol, 10 equiv) was then added to the resin and the mixture was bubbled 
with Ar for 1 hr 30 min. The coupling solution was removed and the resin was washed with 
DMF (6 x 1.2 mL). The terminal Fmoc group was removed with piperidine (40 % in DMF, 2 
mL) with Ar bubbling for 30 min, followed by thorough washing with DMF (6 x 1.2 mL). 
 
Fmoc-Met-OH (0.074 g, 0.20 mmol, 10 equiv), HBTU (0.075 g, 0.20 mmol, 10 equiv) were 
dissolved in DMF (1 mL) and added to the resin. DIPEA (0.069 mL, 0.40 mmol, 20 equiv) 
was then added, and the mixture was bubbled with Ar for 1 hr 15 min. The coupling solution 
257 
 
was removed and the resin was washed with DMF (6 x 1.2 mL). The terminal Fmoc group 
was removed with piperidine (40 % in DMF, 2 mL) with Ar bubbling for 30 min, followed 
by thorough washing with DMF (6 x 1.2 mL). 
 
Fmoc-Ala-OH (0.062 g, 0.20 mmol, 10 equiv), HBTU (0.075 g, 0.20 mmol, 10 equiv) were 
dissolved in DMF (1 mL) and added to the resin. DIPEA (0.069 mL, 0.40 mmol, 20 equiv) 
was then added, and the mixture bubbled with Ar for 1 hr 15 min. The coupling solution was 
removed and the resin was washed with DMF (6 x 1.2 mL) to give the linear resin-bound 
peptide 217. 
  
Deprotection and cyclisation to give cyclic resin-bound peptide 219 
Before the cyclisation step, the fully protected, resin-bound peptide 217 was treated with 
tetrabutylammonium fluoride (TBAF) (0.522 g, 2.00 mmol, 100 equiv) which was dissolved 
in DMF (2 mL). The mixture was gently bubbled with Ar for 1 hr. The resin was then washed 
successively with DMF (10 x 1.2 mL). Removal of the terminal Fmoc group with piperidine 
(40 % in DMF, 2 mL) with Ar bubbling for 30 min was followed by washing with DMF (6 x 
1.2 mL). 
 
During Fmoc deprotection the cyclization reagents were prepared. HOAt (0.013 g, 0.099 
mmol, 4 equiv) was dissolved in DMF (1 mL) and mixed with a solution of PyAOP (0.051 g, 
0.098 mmol, 4 equiv) dissolved in DMF (1 mL). The cyclisation reagents mixture was then 
added to the syringe containing the resin-bound peptide. This was followed by addition of 
DIPEA (0.034 mL, 0.20 mmol, 10 equiv). The mixture was gently bubbled with Ar for 1 hr 
15 min, giving the cyclised resin-bound peptide 219. The resin was then washed with DMF 
(6 x 1.2 mL).  
 
Chain elongation to give ring D analogue 220 
Fmoc-Lys(Boc)-OH (0.094 g, 0.19 mmol, 10 equiv) and HBTU (0.075 g, 0.20 mmol, 10 
equiv) were dissolved in DMF (1 mL). The mixture was added to the resin followed by 
DIPEA (0.069 mL, 0.40 mmol, 20 equiv) and gently bubbled with Ar for 1 hr 15 min. The 
coupling solution was removed and the resin was washed with DMF (6 x 1.2 mL).  
 
In order to cleave the peptide from the solid support and remove the side-chain protecting 
groups, a solution of TFA (94 %), H2O (2.5 %), TIPS (1 %) and EDT (2.5 %) was added to 
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the resin and gently bubbled with Ar for 3 hr. The cleavage cocktail solution was collected in 
a Falcon tube. Diethyl ether was added until the crude peptide precipitated. The solution was 
centrifuged at 4000 rpm for 7 min at 4 ºC after which the ether layer was decanted. The 
centrifuging and decanting process was repeated, washing on each occasion with diethyl 
ether (5 x 13 mL). The precipitate was dissolved in water, and the solution freeze dried 
overnight, yielding the crude peptide (18 mg). The peptide was purified by preparative HPLC 
(Onyx Monolithic C18) in H2O/0.5 % TFA and acetonitrile/0.5 % TFA at a gradient of 15 % 
- 60 % acetonitrile over 30 min to give peptide 220, which eluted at 14.4 min. 
 
Yield: 1.0 mg, 1.13 x 10
-3
 mmol, 5.6 %; 
Analytical HPLC: (Onyx Monolithic C18) RT 16.6 min; A: H2O/0.5 % TFA; B: 
acetonitrile/0.5 % TFA; gradient 10 % - 60 % over 30 min. 
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NMR: δH (600 MHz, CD3OD), 8.79 (1 H, s, His 2H), 7.80 (2 H, dd, J = 7.6, 2.9  Hz, Fmoc 
Ar), 7.62 (1 H, d J = 7.5 Hz, Fmoc Ar), 7.59 (1 H, d, J = 7.5 Hz, Fmoc Ar), 7.42-7.28 (5 H, 
m, Fmoc Ar + His 4H), 5.07 (1 H, t, J = 2.9 Hz,  Lan H9 or H29), 4.71 (2 H, m,  His H2 + 
Met H20) 4.40 (2 H, m, CH2Fmoc H43, 44), 4.23 (1 H, t, J = 7.0 Hz, CHFmoc H45), 4.02 (2 
H, m, α Lan H9 or H29 + α Ala H25), 3.92 (1 H, t, J = 7.3 Hz, α Lys H31), 3.47 (1 H, dd, J = 
12.8, 2.8 Hz,  Lan H10 or 11 or 27 or 28), 3.35 (1 H, m,  His H3 or 4), 3.15 (2 H, m,  Lan H10 
or 11 or 27 or 28 +  His H3 or 4), 2.99 (1 H, dd, J = 14.8, 3.5 Hz,  Lan H10 or 11 or 27 or 28), 2.91 
(3 H, m, β Lan H10 or 11 or 27 or 28 + Lys H38, 39), 2.55 (1 H, m, Met H13 or 14), 2.44 (1 H, m, 
Met H13 or 14), 2.08 (3 H, s,  Met, H15, 16, 17), 1.77-1.34 (8 H, m, Lys, Lys, Lys,  Met, 
H32, 33, 36, 37, 34, 35, 18, 19 ), 1.29 (3 H, d, J = 7.3 Hz, Ala  H22, 23, 24), Assignments are carried 
out on 1-d and 2-d spectras (Figure 62 b and c, Chapter 4, Appendix 25); 
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NMR: δC (150 MHz, CD3OD), 176.2 (C1), 174.6 (CONH), 174.2 (CONH), 173.7 (CONH), 
172.5 (2 signals, CONH), 158.9 (C27), 145.2 (CAr), 142.6 (CAr), 134.9 (C6), 130.9 (C4), 128.9 
(CAr), 128.2 (CAr), 126.2 (CAr), 121.1 (CAr), 118.7 (C5), 67.9 (C28), 57.3 (C22), 55.1 (C8 or 
C11), 54.7 (C2 or 13), 53.9 (C8 or 11 or 13), 52.5 (2 signals, C8 or 11 or 13), C29 missing, 40.4 
(C26), 38.7 (C9 or 10), 37.4 (C9 or 10), 31.7 (2 signals C18 or 23), 31.4 (C3), 30.6 (C17), 28.3 
(C25), 23.9 (C24), 16.9 (C14), 15.4 (C19), (Appendices 26-31); 
HRMS: (ES
-
), m/z: Found: 878.3363 [M-H]
-
, C41H52N9O9S2 requires 878.3329, (Figure 62 a, 
Chapter 4); 
MALDI-TOF, C41H53N9O9S2, m/z: 879 [M + H]
+
, (Figure 59, Chapter 4).  
 
Synthesis of an analogue of rings D and E of nisin 141 
  
Coupling of Aloc/allyl lanthionine to Fmoc-Ser(tBu)-NovaSyn TGT resin 
 
AlocHN
S
NH2
N
H
O
O
O
OtBu
COOAllyl
FmocHN
O
O
OtBu
i) 40 % piperidne/DMF
ii) SPPS Coupling of Lanthionine 103 (4 equiv)
   
   
   
   HOAt (5 equiv), PyAOP (5 equiv), DIPEA (10 equiv)
iii) 40 % piperidne/DMF
HH
199 205  
 
Fmoc-Ser(tBu)-NovaSyn TGT resin 199 (0.100 g 0.021 mmol) was suspended in DMF (2 
mL) for 1 hr in a 2 mL syringe in order to pre-swell the resin. The terminal Fmoc group was 
removed by treatment with piperidine (40% piperidine in DMF, 2 mL) with Ar bubbling for 
30 min followed by thorough washing with DMF (6 x 0.9 mL). 
 
3-(2-Allyloxycarbonyl-2-allyloxycarbonylamino-ethylsulfanyl)-2-(9H-fluoren-9-
ylmethoxycarbonylamino)-propionic acid 103 (0.047 g, 0.084 mmol, 4 equiv), HOAt (0.014 
g, 0.10 mmol, 5 equiv) and PyAOP (0.055 g, 0.10 mmol, 5 equiv) were dissolved in DMF (1 
mL). The mixture was added to the syringe containing the resin, followed by DIPEA (0.036 
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mL, 0.21 mmol, 10 equiv) and the mixture was bubbled with Ar for 1 hr 30 min. The 
coupling solution was removed and the resin was washed with DMF (6 x 0.9 mL). The 
terminal Fmoc group was removed with piperidine (40 % in DMF, 2 mL) with Ar bubbling 
for 30 min, followed by thorough washing with DMF (6 x 0.9 mL).  
 
Elongation by SPPS to give linear resin-bound peptide 221 
 
AlocHN
S
NH2
N
H
O
O
O
OtBu
COOAllyl
HH
i) SPPS Coupling of Histidine
    HBTU (10 equiv), DIPEA (20 equiv),
ii) 40 % piperidne/DMF
    
   
   
iii) Teoc/TMSE Lanthionine 169 (4 equiv),    
     HOAt (5 equiv), PyAOP (5 equiv), DIPEA
     (10 equiv)
205
OtBu
COON
H
O
HN
O
N
H NTrt
N
COOAllyl
S
AlocHN
HH
221
O
FmocHN
S
H
COOTMSE
TeocHN
H
 
 
Fmoc-His(Trt)-OH (0.13 g, 0.21 mmol, 10 equiv) and HBTU (0.079 g, 0.21 mmol, 10 equiv) 
were dissolved in DMF (1 mL). The mixture was added to the resin followed by DIPEA 
(0.073 mL, 0.42 mmol, 20 equiv) and bubbled with Ar for 1 hr 15 min. The coupling solution 
was removed and the resin was washed with DMF (6 x 0.9 mL). The terminal Fmoc group 
was removed with piperidine (40 % in DMF, 2 mL) with Ar bubbling for 30 min, followed 
by thorough washing with DMF (6 x 0.9 mL). 
 
2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-[2-(2-trimethylsilanyl-ethoxycarbonyl)-2-(2-
trimethylsilanyl-ethoxycarbonylamino)-ethylsulfanyl]-propionic acid 169 (0.0566 g, 0.084 
mmol, 4 equiv), HOAt (0.014 g, 0.10 mmol, 5 equiv) and PyAOP (0.055 g, 0.10 mmol, 5 
equiv) were dissolved in DMF (1 mL). The mixture was added to the syringe containing the 
resin followed by DIPEA (0.036 mL, 0.21 mmol, 10 equiv) and bubbled with Ar for 1 hr 30 
min. The coupling solution was removed and the resin was washed with DMF (6 x 1.2 mL) to 
give resin-bound peptide 221.  
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Removal of the Aloc/allyl and Fmoc protecting groups 
 
OtBu
COON
H
O
HN
O
N
H NTrt
N
COOAllyl
S
AlocHN
HH
221
O
FmocHN
S
H
COOTMSE
TeocHN
H
i) Pd(PPh3)4 (1 equiv), NDMBA (10 equiv),
   CHCl3:DMF (1:1)
ii) 40 % piperidne/DMF
OtBu
COON
H
O
HN
O
N
H NTrt
N
COOH
S
H2N
HH
O
H2N
S
H
COOTMSE
TeocHN
H
222
 
 
1,3-Dimethyl barbituric acid (0.033 g, 0.21 mmol, 10 equiv) was dissolved in a mixture of  
DMF/CHCl3 (1:1, volume 1.0/1.0 mL, total volume 2 mL). 
Tetrakis(triphenylphosphine)Palladium (0) (0.024 g, 0.020 mmol, 1.0 equiv) was then added 
and the mixture was gently heated to completely dissolve the Palladium reagent ensuring the 
colour remains close to yellow. (It is important that the 
tetrakis(triphenylphosphine)Palladium (0) reagent used is yellow: if the reagent is dark or 
discoloured recrystallisation, or the use of a freshly synthesised batch, is recommended). The 
solution was added to the fully protected, resin-bound linear peptide 221, and the mixture was 
gently bubbled with Ar for 2 hr 15 min in the dark. The resin was then washed successively 
with DMF (6 x 0.9 mL) followed by a solution of DIPEA in DMF (0.5 % v/v, 6 x 1 mL) 
followed by further washing with DMF (6 x 0.9 mL). It was then washed with sodium 
diethyldithiocarbamate trihydrate in DMF (0.5 % w/v, 8 x 1 mL) followed by a final wash 
with DMF (6 x 0.9 mL). Removal of the terminal Fmoc group with piperidine (40 % in DMF, 
2 mL) with Ar bubbling for 30 min was followed by washing with DMF (6 x 0.9 mL). 
 
Cyclisation to form ring E of nisin and SPPS elongation 224 
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O
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H
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i)  Cyclisation, HOAt (5 equiv), PyAOP (5 equiv), 
     DIPEA (10 equiv)
ii) SPPS Coupling of Alanine
    HBTU (10 equiv), DIPEA (20 equiv)
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During the preceding Fmoc deprotection step, the cyclization reagents were prepared. HOAt 
(0.014 g, 0.10 mmol, 5 equiv) and PyAOP (0.055 g, 0.10 mmol, 5 equiv) were dissolved in 
DMF (1 mL). The mixture was added to the syringe containing the resin, this was followed 
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by addition of DIPEA (0.036 mL, 0.21 mmol, 10 equiv) and the mixture was left bubbling 
under Ar for 1 hr 30 min. The coupling solution was removed and resin was then washed 
with DMF (6 x 0.9 mL).  
 
Fmoc-Ala-OH (0.065 g, 0.21 mmol, 10 equiv) and HBTU (0.079 g, 0.21 mmol, 10 equiv) 
were dissolved in DMF (1 mL). The mixture was added to the resin followed by DIPEA 
(0.073 mL, 0.42 mmol, 20 equiv) and bubbled with Ar for 1 hr 15 min. The coupling solution 
was removed and the resin was washed with DMF (6 x 0.9 mL) to give cyclised and 
elongated resin-bound peptide 224.  
 
Removal of the Teoc/TMSE and Fmoc protecting groups 
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i)  TBAF (100 equiv) in DMF
ii) 40 % piperidne/DMF
224
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H
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The fully protected, resin-bound peptide 224 was treated with tetrabutylammonium fluoride 
(TBAF) (0.522 g, 2.00 mmol, 100 equiv) dissolved in DMF (2 mL). The mixture was gently 
bubbled with Ar for 1 hr. The resin was then washed successively with DMF (10 x 1.2 mL). 
Removal of the terminal Fmoc group with piperidine (40 % in DMF, 2 mL) with Ar bubbling 
for 30 min was followed by washing with DMF (6 x 1.2 mL), leading to the cyclization 
substrate 225.  
 
Cyclisation to form ring D of nisin and SPPS elongation  
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i)  Cyclisation, HOAt (5 equiv), PyAOP (5 equiv), 
     DIPEA (10 equiv)
ii) SPPS Coupling of Lysine
    HBTU (10 equiv), DIPEA (20 equiv)
225
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During Fmoc deprotection the cyclization reagents were prepared. HOAt (0.014 g, 0.10 
mmol, 5 equiv) and PyAOP (0.055 g, 0.10 mmol, 5 equiv) were dissolved in DMF (1 mL). 
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The mixture was added to the syringe containing the resin. This was followed by addition of 
DIPEA (0.036 mL, 0.21 mmol, 10 equiv) and the mixture was bubbled with Ar for 1 hr 30 
min. The coupling solution was removed and resin was then washed with DMF (6 x 0.9 mL).    
 
Fmoc-Lys(Boc)-OH (0.098 g, 0.21 mmol, 10 equiv) and HBTU (0.079 g, 0.21 mmol, 10 
equiv) were dissolved in DMF (1 mL). The mixture was added to the resin, followed by 
DIPEA (0.073 mL, 0.42 mmol, 20 equiv) and bubbled with Ar for 1 hr 15 min. The coupling 
solution was removed and the resin was washed with DMF (6 x 0.9 mL).  
 
Deprotection, cleavage from the resin and purification to give bicyclic analogue of nisin 
rings D and E 141 
OH
COOHN
H
O
HN
O
N
H NH
N
S
H
N
H H
HN
O O
H
HN
O
O
SN
H
O
FmocHN
NH2
H
141  
 
A solution of cleavage cocktail (TFA (94 %), H2O (2.5 %), TIPS (1 %) and EDT (2.5 %), 
2mL) was added to the resin-bound peptide and gently bubbled with Ar for 3 hr. The 
cleavage cocktail was collected in a Falcon tube. Diethyl ether was added until the crude 
peptide precipitated. The solution was centrifuged at 4000 rpm for 7 min, after which the 
ether layer was decanted. The centrifuging and decanting procedure was repeated, washing 
on each occasion with diethyl ether (5 x 13 mL). The precipitate was dissolved in water, and 
the solution was freeze dried overnight, yielding the crude peptide as a yellow fluffy solid (20 
mg, 0.019 mmol, 94.5 % crude yield). 
 
The peptide proved difficult to purify by HPLC due to tailing of impurities, and an alternative 
strategy involving two SPE columns was therefore developed. The first column was carried 
out using a Bond Elute C18 column with a capacity of 100 mg in 1 mL. The column was 
loaded with the crude peptide dissolved in water (1 mL) and the eluant collected as a flow 
through fraction. The column was then washed with water (3 x 1 mL) and the eluant collected 
as a second fraction. The column was then eluted with a water: acetonitrile: TFA mixture: 
Solvent A, H2O/0.5% TFA; Solvent B, acetonitrile/0.5 % TFA. A mixture of 95 % A and 5 % 
B (1 mL) was applied to the column and the eluant collected as the third fraction. This 
process was repeated with successive batches (1 mL) of eluant in which the fraction of 
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Solvent B was increased by 5 % each time until a fraction containing 60 % Solvent B and 40 
% Solvent A was reached. The percentage of Solvent B was then increased by 10 % in each 
successive batch of eluant, and the eluant was collected until 100 %.  Each of the 1 mL 
fractions were collected and freeze-dried separately to give cream fluffy solids. MS analysis 
indicated that the majority of the desired peptide was found in the fraction collected at 25 % 
acetonitrile, 75 % water. 
 
The second purification was carried out using a Bond Elute C18 column with a capacity of 50 
mg in 1 mL to further purify the fraction collected at 25 % of the first column. The column 
was loaded with the 25 % fraction dissolved in D2O (1 mL). The column was first eluted with 
a mixture of 17 % CD3CN, 83% D2O and 0.15 % TFA (2 x 0.5 mL) and the eluant collected. 
This process was repeated with successive batches of eluant (2 x 0.5 mL) in which the 
fraction of CD3CN was increased by 2 % each time until a fraction of 29 % CD3CN, 71% 
D2O, (0.15% TFA) was reached. The fraction of CD3CN was then increased by 10 % each 
time until 100 % CD3CN (0.15% TFA) was reached. MS analysis indicated that the majority 
of the desired peptide was found in the fraction collected at 23 % acetonitrile, 77% water. A 
yield of less than 0.1 mg of the peptide was obtained, which was not sufficient for detailed 
NMR analysis. 
Analytical HPLC (Onyx Monolithic C18) RT 19.4 min; A: H2O/0.5 % TFA; B: 
acetonitrile/0.5 % TFA; gradient 10 % - 60 % B over 30 min. 
HRMS (ES
+
), m/z: Found: 1008.3724 [M+H]
+
. C45H56N11O12S2 requires 1008.3708. 
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7. Appendices 
 
Appendix 1 
 
Mass spectrum for 167 showing the presence of oxidised tributylphosphine.  
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Appendix 2 
 
Mass spectrum of (Teoc, OH / Fmoc, tBu) lanthionine after removal of allyl group and 
protected with TMSE group:  
(3-[2-tert-Butoxycarbonyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethylsulfanyl]-2-(2-
trimethylsilanyl-ethoxycarbonylamino)-propionic acid).  
'' B-side'' (R)
'' A-side'' (S)
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O
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Appendix 3 
 
1
H NMR of (Teoc, OH / Fmoc, tBu) lanthionine, co-eluting with an allylic impurity: 
(3-[2-tert-Butoxycarbonyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethylsulfanyl]-2-(2-
trimethylsilanyl-ethoxycarbonylamino)-propionic acid).  
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Appendix 4 
 
Mass spectrum of (Teoc, TMSE / Fmoc, tBu) lanthionine 176. 
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Appendix 5 
 
1
H NMR of (Teoc, TMSE / Fmoc, tBu) lanthionine 176 before purification. 
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Appendix 6 
  
1
H NMR of (Teoc, TMSE / Fmoc, tBu) lanthionine 176 after purification by flash column 
chromatography. 
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Appendix 7 
 
Analytical HPLC of crude (Teoc, TMSE / Fmoc, OH) lanthionine 169. 
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Appendix 8 
 
Preparative HPLC of (Teoc, TMSE / Fmoc, OH) lanthionine 169. 
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Appendix 9 
 
Analytical HPLC of (Teoc, TMSE / Fmoc, tBu) lanthionine 176. 
 
 
         
O
OHN
O
O
S
OO
Si
HNO
O
Si H H
 
 
 
 
273 
 
Appendix 10 
 
Preparative HPLC of (Teoc, TMSE / Fmoc, tBu) lanthionine 176. 
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Appendix 11 
 
Proton NMR of (Teoc, TMSE / Fmoc, tBu) lanthionine 176. 
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Appendix 12 
 
Proton NMR of the reaction mixture: during the synthesis of the (Teoc, TMSE / Fmoc, OH) 
lanthionine 169. 
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Appendix 13 
Proton NMR at 10 min: during the synthesis of the (Teoc, TMSE / Fmoc, OH) lanthionine 
169. 
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Appendix 14 
 
Proton NMR at 1 hour: during the synthesis of the (Teoc, TMSE / Fmoc, OH) lanthionine 
169. 
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Appendix 15 
 
Proton NMR at 2 hour: during the synthesis of the (Teoc, TMSE / Fmoc, OH) lanthionine 
169. 
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Appendix 16 
 
Proton NMR at 3 hour: during the synthesis of the (Teoc, TMSE / Fmoc, OH) lanthionine 
169. 
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Appendix 17 
 
Proton NMR of (Teoc, TMSE / Fmoc, OH) lanthionine 169. 
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Appendix 18 
 
Carbon NMR of (Teoc, TMSE / Fmoc, OH) lanthionine 169. 
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Appendix 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) Analytical HPLC of model peptide 198: Met-His-Met-Ser. 
 
M + H +
 
 
(b) Mass spectrum of model peptide 198: Met-His-Met-Ser. 
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Appendix 20 
 
Purity test by LCMS on a third attempt on sample of analogue of ring E of nisin 210.  
 
Product
 
 
OH
OH
O
N
H
O
HN
O
HN
HN
N
O
NH
S
O
S
H
N
O
N
H
O
O
H H
 
 
 
 
 
 
 
 
 
 
 
 
 
284 
 
Appendix 21 
 
COSY NMR of an analogue of ring E of nisin 210. 
Fmoc + His
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Appendix 22 
 
Carbon DEPT NMR of an analogue of ring E of nisin 210. 
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Appendix 23 
 
HSQC NMR of an analogue of ring E of nisin 210. 
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Appendix 24 
 
Carbon NMR of an analogue of ring E of nisin 210. 
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Appendix 25 
 
COSY NMR of an analogue of ring D of nisin 220. 
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Appendix 26 
 
Carbon DEPT NMR of an analogue of ring D of nisin 220. 
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Appendix 27 
 
HSQC NMR of an analogue of ring D of nisin 220. 
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Appendix 28 
 
HMBC NMR of an analogue of ring D of nisin 220. 
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Appendix 29 
 
Carbon NMR of an analogue of ring D of nisin 220. 
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Appendix 30 
 
Accurate mass spectrum of an analogue of rings D and E of nisin 141: HPLC fraction eluting 
at 26-27 min. 
 
 
 
 
 
 
 
 
 
 
 
294 
 
Appendix 31 
 
Analytical HPLC trace of an analogue of rings D and E of nisin 141 collected at 26-27 min. 
A: H2O/0.5 % TFA; B: acetonitrile/0.5 % TFA; B gradient 15 % - 50 % over 30 min. 
 
 
Appendix 32 
 
LCMS of the supernatant sample in blue and the pellet sample in red. A: H2O/0.5 % TFA; B: 
acetonitrile/0.5 % TFA; B gradient 10 % - 90 % over 35 min. 
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Appendix 33 
 
Crude analytical HPLC trace of the analogue of rings D and E of nisin 141 obtained from the 
second attempt. A: H2O/0.5 % TFA; B: acetonitrile/0.5 % TFA; B gradient 10 % - 60 % over 
30 min. 
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Appendix 34 
 
Analytical trace of fraction 16 collected after the first purifcation by C18 column. A: H2O/0.5 
% TFA; B: acetonitrile/0.5 % TFA; B gradient 10 % - 90 % over 30 min. 
 
 
 
Appendix 35 
 
Synthesis of Peptides Containing Overlapping Lanthionine Bridges on the Solid Phase: An 
Analogue of Rings D and E of the Lantibiotic Nisin 
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